pyrazinamide has been researched along with Pulmonary Consumption in 1055 studies
pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.
Excerpt | Relevance | Reference |
---|---|---|
" The aim of the study was to document the pharmacokinetics of the first-line anti-TB agents in children <2 years of age comparing previous and revised WHO dosages of isoniazid (INH; 5 versus 10 mg/kg/day), rifampin (RMP; 10 versus 15 mg/kg/day), and pyrazinamide (PZA; 25 versus 35 mg/kg/day) and to investigate the effects of clinical covariates, including HIV coinfection, nutritional status, age, gender, and type of tuberculosis (TB), and the effect of NAT2 acetylator status." | 9.15 | Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. ( Donald, PR; Hesseling, AC; Magdorf, K; Roll, S; Rosenkranz, B; Schaaf, HS; Seddon, JA; Seifart, HI; Thee, S; Werely, CJ, 2011) |
"To study intralesional concentrations of isoniazid (INH), rifampicin (RMP) and pyrazinamide (PZA) in tuberculous pleural effusions and psoas abscesses, and to compare these to reference serum values and minimal inhibitory concentration (MIC)." | 9.11 | Penetration of isoniazid, rifampicin and pyrazinamide in tuberculous pleural effusion and psoas abscess. ( Jutte, PC; Rutgers, SR; Uges, DR; Van Altena, R; Van Horn, JR, 2004) |
"A case of isoniazid induced gynecomastia is being reported in an 18-year old male, who received a re-treatment regimen for the relapse of pulmonary tuberculosis (TB)." | 8.87 | Unilateral and painless development of isoniazid induced gynecomastia during re-treatment of pulmonary tuberculosis. ( Behera, D; Gupta, R; Jaiswal, A; Kumar, L; Murar, A; Puri, MM, 2011) |
"Lopinavir-ritonavir forms the backbone of current first-line antiretroviral regimens in young HIV-infected children." | 7.88 | Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. ( de Kock, M; Denti, P; Garcia-Prats, AJ; Hesseling, AC; McIlleron, H; Norman, J; Schaaf, HS; Tikiso, T; van der Laan, LE; Wiesner, L; Winckler, J, 2018) |
"We report the case of a 35-year-old man treated by RHEZ for a first episode of a smear positive pulmonary tuberculosis and who developed a DRESS syndrome due to pyrazinamide after twenty days of treatment, associated with a viral reactivation to Human Herpes Virus 6 (HHV6)." | 7.88 | [DRESS syndrome secondary to pyrazinamide: An uncommon complication of tuberculosis treatment]. ( Dia Kane, Y; Diouf, NF; Fall, L; Ka, W; Kombila, UD; Koutonin, ANE; Mbaye, FBR; Ouedraogo, P; Oumar Toure Badiane, N, 2018) |
"Rifampin (RIF) mono-resistant tuberculosis (RMR-TB) is a rare disease." | 7.85 | Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis. ( Jo, KW; Kim, WS; Lee, SD; Park, S; Shim, TS, 2017) |
"Pyrazinamide (PZA) has been in use for almost 50 years as a first-line drug for short-course chemotherapy against Mycobacterium tuberculosis." | 7.76 | Molecular epidemiological study of pyrazinamide-resistance in clinical isolates of mycobacterium tuberculosis from South India. ( Ayalusamy, N; Jagadeesan, S; Muthaiah, M; Muthuraj, U; Prabhu, SS; Senthilkumar, K; Sreenivasan, M; Veerappan, S, 2010) |
"In this study we investigated whether leptin and TNFalpha levels change with improvement in body weight with antituberculotic therapy in active tuberculosis patients." | 7.70 | Relation of leptin and tumor necrosis factor alpha to body weight changes in patients with pulmonary tuberculosis. ( Aral, Y; Cakir, B; Demirbaş, B; Güler, S; Gürsoy, G; Odabaşi, E; Yönem, A, 1999) |
"We report three patients who experienced hepatotoxic reactions in association with acetaminophen ingestion while undergoing treatment for active tuberculosis with isoniazid, rifampin, and other agents." | 7.69 | Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. ( Nelson, SD; Nolan, CM; Sandblom, RE; Slattery, JT; Thummel, KE, 1994) |
"Noncaseating granulomatous hepatitis may be caused by a variety of drugs, but we have not found, by computer search of the literature, a previous describe of granulomatous hepatitis associated with pyrazinamide." | 7.69 | Pyrazinamide-induced granulomatous hepatitis. ( Buyanowsky, G; Dan, M; Knobel, B; Zaidel, L, 1997) |
"A case of thrombocytopenia caused by pyrazinamide is reported in a patient receiving chemotherapy for pulmonary tuberculosis." | 7.67 | Pyrazinamide induced thrombocytopenia. ( Jain, VK; Prakash, OM; Vardhan, H, 1988) |
"Results are presented of the incidence of hepatitis, nearly always with jaundice, among 1686 patients in clinical trials of the treatment of spinal tuberculosis, of tuberculosis meningitis and of pulmonary tuberculosis with short-course regimens containing rifampicin, isoniazid, streptomycin and pyrazinamide." | 7.67 | Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. ( Janardhanam, B; Parthasarathy, R; Ramachandran, P; Santha, T; Sarma, GR; Sivasubramanian, S; Somasundaram, PR; Tripathy, SP, 1986) |
" PZA dosage was less than 1." | 6.69 | [Hyperuricemia and arthralgia during pyrazinamide treatment]. ( Ikeda, N; Ikeda, T; Inoue, T; Kurasawa, T; Nakatani, K; Sato, A; Yoshimatsu, H, 1999) |
" One hundred patients with pulmonary tuberculosis (65% coinfected with HIV-1) were intensively sampled to determine rifampin, isoniazid, and pyrazinamide plasma concentrations after 7 to 8 weeks of a daily quadruple-therapy regimen dosed according to World Health Organization (WHO) weight bands." | 5.43 | HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients. ( Chirehwa, M; Denti, P; McIlleron, H; Meintjes, G; Rockwood, N; Wiesner, L; Wilkinson, RJ, 2016) |
"Rosacea is a common chronic inflammatory cutaneous disease of unknown etiology, characterized by remissions and exacerbations, presenting with centrofacial erythema and telangiectasias." | 5.42 | Pyridoxine induced rosacea-like dermatitis. ( Mokos, ZB; Paštar, Z; Rezaković, S, 2015) |
"Pyrazinamide is an antituberculous drug that is administered as a two-month course during treatment of pulmonary tuberculosis." | 5.35 | Epidemiological survey of hyperuricemia as an adverse reaction to antituberculous therapy with pyrazinamide. ( Murakami, T; Nikai, T; Ogawa, K; Taki, H, 2008) |
"The isoniazid was discontinued, and the gynecomastia was partially resolved by the end of treatment." | 5.35 | Gynecomastia: a rare adverse effect of isoniazid. ( Braz, AG; Maia, JA; Morrone Junior, N; Morrone, N, 2008) |
"Pyrazinamide therapy has been associated with dose-dependent hepatotoxicity, hyperuricaemia, arthralgia and arthritis." | 5.28 | Tubulointerstitial nephritis associated with pyrazinamide. ( Kauffmann, RH; Sanwikarja, S; Serlie, J; te Velde, J, 1989) |
" The aim of the study was to document the pharmacokinetics of the first-line anti-TB agents in children <2 years of age comparing previous and revised WHO dosages of isoniazid (INH; 5 versus 10 mg/kg/day), rifampin (RMP; 10 versus 15 mg/kg/day), and pyrazinamide (PZA; 25 versus 35 mg/kg/day) and to investigate the effects of clinical covariates, including HIV coinfection, nutritional status, age, gender, and type of tuberculosis (TB), and the effect of NAT2 acetylator status." | 5.15 | Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. ( Donald, PR; Hesseling, AC; Magdorf, K; Roll, S; Rosenkranz, B; Schaaf, HS; Seddon, JA; Seifart, HI; Thee, S; Werely, CJ, 2011) |
"To study intralesional concentrations of isoniazid (INH), rifampicin (RMP) and pyrazinamide (PZA) in tuberculous pleural effusions and psoas abscesses, and to compare these to reference serum values and minimal inhibitory concentration (MIC)." | 5.11 | Penetration of isoniazid, rifampicin and pyrazinamide in tuberculous pleural effusion and psoas abscess. ( Jutte, PC; Rutgers, SR; Uges, DR; Van Altena, R; Van Horn, JR, 2004) |
"A case of isoniazid induced gynecomastia is being reported in an 18-year old male, who received a re-treatment regimen for the relapse of pulmonary tuberculosis (TB)." | 4.87 | Unilateral and painless development of isoniazid induced gynecomastia during re-treatment of pulmonary tuberculosis. ( Behera, D; Gupta, R; Jaiswal, A; Kumar, L; Murar, A; Puri, MM, 2011) |
"Lopinavir-ritonavir forms the backbone of current first-line antiretroviral regimens in young HIV-infected children." | 3.88 | Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. ( de Kock, M; Denti, P; Garcia-Prats, AJ; Hesseling, AC; McIlleron, H; Norman, J; Schaaf, HS; Tikiso, T; van der Laan, LE; Wiesner, L; Winckler, J, 2018) |
"We report the case of a 35-year-old man treated by RHEZ for a first episode of a smear positive pulmonary tuberculosis and who developed a DRESS syndrome due to pyrazinamide after twenty days of treatment, associated with a viral reactivation to Human Herpes Virus 6 (HHV6)." | 3.88 | [DRESS syndrome secondary to pyrazinamide: An uncommon complication of tuberculosis treatment]. ( Dia Kane, Y; Diouf, NF; Fall, L; Ka, W; Kombila, UD; Koutonin, ANE; Mbaye, FBR; Ouedraogo, P; Oumar Toure Badiane, N, 2018) |
"Rifampin (RIF) mono-resistant tuberculosis (RMR-TB) is a rare disease." | 3.85 | Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis. ( Jo, KW; Kim, WS; Lee, SD; Park, S; Shim, TS, 2017) |
"A 26-year-old man, who had started treatment for pulmonary tuberculosis, developed polyarthralgia, generalised myalgia, weakness, and elevated uric acid and creatine kinase levels." | 3.81 | Drug-induced myopathy in a patient with pulmonary tuberculosis. ( Shah, R; Venkatesan, P, 2015) |
" The objectives of this investigation were to evaluate the impact of body weight on the overall systemic exposure to pyrazinamide (PZA) and to assess whether the use of one fixed dose, without adjustment according to weight, would ensure target exposure and safety requirements across the overall patient population." | 3.78 | Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis. ( Della Pasqua, O; Sahota, T, 2012) |
"Pyrazinamide (PZA) has been in use for almost 50 years as a first-line drug for short-course chemotherapy against Mycobacterium tuberculosis." | 3.76 | Molecular epidemiological study of pyrazinamide-resistance in clinical isolates of mycobacterium tuberculosis from South India. ( Ayalusamy, N; Jagadeesan, S; Muthaiah, M; Muthuraj, U; Prabhu, SS; Senthilkumar, K; Sreenivasan, M; Veerappan, S, 2010) |
"We present the case of an elderly patient who died of fulminant hepatic failure in the course of receiving 2 months of treatment with pyrazinamide and rifampin for his latent tuberculosis." | 3.71 | Death associated with rifampin and pyrazinamide 2-month treatment of latent mycobacterium tuberculosis. ( Medinger, A, 2002) |
"In this study we investigated whether leptin and TNFalpha levels change with improvement in body weight with antituberculotic therapy in active tuberculosis patients." | 3.70 | Relation of leptin and tumor necrosis factor alpha to body weight changes in patients with pulmonary tuberculosis. ( Aral, Y; Cakir, B; Demirbaş, B; Güler, S; Gürsoy, G; Odabaşi, E; Yönem, A, 1999) |
"We report three patients who experienced hepatotoxic reactions in association with acetaminophen ingestion while undergoing treatment for active tuberculosis with isoniazid, rifampin, and other agents." | 3.69 | Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. ( Nelson, SD; Nolan, CM; Sandblom, RE; Slattery, JT; Thummel, KE, 1994) |
"To test the efficacy of a short-course regimen of 6 months rifampicin and isoniazid supplemented by 2 months initial pyrazinamide (2HRZ-4HR), in the treatment of smear and culture-negative pulmonary tuberculosis and tuberculous pleural effusion in routine clinical practice." | 3.69 | Short-course chemotherapy for tuberculous pleural effusion and culture-negative pulmonary tuberculosis. ( Horsfield, N; McCarthy, OR; Ormerod, LP; Rudd, RM, 1995) |
"Noncaseating granulomatous hepatitis may be caused by a variety of drugs, but we have not found, by computer search of the literature, a previous describe of granulomatous hepatitis associated with pyrazinamide." | 3.69 | Pyrazinamide-induced granulomatous hepatitis. ( Buyanowsky, G; Dan, M; Knobel, B; Zaidel, L, 1997) |
"A case of thrombocytopenia caused by pyrazinamide is reported in a patient receiving chemotherapy for pulmonary tuberculosis." | 3.67 | Pyrazinamide induced thrombocytopenia. ( Jain, VK; Prakash, OM; Vardhan, H, 1988) |
"Results are presented of the incidence of hepatitis, nearly always with jaundice, among 1686 patients in clinical trials of the treatment of spinal tuberculosis, of tuberculosis meningitis and of pulmonary tuberculosis with short-course regimens containing rifampicin, isoniazid, streptomycin and pyrazinamide." | 3.67 | Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. ( Janardhanam, B; Parthasarathy, R; Ramachandran, P; Santha, T; Sarma, GR; Sivasubramanian, S; Somasundaram, PR; Tripathy, SP, 1986) |
"An analysis carried out on the dosage schemes adopted in several controlled clinical trials in tuberculosis has indicated that preestablishing the daily doses of isoniazid, rifampicin, and pyrazinamide in the initial intensive phase results in large deviations of the doses administered from those considered appropriate in mg/kg body weight." | 3.67 | Short-course chemotherapy of pulmonary tuberculosis: a new approach to drug dosage in the initial intensive phase. ( Acocella, G; Angel, JH, 1986) |
" Secondary outcomes were clinical signs and symptoms of pulmonary TB and adverse drug reactions (ADRs) related to anti-TB agents." | 3.01 | Efficacy and safety of combined isoniazid-rifampicin-pyrazinamide-levofloxacin dry powder inhaler in treatment of pulmonary tuberculosis: A randomized controlled trial. ( Kawkitinarong, K; Laohapojanart, N; Ratanajamit, C; Srichana, T, 2021) |
"Linezolid is increasingly used for the treatment of tuberculosis resistant to first-line agents, but the most effective dosing strategy is yet unknown." | 2.94 | Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis. ( Burger, DA; Dawson, R; De Jager, VR; Diacon, AH; Everitt, D; Mendel, CM; Narunsky, K; Nedelman, J; Pappas, F; Vanker, N, 2020) |
" We investigated the incidence of adverse events and cure rates according to HIV status for patients receiving standard TB therapy in the trial." | 2.90 | Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status. ( Crook, AM; Dawson, R; Diacon, AH; Gillespie, SH; McHugh, TD; Mendel, CM; Meredith, SK; Mohapi, L; Murphy, ME; Nunn, AJ; Phillips, PPJ; Singh, KP; Spigelman, M; Tweed, CD, 2019) |
"Linezolid improves the treatment outcomes of multidrug-resistant tuberculosis substantially." | 2.90 | Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial. ( Ahn, H; Cho, YJ; Choi, HS; Choi, SM; Hahn, S; Han, J; Heo, EY; Hwang, YR; Jeong, I; Jo, YS; Joh, JS; Ki, J; Kim, DK; Kim, H; Kim, HS; Kim, J; Kim, SJ; Kwak, N; Lee, CH; Lee, J; Lee, JH; Lee, JK; Lee, JY; Lee, M; Lee, SH; Lee, SM; Lee, YJ; Lim, JN; Park, JH; Park, JS; Park, SS; Park, YS; Song, T; Yim, JJ; Yoon, HI, 2019) |
"Treatment success rates of multidrug-resistant tuberculosis (MDR-TB) remain unsatisfactory, and long-term use of second-line anti-TB drugs is accompanied by the frequent occurrence of adverse events, low treatment compliance, and high costs." | 2.90 | Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, m ( Ahn, H; Ahn, JH; Cho, SN; Hahn, S; Jang, JY; Jeon, D; Jhun, BW; Jo, KW; Kang, YA; Kim, CK; Kim, DK; Kim, JS; Kim, SY; Kim, YR; Koh, WJ; Lee, JH; Lee, JY; Lee, M; Lee, SH; Lee, T; Mok, J; Park, JS; Shim, TS; Shin, S; Shin, SJ; Song, T; Won, HJ; Yim, JJ, 2019) |
" Incidence rate of adverse effects was 19." | 2.90 | Efficacy and safety of cholecalciferol-augmented anti-tuberculosis therapy for treatment of naïve patients with pulmonary tuberculosis: A randomized, controlled, clinical study. ( Abd-Ellatief, RB; Hasanain, AFA; Nafee, AMA; Zayed, AAH, 2019) |
" In conclusion, regimen including PZA seems to be safe for late elderly patients with pulmonary TB." | 2.90 | Safety of pyrazinamide-including regimen in late elderly patients with pulmonary tuberculosis: A prospective randomized open-label study. ( Asaoka, M; Baba, T; Hagiwara, E; Katano, T; Kitamura, H; Komatsu, S; Ogura, T; Okuda, R; Sekine, A; Suido, Y, 2019) |
" Intensive pharmacokinetic sampling occurred in 63 patients after 6 weeks of treatment, and safety/tolerability was assessed." | 2.84 | Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis. ( Aarnoutse, RE; Boeree, MJ; Colbers, A; Gillespie, SH; Haraka, F; Hoelscher, M; Kibiki, GS; Logger, JGM; Magis-Escurra, C; Mpagama, SG; Mtabho, CM; Phillips, PPJ; Plemper van Balen, G; Reither, K; Semvua, HH; Sumari-de Boer, IM; Te Brake, LHM; van den Boogaard, J; Wattenberg, M, 2017) |
" Nonlinear mixed-effects modeling found that influential covariates for the pharmacokinetics were weight, sex, and a 30% increased bioavailability among heterozygous carriers of SLCO1B1 rs1104581 (previously associated with low rifampin concentrations)." | 2.82 | Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis. ( Egan, D; Hennig, S; Kellerman, T; McIlleron, H; Naiker, S; Owen, A; Pym, A; Reddy, T; Wiesner, L, 2016) |
"There are limited pharmacokinetic data for use of the first-line antituberculosis drugs during infancy (<12 months of age), when drug disposition may differ." | 2.82 | Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. ( Bekker, A; Donald, PR; Draper, HR; Hesseling, AC; McIlleron, HM; Murray, S; Schaaf, HS; van der Laan, L; Wiesner, L, 2016) |
"To assess whether increasing the dose of rifampicin (RMP) from 10 mg/kg to 15 or 20 mg/kg results in an increase in grade 3 or 4 hepatic adverse events and/or serious adverse events (SAE)." | 2.82 | A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis. ( Atwine, D; Bonnet, M; Borgulya, G; Burgos, M; Checkley, AM; de Fernandes, RA; de Patiño, IW; Dubash, F; Gonzales, T; Harrison, TS; Jindani, A; Mitchison, D; Patel, N; Shrestha, B, 2016) |
" Median rifapentine area under the concentration-time curve (AUC0-24) was 313 mcg*h/mL, similar to recent studies of rifapentine dosed at 450-600 mg daily." | 2.82 | A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis. ( Armstrong, DT; Barnes, GL; Cavalcante, SC; Chaisson, RE; Cohn, S; Conde, MB; Dalcolmo, M; Dooley, KE; Dorman, SE; Duarte, RS; Durovni, B; Efron, A; Loredo, C; Marzinke, MA; Mello, FC; Moulton, LH; Rolla, V; Savic, RM, 2016) |
" There was a nonlinear increase in exposure to rifampin without an apparent ceiling effect and a greater estimated fall in bacterial load in the higher dosing groups." | 2.80 | A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. ( Aarnoutse, RE; Boeree, MJ; Burger, D; Dawson, R; Diacon, AH; du Bois, J; Gillespie, SH; Heinrich, N; Hoelscher, M; Magis-Escurra, C; McHugh, TD; Narunsky, K; Phillips, PP; Plemper van Balen, G; Rehal, S; van Ingen, J; van Soolingen, D; Venter, A, 2015) |
" We also assessed safety and tolerability by monitoring adverse events." | 2.80 | Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pul ( Burger, DA; Conradie, A; Dawson, R; Diacon, AH; Donald, PR; Eisenach, K; Everitt, D; Ive, P; Mendel, CM; Ntinginya, NE; Page-Shipp, L; Pym, A; Reither, K; Schall, R; Spigelman, M; van Niekerk, C; Variava, E; Venter, A; von Groote-Bidlingmaier, F, 2015) |
"3%] in the RPT 450 mg, RPT 600 mg and RMP groups), as were ⩾grade 3 adverse events (0/54 [0%], 1/51 [2." | 2.80 | Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis. ( Barnes, GL; Carman, D; Chaisson, RE; Dawson, R; Dorman, SE; Efron, A; Gupte, N; Hoffman, J; McIlleron, H; Narunsky, K; Whitelaw, A, 2015) |
"To observe the clinical effect on type 2 diabetes mellitus (T2DM) complicated with pulmonary tuberculosis (TB) of insulin, isoniazid, rifampicin, pyrazinamide and ethambutol (conventional medication) administered together with Qi-boosting and Yin-nourishing decoction derived from Traditional Chinese Medicine (TCM)." | 2.80 | Effects on type 2 diabetes complicated with pulmonary tuberculosis: regiment of insulin, isoniazid, rifampicin, pyrazinamide and ethambutol versus the regiment plus Qi-boosting and Yin-nourishing decoction of Traditional Chinese Medicine. ( Shi, G; Zhang, L, 2015) |
" Data was analysed using population pharmacokinetic modelling." | 2.80 | Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania. ( Andersen, AB; Castel, S; Changalucha, J; Chigutsa, E; Christiansen, M; Denti, P; Faurholt-Jepsen, D; Friis, H; Hagen, CM; Jeremiah, K; McIlleron, H; PrayGod, G; Range, N; Wiesner, L, 2015) |
"The pyrazinamide MIC range was 12." | 2.79 | The pyrazinamide susceptibility breakpoint above which combination therapy fails. ( Chigutsa, E; Gumbo, T; McIlleron, H; Pasipanodya, J; Sirgel, FA; van Helden, PD; Visser, M, 2014) |
" Adverse events were mostly mild and no serious adverse events or drug discontinuations were reported." | 2.78 | Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study. ( Aarnoutse, RE; Boeree, MJ; Burger, DM; Fillekes, Q; Kibiki, GS; Kisanga, ER; Kisonga, RM; Mleoh, L; Mtabho, CM; Ndaro, A; Semvua, HH; van den Boogaard, J; van der Ven, A, 2013) |
" Noninferiority was dependent on consistent results from a per-protocol and modified intention-to-treat analysis, using 2 different models for the latter, classifying all changes of treatment or refusal to continue treatment (eg, bacteriological failure/relapse, adverse event, default, drug resistance) as unfavorable (model 1) and classifying changes of treatment for reasons other than therapeutic outcomes according to their 18-month bacteriological outcome if available (post hoc model 2)." | 2.76 | Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial. ( Anyo, G; Burgos, M; Cook, SV; Enarson, DA; Jindani, A; Kim, SJ; Lienhardt, C; Nunn, AJ; Rigouts, L; Yorke-Edwards, V, 2011) |
"Rifampin is a key drug for tuberculosis (TB) treatment." | 2.73 | Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. ( Aarnoutse, RE; Alisjahbana, B; Nijland, HM; Parwati, I; Ruslami, R; van Crevel, R, 2007) |
"The patients with drug susceptible pulmonary tuberculosis treated with 2HRZE/4H2R2 under the supervision by the pharmacists or the patients treated with 2HRZE/4HR by self-administration were followed-up for two years after completion of chemotherapy." | 2.73 | [Relapse rate of pulmonary tuberculosis within two years following completion of twice weekly intermittent chemotherapy]. ( Hoshino, H; Mitarai, S; Ogata, H; Ohmori, M; Okumura, M; Uchimura, K; Wada, M; Yoshiyama, T, 2008) |
" With a dosage of 30 mg/kg PZA, efficient serum levels were reached." | 2.73 | Pyrazinamide serum levels in childhood tuberculosis. ( Detjen, A; Magdorf, K; Thee, S; Wahn, U, 2008) |
"Patients were treated in a controlled clinical trial with 2HRZE3/6HE with thrice-weekly direct dosing in the intensive phase and once-weekly with six doses self-administered in the continuation phase." | 2.73 | Evaluation of a non-rifampicin continuation phase (6HE) following thrice-weekly intensive phase for the treatment of new sputum positive pulmonary tuberculosis. ( , 2007) |
" The occurrence of adverse effects was also monitored." | 2.73 | Clinical evaluation and monitoring of adverse effects for fixed multidose combination against single drug therapy in pulmonary tuberculosis patients. ( Chaudhry, A; Jamshaid, M; Zaka-Ur-Rehman, Z, 2008) |
"The concentration and half-life of theophylline was decreased and its clearance was increased significantly at days 5-7 after administration of antituberculosis agents compared to before the therapy was started." | 2.71 | The clearance of theophylline is increased during the initial period of tuberculosis treatment. ( Ahn, HC; Lee, YC, 2003) |
"Thirty-one patients with documented pulmonary tuberculosis were treated with rifampin/isoniazid for six months, plus pyrazinamide for the first two months." | 2.71 | Use of Rhu-GM-CSF in pulmonary tuberculosis patients: results of a randomized clinical trial. ( Badaró, R; Bandeira, AC; Barberin, MG; Brites, C; Guerra, C; Netto, EM; Pedral-Sampaio, DB, 2003) |
" There was no significant difference in the pharmacokinetic parameters of rifampicin as a component of Mairin-P and in combination with antitubercuous agents as free dosage forms." | 2.71 | [Assessment of the use of a multicomponent drug in the treatment of new cases of pulmonary tuberculosis]. ( Semenova, OV, 2003) |
"Fifty patients with drug-resistant pulmonary tuberculosis were managed by withdrawing all anti-tuberculosis drugs until the results of a drug sensitivity test were obtained (approximately 3 months), and then a 12-month self-administered regimen with four to six anti-tuberculosis drugs at full daily doses was initiated, based primarily on the sensitivity test and secondarily on the history of previous treatment." | 2.70 | Results of a 12-month regimen for drug-resistant pulmonary tuberculosis. ( Martínez-Rossier, LA; Pérez-Guzmán, C; Torres-Cruz, A; Vargas, MH; Villarreal-Velarde, H, 2002) |
" Group II also registered; the maximum cost and highest incidence of adverse effects." | 2.70 | Comparative evaluation of efficacy and safety profile of three anti-tuberculous regimens in Mangalore. ( Beena, S; Pai, MR; Rao, KN, 2002) |
" Further studies with increased rifapentine dosage are necessary." | 2.70 | Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. ( Chan, SL; Goodall, RL; Kam, KM; Mitchison, DA; Tam, CM, 2002) |
" Because of poor bioavailability of the rifapentine used (produced in China), its dose size was increased from 600 mg initially to about 750 mg in the last third of patients to obtain serum concentrations similar to those with rifapentine of Western origin; all doses were given after a meal promoting absorption." | 2.69 | Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report. ( Chan, SL; Kam, KM; Lam, CW; Leung, CC; Mitchison, DA; Morris, JS; Tam, CM, 1998) |
" PZA dosage was less than 1." | 2.69 | [Hyperuricemia and arthralgia during pyrazinamide treatment]. ( Ikeda, N; Ikeda, T; Inoue, T; Kurasawa, T; Nakatani, K; Sato, A; Yoshimatsu, H, 1999) |
"Ethambutol (E) was sometimes substituted for streptomycin." | 2.69 | Modified short-course chemotherapy of pulmonary tuberculosis in Ibadan, Nigeria--a preliminary report. ( Bakare, NA; Ige, OM; Onadeko, BO, 2000) |
"Three hundred eight new smear positive pulmonary tuberculosis patients were randomly allocated with a ratio of 2 to 1 into treatment group (227 cases, receiving 2RIFATER/4RIFINAH regimen) and controls (81 cases, 2HRZ/4HR) for observation." | 2.69 | [Controlled clinical study on efficacy of fixed-dose compounds rifater/rifinah in antituberculous chemotherapy]. ( Ma, W; Yan, B; Zhu, L, 1998) |
"The triple combination studied could replace the separate drugs in the initial treatment phase in countries where the bioavailability of the drugs used has been proven." | 2.68 | [Clinical trial of a combination of three drugs in fixed proportions in the treatment of tuberculosis. Groupe de Travail sur la Chimiothérapie de la Tuberculose]. ( Boulahbal, F; Chaulet, P, 1995) |
" Food may however decrease the oral bioavailability of rifampicin and isoniazid." | 2.68 | Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide. ( Smith, P; Zent, C, 1995) |
"To compare the pharmacokinetic parameters and the clinical efficacy of isoniazid, administered in 10 mg/kg or 5 mg/kg to children suffering from pulmonary tuberculosis." | 2.68 | Pharmacokinetics of isoniazid in pulmonary tuberculosis--a comparative study at two dose levels. ( Chopra, K; Roy, V; Tekur, U, 1996) |
"310 patients with pulmonary tuberculosis disseminating bacteria received isoniazid, rifampicin, streptomycin (ethambutol) and pirazinamid in different regimens and dosage forms." | 2.67 | [Combined chemotherapy of patients with tuberculosis - new regimens and dosage forms]. ( Elistratova, NA; Khalbaeva, IV; Koriakin, VA; Sokolova, GB; Ziia, AV, 1993) |
" The formulation employed contained 125 mg of isoniazid (H), 100 mg of rifampicin (R) and 375 mg of pyrazinamide (Z) per tablet; six tablets were administered to every subject, giving a total dosage of 750 mg of isoniazid, 600 mg of rifampicin and 2,250 mg of pyrazinamide." | 2.67 | Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy. ( Acocella, G; Grassi, C; Grassi, GG; Luisetti, M; Peona, V; Pozzi, E, 1993) |
"250 patients suffering from pulmonary tuberculosis who were smear positive received a chemotherapy regime for 6 months combining Rifampicin and Isoniazid every day with a daily supplement of Pyrazinamide for the first 8 weeks." | 2.67 | [A therapeutic trial of a combination of 3 essential drugs in a short course of chemotherapy in tuberculosis. Results 6 months after the end of treatment]. ( Agounitestane, D; Ait Khaled, N; Boulahbal, F; Chaulet, P; Chiheb, M; Khaled, S, 1990) |
"7%]); had similar rates of adverse drug reactions (7." | 2.67 | USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results. ( Combs, DL; Geiter, LJ; O'Brien, RJ, 1990) |
" New data on optimal drug selection and dosing are emerging with the inclusion of children in clinical trials and ongoing research on age-related pharmacokinetics and pharmacodynamics." | 2.66 | Tuberculosis treatment in children: The changing landscape. ( Huynh, J; Marais, BJ; Schaaf, HS; Thwaites, G, 2020) |
"Intracranial tuberculomas are rare yet lethal forms of tuberculosis." | 2.66 | Multiple tuberculomas in an immunocompetent patient and their diagnostic challenge in a high prevalence country: Case report and literature review. ( Alva-Diaz, C; Esteban-Arias, D; López-Saavedra, A; Metcalf, T; Orellana-Tovar, I; Pacheco-Barrios, K; Rodriguez-López, E; Velásquez-Rimachi, V, 2020) |
" The dosage of each drug was very similar whether it was given combined or separately." | 2.66 | Acceptability, compliance, and adverse reactions when isoniazid, rifampin, and pyrazinamide are given as a combined formulation or separately during three-times-weekly antituberculosis chemotherapy. ( , 1989) |
"Patients with pulmonary tuberculosis who were failures of primary chemotherapy with strains resistant to isoniazid or to isoniazid and streptomycin were allocated at random to receive a regimen of rifampicin and ethambutol for 6 (4RE) or 9 months (7RE), supplemented in both treatment series by streptomycin plus pyrazinamide for the first 2 months." | 2.66 | Controlled clinical trial of a regimen of two durations for the treatment of isoniazid resistant pulmonary tuberculosis. ( Aluoch, JA; Babu Swai, O; Darbyshire, JH; Edwards, EA; Githui, WA; Nunn, AJ; Thiong'o, R, 1988) |
"To measure the effectiveness of treatment for pulmonary tuberculosis in Peru we evaluated the fate of 2,669 patients who had tuberculosis diagnosed in 1981." | 2.66 | Operational evaluation of treatment for tuberculosis. Results of 8- and 12-month regimens in Peru. ( Baron, RB; Ganter, B; Hopewell, PC; Sanchez-Hernandez, M, 1985) |
" tuberculosis were treated in the initial phase as inpatients for 2-3 months at random with either pyrazinamide (Z) or ethambutol (E) in combination with isoniazid (H) and rifampicin (R)." | 2.66 | [Which is the best drug combination for the short-term therapy of tuberculosis? A prospective randomized study with 190 patients]. ( Bezel, R; Brändli, O; Häcki, M; Karrer, W; Röthlisberger, K; Rubin, S, 1985) |
"When pyrazinamide was omitted in the first 2 months the relapse rates were 18% for the 6-month and 6% for the 8-month series." | 2.65 | Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report. Third East African/British Medical Research Council Study. ( , 1980) |
"A cooperative french trial in the treatment of pulmonary tuberculosis has compared the efficacy and the tolerance of daily antituberculous regimes, one of short duration of 18 weeks (HRSZ/HRZ), the other of standard duration of 9 months (HRE)." | 2.65 | [Short-term chemotherapy of tuberculosis. Cooperative French trial]. ( Pretet, S, 1983) |
"Relapses have occurred in two of 119 SHRZ6 patients, four of 127 EHRZ6 patients and two of 127 EHR9 patients." | 2.65 | A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. British Thoracic Society. ( , 1984) |
" In a controlled study of culture-positive advanced pulmonary tuberculosis we have compared treatment regimens with PZA in a dosage of less than 2 g and with ethambutol (EMB)." | 2.65 | [Pyrazinamide versus ethambutol in short-term therapy of lung tuberculosis. A randomized study]. ( Brändli, O; Fiala, W; Häcki, MA, 1983) |
"Relapse has occurred in 1 of 125 SHRZ6 patients, 3 of 132 EHRZ6, and 2 of 136 EHR9 patients." | 2.65 | A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second report: results during the 24 months after the end of chemotherapy. British Thoracic Association. ( , 1982) |
" It is concluded that the arthralgia was often self-limiting, that aspirin had a small beneficial effect, that allopurinol, in the dosage studied, may have had a slightly deleterious effect, but that it would be worth studying larger dosages of allopurinol because the dosage studied did not affect the serum uric acid concentration." | 2.65 | Double blind controlled comparison of aspirin, allopurinol and placebo in the management of arthralgia during pyrazinamide administration. ( Allan, WG; Fox, W; Girling, DJ; Horsfall, PA; Nunn, AJ; Plummer, J, 1979) |
"All 33 relapses were with strains sensitive to isoniazid and streptomycin, and 76 per cent of them occurred in the first 3 months after the end of chemotherapy." | 2.64 | Controlled trial of 6- and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. ( , 1975) |
" The results confirm that the twice-weekly regimen is highly effective and demonstrate that its efficacy is not influenced by the rate of inactivation of isoniazid or by a reduction (by one-fourth) in the dosage of streptomycin." | 2.63 | A controlled comparison of a twice-weekly and three once-weekly regimens in the initial treatment of pulmonary tuberculosis. ( , 1970) |
"To supplement previous state-of-art reviews on anti-tuberculosis treatment and to pave the way forward with reference to the current status, we systematically reviewed published literature on clinical research on tuberculosis (TB) over the past decade in the treatment of drug-susceptible and multidrug-resistant TB (MDR-TB), with a focus on drugs, dosing factors and regimens." | 2.52 | Clinical research in the treatment of tuberculosis: current status and future prospects. ( Chang, KC; Sotgiu, G; Yew, WW, 2015) |
"This review will introduce pharmacokinetic parameters for key anti-TB drugs, as well as the indications and limitations of measuring these parameters in clinical practice." | 2.50 | Understanding pharmacokinetics to improve tuberculosis treatment outcome. ( Heysell, SK; Reynolds, J, 2014) |
"Pyrazinamide (PZA) is an essential sterilizing drug and with rifampicin enables six-month short-course antituberculosis chemotherapy." | 2.48 | Pyrazinamide pharmacokinetics and efficacy in adults and children. ( Diacon, AH; Donald, PR; Maritz, JS, 2012) |
" The rifamycin activity could be improved by increasing the dose size of rifampicin or by daily dosing with long acting rifapentine." | 2.46 | The near future: improving the activity of rifamycins and pyrazinamide. ( Fourie, PB; Mitchison, DA, 2010) |
"About 97% of patients with pulmonary tuberculosis became bacteriologically quiescent by the 12 months of streptomycin, para-aminosalicylate and isoniazid." | 2.41 | [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients]. ( Wada, M, 2001) |
"Treatment of tuberculosis has three major goals: healing the patient, preventing selection of resistant strains and control transmission of tuberculosis." | 2.40 | [Antitubercular chemotherapy]. ( Dautzenberg, B; Jouveshomme, S, 1997) |
"appearance of a bilateral bacillary pulmonary tuberculosis with a severe involvement of the right lung." | 2.40 | [Sharp syndrome complicating pulmonary tuberculosis: apropos of a case]. ( Ba, O; Cissokho, S; Diatta, A; Dieng, MT; Hane, AA; Kandji, M; Ndiaye, B; Ndiaye, M; Ndir, M; Niang, A, 1999) |
"The here described investigations show correspondingly that the administration of isoniazid, rifampicin and pyrazinamide in a fixed combination of the administration of the individual substances is bioequivalent under pharmacokinetic aspects." | 2.38 | [Pharmacokinetic aspects of tuberculosis therapy with a fixed combination of rifampicin, isoniazide and pyrazinamide]. ( Lode, H; Schaberg, T, 1991) |
"Pyrazinamide is an antituberculosis drug synthesized in the 1950s and formerly used only as salvage therapy." | 2.37 | The role of pyrazinamide in tuberculosis chemotherapy. ( Des Prez, RM; Steele, MA, 1988) |
" Population pharmacokinetic models used plasma and intrapulmonary drug levels at 8 and 16 weeks." | 1.72 | High Intrapulmonary Rifampicin and Isoniazid Concentrations Are Associated With Rapid Sputum Bacillary Clearance in Patients With Pulmonary Tuberculosis. ( Chasweka, M; Chirambo, AP; Chitani, A; Corbett, EL; Davies, GR; Ghany, JF; Gordon, SB; Khoo, SH; Malamba, R; Mallewa, JE; McCallum, AD; Meghji, JZ; Mwandumba, HC; Pertinez, HE; Shani, D; Sheha, I; Sloan, DJ, 2022) |
" The effect of CART-derived thresholds for individualized dosing on treatment outcome should be studied in a randomized controlled trial." | 1.62 | Drug Exposure and Minimum Inhibitory Concentration Predict Pulmonary Tuberculosis Treatment Response. ( Alffenaar, JW; Bao, Z; Bruchfeld, J; Forsman, LD; Gao, Y; Hoffner, S; Hu, Y; Li, X; Ren, W; Zheng, X, 2021) |
"This features mimic Gitelman's syndrome which is an autosomal recessive disorder affecting kidneys causing electrolyte disturbances." | 1.56 | Gitelman-like syndrome: A rare complication of using aminoglycosides in tuberculosis - A case report. ( E R, V; Keny, S; Lawande, D; Parrikar, A, 2020) |
" Blood sampling was also performed 120 minutes after dosing for the detection of Cmax purpose." | 1.56 | Effect of interval between food intake and drug administration at fasting condition on the plasma concentrations of first-line anti-tuberculosis drugs in Chinese population. ( Chu, N; Du, Y; Guo, R; Han, X; Pang, Y; Wang, J; Wang, Q, 2020) |
"There is a need for individualized dosing of isoniazid and rifampicin based on plasma concentration measurements (therapeutic drug monitoring) and for clinical trials on higher doses of these TB drugs in patients with TB and DM." | 1.51 | Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients. ( Aarnoutse, RE; Boeree, MJ; Burger, DM; Colbers, A; Irongo, CF; Kibiki, GS; Mtabho, CM; Semvua, HH; Tostmann, A; van Crevel, R; van den Boogaard, J; van der Ven, AJAM, 2019) |
" Stochastic PK/pharmacodynamic (PD) simulations were carried out to evaluate current regimen combinations and dosing guidelines in distinct patient strata." | 1.51 | Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization. ( Bang, H; Barry, CE; Dartois, V; Eum, S; Fox, WS; Gupta, SV; Lee, M; Savic, RM; Shim, T; Strydom, N; Via, LE; Zimmerman, M, 2019) |
"Treatment of isoniazid, rifampicin, pyrazinamide with the diagnosis of epituberculosis was started by taking a sample of gastric aspirate culture sample." | 1.48 | [Management and treatment difficulties of multi-drug resistant pulmonary tuberculosis in a pediatric case]. ( Acar, EM; Bayramoğlu, Z; Çalışkan, E; Erköse, G; Hançerli Törün, S; Kılıçaslan, Z; Şatana, D; Somer, A, 2018) |
"Ulcerative skin tuberculosis (TB) is a rare form of extrapulmonary TB." | 1.48 | Perianal ulcerative skin tuberculosis: A case report. ( Chen, H; Song, X; Wang, W; Wu, S; Xiong, W; Yu, X, 2018) |
"Pyrazinamide (PZA) is a critical component of current first-line TB therapy." | 1.48 | Efficacy of pyrazinoic acid dry powder aerosols in resolving necrotic and non-necrotic granulomas in a guinea pig model of tuberculosis. ( Braunstein, M; Durham, PG; Hayden, JD; Hickey, AJ; Lin, FC; Miller, BK; Montgomery, SA; Rank, L; Welch, JT; Young, EF; Zulauf, KE, 2018) |
" Pyrazinamide pharmacokinetic (PK) data from 61 HIV/TB-coinfected patients in South Africa were used in the analysis." | 1.46 | Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis. ( Chirehwa, MT; Denti, P; McIlleron, H; Mthiyane, T; Onyebujoh, P; Rustomjee, R; Smith, P, 2017) |
"Upon diagnosis, Pulmonary Tuberculosis patients are treated for TB for a period of 6-9 months." | 1.46 | Serum levels of soluble urokinase plasminogen activator receptor (suPAR) as a marker of tuberculosis treatment efficacy. ( Indumati, V; Krishnaswamy, D; Rajeshwari, V; Ramesh, A; Shantala, D; Shilpa, A; Vijay, V, 2017) |
" As irrational use and inadequate dosing of anti-TB drugs may contribute to the epidemic of drug-resistant TB, we assessed the drug types and dosages prescribed in the treatment of TB cases in a representative sample of health care facilities in Yunnan." | 1.46 | Prescription practice of anti-tuberculosis drugs in Yunnan, China: A clinical audit. ( Chen, J; Chiang, CY; Innes, AL; Li, L; Xu, L, 2017) |
"The currently preferred regimen for treatment of pulmonary tuberculosis (PTB) is isoniazid, rifampin, pyrazinamide, and ethambutol, which has been used either as separate tablets (ST) or as fixed-dose combination (FDC)." | 1.46 | Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar. ( Al-Shaer, MH; Elewa, H; Iqbal, F; Mansour, H; Salameh, P, 2017) |
"If isoniazid Cmax was <4." | 1.46 | Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis. ( Denti, P; Gumbo, T; Lesosky, M; McIlleron, H; Meintjes, G; Pasipanodya, JG; Rockwood, N; Sirgel, F; Wilkinson, RJ, 2017) |
"Seventeen (4." | 1.43 | Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome. ( Cho, YJ; Kim, SJ; Lee, CT; Lee, JH; Lee, JY; Lee, YJ; Park, JS; Song, J; Yoon, HI, 2016) |
"Pyrazinamide (PZA) is a key sterilizing drug in first-line tuberculosis (TB) regimens and exerts its activity entirely during the first 2 months in human infections." | 1.43 | Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis. ( Betoudji, F; Lanoix, JP; Nuermberger, E, 2016) |
"Pyrazinamide (PZA) is an important first-line anti-tuberculosis drug, however, there are relatively few available data on PZA resistant (PZA-R) rate in China." | 1.43 | Prevalence and transmission of pyrazinamide resistant Mycobacterium tuberculosis in China. ( Gao, Q; Gicquel, B; Luo, T; Nsofor, CA; Shen, X; Wu, J; Xu, P; Yang, C; Zhang, Y; Zhu, G, 2016) |
"A population-based multicenter study of pulmonary tuberculosis (TB) cases was carried out from 2011 to 2013 in four Chinese districts/counties with different geographic and socioeconomic features." | 1.43 | Multicenter Study of the Emergence and Genetic Characteristics of Pyrazinamide-Resistant Tuberculosis in China. ( Drobniewski, F; Hoffner, S; Hu, Y; Li, D; Mansjö, M; Werngren, J; Xu, B; Zheng, X, 2016) |
"Pyrazinamide resistance was assessed in 4972 patients." | 1.43 | Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. ( Alikhanova, N; Andres, S; Cabibbe, AM; Cirillo, DM; Dadu, A; Dean, AS; Dreyer, A; Driesen, M; Floyd, K; Gilpin, C; Hasan, R; Hasan, Z; Hoffner, S; Husain, A; Hussain, A; Ismail, N; Kamal, M; Kimerling, M; Mansjö, M; Mukadi, YD; Mvusi, L; Niemann, S; Omar, SV; Qadeer, E; Raviglione, MC; Rigouts, L; Ruesch-Gerdes, S; Schito, M; Seyfaddinova, M; Skrahina, A; Tahseen, S; Wells, WA; Weyer, K; Zignol, M, 2016) |
" One hundred patients with pulmonary tuberculosis (65% coinfected with HIV-1) were intensively sampled to determine rifampin, isoniazid, and pyrazinamide plasma concentrations after 7 to 8 weeks of a daily quadruple-therapy regimen dosed according to World Health Organization (WHO) weight bands." | 1.43 | HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients. ( Chirehwa, M; Denti, P; McIlleron, H; Meintjes, G; Rockwood, N; Wiesner, L; Wilkinson, RJ, 2016) |
"Pirfenidone is a recently approved antifibrotic drug for the treatment of idiopathic pulmonary fibrosis (IPF)." | 1.43 | The antifibrotic drug pirfenidone promotes pulmonary cavitation and drug resistance in a mouse model of chronic tuberculosis. ( Ahidjo, BA; Andrade, BB; Beck, S; Bishai, WR; Cheung, LS; Ihms, EA; Jain, S; Maiga, M; Maiga, MC; Ordonez, AA, 2016) |
"Anti-tuberculosis drug-induced hepatotoxicity (ATDH) is a serious adverse reaction to anti-tuberculosis (TB) treatment." | 1.43 | Association between TXNRD1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a prospective study. ( He, JQ; Ji, GY; Liu, QQ; Sandford, AJ; Wang, Y; Wu, JC; Wu, SQ; Zhang, MM, 2016) |
"33 patients with pulmonary tuberculosis were treated with one Risorine kit, daily consisting of one capsule of Risorine, one tablet of ethambutol (800 mg) and two tablets of Pyrazinamide 750 mg each, for first two months of therapy." | 1.43 | Role of Risorine in the Treatment of Drug - Susceptible Pulmonary Tuberculosis: A Pilot Study. ( Patel, K; Patel, S; Vora, A, 2016) |
"The available pharmacokinetic data on anti-tubercular drugs in children raises the concern of suboptimal plasma concentrations attained when doses extrapolated from adult studies are used." | 1.42 | Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children. ( Kabra, SK; Kanhiya, K; Lodha, R; Mukherjee, A; Singla, M; Velpandian, T, 2015) |
"Rosacea is a common chronic inflammatory cutaneous disease of unknown etiology, characterized by remissions and exacerbations, presenting with centrofacial erythema and telangiectasias." | 1.42 | Pyridoxine induced rosacea-like dermatitis. ( Mokos, ZB; Paštar, Z; Rezaković, S, 2015) |
"Pyrazinamide (PZA) is an important first-line anti-tuberculosis drug that is generally administered with isoniazid, rifampicin, ethambutol and streptomycin." | 1.40 | Characterisation of pyrazinamide-resistant Mycobacterium tuberculosis strains isolated in Poland and Germany. ( Augustynowicz-Kopeć, E; Hillemann, D; Napiórkowska, A; Richter, E; Rüsch-Gerdes, S, 2014) |
" In this study, we sought to investigate the sterilizing activity of human-equivalent doses of thioridazine when given in combination with the "Denver regimen" against acute murine tuberculosis." | 1.40 | Sterilizing activity of thioridazine in combination with the first-line regimen against acute murine tuberculosis. ( Dutta, NK; Karakousis, PC; Pinn, ML, 2014) |
"Seventy-five male patients with pulmonary tuberculosis (mean age, 40." | 1.40 | Association of serum levels of iron, copper, and zinc, and inflammatory markers with bacteriological sputum conversion during tuberculosis treatment. ( de Melo Guedes de Oliveira, HM; de Oliveira, MM; Delogo, KN; Dos Anjos, MJ; Kritski, AL; Mesquita, ED; Miranda, PF; Moraes, ML; Netto, AR; Ramalho, DM, 2014) |
"Gastrointestinal events, hepatitis, hearing impairment, arthralgia, psychosis, hypothyroidism, visual disturbances, giddiness, peripheral neuropathy, skin reactions, swelling or pain at injection site, anorexia and sleep disturbances were important amongst these." | 1.40 | Profile of adverse drug reactions in drug resistant tuberculosis from Punjab. ( Bharti, H; Bhushan, B; Chander, R; Gupta, A; Kajal, NC; Ranga, V, 2014) |
" We therefore determined the pharmacokinetic characteristics of first-line TB drugs in Tanzanian patients using intensive pharmacokinetic sampling." | 1.39 | Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients. ( Aarnoutse, RE; Boeree, MJ; Kibiki, GS; Mtabho, CM; Semvua, HH; Tostmann, A; van den Boogaard, J, 2013) |
"[Methods] Thirty-six patients with pulmonary tuberculosis, who were admitted to Yokohama City University Hospital between June 2011 and March 2012 were included." | 1.39 | [Comparison of drug-induced hepatitis occurring in elderly and younger patients during anti-tuberculosis treatment with a regimen including pyrazinamide]. ( Horita, N; Ishigatsubo, Y; Miyazawa, N; Sasaki, M; Takahashi, R; Tomaru, K; Tsukahara, T, 2013) |
"The isoniazid C2 h was noticeably lower in fast versus slow acetylators (0." | 1.39 | Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients. ( Aarnoutse, R; Ascobat, P; Burhan, E; Donders, R; Ginanjar, A; Mangunnegoro, H; Ruesen, C; Ruslami, R; van Crevel, R, 2013) |
" Serum concentration-time profiles, maximum serum concentrations, time to achieve maximum serum concentrations, the half-life and the areas under the serum concentration-time curve for each of the four drugs were determined." | 1.39 | Pharmacokinetics and serum concentrations of antimycobacterial drugs in adult Turkish patients. ( Arpag, H; Babalık, A; Bakirci, N; Çarpaner, E; Dagyildiz, L; Kuyucu, T; Ulus, IH, 2013) |
"The study was performed among 60 pulmonary tuberculosis (TB) in-patients at a tertiary care university-affiliated hospital in Tehran, Iran." | 1.39 | Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis. ( Bozorg, BD; Dastan, F; Emami, S; Fahimi, F; Goodarzi, A; Habibi, M; Kobarfard, F; Salamzadeh, J; Shahsavari, N; Tabarsi, P, 2013) |
" This is despite the availability of antibiotics that have good activity against Mycobacterium tuberculosis in vitro and favorable pharmacokinetic profiles in plasma." | 1.38 | Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. ( Barry, CE; Dartois, V; Goh, A; Kern, S; Kjellsson, MC; Low, KM; Pillai, G; Via, LE; Weiner, D, 2012) |
"Pyrazinamide (PZA) is an important drug in the treatment of tuberculosis." | 1.38 | A new approach for pyrazinamide susceptibility testing in Mycobacterium tuberculosis. ( Cotrina, M; Fuentes, P; Gilman, RH; Gutierrez, A; Kirwan, D; Loli, S; Sheen, P; Zimic, M, 2012) |
"Pyrazinamide was omitted in 15 cases while rifampicin only in one patient." | 1.38 | Management of and risk factors related to hepatotoxicity during tuberculosis treatment. ( Ağca, S; Arda, H; Babalık, A; Bakırcı, N; Calışır, HC; Cetintaş, G; Kızıltaş, S; Oruç, K, 2012) |
"Rifampin-treated BALB/c mice remained culture positive at 3 months." | 1.37 | Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. ( Ahmad, Z; Almeida, DV; Converse, PJ; Grosset, JH; Li, SY; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Zhang, M, 2011) |
"Paragonimiasis is a food-borne zoonosis caused by a trematode of the genus Paragonimus(1,2)." | 1.37 | [Pulmonary paragonimiasis]. ( Fortes-Alen, J; Gómez-Escolar, PF; Gómez-Seco, J; Presa-Abos, T; Rodríguez-Guzmán, MJ; Rodríguez-Nieto, MJ, 2011) |
"Thirteen patients with pulmonary tuberculosis detected." | 1.37 | Pulmonary tuberculosis in infants less than one year old: implications for early diagnosis. ( Bayhan, GI; Ekşioğlu, AS; Kitiş Çelik, B; Tanır, G, 2011) |
"The frequency of late recurrences following treatment completion has not been well-studied." | 1.37 | When tuberculosis comes back: who develops recurrent tuberculosis in california? ( Deriemer, K; Flood, JM; Pascopella, L; Watt, JP, 2011) |
" Intensive pharmacokinetic sampling was performed for rifampin, pyrazinamide, and ethambutol at steady state." | 1.36 | Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. ( Aarnoutse, RE; Adhiarta, IG; Alisjahbana, B; Kariadi, SH; Nijland, HM; Ruslami, R; van Crevel, R, 2010) |
"Pyrazinamide sensitivity was carried out using the BACTEC 7H12 medium." | 1.36 | Drug resistance pattern in multidrug resistance pulmonary tuberculosis patients. ( Irfan, M; Mehfooz, Z; Rao, NA; Soomro, MM, 2010) |
"Pyrazinamide (PZA) is an important first-line antituberculous drug, which is applied together with INH, RMP, EMB and SM." | 1.36 | [Phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis isolated in Poland]. ( Augustynowicz-Kopeć, E; Napiórkowska, A; Zwolska, Z, 2010) |
"Metronidazole treatment (for 6 weeks at 100 mg/kg of body weight) resulted in no reduction in the bacillary burden and significantly worsened lesion inflammation." | 1.35 | Metronidazole lacks antibacterial activity in guinea pigs infected with Mycobacterium tuberculosis. ( Basaraba, RJ; Brooks, EJ; Caraway, ML; Driver, ER; Hoff, DR; Lenaerts, AJ; Orme, IM; Peloquin, CA; Ryan, GJ, 2008) |
"Pyrazinamide was the most sensitive drug i." | 1.35 | Primary drug resistance against Mycobacterium tuberculosis in Karachi. ( Hussain, SJ; Irfan, M; Rao, NA, 2008) |
"Treatment with rifampin and pyrazinamide was more effective than treatment with rifampin, isoniazid, and pyrazinamide at reducing the lung CFU count, consistent with past evidence of isoniazid's antagonism in this model." | 1.35 | Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. ( Grosset, J; Nuermberger, E; Tasneen, R; Tyagi, S; Williams, K, 2008) |
"Pyrazinamide is an antituberculous drug that is administered as a two-month course during treatment of pulmonary tuberculosis." | 1.35 | Epidemiological survey of hyperuricemia as an adverse reaction to antituberculous therapy with pyrazinamide. ( Murakami, T; Nikai, T; Ogawa, K; Taki, H, 2008) |
"tuberculosis isolates from pulmonary tuberculosis patients." | 1.35 | Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. ( Fourie, PB; Grewal, HM; Mannsåker, T; Mphahlele, M; Muthivhi, T; Stavrum, R; Syre, H; Valvatne, H; Weyer, K, 2008) |
"Temozolomide (TMZ) is a cytotoxic agent of the imidazotetrazine class, chemically related to dacarbazine." | 1.35 | Tuberculosis in a patient on temozolomide: a case report. ( de Barros e Silva, MJ; de Paiva, TF; Fanelli, MF; Gimenes, DL; Rinck, JA, 2009) |
"The isoniazid was discontinued, and the gynecomastia was partially resolved by the end of treatment." | 1.35 | Gynecomastia: a rare adverse effect of isoniazid. ( Braz, AG; Maia, JA; Morrone Junior, N; Morrone, N, 2008) |
" Therefore, lowering of pyrazinamide dosage is suggested in children for better patient compliance along with reduction in cost, side-effects and toxicity without compromising its efficacy." | 1.35 | Pharmacokinetics of pyrazinamide in children with primary progressive disease of lungs. ( Arya, DS; Nandave, M; Ojha, SK; Semwal, OP, 2008) |
" Therapy was performed according to regimens 3 and 1, by using individual dosage regimens depending on the extent and severity of a specific process, the presence of complications, and age-related features." | 1.35 | [Optimization of chemotherapy regimens in children with primary pulmonary tuberculosis]. ( Dovgaliuk, IF; Ovchinnikova, IuE; Starshinova, AA, 2009) |
"Isoniazid was stopped and patient was continued on R & E till completion of the treatment up to nine months." | 1.35 | Isoniazid induced gynaecomastia: a case report. ( Garg, R; Mehra, S; Prasad, R, 2009) |
"In previous studies, the diarylquinoline R207910 (also known as TMC207) was demonstrated to have high bactericidal activity when combined with first- or second-line antituberculous drugs." | 1.34 | Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. ( Andries, K; Chauffour, A; Ibrahim, M; Jarlier, V; Lounis, N; Truffot-Pernot, C; Veziris, N, 2007) |
"He was diagnosed as pulmonary tuberculosis, and started treatment with INH, RFP, EB, and PZA." | 1.34 | [A case of tuberculosis showing immune reconstitution syndrome after the initiation of antiretroviral therapy for HIV infection]. ( Izumi, S; Taniguchi, H, 2007) |
"A 65-year-old woman developed a confusional syndrome one week after starting treatment for pulmonary military tuberculosis." | 1.34 | [Aseptic cerebral venous thrombosis and multiple cerebral tuberculomas associated with pulmonary miliary tuberculosis]. ( Amara, B; Belahsen, MF; Benjelloun, FZ; Benjelloun, MC; Messouak, O; Tizniti, S, 2007) |
"Types and frequency of drug-related adverse events and outcomes of treatment." | 1.33 | Adverse events and treatment completion for latent tuberculosis in jail inmates and homeless persons. ( Bock, NN; Grabau, JC; Jasmer, RM; Lobato, MN; Reves, RR; Shang, N, 2005) |
"89 microg/mL) and area under concentration curve (AUC) was 30% of the values observed under fasting conditions." | 1.33 | Population pharmacokinetics of pyrazinamide in elephants. ( Dunker, F; Isaza, R; Maslow, JN; Mikota, SK; Peloquin, CA; Riddle, H; Zhu, M, 2005) |
"MDR-TB can be successfully treated during pregnancy by using a regimen including effective second-line anti-tuberculosis drugs." | 1.33 | [Treatment outcome of patients with multidrug-resistant pulmonary tuberculosis during pregnancy]. ( Ano, H; Danno, K; Han, Y; Kawahara, K; Matsumoto, T; Nagai, T; Takashima, T; Tamura, Y; Tsuyuguchi, I; Yoshida, H, 2006) |
"All cases had evidence of pulmonary tuberculosis." | 1.33 | Ocular tuberculosis in acquired immunodeficiency syndrome. ( Babu, RB; Biswas, J; Kumarasamy, N; Sudharshan, S; Therese, L, 2006) |
"Major adverse reactions to antituberculosis drugs can cause significant morbidity, and compromise treatment regimens for tuberculosis (TB)." | 1.32 | Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. ( Menzies, D; Parisien, I; Pelletier, M; Rocher, I; Valiquette, C; Yee, D, 2003) |
"A healthy 57 year-old woman with past untreated pulmonary tuberculosis, disclosed a bilateral uveitic syndrome characte rized by iritis, vitreitis, multiple peripheral retinal punched-out lesions, and cystoid macular edema." | 1.32 | [Tuberculous peripheral multifocal choroiditis]. ( González Guijarro, J; Pérez Alvarez, MJ; Santos Gil, I, 2003) |
"In total, 45 children with pulmonary tuberculosis participated." | 1.32 | Follow-up of compliance with tuberculosis treatment in children: monitoring by urine tests. ( Gultekin, D; Kayaalp, N; Palanduz, A, 2003) |
" Relative bioavailability of encapsulated drugs was greater than that of free drugs." | 1.32 | Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis. ( Khuller, GK; Sharma, S; Ul-Ain, Q, 2003) |
"All 44 non-private hospitals in Malawi treating pulmonary tuberculosis (PTB) patients with an oral regimen (0." | 1.32 | Prescriptions and dosages of anti-tuberculosis drugs in the National Tuberculosis Control Programme of Malawi. ( Gausi, F; Harries, AD; Salaniponi, FM, 2004) |
"A hundred new cases of active pulmonary tuberculosis whose age was 60 to 87 years were treated by the intensive chemotherapy regimen recommended by the WHO." | 1.32 | [Efficiency of an intensive stage of chemotherapy for tuberculosis in elderly and senile patients]. ( Karachunskiĭ, MA; Uvarova, TE, 2004) |
" Severe adverse reactions included rash (two), toxic hepatitis (six), Immune Reconstitution Syndrome (seven), and four deaths." | 1.32 | Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis. ( Alves, CR; Badaro, R; Brites, C; Netto, EM; Oliveira, AS; Pedral-Sampaio, DB, 2004) |
"A case of Pulmonary Alveolar Proteinosis (PAP), in association with tuberculosis, is described in a 35-year-old diabetic patient." | 1.31 | Pulmonary alveolar proteinosis and tuberculosis in a diabetic patient: a rare or a seldom diagnosed association? ( Coelho JC, JC; Marinho, MM; Pereira-Silva, JL; Veloso, TV, 2002) |
"Lupus vulgaris is the most common cutaneous manifestation of tuberculosis in industrialised countries, but nevertheless it remains rare and it is a very unusual presenting feature of underlying pulmonary tuberculosis." | 1.31 | [Pulmonary tuberculosis presenting as tubercular lupus]. ( Barbaud, A; Fays, S; Martin, S; Schmutz, JL, 2002) |
"Intracranial tuberculomas are a rare manifestation of neurotuberculosis and are due to hematogenous dissemination of distant focuses of Mycobacterium tuberculosis infection." | 1.31 | [Intracranial tuberculomas developing during treatment of pulmonary tuberculosis: case report]. ( Alves, SM; Belo Neto, E; Brandão, RZ; Novis, SA; Pimentel, ML, 2000) |
"Hyponatremia is seen in 40% to 60% of hospitalized acquired immune deficiency syndrome (AIDS) patients." | 1.31 | Normouricemia in the syndrome of inappropriate antidiuretic hormone secretion. ( Akalin, E; Chandrakantan, A; Hamburger, RJ; Keane, J, 2001) |
"Pyrazinamide was not used in the intensive phase in the control group (n = 73)." | 1.31 | [Effectiveness of chemotherapy of intrathoracic tuberculosis in children: late follow-up data]. ( Iukhimenko, NV, 2001) |
"Pericardial effusion was shown by echocardiography and subsequently removed by pericardiocentesis." | 1.31 | Tuberculous pericarditis in an infant evolving during triple chemotherapy. ( Bettendorf, M; Meyburg, J; Nützenadel, W; Schmidt, KG, 2002) |
"Pyrazinamide (PZA) is a first-line drug for short-course tuberculosis therapy." | 1.30 | Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. ( Cynamon, M; Gilman, R; Heifets, L; Lindholm-Levy, P; Scorpio, A; Siddiqi, S; Zhang, Y, 1997) |
"The re-treatment pulmonary tuberculosis with positive spits represent 13." | 1.30 | [The results of retreatment of pulmonary tuberculosis using a short 6-month protocol 1985-1991 in the pneumo-phthisiology department of the Point G hospital in Bamako]. ( Kayantao, D; Keïta, B; Sangaré, S, 1997) |
"Two patients with multidrug-resistant pulmonary tuberculosis were surgically treated after 3 and 7 years of unsuccessful chemotherapy." | 1.30 | [Surgical treatment of patients with multi-resistant pulmonary tuberculosis--case reports]. ( Kuś, J; Michałowska-Mitczuk, D, 1997) |
"Although relapse was more frequent in patients with positive smears than those with negative smears (9." | 1.30 | Should we take a history of prior treatment, and check sputum status at 2-3 months when treating patients for tuberculosis? ( Bechan, S; Connolly, C; Short, GM; Standing, E; Wilkinson, D, 1998) |
"Pyrazinamide, which was readministered last (at the full dose in one case and at progressive doses in the two others), induced a recurrence in two of them." | 1.30 | [Eruption after the 1st dose of standard antitubercular chemotherapy. Thoughts on pyrazinamide]. ( Autret, E; Carré, P; Jonville-Bera, AP; Lemarié, E; Radal, M; Van-Egroo, C, 1998) |
"The management of pulmonary tuberculosis (TB) in Scotland in 1993 was studied by asking the physicians responsible for all 321 adult cases of the disease notified that year to complete a standardized questionnaire relating to drug treatment and bacteriology." | 1.30 | The management of pulmonary tuberculosis in adults notified in Scotland in 1993. ( Heald, SH; Leitch, AG; Simpson, AJ; Sudlow, MF; Watt, B, 1998) |
"Pyrazinamide, which was re-administered last, induced a recurrence." | 1.30 | -Skin eruption after the first dose of antitubercular quadri-therapy: consideration of pyrazinamide-. ( Autret, E; Jonville-Béra, AP; Martel, C; Mazaud, S; Olivier, C; Radal, M, 1998) |
"Out of 1128 new pulmonary tuberculosis patients, six-hundred twenty started treatment with six-month (2HRZS or E/4HRE) in Fukujuji Hospital, JATA, in Tokyo from January 1991 to December 1996." | 1.30 | [Six-months chemotherapy (2HRZS or E/4HRE) of new cases of pulmonary tuberculosis--six year experiences on its effectiveness, toxicity, and acceptability]. ( Ito, K; Mizutani, S; Ogata, H; Sugita, H; Wada, M; Yoshiyama, T, 1999) |
"Seventy-seven patients had pulmonary tuberculosis, 23 extrapulmonary and three had both." | 1.30 | The spectrum of mycobacterial disease in a Dublin teaching hospital. ( McDonnell, T; O'Reilly, P, 1999) |
"Isoniazid resistance was more likely in HIV seronegative patients with M." | 1.30 | Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda. ( Borgdorff, MW; Bretzel, G; Bwire, R; Kawuma, HJ; Rieder, HL; Rüsch-Gerdes, S; Sticht-Groh, V, 1999) |
"The frequency of chromosomal aberrations and sister-chromatid exchanges (SCEs) did not show any statistically significant differences in the patients before treatment and after exposure to combined HRZ therapy as compared to controls (p > 0." | 1.29 | Cytogenetic study of tuberculosis patients before and after tuberculostatic drug treatment. ( Ekmekçi, A; Sayli, A, 1995) |
"Fourteen (30%) infants had extrapulmonary tuberculosis (11 central nervous system disease, 2 disseminated disease, and 1 cervical adenitis)." | 1.29 | Clinical features, diagnosis, and treatment of tuberculosis in infants. ( Ong, LT; Starke, JR; Vallejo, JG, 1994) |
"There are few reports of children with AIDS and TB." | 1.29 | Clinical manifestation and outcome of tuberculosis in children with acquired immunodeficiency syndrome. ( Birnbaum, J; Chan, SP; Rao, M; Steiner, P, 1996) |
"Patients with cavitating pulmonary tuberculosis continue to excrete viable tubercle bacilli for approximately 6 weeks despite supervised treatment." | 1.29 | The duration of excretion of viable bacilli in elderly patients on treatment for cavitating pulmonary tuberculosis. ( Morris, CD, 1996) |
"They are enlarged in acute pulmonary tuberculosis." | 1.29 | Changes in the size of adrenal glands in acute pulmonary tuberculosis with therapy. ( Durak, AC; Gülmez, I; Keleştimur, F; Ozesmi, M, 1996) |
"1,350 smear positive pulmonary tuberculosis cases in the ten research pilot counties of Liaoning province from 1992 to 1993 were selected to receive short-course intermittent chemotherapies under full-course supervision." | 1.29 | [Analysis of short-term effects of short-course intermittent chemotherapies of the World Bank Loaned Project]. ( Su, Y; Wen, S; Zhang, F, 1996) |
"Twenty-nine patients with extensive pulmonary tuberculosis and drug-induced hepatitis were treated with ofloxacin along with other relatively non-hepatotoxic drugs, either during the interim phase to await recovery of liver function in some, or as definitive therapy as required by the compromised hepatic status of others." | 1.28 | Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in presence of hepatic dysfunction. ( Kwan, SY; Lee, J; Wong, PC; Yew, WW, 1992) |
"Patients with direct smear positive pulmonary tuberculosis were admitted to hospital during the initial phase of treatment for two months." | 1.28 | Fixed dose combination short course chemotherapy in the treatment of pulmonary tuberculosis. ( Abdi, A; Lema, E; Roscigno, G; Wolde, K, 1992) |
"Pyrazinamide (PZN) was administered to 10 patients of pulmonary tuberculosis (for 7 consecutive days) each day after an overnight fast." | 1.28 | Effect of simultaneous isoniazid administration on pharmacokinetic parameters of pyrazinamide. ( Singhal, KC; Varshney, MK, 1991) |
"Forty-one of our patients had pulmonary tuberculosis, 38 had extra pulmonary and in 61 it was disseminated." | 1.28 | AIDS and tuberculosis in Spain. A report of 140 cases. ( Adrados, M; Díaz, F; García Aguado, C; González Lahoz, JM; Laguna, F; Martínez, R; Puente, S, 1991) |
"Seven patients received no treatment because tuberculosis was first diagnosed after death." | 1.28 | Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. ( Chaisson, RE; Goodman, PC; Hopewell, PC; Sande, MA; Schecter, GF; Small, PM, 1991) |
"Pyrazinamide was prescribed to 80%, which represents a substantial increase on the 19% recorded in a similar survey of patients notified in 1983." | 1.28 | The management of pulmonary tuberculosis in adults notified in England and Wales in 1988. The British Thoracic Society Research Committee and the Medical Research Council Cardiothoracic Epidemiology Group. ( , 1991) |
"0, 12 experimental groups, each containing 10 mice, were treated for 8 weeks with pyrazinamide (PZA) given in mean daily dosages of 100, 200 or 400 mg/kg/day, with the interval between the doses within each dosage group being 1, 2, 4 or 8 days." | 1.28 | Efficacy of intermittent pyrazinamide in experimental murine tuberculosis. ( Dickinson, JM; Mitchison, DA, 1991) |
" Elderly patients are more sensitive to antituberculous (anti-TB) drugs; therefore, a modification in the dosage for this patient group should be considered." | 1.28 | The disposition of antituberculous drugs in plasma of elderly patients. II. Isoniazid, rifampicin and pyrazinamide. ( Chan, HS; Chan, K; Walubo, A; Wong, CL; Woo, J, 1991) |
"In Zimbabwe patients with pulmonary tuberculosis who are acid-fast bacilli (AFB) negative in the sputum are treated in the two month intensive phase with isoniazid, thiacetazone pyrazinamide and streptomycin (regimen A)." | 1.28 | Effects of two pulmonary tuberculosis drug treatments and acetylator status on liver function in a Zimbabwean population. ( Kusema, T; Mhonda, M; Neill, P; Nhachi, CF; Pringle, D, 1990) |
"No relapse was noted among patients with extrapulmonary tuberculosis." | 1.28 | [Treatment of tuberculosis. Drug combinations, therapeutic problems and results in a 10-year case load]. ( Morland, L, 1990) |
"We investigated the pharmacokinetic interaction of RMP (administered from the first day of treatment onwards), PZA (given from the second day onwards), and INH (day 17 onwards) in ten, previously untreated patients with pulmonary tuberculosis (five slow acetylators and five fast acetylators)." | 1.28 | [Clinico-pharmacokinetic interactions of rifampicin, pyrazinamide and isoniazide]. ( Loos, U; Musch, E; Schwabe, HK, 1990) |
"Pyrazinamide therapy has been associated with dose-dependent hepatotoxicity, hyperuricaemia, arthralgia and arthritis." | 1.28 | Tubulointerstitial nephritis associated with pyrazinamide. ( Kauffmann, RH; Sanwikarja, S; Serlie, J; te Velde, J, 1989) |
"The good results gotten employing short-term (6 months) medication regimes with rifampin, isoniazid and an initial supplement (2 months) of streptomycin and pyrazinamide, gave an impulse to pharmacodynamic research." | 1.27 | [Pharmacokinetics of antitubercular agents in man]. ( Acocella, G, 1984) |
" The therapeutic advantage of using these two drugs in combination should be more readily appreciated." | 1.27 | A comparative evaluation of drug combinations used in the treatment of pulmonary tuberculosis. ( Miller, SD, 1983) |
" Bioavailability of pyrazinamide was only slightly increased in patients, its dialysis extraction coefficient being 55." | 1.27 | Pyrazinamide and pyrazinoic acid pharmacokinetics in patients with chronic renal failure. ( Farinotti, R; Fessi, H; Kenouch, S; Méry, JP; Montes, C; Stamatakis, G; Trouvin, JH, 1988) |
"Due to these findings systemic lupus erythematosus (SLE) was suspected." | 1.27 | [Tuberculostatics-induced systemic lupus erythematosus]. ( Engelhard, M; Layer, P, 1986) |
" Minor adverse reactions occurred with similar frequencies during daily (5%) and intermittent (5%) treatment but in no case was modification of rifampicin dosage required." | 1.27 | Safety of thrice-weekly rifampicin for tuberculosis in South-East Asian refugees. ( McKenzie, DK; Mukerjee, CM, 1985) |
"The adverse effects of drugs which caused changes in therapeutic regimens have been studied in 511 patients with pulmonary tuberculosis, at the Pavilion Koch of Buenos Aires University." | 1.26 | Adverse effects of antituberculosis drugs causing changes in treatment. ( Dambrosi, A; Dambrosi, VM; Gonzalez Montaner, LJ; Manassero, M, 1982) |
"Pyrazinamide was found to be capable of significantly inducing amino-levulinic acid synthetase activity; the other antituberculous drugs caused either slight or no induction of amino-levulinic acid synthetase." | 1.26 | Exacerbation of porphyria during treatment of pulmonary tuberculosis. ( Magnussen, CR; Patterson, JR; Treece, GL; Tschudy, DP, 1976) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 481 (45.59) | 18.7374 |
1990's | 168 (15.92) | 18.2507 |
2000's | 165 (15.64) | 29.6817 |
2010's | 208 (19.72) | 24.3611 |
2020's | 33 (3.13) | 2.80 |
Authors | Studies |
---|---|
Ibrahim, M | 2 |
Andries, K | 3 |
Lounis, N | 2 |
Chauffour, A | 1 |
Truffot-Pernot, C | 3 |
Jarlier, V | 2 |
Veziris, N | 2 |
Ruslami, R | 5 |
Nijland, HM | 2 |
Alisjahbana, B | 2 |
Parwati, I | 1 |
van Crevel, R | 5 |
Aarnoutse, RE | 7 |
Hoff, DR | 1 |
Caraway, ML | 2 |
Brooks, EJ | 1 |
Driver, ER | 1 |
Ryan, GJ | 1 |
Peloquin, CA | 13 |
Orme, IM | 3 |
Basaraba, RJ | 2 |
Lenaerts, AJ | 3 |
Adhiarta, IG | 1 |
Kariadi, SH | 1 |
Rullas, J | 1 |
García, JI | 1 |
Beltrán, M | 1 |
Cardona, PJ | 1 |
Cáceres, N | 1 |
García-Bustos, JF | 1 |
Angulo-Barturen, I | 1 |
Shaikh, A | 1 |
Sriraman, K | 1 |
Vaswani, S | 1 |
Oswal, V | 1 |
Rao, S | 1 |
Mistry, N | 1 |
Kim, JS | 2 |
Kim, YH | 3 |
Lee, SH | 4 |
Kim, JW | 1 |
Kang, JY | 1 |
Kim, SK | 1 |
Kim, SJ | 7 |
Kang, YS | 1 |
Kim, TH | 1 |
Mok, J | 3 |
Byun, MK | 1 |
Park, HJ | 1 |
Joh, JS | 2 |
Park, YB | 1 |
Lim, HS | 1 |
Choi, H | 1 |
Kim, H | 4 |
Yang, J | 1 |
Shen, X | 2 |
Alsultan, A | 2 |
Cho, I | 1 |
Geiter, L | 2 |
Shim, TS | 3 |
Carr, W | 1 |
Kurbatova, E | 1 |
Starks, A | 1 |
Goswami, N | 1 |
Allen, L | 1 |
Winston, C | 1 |
McCallum, AD | 1 |
Pertinez, HE | 1 |
Chirambo, AP | 1 |
Sheha, I | 1 |
Chasweka, M | 1 |
Malamba, R | 1 |
Shani, D | 1 |
Chitani, A | 1 |
Mallewa, JE | 1 |
Meghji, JZ | 1 |
Ghany, JF | 1 |
Corbett, EL | 1 |
Gordon, SB | 1 |
Davies, GR | 3 |
Khoo, SH | 2 |
Sloan, DJ | 1 |
Mwandumba, HC | 1 |
Lopez-Varela, E | 1 |
Abulfathi, AA | 1 |
Strydom, N | 2 |
Goussard, P | 1 |
van Wyk, AC | 1 |
Demers, AM | 1 |
Deventer, AV | 1 |
Garcia-Prats, AJ | 2 |
van der Merwe, J | 1 |
Zimmerman, M | 2 |
Carter, CL | 1 |
Janson, J | 1 |
Morrison, J | 1 |
Reuter, H | 1 |
Decloedt, EH | 1 |
Seddon, JA | 2 |
Svensson, EM | 1 |
Warren, R | 1 |
Savic, RM | 3 |
Dartois, V | 5 |
Hesseling, AC | 4 |
Heysell, SK | 3 |
Mpagama, SG | 4 |
Ogarkov, OB | 1 |
Conaway, M | 1 |
Ahmed, S | 1 |
Zhdanova, S | 1 |
Pholwat, S | 1 |
Alshaer, MH | 1 |
Chongolo, AM | 1 |
Mujaga, B | 1 |
Sariko, M | 1 |
Saba, S | 1 |
Rahman, SMM | 1 |
Uddin, MKM | 1 |
Suzdalnitsky, A | 1 |
Moiseeva, E | 1 |
Zorkaltseva, E | 1 |
Koshcheyev, M | 1 |
Vitko, S | 1 |
Mmbaga, BT | 1 |
Kibiki, GS | 8 |
Pasipanodya, JG | 4 |
Banu, S | 1 |
Houpt, ER | 2 |
Kwak, N | 2 |
Jeon, D | 2 |
Park, Y | 1 |
Kang, YA | 2 |
Kim, KJ | 1 |
Kim, YR | 2 |
Kwon, BS | 1 |
Kwon, YS | 1 |
Kim, HJ | 2 |
Lee, JH | 5 |
Lee, JY | 4 |
Lee, JK | 3 |
Cheon, M | 1 |
Park, J | 1 |
Hahn, S | 3 |
Yim, JJ | 3 |
Lyons, MA | 1 |
Dooley, KE | 5 |
Hendricks, B | 3 |
Gupte, N | 5 |
Barnes, G | 3 |
Narunsky, K | 8 |
Whitelaw, C | 3 |
Smit, T | 3 |
Ignatius, EH | 4 |
Friedman, A | 3 |
Dorman, SE | 5 |
Dawson, R | 13 |
Paton, NI | 1 |
Cousins, C | 1 |
Suresh, C | 1 |
Burhan, E | 3 |
Chew, KL | 1 |
Dalay, VB | 1 |
Lu, Q | 1 |
Kusmiati, T | 1 |
Balanag, VM | 1 |
Lee, SL | 1 |
Pokharkar, Y | 1 |
Djaharuddin, I | 1 |
Sugiri, JJR | 1 |
Veto, RS | 1 |
Sekaggya-Wiltshire, C | 2 |
Avihingsanon, A | 1 |
Sarin, R | 1 |
Papineni, P | 1 |
Nunn, AJ | 13 |
Crook, AM | 3 |
Tweed, CD | 1 |
Diacon, AH | 9 |
McHugh, TD | 6 |
Mendel, CM | 6 |
Meredith, SK | 3 |
Mohapi, L | 1 |
Murphy, ME | 1 |
Phillips, PPJ | 3 |
Singh, KP | 1 |
Spigelman, M | 2 |
Gillespie, SH | 9 |
Esmail, H | 1 |
Lipman, MC | 2 |
Nunn, A | 2 |
Walker, TM | 1 |
Mtabho, CM | 4 |
Semvua, HH | 5 |
van den Boogaard, J | 4 |
Irongo, CF | 1 |
Boeree, MJ | 6 |
Colbers, A | 3 |
Burger, DM | 2 |
van der Ven, AJAM | 1 |
Tostmann, A | 2 |
Peetluk, LS | 1 |
Rebeiro, PF | 1 |
Cordeiro-Santos, M | 1 |
Kritski, A | 1 |
Andrade, BB | 2 |
Durovni, B | 2 |
Calvacante, S | 1 |
Arriaga, MB | 1 |
Turner, MM | 1 |
Figueiredo, MC | 1 |
Rolla, VC | 1 |
Sterling, TR | 1 |
McKenna, L | 1 |
Furin, J | 1 |
Filipenko, ML | 1 |
Dymova, MA | 1 |
Cherednichenko, AG | 1 |
Khrapov, EA | 1 |
Mishukova, OV | 1 |
Schwartz, YS | 1 |
De Jager, VR | 2 |
Vanker, N | 2 |
Burger, DA | 2 |
Everitt, D | 3 |
Pappas, F | 2 |
Nedelman, J | 1 |
Genestet, C | 1 |
Hodille, E | 1 |
Berland, JL | 1 |
Ginevra, C | 1 |
Bryant, JE | 1 |
Ader, F | 1 |
Lina, G | 1 |
Dumitrescu, O | 1 |
Cho, HJ | 1 |
Lim, YJ | 1 |
Kim, J | 3 |
Koh, WJ | 3 |
Song, CH | 1 |
Kang, MW | 1 |
Decroo, T | 1 |
de Jong, BC | 5 |
Piubello, A | 1 |
Lynen, L | 1 |
Van Deun, A | 2 |
Rahimi, BA | 1 |
Rahimy, N | 1 |
Ahmadi, Q | 1 |
Hayat, MS | 1 |
Wasiq, AW | 1 |
van Niekerk, C | 4 |
Hutchings, J | 1 |
van der Merwe, L | 1 |
Choi, J | 1 |
Nam, K | 1 |
Huynh, J | 1 |
Thwaites, G | 1 |
Marais, BJ | 1 |
Schaaf, HS | 5 |
Manyazewal, T | 1 |
Woldeamanuel, Y | 1 |
Holland, DP | 1 |
Fekadu, A | 1 |
Blumberg, HM | 1 |
Marconi, VC | 1 |
Naluyange, R | 1 |
Mboowa, G | 1 |
Komakech, K | 1 |
Semugenze, D | 1 |
Kateete, DP | 1 |
Ssengooba, W | 1 |
Dean, P | 1 |
Berger, T | 1 |
Matt, M | 1 |
Schlaudecker, E | 1 |
Riney, L | 1 |
Velásquez-Rimachi, V | 1 |
Orellana-Tovar, I | 1 |
Rodriguez-López, E | 1 |
López-Saavedra, A | 1 |
Esteban-Arias, D | 1 |
Pacheco-Barrios, K | 1 |
Metcalf, T | 1 |
Alva-Diaz, C | 1 |
Saroha, D | 1 |
Garg, D | 1 |
Singh, AK | 1 |
Dhamija, RK | 1 |
E R, V | 1 |
Parrikar, A | 1 |
Keny, S | 1 |
Lawande, D | 1 |
Swindells, S | 1 |
Zheng, X | 3 |
Bao, Z | 1 |
Forsman, LD | 2 |
Hu, Y | 4 |
Ren, W | 1 |
Gao, Y | 1 |
Li, X | 3 |
Hoffner, S | 4 |
Bruchfeld, J | 1 |
Alffenaar, JW | 2 |
Wang, J | 4 |
Du, Y | 1 |
Guo, R | 1 |
Han, X | 1 |
Wang, Q | 4 |
Pang, Y | 1 |
Chu, N | 2 |
Fernandez Do Porto, DA | 1 |
Monteserin, J | 1 |
Campos, J | 1 |
Sosa, EJ | 1 |
Matteo, M | 1 |
Serral, F | 1 |
Yokobori, N | 1 |
Benevento, AF | 1 |
Poklepovich, T | 1 |
Pardo, A | 1 |
Wainmayer, I | 1 |
Simboli, N | 1 |
Castello, F | 1 |
Paul, R | 2 |
Martí, M | 1 |
López, B | 1 |
Turjanski, A | 1 |
Ritacco, V | 1 |
Xu, X | 1 |
Hu, X | 1 |
Hase, I | 1 |
Toren, KG | 1 |
Hirano, H | 1 |
Sakurai, K | 1 |
Horne, DJ | 2 |
Saito, T | 1 |
Narita, M | 3 |
Laohapojanart, N | 1 |
Ratanajamit, C | 1 |
Kawkitinarong, K | 1 |
Srichana, T | 1 |
Chiwala, G | 1 |
Liu, Z | 1 |
Mugweru, JN | 1 |
Wang, B | 1 |
Khan, SA | 1 |
Bate, PNN | 1 |
Yusuf, B | 1 |
Hameed, HMA | 1 |
Fang, C | 1 |
Tan, Y | 1 |
Guan, P | 1 |
Hu, J | 1 |
Tan, S | 2 |
Liu, J | 1 |
Zhong, N | 1 |
Zhang, T | 1 |
Wang, Y | 4 |
Xiang, X | 1 |
Wu, SQ | 3 |
Chen, G | 2 |
Zhang, MM | 3 |
Wang, MG | 1 |
Wang, FJ | 1 |
Sandford, AJ | 2 |
He, JQ | 3 |
Dutta, NK | 3 |
Pinn, ML | 4 |
Karakousis, PC | 5 |
Driesen, M | 2 |
Kondo, Y | 1 |
Torrea, G | 2 |
Asnong, S | 1 |
Desmaretz, C | 1 |
Mostofa, KSM | 1 |
Tahseen, S | 2 |
Whitfield, MG | 1 |
Cirillo, DM | 2 |
Miotto, P | 1 |
Cabibbe, AM | 2 |
Rigouts, L | 5 |
Omonge, E | 1 |
Otieno, F | 1 |
Kubo, M | 1 |
Shiruli, B | 1 |
Chirehwa, MT | 1 |
McIlleron, H | 13 |
Rustomjee, R | 4 |
Mthiyane, T | 3 |
Onyebujoh, P | 1 |
Smith, P | 4 |
Denti, P | 7 |
de Knegt, GJ | 2 |
Dickinson, L | 1 |
Pertinez, H | 2 |
Evangelopoulos, D | 2 |
Bakker-Woudenberg, IAJM | 1 |
de Steenwinkel, JEM | 2 |
Li, SY | 3 |
Tasneen, R | 6 |
Tyagi, S | 7 |
Soni, H | 1 |
Converse, PJ | 3 |
Mdluli, K | 1 |
Nuermberger, EL | 6 |
Namasivayam, S | 1 |
Maiga, M | 2 |
Yuan, W | 1 |
Thovarai, V | 1 |
Costa, DL | 1 |
Mittereder, LR | 1 |
Wipperman, MF | 1 |
Glickman, MS | 1 |
Dzutsev, A | 1 |
Trinchieri, G | 1 |
Sher, A | 1 |
Goel, N | 1 |
Kumar, V | 1 |
Arora, S | 1 |
Ghosh, B | 1 |
Indumati, V | 1 |
Vijay, V | 1 |
Krishnaswamy, D | 1 |
Rajeshwari, V | 1 |
Ramesh, A | 1 |
Shantala, D | 1 |
Shilpa, A | 1 |
Mourik, BC | 1 |
Verbon, A | 1 |
Mouton, JW | 1 |
Bax, HI | 1 |
Calderón, RI | 1 |
Velásquez, GE | 1 |
Becerra, MC | 2 |
Zhang, Z | 3 |
Contreras, CC | 1 |
Yataco, RM | 1 |
Galea, JT | 1 |
Lecca, LW | 1 |
Kritski, AL | 3 |
Murray, MB | 1 |
Mitnick, CD | 3 |
Reither, K | 3 |
Haraka, F | 1 |
Sumari-de Boer, IM | 1 |
Magis-Escurra, C | 2 |
Wattenberg, M | 1 |
Logger, JGM | 1 |
Te Brake, LHM | 1 |
Hoelscher, M | 3 |
Plemper van Balen, G | 2 |
Díaz, A | 1 |
Bongiovanni, B | 1 |
D'Attilio, L | 1 |
Santucci, N | 1 |
Dídoli, G | 1 |
Fernández, RDV | 1 |
Kovalevski, L | 1 |
Lioi, S | 1 |
Gardeñez, W | 1 |
Brandan, N | 1 |
Nannini, LJ | 1 |
Besedovsky, H | 1 |
Del Rey, A | 1 |
Bottasso, O | 1 |
Bay, ML | 1 |
Castelnuovo, B | 1 |
von Braun, A | 1 |
Musaazi, J | 1 |
Muller, D | 1 |
Buzibye, A | 1 |
Gutteck, U | 1 |
Henning, L | 1 |
Ledergerber, B | 1 |
Corti, N | 1 |
Lamorde, M | 1 |
Fehr, J | 1 |
Kambugu, A | 1 |
Feng, M | 1 |
Wu, JC | 2 |
Ji, GY | 2 |
Liu, QQ | 2 |
Park, S | 1 |
Jo, KW | 2 |
Lee, SD | 1 |
Kim, WS | 1 |
Xu, L | 1 |
Chen, J | 2 |
Innes, AL | 1 |
Li, L | 2 |
Chiang, CY | 3 |
Ngabonziza, JCS | 1 |
Diallo, AB | 1 |
Tagliani, E | 1 |
Diarra, B | 1 |
Kadanga, AE | 1 |
Togo, ACG | 1 |
Thiam, A | 1 |
de Rijk, WB | 1 |
Alagna, R | 1 |
Houeto, S | 1 |
Ba, F | 1 |
Dagnra, AY | 1 |
Ivan, E | 1 |
Affolabi, D | 1 |
Schwoebel, V | 1 |
Trebucq, A | 3 |
Daneau, G | 1 |
Sigal, GB | 1 |
Segal, MR | 1 |
Mathew, A | 1 |
Jarlsberg, L | 1 |
Wang, M | 2 |
Barbero, S | 1 |
Small, N | 1 |
Haynesworth, K | 1 |
Davis, JL | 1 |
Weiner, M | 1 |
Whitworth, WC | 1 |
Jacobs, J | 1 |
Schorey, J | 1 |
Lewinsohn, DM | 1 |
Nahid, P | 1 |
Yeboah-Manu, D | 1 |
Gehre, F | 1 |
van der Laan, LE | 1 |
Tikiso, T | 1 |
Wiesner, L | 5 |
de Kock, M | 1 |
Winckler, J | 1 |
Norman, J | 1 |
Kim, S | 1 |
Lee, H | 1 |
Park, HY | 1 |
Jeon, K | 1 |
Huh, HJ | 1 |
Lee, NY | 1 |
Jeong, BH | 1 |
Wondale, B | 1 |
Medihn, G | 1 |
Teklu, T | 1 |
Mersha, W | 1 |
Tamirat, M | 1 |
Ameni, G | 1 |
Hsia, YC | 1 |
Naseri, A | 1 |
Schallhorn, JM | 1 |
Nansumba, M | 1 |
Kumbakumba, E | 1 |
Orikiriza, P | 1 |
Bastard, M | 1 |
Mwanga, JA | 1 |
Boum, Y | 1 |
de Beaudrap, P | 1 |
Bonnet, M | 2 |
Cerezo Lajas, A | 1 |
Caminero Luna, JA | 1 |
Rodríguez Guzmán, MDC | 1 |
de Miguel Díez, J | 1 |
Kombila, UD | 1 |
Ka, W | 1 |
Mbaye, FBR | 1 |
Diouf, NF | 1 |
Fall, L | 1 |
Ouedraogo, P | 1 |
Koutonin, ANE | 1 |
Dia Kane, Y | 1 |
Oumar Toure Badiane, N | 1 |
Adane, K | 1 |
Spigt, M | 1 |
Dinant, GJ | 1 |
Bwalya, P | 1 |
Yamaguchi, T | 1 |
Mulundu, G | 1 |
Nakajima, C | 1 |
Mbulo, G | 1 |
Solo, ES | 1 |
Fukushima, Y | 1 |
Kasakwa, K | 1 |
Suzuki, Y | 2 |
Eedara, BB | 1 |
Rangnekar, B | 1 |
Sinha, S | 1 |
Doyle, C | 1 |
Cavallaro, A | 1 |
Das, SC | 1 |
Hançerli Törün, S | 1 |
Acar, EM | 1 |
Somer, A | 1 |
Erköse, G | 1 |
Şatana, D | 1 |
Bayramoğlu, Z | 1 |
Çalışkan, E | 1 |
Kılıçaslan, Z | 1 |
Wu, S | 1 |
Wang, W | 2 |
Chen, H | 1 |
Xiong, W | 1 |
Song, X | 1 |
Yu, X | 1 |
Alfarisi, O | 1 |
Mave, V | 1 |
Gaikwad, S | 1 |
Sahasrabudhe, T | 1 |
Ramachandran, G | 2 |
Kumar, H | 2 |
Kulkarni, V | 1 |
Deshmukh, S | 1 |
Atre, S | 1 |
Raskar, S | 1 |
Lokhande, R | 1 |
Barthwal, M | 1 |
Kakrani, A | 1 |
Chon, S | 1 |
Gupta, A | 2 |
Golub, JE | 2 |
Yates, WB | 1 |
Nothling, S | 1 |
Lawlor, M | 1 |
Montgomery, SA | 1 |
Young, EF | 1 |
Durham, PG | 1 |
Zulauf, KE | 1 |
Rank, L | 1 |
Miller, BK | 1 |
Hayden, JD | 1 |
Lin, FC | 1 |
Welch, JT | 2 |
Hickey, AJ | 1 |
Braunstein, M | 1 |
McAulay, K | 1 |
Saito, K | 1 |
Warrier, T | 1 |
Walsh, KF | 1 |
Mathurin, LD | 1 |
Royal-Mardi, G | 1 |
Lee, MH | 1 |
Ocheretina, O | 1 |
Pape, JW | 1 |
Fitzgerald, DW | 1 |
Nathan, CF | 1 |
Kim, DK | 2 |
Yoon, HI | 3 |
Jeong, I | 2 |
Heo, EY | 1 |
Park, YS | 1 |
Jo, YS | 1 |
Park, SS | 1 |
Park, JS | 4 |
Lee, SM | 1 |
Lee, CH | 1 |
Lee, J | 2 |
Choi, SM | 1 |
Park, JH | 1 |
Cho, YJ | 3 |
Lee, YJ | 2 |
Hwang, YR | 1 |
Ki, J | 1 |
Lim, JN | 1 |
Choi, HS | 1 |
Lee, M | 3 |
Song, T | 2 |
Kim, HS | 1 |
Han, J | 1 |
Ahn, H | 2 |
Smythe, W | 2 |
Merle, CS | 3 |
Olliaro, PL | 3 |
Deshpande, D | 1 |
Magombedze, G | 1 |
Gumbo, T | 4 |
Lee, T | 1 |
Kim, SY | 1 |
Jhun, BW | 1 |
Ahn, JH | 1 |
Kim, CK | 1 |
Shin, S | 1 |
Shin, SJ | 1 |
Won, HJ | 1 |
Jang, JY | 1 |
Cho, SN | 1 |
Khan, N | 1 |
Mendonca, L | 1 |
Dhariwal, A | 1 |
Fontes, G | 1 |
Menzies, D | 4 |
Xia, J | 1 |
Divangahi, M | 1 |
King, IL | 1 |
Hasanain, AFA | 1 |
Zayed, AAH | 1 |
Abd-Ellatief, RB | 1 |
Nafee, AMA | 1 |
Padmapriyadarsini, C | 2 |
Bhavani, PK | 1 |
Natrajan, M | 1 |
Ponnuraja, C | 1 |
Gomathy, SN | 1 |
Guleria, R | 1 |
Jawahar, SM | 1 |
Singh, M | 2 |
Balganesh, T | 1 |
Swaminathan, S | 4 |
Gupta, SV | 1 |
Fox, WS | 1 |
Via, LE | 3 |
Bang, H | 1 |
Eum, S | 1 |
Shim, T | 1 |
Barry, CE | 4 |
Gardner Toren, K | 1 |
Spitters, C | 1 |
Pecha, M | 1 |
Bhattarai, S | 1 |
Lucena, SMA | 1 |
Alberio, CAA | 1 |
Pinto, ACG | 1 |
Vieira, JLF | 1 |
Suárez, I | 1 |
Maria Fünger, S | 1 |
Jung, N | 1 |
Lehmann, C | 1 |
Reimer, RP | 1 |
Mehrkens, D | 1 |
Bunte, A | 1 |
Plum, G | 1 |
Jaspers, N | 1 |
Schmidt, M | 2 |
Fätkenheuer, G | 1 |
Rybniker, J | 1 |
Hagiwara, E | 1 |
Suido, Y | 1 |
Asaoka, M | 1 |
Katano, T | 1 |
Okuda, R | 1 |
Sekine, A | 1 |
Kitamura, H | 1 |
Baba, T | 1 |
Komatsu, S | 1 |
Ogura, T | 1 |
Muntean, PE | 1 |
Svensson, RJ | 1 |
Sabiiti, W | 1 |
Ntinginya, NE | 3 |
Bhatt, N | 1 |
Davies, G | 2 |
Simonsson, USH | 1 |
Ishiwada, N | 1 |
Tokunaga, O | 1 |
Nagasawa, K | 1 |
Ichimoto, K | 1 |
Kinoshita, K | 2 |
Hishiki, H | 1 |
Kohno, Y | 1 |
O'Donnell, MR | 1 |
Padayatchi, N | 1 |
Kvasnovsky, C | 1 |
Werner, L | 1 |
Master, I | 1 |
Horsburgh, CR | 1 |
Miyazawa, N | 1 |
Horita, N | 1 |
Tomaru, K | 1 |
Tsukahara, T | 1 |
Takahashi, R | 1 |
Sasaki, M | 1 |
Ishigatsubo, Y | 1 |
Diacon, A | 1 |
Ruesen, C | 2 |
Ginanjar, A | 1 |
Mangunnegoro, H | 1 |
Ascobat, P | 1 |
Donders, R | 1 |
Aarnoutse, R | 3 |
Gniadek, TJ | 1 |
Belchis, DA | 1 |
Mdluli, KE | 3 |
Gninafon, M | 2 |
Lo, MB | 2 |
Bah-Sow, O | 1 |
Lienhardt, C | 4 |
Horton, J | 2 |
Simonsson, US | 1 |
Wejse, C | 1 |
Furtado, A | 1 |
Camara, C | 1 |
Lüneborg-Nielsen, M | 1 |
Sodemann, M | 1 |
Gerstoft, J | 1 |
Katzenstein, TL | 1 |
Burger, A | 1 |
Wash, PA | 1 |
Pérez-Guzmán, C | 2 |
Vargas, MH | 2 |
Pérez-Arellano, CP | 1 |
García-Toledo, D | 1 |
Wallis, RS | 3 |
Wang, C | 1 |
Meyer, D | 1 |
Thomas, N | 1 |
Babalik, A | 3 |
Ulus, IH | 2 |
Bakirci, N | 3 |
Kuyucu, T | 2 |
Arpag, H | 2 |
Dagyildizi, L | 1 |
Capaner, E | 1 |
Colasanti, P | 1 |
Cardone, M | 1 |
Zanchini, R | 1 |
Cordedda, M | 1 |
Grande, A | 1 |
Mozzillo, R | 1 |
Manca, C | 1 |
Koo, MS | 1 |
Peixoto, B | 1 |
Fallows, D | 1 |
Kaplan, G | 1 |
Subbian, S | 1 |
Tsou, CC | 1 |
Chien, JY | 1 |
Dagyildiz, L | 1 |
Çarpaner, E | 1 |
Bark, CM | 1 |
Gitta, P | 2 |
Ogwang, S | 1 |
Nsereko, M | 1 |
Thiel, BA | 1 |
Boom, WH | 2 |
Eisenach, KD | 2 |
Joloba, ML | 1 |
Johnson, JL | 4 |
Hung, NV | 1 |
Ando, H | 1 |
Thuy, TT | 1 |
Kuwahara, T | 1 |
Hang, NT | 1 |
Sakurada, S | 1 |
Thuong, PH | 1 |
Lien, LT | 1 |
Keicho, N | 1 |
Fahimi, F | 2 |
Tabarsi, P | 2 |
Kobarfard, F | 1 |
Bozorg, BD | 1 |
Goodarzi, A | 1 |
Dastan, F | 1 |
Shahsavari, N | 1 |
Emami, S | 1 |
Habibi, M | 1 |
Salamzadeh, J | 1 |
Li, H | 1 |
Zhou, M | 1 |
Geng, X | 1 |
Yu, J | 1 |
Zhang, XE | 1 |
Wei, H | 1 |
Ndusilo, N | 1 |
Stroup, S | 1 |
Kumburu, H | 1 |
Gratz, J | 1 |
Neino Mourtala Mohamed, A | 1 |
Tummino, C | 1 |
Gouitaa, M | 1 |
Chanez, P | 1 |
Nomi, F | 1 |
Hosaka, K | 1 |
Kurosawa, T | 1 |
Akkerman, OW | 1 |
van Altena, R | 2 |
Bolhuis, MS | 1 |
van der Werf, TS | 1 |
Gutiérrez-Aroca, JB | 1 |
Ruiz, P | 1 |
Casal, M | 1 |
Xiang, Y | 1 |
Ma, L | 2 |
Wu, W | 1 |
Liu, W | 1 |
Li, Y | 1 |
Zhu, X | 1 |
Ma, J | 1 |
Cao, M | 1 |
Yao, X | 1 |
Yang, L | 1 |
Wubuli, A | 1 |
Merle, C | 1 |
Milligan, P | 1 |
Mao, Y | 1 |
Gu, J | 1 |
Xin, X | 1 |
Reynolds, J | 1 |
Oualil, H | 1 |
Nejjari, S | 1 |
Bourkadi, JE | 1 |
Iraqi, G | 1 |
Napiórkowska, A | 2 |
Rüsch-Gerdes, S | 2 |
Hillemann, D | 1 |
Richter, E | 1 |
Augustynowicz-Kopeć, E | 2 |
Chigutsa, E | 3 |
Pasipanodya, J | 1 |
Visser, M | 2 |
van Helden, PD | 1 |
Sirgel, FA | 2 |
Xia, Y | 2 |
Goel, S | 1 |
Harries, AD | 3 |
Gao, T | 1 |
Wang, L | 1 |
Cheng, S | 1 |
Lin, Y | 1 |
Du, X | 1 |
Moraes, ML | 1 |
Ramalho, DM | 1 |
Delogo, KN | 1 |
Miranda, PF | 1 |
Mesquita, ED | 1 |
de Melo Guedes de Oliveira, HM | 1 |
Netto, AR | 1 |
Dos Anjos, MJ | 1 |
de Oliveira, MM | 1 |
Fu, EQ | 1 |
Jin, FG | 1 |
Pouplin, T | 1 |
Phuong, PN | 1 |
Toi, PV | 1 |
Nguyen Pouplin, J | 1 |
Farrar, J | 1 |
Saitou, Y | 1 |
Hatazi, O | 1 |
Aonuma, H | 1 |
Ogura, S | 1 |
Yamamoto, N | 1 |
Kobayashi, T | 1 |
Murray, SR | 1 |
Phillips, PP | 4 |
Rusen, ID | 1 |
Squire, SB | 1 |
Madan, J | 1 |
Cook, SV | 2 |
Burgos, M | 3 |
Yorke-Edwards, V | 2 |
Anyo, G | 2 |
Enarson, DA | 4 |
Jindani, A | 9 |
Mathys, V | 1 |
van de Vyvere, M | 1 |
de Droogh, E | 1 |
Soetaert, K | 1 |
Groenen, G | 1 |
Fielding, K | 1 |
Sow, OB | 1 |
Odhiambo, J | 1 |
Amukoye, E | 1 |
Bah, B | 1 |
Kassa, F | 1 |
N'Diaye, A | 1 |
Perronne, C | 1 |
Sismanidis, C | 1 |
Lapujade, O | 1 |
Harrison, TS | 2 |
Churchyard, GJ | 1 |
Charalambous, S | 2 |
Hatherill, M | 1 |
Geldenhuys, H | 1 |
McIlleron, HM | 2 |
Zvada, SP | 1 |
Mungofa, S | 1 |
Shah, NA | 1 |
Zizhou, S | 1 |
Magweta, L | 1 |
Shepherd, J | 1 |
Nyirenda, S | 1 |
van Dijk, JH | 1 |
Clouting, HE | 1 |
Coleman, D | 1 |
Bateson, AL | 1 |
Butcher, PD | 1 |
Mitchison, DA | 21 |
Oshi, SN | 2 |
Alobu, I | 2 |
Ukwaja, KN | 2 |
Oshi, DC | 2 |
Yamana, H | 1 |
Matsui, H | 1 |
Fushimi, K | 1 |
Yasunaga, H | 1 |
Song, J | 2 |
Lee, CT | 2 |
du Bois, J | 2 |
Venter, A | 5 |
Heinrich, N | 2 |
Rehal, S | 2 |
van Soolingen, D | 1 |
van Ingen, J | 1 |
Burger, D | 1 |
Franke, MF | 1 |
Tierney, DB | 1 |
Rich, ML | 1 |
Bonilla, C | 1 |
Bayona, J | 1 |
McLaughlin, MM | 1 |
Bhushan, B | 1 |
Chander, R | 1 |
Kajal, NC | 1 |
Ranga, V | 1 |
Bharti, H | 1 |
Honeyborne, I | 1 |
Eckold, C | 1 |
Pym, A | 4 |
Stehr, M | 1 |
Elamin, AA | 1 |
Mayor, S | 1 |
Sotgiu, G | 2 |
Migliori, GB | 1 |
Donald, PR | 8 |
Schall, R | 1 |
Conradie, A | 1 |
Eisenach, K | 1 |
Ive, P | 1 |
Page-Shipp, L | 1 |
Variava, E | 1 |
von Groote-Bidlingmaier, F | 2 |
Braga, JU | 1 |
Trajman, A | 1 |
Mukherjee, A | 1 |
Velpandian, T | 1 |
Singla, M | 1 |
Kanhiya, K | 1 |
Kabra, SK | 1 |
Lodha, R | 1 |
Peppard, T | 2 |
Hermann, D | 1 |
Igari, H | 1 |
Imasawa, T | 1 |
Noguchi, N | 1 |
Nagayoshi, M | 1 |
Mizuno, S | 1 |
Ishikawa, S | 1 |
Kadomura, M | 1 |
Nishimura, M | 1 |
Yamagishi, F | 3 |
Carman, D | 1 |
Whitelaw, A | 1 |
Efron, A | 4 |
Barnes, GL | 3 |
Hoffman, J | 1 |
Chaisson, RE | 7 |
Rezaković, S | 1 |
Mokos, ZB | 1 |
Paštar, Z | 1 |
Huang, Z | 1 |
Gao, C | 1 |
Chi, X | 1 |
Hu, YW | 1 |
Zheng, L | 1 |
Zeng, T | 1 |
Shah, R | 1 |
Venkatesan, P | 1 |
Shi, G | 1 |
Zhang, L | 2 |
Chen, M | 1 |
Deng, J | 1 |
Li, W | 1 |
Su, C | 1 |
Abuaku, BK | 1 |
Tan, H | 1 |
Wen, SW | 1 |
Fan, L | 1 |
Zhang, Y | 8 |
Yang, X | 1 |
Bai, D | 1 |
Yao, J | 1 |
Yi, L | 1 |
Hennig, S | 1 |
Naiker, S | 1 |
Reddy, T | 1 |
Egan, D | 1 |
Kellerman, T | 1 |
Owen, A | 1 |
Jeremiah, K | 1 |
Faurholt-Jepsen, D | 1 |
PrayGod, G | 1 |
Range, N | 1 |
Castel, S | 1 |
Hagen, CM | 1 |
Christiansen, M | 1 |
Changalucha, J | 1 |
Friis, H | 1 |
Andersen, AB | 1 |
Betoudji, F | 2 |
Williams, K | 4 |
Yang, T | 1 |
Lanoix, JP | 2 |
Ioerger, T | 1 |
Ormond, A | 1 |
Kaya, F | 1 |
Sacchettini, J | 1 |
Nuermberger, E | 7 |
Chang, KC | 3 |
Yew, WW | 7 |
Bekker, A | 1 |
Draper, HR | 1 |
van der Laan, L | 1 |
Murray, S | 1 |
Dobler, CC | 1 |
Chidiac, R | 1 |
Williamson, JP | 1 |
Jelfs, PJ | 1 |
Das, MK | 1 |
Arya, R | 1 |
Debnath, S | 1 |
Debnath, R | 1 |
Lodh, A | 1 |
Bishwal, SC | 1 |
Das, A | 1 |
Nanda, RK | 1 |
Gao, J | 1 |
Ma, Y | 1 |
Du, J | 1 |
Zhu, G | 2 |
Fu, Y | 2 |
Liu, F | 1 |
Hu, D | 1 |
Li, Q | 1 |
Borgulya, G | 1 |
de Patiño, IW | 1 |
Gonzales, T | 1 |
de Fernandes, RA | 1 |
Shrestha, B | 1 |
Atwine, D | 1 |
Dubash, F | 1 |
Patel, N | 1 |
Checkley, AM | 1 |
Mitchison, D | 1 |
Xu, P | 1 |
Wu, J | 1 |
Yang, C | 1 |
Luo, T | 1 |
Nsofor, CA | 1 |
Gicquel, B | 2 |
Gao, Q | 1 |
Conde, MB | 3 |
Mello, FC | 1 |
Duarte, RS | 1 |
Cavalcante, SC | 1 |
Rolla, V | 1 |
Dalcolmo, M | 1 |
Loredo, C | 2 |
Armstrong, DT | 1 |
Marzinke, MA | 1 |
Cohn, S | 1 |
Moulton, LH | 2 |
Ortega-Muro, F | 1 |
Alameda-Martin, L | 1 |
Liu, Y | 1 |
Schipani, A | 1 |
Coates, A | 1 |
Zheng, R | 1 |
Werngren, J | 2 |
Mansjö, M | 3 |
Xu, B | 2 |
Li, D | 1 |
Drobniewski, F | 1 |
Aseffa, A | 1 |
Chukwu, JN | 1 |
Vahedi, M | 2 |
Aguwa, EN | 1 |
Bedru, A | 1 |
Mebrahtu, T | 1 |
Ezechi, OC | 1 |
Yimer, G | 1 |
Yamuah, LK | 1 |
Medhin, G | 1 |
Connolly, C | 3 |
Rida, W | 2 |
Aderaye, G | 1 |
Zumla, AI | 1 |
Onyebujoh, PC | 2 |
Zignol, M | 1 |
Dean, AS | 1 |
Alikhanova, N | 1 |
Andres, S | 1 |
Dadu, A | 1 |
Dreyer, A | 1 |
Gilpin, C | 1 |
Hasan, R | 1 |
Hasan, Z | 1 |
Husain, A | 1 |
Hussain, A | 1 |
Ismail, N | 1 |
Kamal, M | 1 |
Mvusi, L | 1 |
Niemann, S | 1 |
Omar, SV | 1 |
Qadeer, E | 1 |
Ruesch-Gerdes, S | 1 |
Schito, M | 1 |
Seyfaddinova, M | 1 |
Skrahina, A | 1 |
Wells, WA | 1 |
Mukadi, YD | 1 |
Kimerling, M | 1 |
Floyd, K | 1 |
Weyer, K | 2 |
Raviglione, MC | 1 |
Meinzen, C | 1 |
Proaño, A | 1 |
Gilman, RH | 2 |
Caviedes, L | 1 |
Coronel, J | 1 |
Zimic, M | 2 |
Sheen, P | 2 |
Rockwood, N | 2 |
Meintjes, G | 2 |
Chirehwa, M | 1 |
Wilkinson, RJ | 2 |
Shenai, S | 1 |
Ronacher, K | 1 |
Malherbe, S | 1 |
Stanley, K | 1 |
Kriel, M | 1 |
Winter, J | 1 |
Dodd, LE | 1 |
Walzl, G | 1 |
Alland, D | 1 |
McNaughton, A | 1 |
Blackmore, T | 1 |
McNaughton, H | 1 |
Ahidjo, BA | 1 |
Maiga, MC | 1 |
Ihms, EA | 1 |
Ordonez, AA | 2 |
Cheung, LS | 1 |
Beck, S | 1 |
Jain, S | 1 |
Bishai, WR | 4 |
Santra, G | 1 |
Karak, A | 1 |
Mukhopadhay, S | 1 |
Vora, A | 1 |
Patel, S | 1 |
Patel, K | 2 |
Fofana, MO | 1 |
Shrestha, S | 1 |
Knight, GM | 1 |
Cohen, T | 1 |
White, RG | 1 |
Cobelens, F | 1 |
Dowdy, DW | 1 |
Churchyard, G | 1 |
Sanne, I | 1 |
Minja, LT | 1 |
Hunt, RD | 1 |
Hanekom, M | 1 |
Manyama, C | 1 |
Mtafya, B | 1 |
Mekota, A | 1 |
Henne, S | 1 |
van Balen, GP | 1 |
Smith-Jones, P | 1 |
Wang, H | 1 |
Gogarty, KR | 1 |
Daryaee, F | 1 |
Bambarger, LE | 1 |
Chang, YS | 1 |
Jain, SK | 1 |
Tonge, PJ | 1 |
Al-Shaer, MH | 1 |
Mansour, H | 1 |
Elewa, H | 1 |
Salameh, P | 1 |
Iqbal, F | 1 |
Sirgel, F | 1 |
Lesosky, M | 1 |
Agibothu Kupparam, HK | 1 |
Vedhachalam, C | 1 |
Thiruvengadam, K | 1 |
Rajagandhi, V | 1 |
Dusthackeer, A | 1 |
Karunaianantham, R | 1 |
Jayapal, L | 1 |
Wada, M | 7 |
Okumura, M | 1 |
Hoshino, H | 1 |
Mitarai, S | 1 |
Ohmori, M | 1 |
Uchimura, K | 1 |
Yoshiyama, T | 2 |
Ogata, H | 4 |
Rao, NA | 3 |
Irfan, M | 2 |
Hussain, SJ | 1 |
Gevers, T | 1 |
Van Den Berg, J | 1 |
Grosset, J | 6 |
Taki, H | 1 |
Ogawa, K | 1 |
Murakami, T | 1 |
Nikai, T | 1 |
Thee, S | 2 |
Detjen, A | 1 |
Wahn, U | 2 |
Magdorf, K | 3 |
Mphahlele, M | 1 |
Syre, H | 1 |
Valvatne, H | 1 |
Stavrum, R | 1 |
Mannsåker, T | 1 |
Muthivhi, T | 1 |
Fourie, PB | 2 |
Grewal, HM | 2 |
Acharya, PR | 1 |
Sahoo, R | 1 |
Baliga, P | 1 |
de Paiva, TF | 1 |
de Barros e Silva, MJ | 1 |
Rinck, JA | 1 |
Fanelli, MF | 1 |
Gimenes, DL | 1 |
Barboza, CE | 1 |
Winter, DH | 1 |
Seiscento, M | 1 |
Santos, Ude P | 1 |
Terra Filho, M | 1 |
Morrone, N | 1 |
Morrone Junior, N | 1 |
Braz, AG | 1 |
Maia, JA | 1 |
Cailleaux-Cezar, M | 1 |
de A Melo, D | 1 |
Xavier, GM | 1 |
de Salles, CL | 1 |
de Mello, FC | 1 |
Ruffino-Netto, A | 1 |
Arya, DS | 1 |
Ojha, SK | 1 |
Semwal, OP | 2 |
Nandave, M | 1 |
Kamal, A | 1 |
Azeeza, S | 1 |
Malik, MS | 1 |
Shaik, AA | 1 |
Rao, MV | 1 |
Skvortsova, LA | 1 |
Pavlova, MV | 1 |
Kondakova, MN | 1 |
Vinogradova, TI | 1 |
Kovaleva, RG | 1 |
Archakova, LI | 1 |
Wikman, PE | 1 |
Jover, F | 1 |
Peris, J | 1 |
Cuadrado, JM | 1 |
Ovchinnikova, IuE | 1 |
Starshinova, AA | 1 |
Dovgaliuk, IF | 1 |
Naidu, VG | 1 |
Tammineni, AK | 1 |
Biscopink, RJ | 1 |
Davis, TL | 1 |
Veerabagu, MP | 1 |
De Souza, GR | 1 |
Graça, NP | 1 |
Cezar, MC | 1 |
Ram, M | 1 |
Chaudhary, MA | 1 |
Garg, R | 1 |
Mehra, S | 1 |
Prasad, R | 1 |
Ramos, A | 1 |
Daza, R | 2 |
Alvarez-Espejo, T | 1 |
Guzmán, MF | 1 |
Chideya, S | 1 |
Winston, CA | 1 |
Bradford, WZ | 2 |
Hopewell, PC | 4 |
Wells, CD | 1 |
Reingold, AL | 3 |
Kenyon, TA | 2 |
Moeti, TL | 2 |
Tappero, JW | 2 |
Bartacek, A | 1 |
Schütt, D | 1 |
Panosch, B | 1 |
Borek, M | 1 |
Hadad, DJ | 1 |
Dietze, R | 1 |
Maciel, EL | 1 |
Sewali, B | 1 |
Okwera, A | 4 |
Mugerwa, RD | 3 |
Alcaneses, MR | 1 |
Quelapio, MI | 1 |
Tupasi, TE | 1 |
Horter, L | 1 |
Debanne, SM | 1 |
Yüksel, P | 1 |
Tansel, O | 1 |
Lancioni, C | 1 |
LaBeaud, AD | 1 |
Esper, F | 1 |
Abughali, N | 1 |
Auletta, J | 1 |
Almeida, D | 4 |
Rosenthal, I | 3 |
Peloquin, C | 1 |
Wang, JY | 1 |
Lee, LN | 1 |
Yu, CJ | 1 |
Chien, YJ | 1 |
Yang, PC | 1 |
Albini, TA | 1 |
Kumaradas, M | 1 |
Fraig, MM | 1 |
Kuaban, C | 2 |
Bame, R | 1 |
Mouangue, L | 1 |
Djella, S | 1 |
Yomgni, C | 1 |
Ordway, DJ | 1 |
Shanley, CA | 1 |
Orme, EA | 1 |
Bucy, DS | 1 |
Hascall-Dove, L | 1 |
Henao-Tamayo, M | 1 |
Harton, MR | 1 |
Shang, S | 1 |
Ackart, D | 1 |
Kraft, SL | 1 |
Façanha, MC | 1 |
Gondim, AM | 1 |
Pinheiro, VG | 1 |
Barroso, EC | 1 |
Guerrant, RL | 1 |
Lima, AA | 1 |
Soomro, MM | 1 |
Mehfooz, Z | 1 |
Baniasadi, S | 1 |
Eftekhari, P | 1 |
Raoufy, MR | 1 |
Masjedi, MR | 1 |
Velayati, AA | 1 |
Jesinger, RA | 1 |
Ballard, EA | 1 |
Allton, DR | 1 |
Lane, JW | 1 |
Folio, L | 1 |
Su, WJ | 2 |
Feng, JY | 1 |
Chiu, YC | 1 |
Huang, SF | 1 |
Lee, YC | 2 |
Tutor-Ureta, P | 1 |
Martín-Jiménez, ML | 1 |
Vargas, JA | 1 |
Guo, N | 1 |
Marra, F | 2 |
Fitzgerald, JM | 3 |
Elwood, RK | 3 |
Marra, CA | 1 |
Cheigh, CI | 1 |
Senaratne, R | 1 |
Uchida, Y | 1 |
Casali, N | 1 |
Kendall, LV | 1 |
Riley, LW | 1 |
Zwolska, Z | 1 |
Muthaiah, M | 1 |
Jagadeesan, S | 1 |
Ayalusamy, N | 1 |
Sreenivasan, M | 1 |
Prabhu, SS | 1 |
Muthuraj, U | 1 |
Senthilkumar, K | 1 |
Veerappan, S | 1 |
Morais, P | 1 |
Ferreira, O | 1 |
Nogueira, A | 1 |
Bettencourt, H | 1 |
Azevedo, F | 1 |
Gulati, K | 1 |
Ray, A | 1 |
Vijayan, VK | 2 |
Wateba, MI | 1 |
Diop, SA | 1 |
Salou, M | 1 |
Womitso, K | 1 |
Nichols, S | 1 |
Tidjani, O | 1 |
Zhang, M | 2 |
Rosenthal, IM | 3 |
Almeida, DV | 1 |
Ahmad, Z | 1 |
Grosset, JH | 6 |
Leung, CC | 5 |
Khajotia, R | 1 |
Manthari, K | 1 |
Gómez-Seco, J | 1 |
Rodríguez-Guzmán, MJ | 1 |
Rodríguez-Nieto, MJ | 1 |
Gómez-Escolar, PF | 1 |
Presa-Abos, T | 1 |
Fortes-Alen, J | 1 |
Mulliez, P | 1 |
Mbassi Fouda, FL | 1 |
Roy Saint-Georges, F | 1 |
Bayhan, GI | 1 |
Ekşioğlu, AS | 1 |
Kitiş Çelik, B | 1 |
Tanır, G | 1 |
Tripathy, S | 1 |
Anand, A | 1 |
Inamdar, V | 1 |
Manoj, MM | 1 |
Khillare, KM | 1 |
Datye, AS | 1 |
Iyer, R | 1 |
Kanoj, DM | 1 |
Thakar, M | 1 |
Kale, V | 1 |
Pereira, M | 1 |
Risbud, AR | 1 |
Baek, SH | 1 |
Li, AH | 1 |
Sassetti, CM | 1 |
Bounouar, M | 1 |
Baybay, H | 1 |
Gallouj, S | 1 |
Meziane, M | 1 |
Mikou, O | 1 |
Mernissi, F | 1 |
Chraibi, M | 1 |
Harmouch, T | 1 |
Amarti, A | 1 |
Maritz, JS | 1 |
Consunji-Araneta, R | 1 |
Higgins, R | 1 |
Qing, G | 1 |
Bouhasan, L | 1 |
Seifart, HI | 1 |
Werely, CJ | 1 |
Rosenkranz, B | 1 |
Roll, S | 1 |
Kjellsson, MC | 1 |
Goh, A | 1 |
Weiner, D | 1 |
Low, KM | 1 |
Kern, S | 1 |
Pillai, G | 1 |
Pascopella, L | 1 |
Deriemer, K | 1 |
Watt, JP | 1 |
Flood, JM | 1 |
Losada, I | 1 |
Cifuentes, C | 1 |
Martín, C | 1 |
García, M | 1 |
De Groote, MA | 1 |
Gruppo, V | 1 |
Woolhiser, LK | 1 |
Gilliland, JC | 1 |
Loli, S | 1 |
Gutierrez, A | 1 |
Fuentes, P | 1 |
Cotrina, M | 1 |
Kirwan, D | 1 |
Smith, PJ | 2 |
Erondu, N | 1 |
Ginsberg, AM | 1 |
Becker, P | 2 |
Spigelman, MK | 2 |
Kumar, L | 3 |
Gupta, R | 2 |
Puri, MM | 1 |
Jaiswal, A | 1 |
Murar, A | 1 |
Behera, D | 1 |
Gönlügür, U | 1 |
Koşar, S | 1 |
Mirici, A | 1 |
Chu, NH | 1 |
Wang, QF | 1 |
Sahota, T | 1 |
Della Pasqua, O | 1 |
Arda, H | 1 |
Ağca, S | 1 |
Oruç, K | 1 |
Kızıltaş, S | 1 |
Cetintaş, G | 1 |
Calışır, HC | 1 |
Symons, G | 1 |
Winter, H | 1 |
Leung, EC | 2 |
Leung, WM | 2 |
Tam, CM | 5 |
Bhardwaj, A | 1 |
Narang, RK | 3 |
Murthy, RS | 1 |
Fillekes, Q | 1 |
Kisonga, RM | 1 |
Mleoh, L | 1 |
Ndaro, A | 1 |
Kisanga, ER | 1 |
van der Ven, A | 1 |
González, C | 1 |
Sáenz, C | 1 |
Herrmann, E | 1 |
Jajati, M | 1 |
Kaplan, P | 1 |
Monzón, D | 1 |
Smith, T | 1 |
Wolff, KA | 1 |
Nguyen, L | 1 |
Maartens, G | 2 |
Kirkpatrick, CM | 1 |
Karlsson, MO | 1 |
Trindade, MÂ | 1 |
Miyamoto, D | 1 |
Benard, G | 1 |
Sakai-Valente, NY | 1 |
Vasconcelos, Dde M | 1 |
Naafs, B | 1 |
Shaweno, D | 1 |
Worku, A | 1 |
Teleman, MD | 1 |
Chee, CB | 1 |
Earnest, A | 1 |
Wang, YT | 1 |
Yamazaki, Y | 1 |
Matsumoto, H | 1 |
Fujiuchi, S | 1 |
Pereira-Silva, JL | 1 |
Marinho, MM | 1 |
Veloso, TV | 1 |
Coelho JC, JC | 1 |
Kawakami, K | 2 |
Turner, DJ | 1 |
Hoyle, SL | 1 |
Snewin, VA | 1 |
Gares, MP | 1 |
Brown, IN | 1 |
Young, DB | 1 |
Kellman, M | 1 |
Franchini, DL | 1 |
McMillan, ME | 1 |
Hollender, ES | 1 |
Ashkin, D | 1 |
Chakaya, JM | 1 |
Kibuga, D | 1 |
Ng'ang'a, L | 1 |
Githui, WA | 2 |
Mansoer, JR | 1 |
Gakiria, G | 1 |
Kwamanga, D | 1 |
Maende, J | 1 |
Fays, S | 1 |
Martin, S | 1 |
Barbaud, A | 1 |
Schmutz, JL | 1 |
Sokolova, GB | 4 |
Semenova, OV | 2 |
Bogadel'nikova, IV | 1 |
Kunichan, AD | 2 |
Zeliger, LR | 1 |
Elistratova, NA | 3 |
Nolan, CM | 3 |
Goldberg, SV | 2 |
Lee, AM | 1 |
Mennone, JZ | 1 |
Jones, RC | 1 |
Paul, WS | 1 |
Perng, RP | 1 |
Gierek, T | 1 |
Markowski, J | 1 |
Kieda-Szurkowska, J | 1 |
Paluch, J | 1 |
Bielecki, I | 1 |
Doré, CJ | 1 |
McNeill, L | 1 |
Allen, M | 1 |
Estrada, C | 1 |
Cook, P | 1 |
Martínez-Rossier, LA | 1 |
Torres-Cruz, A | 1 |
Villarreal-Velarde, H | 1 |
Yee, D | 1 |
Valiquette, C | 1 |
Pelletier, M | 1 |
Parisien, I | 1 |
Rocher, I | 1 |
Miteva, L | 1 |
Bardarov, E | 1 |
Phyu, S | 1 |
Ti, T | 1 |
Jureen, R | 1 |
Hmun, T | 1 |
Myint, H | 1 |
Htun, A | 1 |
Bjorvatn, B | 1 |
Lu, PL | 1 |
Lee, YW | 1 |
Peng, CF | 1 |
Tsai, JJ | 1 |
Chen, YH | 1 |
Hwang, KP | 1 |
Chen, TP | 1 |
Beena, S | 1 |
Rao, KN | 1 |
Pai, MR | 1 |
Palanduz, A | 2 |
Gültekin, D | 2 |
Erdem, E | 1 |
Kayaalp, N | 2 |
Inoue, T | 2 |
Tanaka, E | 1 |
Oida, K | 1 |
Taguchi, Y | 1 |
Kato, T | 1 |
Sakuramoto, M | 1 |
Maeda, Y | 1 |
Maniwa, K | 1 |
Samman, Y | 2 |
Krayem, A | 1 |
Haidar, M | 1 |
Mimesh, S | 1 |
Osoba, A | 1 |
Al-Mowaallad, A | 1 |
Abdelaziz, M | 1 |
Wali, S | 2 |
Pérez Alvarez, MJ | 1 |
González Guijarro, J | 1 |
Santos Gil, I | 1 |
Han, JP | 1 |
Sun, SL | 1 |
Li, RZ | 1 |
Zhang, FS | 1 |
Wang, SC | 1 |
Cheng, J | 1 |
Deng, YF | 1 |
Yu, CB | 1 |
Xu, WG | 2 |
Gao, Z | 1 |
Fan, BD | 1 |
Ahn, HC | 1 |
Nguyen, D | 1 |
Brassard, P | 1 |
Westley, J | 1 |
Thibert, L | 2 |
Proulx, M | 1 |
Henry, K | 1 |
Schwartzman, K | 2 |
Behr, MA | 1 |
Ul-Ain, Q | 1 |
Sharma, S | 1 |
Khuller, GK | 1 |
Irtuganova, OA | 1 |
Smirnova, NS | 1 |
Slogotskaia, LV | 1 |
YEAGER, RL | 2 |
MUNROE, WG | 2 |
DESSAU, FI | 2 |
CAMPAGNA, M | 2 |
CALIX, A | 1 |
HAUSER, G | 1 |
PHILLIPS, S | 4 |
LARKIN, JC | 1 |
LITZENBERGER, WL | 1 |
HORTON, GE | 2 |
HAIMSOHN, JS | 1 |
SCHWARTZ, WS | 3 |
MOYER, RE | 2 |
MUSCHENHEIM, C | 2 |
McDERMOTT, W | 4 |
McCUNE, R | 1 |
DEUSCHLE, K | 2 |
ORMOND, L | 1 |
TOMPSETT, R | 2 |
POTTER, BP | 1 |
CHANG, SF | 1 |
ORGANICK, A | 1 |
MCCUNE, RM | 3 |
BATTEN, J | 1 |
DE SIMONI, G | 7 |
SPINA, G | 4 |
ZORINI, AO | 3 |
DUGGELI, O | 1 |
NICK, J | 1 |
STEWART, SM | 3 |
MURDOCH, JM | 1 |
CROFTON, JW | 1 |
HAY, D | 2 |
GRIVA, L | 1 |
MARENGO, G | 1 |
RANDONE, M | 1 |
SESIA, L | 1 |
STORNIELLO, G | 1 |
FANTOLI, U | 2 |
BISETTI, A | 2 |
CATTENEO, C | 1 |
FANTILI, U | 1 |
CATTANEGO, C | 1 |
SACCO, F | 4 |
ZUCCHETTI, B | 3 |
GUALA, B | 4 |
GUERRA, P | 4 |
DONNERBERG, RL | 1 |
ATWELL, RJ | 2 |
BROWNING, RH | 2 |
REALE, M | 1 |
GARAVENTA, A | 1 |
PAOLI, G | 1 |
COSTA, G | 2 |
MORETTI, E | 2 |
DI PORTO, A | 1 |
RELLINI, G | 1 |
ROCCHI, V | 1 |
MAZZINI, C | 1 |
SCHWARTZ, JA | 1 |
POGGIO, G | 1 |
WRUBL, A | 1 |
ROTTINI, E | 2 |
PICCHIO, E | 2 |
FIORENTINI, M | 2 |
CROISSANT, J | 1 |
GYSELEN, A | 1 |
DE BRABANDERE, R | 1 |
CALLENS, L | 2 |
PECORA, DV | 1 |
SISTI, MA | 1 |
SCODITTI, G | 1 |
SALVETTI, F | 2 |
CELLERINO, A | 3 |
PIOVANO, V | 2 |
EMANUELE, B | 1 |
GIOVA, C | 1 |
DI RUGGIERO, A | 1 |
MARINELLI, N | 1 |
CANIGLIA, M | 1 |
DE SIMONI, GE | 1 |
KAMEYAMA, Y | 1 |
WEBB, WR | 1 |
SPARKUHL, K | 1 |
RITCHIE, JA | 1 |
CAMPBELL, AE | 1 |
CUTHBERT, J | 1 |
BRUCE, LG | 1 |
TOGURI, E | 1 |
ALLISON, ST | 1 |
MACLEOD, HM | 1 |
SANTOPADRE, I | 1 |
POLIMENI, L | 1 |
BUTT, H | 1 |
HAAPANEN, J | 1 |
GILL, R | 1 |
RUSSELL, WF | 1 |
KASS, I | 4 |
OSEWSKI, T | 1 |
SALIBA, A | 2 |
BEATTY, OA | 2 |
SESSNER, HH | 1 |
KIMEL, VM | 1 |
JACOBS, S | 1 |
van DIJK, B | 1 |
KRAAN, JK | 1 |
SMALL, MJ | 1 |
DE PALMA, M | 1 |
MIRABELLI, S | 1 |
CINQUEGRANA, A | 1 |
FRENKEL, S | 1 |
JAWORSKI, J | 1 |
LUKIANSKA, D | 1 |
SMOL, Z | 1 |
STEINBRUECK, P | 1 |
ZAUMSEIL, I | 1 |
PETTY, TL | 2 |
MITCHELL, RS | 1 |
PINES, A | 4 |
GORGENYI-GOTTCHE, O | 1 |
SZOCSKA, M | 1 |
HEYMER, A | 1 |
RIVERA, E | 1 |
SOMNER, AR | 4 |
BRACE, AA | 2 |
TODOROFF, T | 1 |
FRANZOSI, P | 1 |
HALL, E | 1 |
RIDDELL, RW | 1 |
CATTANEO, C | 1 |
FOSTER, JH | 1 |
KILLEN, DA | 1 |
RHEA, WG | 1 |
DIVELEY, WL | 1 |
MCCRACKEN, RL | 1 |
HUBBARD, WW | 1 |
KITAMOTO, O | 1 |
MIGLIOLI, S | 1 |
CALABRESE, L | 1 |
WOLINSKY, E | 1 |
TANI, P | 2 |
POPPIUS, H | 1 |
HORNUNG, S | 1 |
KRAKOWSKA, M | 1 |
GRECO, S | 1 |
DUSI, U | 1 |
MENOZZI, V | 1 |
STUPENENGO, RH | 1 |
WENDY, CD | 1 |
RUSSO, V | 1 |
PFUETZE, KH | 1 |
PYLE, MM | 1 |
JANCIK, E | 4 |
ZELENKA, M | 3 |
TOUSEK, J | 5 |
MAKOVA, M | 1 |
WAGNER, J | 2 |
MONDESHKI, M | 1 |
PASHMAKOV, I | 1 |
MITCHELL, JH | 1 |
RUIZ, RC | 1 |
OKULICZ JASINKA, H | 1 |
ZIERSKI, M | 16 |
SNAJDR, V | 1 |
KRAKORA, P | 1 |
FISER, F | 1 |
CHODOUNSKA, V | 1 |
LUCCHESI, M | 1 |
BANCALE, A | 1 |
ROSSI, P | 1 |
SABAR, IR | 1 |
BAYGIN, R | 1 |
DEENSTRA, H | 1 |
CORPE, RF | 4 |
GOMAA, TM | 1 |
BERNARD, E | 2 |
PIERON, R | 1 |
GROUNDS, JG | 1 |
ACEVEDO, RC | 1 |
HERRERO, JJ | 1 |
PILHEU, J | 1 |
RODRIGUEZ, E | 1 |
DALRYMPLE, GV | 1 |
PEREZ, JA | 1 |
FARIAS, CE | 1 |
BRONSTEIN, DL | 1 |
CONTRERAS, H | 1 |
MUNARO, N | 1 |
CHAVES, AD | 1 |
VELU, S | 2 |
DAWSON, JJ | 1 |
DEVADATTA, S | 1 |
FOX, W | 10 |
KULKARNI, KG | 1 |
MOHAN, K | 1 |
RAMAKRISHNAN, CV | 3 |
STOTT, H | 3 |
RICHARDSON, RJ | 1 |
VILARDO, S | 1 |
COTTIN, S | 1 |
COZAN, R | 1 |
VERAN, P | 1 |
LESTON, JM | 2 |
FOSTIKOV, B | 1 |
DRAGANIC, J | 1 |
VRANJESEVIC, G | 1 |
SERI, I | 1 |
KOLUMBAN, K | 1 |
BALOGH, Z | 1 |
FILLA, E | 1 |
COMENALE, D | 1 |
ROSSI, F | 1 |
BLALOCK, FA | 3 |
ENTZ, A | 1 |
LARSON, CL | 1 |
WICHT, WC | 1 |
VULLIEMOZ, P | 1 |
FAVEZ, G | 1 |
GIUNIO, N | 1 |
GROSS, JH | 1 |
GOLDHAMMER, EJ | 1 |
SMITH, AE | 1 |
ASPEVIK, E | 1 |
EVENSTAD, E | 1 |
HAUKENES, G | 1 |
VERWILGHEN, R | 1 |
REYBROUCK, G | 1 |
COSEMANS, J | 1 |
TANNER, E | 1 |
MEDINA, G | 1 |
CHAPMAN, PT | 1 |
SHENNAN, DH | 2 |
VANWYCK, PJ | 1 |
SCHLESS, JM | 1 |
ALLISON, RF | 1 |
INGLIS, RM | 1 |
WHITE, EF | 1 |
TOPPERMAN, S | 1 |
BARRAS, G | 1 |
VOIGT, H | 1 |
WILLROTH, P | 1 |
BOESZOERMENYI, M | 1 |
FAUSZT, I | 1 |
BARAT, I | 1 |
SCHWEIGER, O | 1 |
KULKA, F | 1 |
SCHERER, E | 1 |
POSZLER, L | 1 |
ROMEO, G | 1 |
SCARPA, A | 1 |
ZANELLA, A | 1 |
KALLOS, Z | 1 |
LACZKO, E | 1 |
DUBRA, FA | 1 |
PALERMO, FM | 1 |
NAITO, M | 1 |
ROZEWSKA, M | 1 |
Chen, QL | 1 |
Chen, L | 1 |
Yin, JJ | 1 |
Yotsumoto, H | 2 |
Yonemaru, M | 1 |
Suzuki, K | 1 |
Kawabe, Y | 2 |
Sasaki, Y | 1 |
Toyoda, E | 1 |
Kudoh, K | 1 |
Kurasawa, T | 2 |
Ito, M | 1 |
Kawashiro, T | 1 |
Sakatani, M | 1 |
Mori, M | 1 |
Pedral-Sampaio, DB | 2 |
Netto, EM | 2 |
Brites, C | 2 |
Bandeira, AC | 1 |
Guerra, C | 1 |
Barberin, MG | 1 |
Badaró, R | 2 |
Saito, W | 1 |
Nagayama, N | 1 |
Miyamoto, M | 1 |
Hara, H | 1 |
Suzuki, J | 1 |
Masuda, K | 1 |
Baba, M | 1 |
Tamura, A | 1 |
Nagai, H | 1 |
Akagawa, S | 1 |
Machida, K | 1 |
Kurashima, A | 1 |
Long, R | 1 |
Bochar, K | 1 |
Chomyc, S | 1 |
Talbot, J | 1 |
Barrie, J | 1 |
Kunimoto, D | 1 |
Tilley, P | 1 |
Choudhary, J | 1 |
Mubarik, M | 1 |
Parvez, A | 1 |
Naikoo, MA | 1 |
Santha, T | 3 |
Rehman, F | 1 |
Sarma, GR | 4 |
Reetha, AM | 1 |
Prabhaker, R | 1 |
Chan, CK | 1 |
Visser, ME | 1 |
Texeira-Swiegelaar, C | 1 |
Park, SK | 1 |
Lee, WC | 1 |
Lee, DH | 1 |
Han, L | 1 |
Seung, KJ | 2 |
Gausi, F | 2 |
Chimzizi, R | 1 |
Salaniponi, FM | 2 |
Stout, JE | 1 |
Story, RE | 1 |
Ditto, AM | 1 |
Cox, VC | 1 |
Moadebi, S | 1 |
Karachunskiĭ, MA | 3 |
Uvarova, TE | 1 |
Krasnov, VA | 2 |
Ursov, IG | 1 |
Yepes, JF | 1 |
Sullivan, J | 1 |
Pinto, A | 1 |
Alves, CR | 1 |
Oliveira, AS | 1 |
Gelmanova, IE | 1 |
Peremitin, GG | 1 |
Golubchikova, VT | 1 |
Pavlova, VE | 1 |
Sirotkina, OB | 1 |
Yanova, GV | 1 |
Strelis, AK | 1 |
Suárez-Méndez, R | 1 |
García-García, I | 1 |
Fernández-Olivera, N | 1 |
Valdés-Quintana, M | 1 |
Milanés-Virelles, MT | 1 |
Carbonell, D | 1 |
Machado-Molina, D | 1 |
Valenzuela-Silva, CM | 1 |
López-Saura, PA | 1 |
Lambert, ML | 1 |
Delgado, R | 1 |
Michaux, G | 1 |
Volz, A | 1 |
Van der Stuyft, P | 1 |
Jutte, PC | 1 |
Rutgers, SR | 1 |
Uges, DR | 1 |
Van Horn, JR | 1 |
Perel'man, MI | 1 |
Cokolova, GB | 1 |
Mozhokina, GN | 1 |
Lazareva, IaV | 2 |
Strekchev, AIu | 1 |
Nakanishi, N | 1 |
Moritaka, T | 1 |
Ueda, N | 1 |
Farah, MG | 1 |
Tverdal, A | 1 |
Steen, TW | 1 |
Heldal, E | 1 |
Brantsaeter, AB | 1 |
Bjune, G | 1 |
Chernykh, NA | 1 |
Kaminskaia, GO | 2 |
Kossiĭ, IuE | 1 |
Tortajada, C | 1 |
Martínez-Lacasa, J | 1 |
Sánchez, F | 1 |
Jiménez-Fuentes, A | 1 |
De Souza, ML | 1 |
García, JF | 1 |
Martínez, JA | 1 |
Caylà, JA | 1 |
Ige, OM | 2 |
Sogaolu, OM | 1 |
Odaibo, GN | 1 |
Olaleye, OD | 1 |
Lobato, MN | 1 |
Reves, RR | 1 |
Jasmer, RM | 1 |
Grabau, JC | 1 |
Bock, NN | 1 |
Shang, N | 1 |
Toyama, T | 1 |
Kato, H | 1 |
Kobayashi, E | 1 |
Kusakabe, A | 1 |
Fuziwara, K | 1 |
Nemoto, A | 1 |
Hayashi, K | 1 |
Ogino, M | 1 |
Tsuzuki, T | 1 |
Tasduq, SA | 1 |
Kaisar, P | 1 |
Gupta, DK | 1 |
Kapahi, BK | 1 |
Maheshwari, HS | 1 |
Jyotsna, S | 1 |
Johri, RK | 1 |
Raghavan, A | 1 |
Duraipandian, M | 1 |
Kripasankar, AS | 1 |
Ramachandran, P | 2 |
Agerton, TB | 1 |
Hopewell, P | 1 |
Lockman, S | 1 |
Oyewo, A | 1 |
Talbot, EA | 1 |
Moffat, HJ | 1 |
Lu, W | 1 |
He, HJ | 1 |
Gu, XR | 1 |
Zhu, M | 1 |
Maslow, JN | 1 |
Mikota, SK | 1 |
Isaza, R | 1 |
Dunker, F | 1 |
Riddle, H | 1 |
Yano, S | 1 |
Kobayashi, K | 1 |
Kato, K | 1 |
Ikeda, T | 2 |
Currie, GP | 1 |
Emmanuel, FX | 1 |
Ford, D | 1 |
Devereux, G | 1 |
Schechter, M | 1 |
Zajdenverg, R | 1 |
Falco, G | 1 |
Faulhaber, JC | 1 |
Coberly, JS | 2 |
Moore, RD | 1 |
Vernon, AA | 1 |
Freier, G | 1 |
Wright, A | 1 |
Nelson, G | 1 |
Brenner, E | 1 |
Mase, S | 1 |
Tasker, S | 1 |
Matthews, KL | 1 |
Bohnker, BK | 1 |
Takashima, T | 1 |
Danno, K | 1 |
Tamura, Y | 1 |
Nagai, T | 1 |
Matsumoto, T | 1 |
Han, Y | 1 |
Ano, H | 1 |
Yoshida, H | 1 |
Kawahara, K | 1 |
Tsuyuguchi, I | 1 |
Williams, KN | 2 |
Moniruzzaman, A | 1 |
Schulzer, M | 1 |
Jacquet, V | 1 |
Morose, W | 1 |
Oxlade, O | 1 |
Barr, G | 1 |
Grimard, F | 1 |
Babu, RB | 1 |
Sudharshan, S | 1 |
Kumarasamy, N | 1 |
Therese, L | 1 |
Biswas, J | 1 |
Brindle, R | 1 |
Aarons, LJ | 1 |
Wong, HY | 1 |
Chau, CH | 1 |
Taniguchi, H | 1 |
Izumi, S | 2 |
Messouak, O | 1 |
Amara, B | 1 |
Benjelloun, FZ | 1 |
Tizniti, S | 1 |
Benjelloun, MC | 1 |
Belahsen, MF | 1 |
Bai, GH | 1 |
Park, YK | 1 |
Choi, YW | 1 |
Bai, JI | 1 |
Chang, CL | 1 |
Sirmatel, O | 1 |
Yazgan, P | 1 |
Gursoy, B | 1 |
Sirmatel, F | 1 |
Zeyrek, FY | 1 |
Ozturk, A | 1 |
Byrne, ST | 1 |
Denkin, SM | 1 |
Gu, P | 1 |
Ovsiankina, ES | 1 |
Gubkina, MF | 1 |
Kuz'mina, IK | 1 |
Stakheeva, LB | 1 |
Borodina, NN | 1 |
Zaletina, EIu | 1 |
Harada, Y | 1 |
Koyama, K | 1 |
Yamaryo, T | 1 |
Kimura, Y | 1 |
P V, K | 1 |
Palaian, S | 1 |
Ojha, P | 1 |
P R, S | 1 |
Ida, N | 1 |
Yamamoto, K | 3 |
Gonda, H | 1 |
Oishi, T | 1 |
Suganuma, N | 1 |
Yamaguchi, I | 1 |
Suzuki, R | 1 |
Suh, GY | 1 |
Chung, MP | 1 |
Kwon, OJ | 1 |
Lim, SY | 2 |
Kam, KM | 3 |
Yip, CW | 1 |
Ma, CH | 1 |
Law, WS | 1 |
Sukumar, B | 1 |
Iliayas, S | 1 |
Kumar, SR | 1 |
Triveni, C | 1 |
Gomathy, P | 1 |
Thomas, B | 1 |
Mathew, M | 1 |
Narayanan, PR | 1 |
Zaka-Ur-Rehman, Z | 1 |
Jamshaid, M | 1 |
Chaudhry, A | 1 |
Cakir, E | 1 |
Gocmen, B | 1 |
Uyan, ZS | 1 |
Oktem, S | 1 |
Kiyan, G | 1 |
Karakoc, F | 1 |
Ersu, R | 1 |
Karadag, B | 1 |
Dagli, T | 1 |
Dagli, E | 1 |
Lachowicz, D | 1 |
Siekierzyńska, A | 1 |
Styszewska, H | 2 |
Ramirez, J | 1 |
Danan, G | 1 |
Pessayre, D | 1 |
Larrey, D | 1 |
Benhamou, JP | 1 |
Carpenter, JL | 1 |
Covelli, HD | 1 |
Avant, ME | 1 |
McAllister, CK | 1 |
Higbee, JW | 1 |
Ognibene, AJ | 1 |
Pretet, S | 3 |
Marsac, J | 1 |
Choudat, D | 1 |
Bollinelli, R | 1 |
Flenley, DC | 1 |
Kroening, U | 1 |
Acocella, G | 3 |
Girling, DJ | 7 |
Nagasawa, S | 1 |
Valenzuela, P | 4 |
Valenzuela, MT | 4 |
Farga, V | 3 |
Yañez, A | 2 |
Scheel, G | 2 |
Mendoza, F | 2 |
Torres, E | 2 |
Icekson, I | 2 |
Grinspun, M | 2 |
Fernández, M | 3 |
Tynystanova, RI | 1 |
Kozlova, NV | 1 |
Cataldi Amatriain, RM | 1 |
Rossi Case, E | 1 |
Miles, SH | 1 |
Maat, RB | 1 |
Snider, DE | 4 |
Graczyk, J | 2 |
Bek, E | 6 |
Rogowski, J | 2 |
Pilheu, JA | 3 |
de Salvo, MC | 3 |
Koch, OR | 2 |
Arias, RF | 2 |
Sjögren, I | 1 |
Boman, G | 2 |
Löfdahl, CG | 1 |
Skoogh, BE | 1 |
Nikodemowicz, E | 2 |
Kamińska, M | 2 |
Caban, M | 1 |
Struzik, T | 1 |
Acharyulu, GS | 1 |
Kannapiran, M | 2 |
Murthy, PV | 1 |
Gurumurthy, P | 2 |
Tripathy, SP | 6 |
Kleeberg, HH | 3 |
Swart, DJ | 1 |
Carey, SM | 1 |
Chaulet, P | 7 |
Boulahbal, F | 6 |
Ait Khaled, N | 2 |
El Awadi, Z | 2 |
Tazir, M | 3 |
Fiala, W | 1 |
Häcki, MA | 1 |
Brändli, O | 3 |
Suzuki, T | 1 |
Shimada, M | 1 |
Yamaguchi, W | 1 |
Kameda, K | 1 |
Okamura, S | 1 |
Aizawa, H | 2 |
Mehrotra, ML | 3 |
Gautam, KD | 3 |
Chaube, CK | 2 |
Khaled, S | 3 |
Aber, VR | 2 |
Edwards, EA | 2 |
Moulding, TS | 1 |
Pivet, HT | 1 |
Barrios, J | 1 |
Lefrock, JL | 1 |
Smith, BR | 1 |
Miller, SD | 1 |
Cohen, CD | 1 |
Sayed, AR | 1 |
Kirsch, RE | 1 |
Gonzalez Montaner, LJ | 1 |
Dambrosi, A | 1 |
Manassero, M | 1 |
Dambrosi, VM | 1 |
Sbarbaro, JA | 2 |
Stead, WW | 3 |
Dutt, AK | 3 |
Krishnamurthy, PV | 2 |
Garhupati Sarma, G | 1 |
Angel, JH | 3 |
Escreet, BC | 2 |
Cowie, RL | 5 |
Long, MW | 1 |
Zabow, M | 1 |
Pearson, JO | 3 |
Schröder, KH | 1 |
Müller, U | 1 |
Sighart, H | 3 |
Opl, G | 3 |
Weirich, H | 1 |
Ishiguro, S | 1 |
Koch, O | 1 |
Jenner, PJ | 1 |
Ellard, GA | 4 |
Allan, WG | 4 |
Singh, D | 1 |
Burkhardt, KR | 1 |
Nel, EE | 1 |
Humber, DP | 1 |
Nsanzumuhire, H | 1 |
Aluoch, JA | 2 |
Webster, AD | 1 |
Sandblom, RE | 1 |
Thummel, KE | 1 |
Slattery, JT | 1 |
Nelson, SD | 1 |
Whalen, C | 1 |
Byekwaso, F | 1 |
Vjecha, M | 1 |
Johnson, J | 1 |
Huebner, R | 3 |
Mugerwa, R | 1 |
Ellner, J | 1 |
Walubo, A | 3 |
Folb, PI | 1 |
Punnotok, J | 1 |
Pumprueg, U | 1 |
Chakorn, T | 1 |
Sedlaczek, AM | 1 |
Serwatowski, P | 1 |
Spiewak, W | 1 |
de Villiers, CL | 1 |
Macnab, MF | 1 |
Urban, T | 1 |
Maquarre, E | 1 |
Housset, C | 1 |
Chouaid, C | 1 |
Devin, E | 1 |
Lebeau, B | 1 |
Stevens, JP | 1 |
Daniel, TM | 1 |
Mitinskaia, LA | 1 |
Elufimova, VF | 1 |
Iukhimenko, NV | 3 |
Pogodaeva, NP | 1 |
Iavorskiĭ, KM | 1 |
Ormerod, LP | 3 |
McCarthy, OR | 2 |
Rudd, RM | 2 |
Horsfield, N | 3 |
Ong, EL | 1 |
Schrappe, M | 1 |
Wassermann, K | 1 |
Kroegel, C | 1 |
Zent, C | 1 |
al-Majed, SA | 1 |
Bourke, SJ | 1 |
White, J | 1 |
Stenton, SC | 1 |
Hendrick, DJ | 1 |
Arizzi-Rusche, AF | 1 |
Geiter, LJ | 4 |
O'Brien, RJ | 4 |
Yosiyama, T | 1 |
Yosikawa, M | 1 |
Sugie, T | 1 |
Nakasono, T | 1 |
Sugita, H | 2 |
Dubus, JC | 1 |
Piarroux, R | 1 |
Panuel, M | 1 |
Garnier, JM | 1 |
Faure, F | 1 |
Devred, P | 1 |
Unal, D | 1 |
Ekmekçi, A | 1 |
Sayli, A | 1 |
van der Kooi, K | 1 |
Mottet, JJ | 1 |
Regamey, C | 1 |
Chan, SL | 4 |
Wong, PC | 2 |
Jones, BE | 2 |
Otaya, M | 1 |
Antoniskis, D | 1 |
Sian, S | 1 |
Wang, F | 1 |
Mercado, A | 1 |
Davidson, PT | 1 |
Barnes, PF | 1 |
Yamamoto, S | 1 |
Sugita, N | 1 |
Kino, T | 1 |
Hayashi, A | 1 |
Vallejo, JG | 1 |
Ong, LT | 2 |
Starke, JR | 2 |
Luo, C | 1 |
Chintu, C | 1 |
Bhat, G | 1 |
Raviglione, M | 1 |
Diwan, V | 1 |
DuPont, HL | 1 |
Zumla, A | 1 |
Levée, G | 1 |
Glaziou, P | 1 |
Chanteau, S | 1 |
Seth, V | 1 |
Beotra, A | 1 |
Seth, SD | 1 |
Kabra, S | 1 |
Jain, Y | 1 |
Mukhopadhya, S | 1 |
Robson, SC | 1 |
Pillans, P | 1 |
Willcox, PA | 1 |
Kennedy, N | 2 |
Fox, R | 2 |
Kisyombe, GM | 2 |
Saruni, AO | 2 |
Uiso, LO | 2 |
Ramsay, AR | 2 |
Ngowi, FI | 2 |
Potashova, VA | 1 |
Zyrianova, TV | 1 |
Naryshkina, SL | 1 |
Koriakin, VA | 3 |
Khalbaeva, IV | 1 |
Ziia, AV | 1 |
Jain, A | 1 |
Mehta, VL | 1 |
Kulshrestha, S | 1 |
Kamolratanakul, P | 1 |
Chunhaswasdikul, B | 1 |
Jittinandana, A | 3 |
Tangcharoensathien, V | 1 |
Udomrati, N | 1 |
Akksilp, S | 1 |
Datta, M | 1 |
Radhamani, MP | 1 |
Selvaraj, R | 1 |
Paramasivan, CN | 3 |
Gopalan, BN | 1 |
Sudeendra, CR | 1 |
Prabhakar, R | 2 |
Luisetti, M | 1 |
Grassi, GG | 1 |
Peona, V | 1 |
Pozzi, E | 1 |
Grassi, C | 1 |
Chandrasekaran, V | 1 |
Sudarsanam, NM | 1 |
Atkin, SL | 1 |
Masson, EA | 1 |
Bodmer, CW | 1 |
Walker, BA | 1 |
White, MC | 1 |
Kassim, S | 1 |
Sassan-Morokro, M | 1 |
Ackah, A | 1 |
Abouya, LY | 1 |
Digbeu, H | 1 |
Yesso, G | 1 |
Coulibaly, IM | 1 |
Coulibaly, D | 1 |
Whitaker, PJ | 1 |
Doorly, R | 1 |
Botha, FJ | 1 |
Parkin, DP | 1 |
van de Wal, BW | 1 |
McColloster, P | 1 |
Neff, NE | 1 |
Berger, L | 1 |
Curram, J | 1 |
Gutmann, J | 1 |
Sam, N | 1 |
Tillotson, G | 1 |
Yates, M | 1 |
Chan, SP | 1 |
Birnbaum, J | 1 |
Rao, M | 1 |
Steiner, P | 1 |
Rothe, TB | 1 |
Karrer, W | 2 |
Miller, MA | 1 |
Desjardins, F | 1 |
Siddiqi, SH | 1 |
Dascal, A | 1 |
Roy, V | 2 |
Tekur, U | 2 |
Chopra, K | 2 |
Morris, CD | 1 |
Espinal, MA | 1 |
Pérez, G | 1 |
Camilo, E | 1 |
Soto, S | 1 |
Cruz, E | 1 |
Matos, N | 1 |
Gonzalez, G | 1 |
Fisher, M | 1 |
Tomlinson, DR | 1 |
Coker, RJ | 1 |
Nitta, AT | 1 |
Burman, WJ | 1 |
Brudney, KF | 1 |
Miranda-Massari, JR | 1 |
McGuinness, ME | 1 |
Berning, SE | 1 |
Gerena, GT | 1 |
Schaberg, T | 2 |
Rebhan, K | 1 |
Lode, H | 2 |
Scriven, JM | 1 |
Berry, D | 1 |
Escobar, MA | 1 |
Saravia, NG | 1 |
Weigle, KA | 1 |
Barakat, MT | 1 |
Scott, J | 1 |
Hughes, JM | 1 |
Walport, M | 1 |
Calam, J | 1 |
Friedland, JS | 1 |
Ind, PW | 1 |
McKenna, C | 1 |
Gülmez, I | 1 |
Keleştimur, F | 1 |
Durak, AC | 1 |
Ozesmi, M | 1 |
Schütte, W | 1 |
Berghaus, A | 1 |
Schütte, A | 1 |
Scorpio, A | 1 |
Lindholm-Levy, P | 1 |
Heifets, L | 2 |
Gilman, R | 1 |
Siddiqi, S | 1 |
Cynamon, M | 1 |
Sreevatsan, S | 1 |
Pan, X | 1 |
Kreiswirth, BN | 1 |
Musser, JM | 1 |
Bozóky, G | 1 |
Ruby, E | 1 |
Góhér, I | 1 |
Tóth, J | 1 |
Mohos, A | 1 |
Ridzon, R | 1 |
Meador, J | 1 |
Maxwell, R | 1 |
Higgins, K | 1 |
Weismuller, P | 1 |
Onorato, IM | 1 |
Fattinger, K | 1 |
Braunschweig, S | 1 |
Reichen, J | 1 |
Meier-Abt, PJ | 1 |
Krähenbühl, S | 1 |
Knobel, B | 1 |
Buyanowsky, G | 1 |
Dan, M | 1 |
Zaidel, L | 1 |
Sánchez-Albisua, I | 1 |
Vidal, ML | 1 |
Joya-Verde, G | 1 |
del Castillo, F | 1 |
de José, MI | 1 |
García-Hortelano, J | 1 |
Kayantao, D | 1 |
Keïta, B | 1 |
Sangaré, S | 1 |
Whalen, CC | 2 |
Hom, DL | 2 |
Mugyenyi, P | 1 |
Ellner, JJ | 2 |
Naqvi, A | 1 |
Akhtar, F | 1 |
Naqvi, R | 1 |
Akhtar, S | 1 |
Askari, H | 1 |
Lal, M | 1 |
Bhatti, S | 1 |
Shahzad, A | 1 |
Soomro, S | 1 |
Rizvi, A | 1 |
Blanco Ramos, JR | 1 |
Rosel Rioja, L | 1 |
Dopereiro Gómez, R | 1 |
Oteo Revuelta, JA | 1 |
Sybrecht, GW | 1 |
Yan, S | 1 |
Ye, H | 1 |
Lin, S | 1 |
Erreimi, N | 1 |
Hida, M | 1 |
Mouane, N | 1 |
Bouchta, F | 1 |
Michałowska-Mitczuk, D | 2 |
Kuś, J | 2 |
Jouveshomme, S | 1 |
Dautzenberg, B | 1 |
Beji, M | 1 |
Louzir, B | 1 |
Ben Rhomdane, N | 1 |
Zouari, M | 1 |
Mtimet, B | 1 |
Daghfous, J | 1 |
Halsey, NA | 1 |
Desormeaux, J | 1 |
Losikoff, P | 1 |
Atkinson, J | 1 |
Contave, M | 1 |
Johnson, M | 1 |
Davis, H | 1 |
Johnson, E | 1 |
Boulos, R | 1 |
Park, IW | 1 |
Choi, BW | 1 |
Hue, SH | 1 |
Rieder, HL | 4 |
Wilkinson, D | 1 |
Bechan, S | 1 |
Standing, E | 1 |
Short, GM | 1 |
Bai, KJ | 1 |
Yu, MC | 1 |
Suo, J | 2 |
Chiang, IH | 1 |
Lin, TP | 2 |
Luh, KT | 1 |
Kimerling, ME | 1 |
Phillips, P | 1 |
Patterson, P | 1 |
Hall, M | 1 |
Robinson, CA | 1 |
Dunlap, NE | 1 |
Wen, S | 1 |
Su, Y | 1 |
Zhang, F | 1 |
el-Sadr, WM | 1 |
Perlman, DC | 1 |
Matts, JP | 1 |
Nelson, ET | 1 |
Cohn, DL | 2 |
Salomon, N | 1 |
Olibrice, M | 1 |
Medard, F | 1 |
Chirgwin, KD | 1 |
Mildvan, D | 1 |
Telzak, EE | 1 |
Klein, O | 1 |
Hafner, R | 1 |
Lam, CW | 1 |
Morris, JS | 1 |
Mehta, JB | 1 |
Mejia, E | 1 |
Gallemore, GH | 1 |
Ramsey, GF | 1 |
Zeenreich, A | 1 |
Gochstein, B | 1 |
Grinshpoon, A | 1 |
Miron, M | 1 |
Rosenman, J | 1 |
Ben-Dov, I | 1 |
Bercion, R | 1 |
Koula-Shiro, S | 1 |
Radal, M | 2 |
Jonville-Bera, AP | 2 |
Van-Egroo, C | 1 |
Carré, P | 1 |
Lemarié, E | 1 |
Autret, E | 2 |
de Kantor, IN | 1 |
Latini, O | 1 |
Barrera, L | 1 |
Collazos, J | 2 |
España, P | 1 |
Mayo, J | 2 |
Martínez, E | 2 |
Izquierdo, F | 1 |
Morgan, JR | 1 |
Clarke, KW | 1 |
Brear, SG | 1 |
Tong, FM | 1 |
Chow, SK | 1 |
Sethna, KB | 1 |
Mistry, NF | 1 |
Dholakia, Y | 1 |
Antia, NH | 1 |
Harboe, M | 1 |
Mbaye, PS | 1 |
Talarmin, F | 1 |
Sane, M | 1 |
Eladari, D | 1 |
Klotz, F | 1 |
Goyal, A | 1 |
Nagarkar, NM | 1 |
Uppal, KS | 1 |
Mohan, H | 1 |
Dass, A | 1 |
Mwinga, A | 1 |
Hosp, M | 1 |
Godfrey-Faussett, P | 1 |
Quigley, M | 1 |
Mwaba, P | 1 |
Mugala, BN | 1 |
Nyirenda, O | 1 |
Luo, N | 1 |
Pobee, J | 1 |
Elliott, AM | 1 |
McAdam, KP | 1 |
Porter, JD | 1 |
Asai, S | 1 |
Futsuki, Y | 1 |
Tomari, S | 1 |
Araki, J | 1 |
Simpson, AJ | 1 |
Watt, B | 1 |
Heald, SH | 1 |
Sudlow, MF | 1 |
Leitch, AG | 1 |
Kistler, A | 1 |
Lappin, DW | 1 |
Coward, RA | 1 |
Iseman, MD | 1 |
Teo, SK | 1 |
Ikeda, N | 1 |
Sato, A | 1 |
Nakatani, K | 1 |
Yoshimatsu, H | 1 |
Olivier, C | 1 |
Mazaud, S | 1 |
Martel, C | 1 |
Ito, K | 1 |
Mizutani, S | 1 |
Xiao, C | 1 |
Li, Z | 1 |
Hoashi, S | 1 |
Tai, H | 1 |
Tamari, M | 1 |
O'Reilly, P | 1 |
McDonnell, T | 1 |
Duchin, JS | 1 |
Shields, T | 1 |
Sah, SP | 1 |
Raj, GA | 1 |
Bahadur, T | 1 |
Gach, O | 1 |
Corhay, JL | 1 |
Lousberg, L | 1 |
Bartsch, P | 1 |
Barker, J | 1 |
Makatini, Z | 1 |
Millard, J | 1 |
Bwire, R | 1 |
Borgdorff, MW | 1 |
Sticht-Groh, V | 1 |
Kawuma, HJ | 1 |
Bretzel, G | 1 |
Te Water Naude, JM | 1 |
Hussey, GD | 1 |
Kibel, MA | 1 |
Louw, A | 1 |
Perkins, DR | 1 |
Rao, GP | 1 |
Sousa, AO | 1 |
Wargnier, A | 1 |
Poinsignon, Y | 1 |
Simonney, N | 1 |
Gerber, F | 1 |
Lavergne, F | 1 |
Herrmann, JL | 1 |
Lagrange, PH | 1 |
Pimentel, ML | 1 |
Alves, SM | 1 |
Novis, SA | 1 |
Brandão, RZ | 1 |
Belo Neto, E | 1 |
Cakir, B | 1 |
Yönem, A | 1 |
Güler, S | 1 |
Odabaşi, E | 1 |
Demirbaş, B | 1 |
Gürsoy, G | 1 |
Aral, Y | 1 |
Draper, P | 1 |
Zimhony, O | 1 |
Cox, JS | 1 |
Vilchèze, C | 1 |
Jacobs, WR | 1 |
Roosihermiatie, B | 1 |
Nishiyama, M | 1 |
Nakae, K | 1 |
Yang, WC | 1 |
Chang, IT | 1 |
Tsai, BL | 1 |
Sharma, AK | 1 |
Tolani, SL | 1 |
Rathi, GL | 1 |
Gupta, HP | 1 |
Asano, T | 1 |
Kawamoto, H | 1 |
Asakuma, J | 1 |
Tanimoto, T | 1 |
Kobayashi, H | 1 |
Hayakawa, M | 1 |
Akalin, E | 1 |
Chandrakantan, A | 1 |
Keane, J | 1 |
Hamburger, RJ | 1 |
Arnadottir, T | 1 |
Yan, B | 2 |
Zhu, L | 2 |
Khan, MY | 1 |
Kinsara, AJ | 1 |
Osoba, AO | 1 |
Memish, Z | 1 |
Bakare, NA | 1 |
Onadeko, BO | 2 |
Ma, W | 1 |
Mayanja, H | 1 |
Mutuluuza Kityo, C | 1 |
Nsubuga, P | 1 |
Nakibali, JG | 1 |
Loughlin, AM | 1 |
Yun, H | 1 |
Mugyenyi, PN | 1 |
Vernon, A | 1 |
Maurya, V | 1 |
Panjabi, C | 1 |
Shah, A | 1 |
de Maria, A | 1 |
Berardi, M | 1 |
Dignetti, P | 1 |
Ferrera, L | 1 |
Viassolo, L | 1 |
Canonica, GW | 1 |
Suzuki, A | 1 |
Tamaru, A | 1 |
Katsukawa, C | 1 |
Oda, H | 1 |
Al-Dossary, FS | 1 |
Correa, AG | 1 |
Chierakul, N | 1 |
Chaiprasert, A | 1 |
Tingtoy, N | 1 |
Arjratanakul, W | 1 |
Pattanakitsakul, SN | 1 |
Goodall, RL | 1 |
Dosumu, EA | 1 |
Ndiaye, M | 1 |
Hane, AA | 1 |
Dieng, MT | 1 |
Ndir, M | 1 |
Ba, O | 1 |
Cissokho, S | 1 |
Kandji, M | 1 |
Diatta, A | 1 |
Niang, A | 1 |
Ndiaye, B | 1 |
Meyburg, J | 1 |
Schmidt, KG | 1 |
Nützenadel, W | 1 |
Bettendorf, M | 1 |
Medinger, A | 1 |
Gned'ko, NI | 1 |
Krüüner, A | 1 |
Pehme, L | 1 |
Ghebremichael, S | 1 |
Koivula, T | 1 |
Hoffner, SE | 1 |
Mikelsaar, M | 1 |
Pregowski, W | 2 |
Rossouw, JE | 1 |
Saunders, SJ | 1 |
Clarke, PD | 1 |
Kalich, R | 1 |
Gerloff, W | 1 |
Neubert, R | 1 |
Ulber, H | 1 |
Mamolat, AS | 1 |
Bialik, IB | 2 |
Khutorskaia, VD | 1 |
Horsfall, PA | 3 |
Plummer, J | 1 |
Aquinas, M | 1 |
Perdrizet, S | 1 |
Eule, H | 2 |
Promisloff, RA | 1 |
Johnston, RF | 3 |
Korotaev, GA | 2 |
Kozulitsyna, TM | 1 |
Utkin, VV | 4 |
Bravo, TC | 1 |
Parthasarathy, R | 2 |
Sambamoorthy, S | 2 |
Somasundaram, PR | 3 |
Subbammal, S | 4 |
Hinshaw, HC | 1 |
Iatsozhinskiĭ, IuD | 1 |
Kulik, NM | 1 |
Molotkov, VN | 1 |
Petrenko, VM | 1 |
Shkol'nyi, LK | 1 |
Dahlström, G | 1 |
Hanngren, A | 1 |
Stavenow, S | 1 |
Wiman, LG | 1 |
Treece, GL | 1 |
Magnussen, CR | 1 |
Patterson, JR | 1 |
Tschudy, DP | 1 |
Kislitsyna, NA | 1 |
Kotova, NI | 1 |
Kwan, SY | 1 |
Wolde, K | 1 |
Lema, E | 1 |
Roscigno, G | 1 |
Abdi, A | 1 |
Kumaresan, JA | 1 |
Maganu, ET | 1 |
Abbo, AW | 1 |
Kortekaas, JC | 1 |
Singhal, KC | 1 |
Varshney, MK | 1 |
Laguna, F | 1 |
Adrados, M | 1 |
Díaz, F | 1 |
Martínez, R | 1 |
García Aguado, C | 1 |
Puente, S | 1 |
González Lahoz, JM | 1 |
Wiesner, B | 1 |
Cramer, G | 1 |
Hamel, U | 1 |
Roth, G | 1 |
Small, PM | 1 |
Schecter, GF | 1 |
Goodman, PC | 1 |
Sande, MA | 1 |
Dickinson, JM | 1 |
del Castillo Martín, F | 1 |
Calvo Rey, C | 1 |
Vidal López, ML | 1 |
del Cerro, MJ | 1 |
García Hortelano, J | 1 |
Chan, K | 3 |
Woo, J | 3 |
Chan, HS | 2 |
Wong, CL | 2 |
Narang, NK | 1 |
Meratwal, S | 1 |
Jain, D | 1 |
Rac, VV | 1 |
Gupta, EV | 1 |
Thomas, IM | 1 |
Catlin, BJ | 1 |
Peterson, KL | 1 |
Judson, FN | 1 |
Agounitestane, D | 1 |
Chiheb, M | 1 |
Nowak, D | 2 |
Radenbach, D | 2 |
Magnussen, H | 2 |
Balasubramanian, R | 1 |
Sivasubramanian, S | 2 |
Ramachandran, R | 1 |
Jawahar, MS | 1 |
Selvakumar, N | 1 |
Combs, DL | 2 |
Brink, BA | 1 |
Campbell, IA | 1 |
Neill, P | 1 |
Pringle, D | 1 |
Mhonda, M | 1 |
Kusema, T | 1 |
Nhachi, CF | 1 |
Onishchenko, VV | 1 |
Shapatava, MN | 1 |
Iurchenko, LN | 1 |
Morland, L | 1 |
Dhand, R | 1 |
Singhi, PD | 1 |
Rao, KL | 1 |
Katariya, S | 1 |
Savula, MM | 1 |
Smolenko, MI | 1 |
Romaniuk, MD | 1 |
Slivka, IuI | 1 |
Musch, E | 1 |
Loos, U | 1 |
Schwabe, HK | 1 |
Roden, S | 1 |
Lagneau, M | 1 |
Homasson, JP | 1 |
Kecharanandana, P | 1 |
Payanandana, W | 1 |
Daramas, M | 1 |
Ladron de Guevara, R | 1 |
Bellabas, M | 1 |
Khaled, NA | 1 |
Haegi, V | 1 |
Villiger, B | 1 |
Bohn, W | 1 |
Baumann, HR | 1 |
Zäch, R | 1 |
Porokhnia, VV | 1 |
Khomenko, VV | 1 |
Petrovich, DI | 1 |
Iusukhno, EE | 1 |
Skvira, VP | 1 |
Felten, MK | 1 |
Schilling, W | 1 |
Schnorr, R | 1 |
Landmann, H | 1 |
Sanwikarja, S | 1 |
Kauffmann, RH | 1 |
te Velde, J | 1 |
Serlie, J | 1 |
le Bourgeois, M | 1 |
de Blic, J | 1 |
Paupe, J | 1 |
Scheinmann, P | 1 |
Ellis, ME | 1 |
Tayoub, F | 1 |
Steele, MA | 1 |
Des Prez, RM | 1 |
Babu Swai, O | 1 |
Thiong'o, R | 1 |
Darbyshire, JH | 2 |
Hong, YP | 1 |
Kim, SC | 1 |
Chang, SC | 1 |
Jin, BW | 1 |
Park, CD | 1 |
Zaman, R | 1 |
Orakzai, SA | 1 |
Yunus, A | 1 |
Xu, RX | 1 |
Baba, H | 2 |
Shinkai, A | 2 |
Izuchi, R | 2 |
Azuma, Y | 2 |
Trivedi, SS | 1 |
Desai, SG | 1 |
Schwartz, MS | 1 |
Kahlstrom, EJ | 1 |
Hawkins, DB | 1 |
Lecoeur, H | 1 |
Stamatakis, G | 1 |
Montes, C | 1 |
Trouvin, JH | 1 |
Farinotti, R | 1 |
Fessi, H | 1 |
Kenouch, S | 1 |
Méry, JP | 1 |
Mignot, P | 1 |
Dumas, R | 1 |
Lavarenne, J | 1 |
Molina, C | 1 |
Lacroix, C | 1 |
Guyonnaud, C | 1 |
Chaou, M | 1 |
Duwoos, H | 1 |
Lafont, O | 1 |
Jain, VK | 1 |
Vardhan, H | 1 |
Prakash, OM | 1 |
Goldberger, MJ | 1 |
Schell, G | 1 |
Lagos, A | 1 |
Nuñez, A | 1 |
Soto, R | 1 |
Araya, D | 1 |
Lee, CN | 1 |
Lee, JJ | 1 |
Yang, SP | 1 |
Szymański, A | 2 |
Czaplińska-Jóźwiak, E | 1 |
Leung, A | 1 |
Lai, KN | 1 |
Teoh, R | 1 |
Spychalski, W | 1 |
Grzegorzewska, A | 1 |
Westfal, I | 1 |
Herlevsen, P | 1 |
Nielsen, C | 1 |
Pedersen, JT | 1 |
Farer, LS | 1 |
Beck, H | 1 |
Evers, H | 1 |
Fischer, P | 1 |
Kwiatkowski, H | 1 |
Merkel, S | 1 |
Reech, R | 1 |
Sieler, R | 1 |
Thomas, E | 1 |
Weinecke, W | 1 |
Awotedu, AA | 1 |
Ogunbanjo, BO | 1 |
Aderinto, EB | 1 |
Dong, SQ | 1 |
Corsello, BF | 1 |
Jonker, R | 1 |
Kopeć, H | 1 |
Maternowska, W | 1 |
Prus, F | 1 |
Sembratowicz, L | 1 |
Berkani, M | 1 |
Summers, RS | 1 |
Crewe-Brown, HH | 1 |
Glatthaar, E | 1 |
McCutcheon, JP | 1 |
Layer, P | 1 |
Engelhard, M | 1 |
Janardhanam, B | 2 |
Mukerjee, CM | 1 |
McKenzie, DK | 1 |
Sandron, D | 1 |
Marin, I | 1 |
Huchon, G | 1 |
Ganter, B | 1 |
Baron, RB | 1 |
Sanchez-Hernandez, M | 1 |
Röthlisberger, K | 1 |
Bezel, R | 1 |
Häcki, M | 1 |
Rubin, S | 1 |
Blanco Quirós, A | 1 |
Mazouni, L | 1 |
Kecharananta, P | 1 |
Rattarasarn, S | 1 |
Sriyabhaya, N | 1 |
Langton, ME | 2 |
Krivinka, R | 1 |
Wilson, TM | 1 |
Schütz, I | 1 |
Radenbach, KL | 1 |
Bartmann, K | 1 |
Virchow, C | 1 |
Flemming, J | 1 |
De ville de Goyet, CA | 1 |
Pätiälä, J | 1 |
Trnka, L | 1 |
Karuga, WK | 1 |
Dingley, HB | 1 |
Pande, DC | 1 |
Grover, KL | 1 |
Wildrick, KH | 1 |
Bartal, M | 1 |
Nejjar, A | 1 |
Laraki, A | 1 |
Rushchak, VA | 1 |
Gartmann, JC | 1 |
Jancikova-Máková, M | 1 |
Bayliss, CG | 1 |
Steiner, M | 1 |
Grumbach, F | 1 |
Iaschenko, BP | 1 |
Steininger, WJ | 1 |
Stýblo, K | 1 |
Kubík, A | 1 |
Langerová, M | 1 |
Matusková, E | 1 |
Morávková, K | 1 |
Kochnowski, G | 1 |
Malinowska, B | 1 |
Pawlak, F | 1 |
Jesiotr, M | 1 |
Crofton, J | 1 |
Lester, W | 2 |
Mital, OP | 1 |
Agarwala, MC | 1 |
Singh, SK | 2 |
Heise, A | 1 |
Blaha, H | 1 |
Reimann, B | 1 |
Vanasin, B | 1 |
Colmer, M | 1 |
Davis, PJ | 1 |
Neumann, G | 1 |
Sirota, DS | 1 |
Man'kovetskiĭ, EF | 1 |
Koĭfman, SG | 1 |
Vatsyk, MZ | 1 |
Beckert, W | 2 |
Gomi, J | 1 |
Aoyagi, T | 1 |
Doster, B | 1 |
Murray, FJ | 1 |
Newman, R | 1 |
Woolpert, SF | 1 |
Sasaoka, M | 1 |
Kawamori, Y | 1 |
Kakuno, J | 1 |
Whitcomb, ME | 1 |
Rocklin, RE | 1 |
Stańczuk-Holub, A | 1 |
Muranda, M | 1 |
Del Solar, JA | 1 |
Jorquera, C | 1 |
Saavedra, L | 1 |
Pemjean, I | 1 |
Greene, ME | 1 |
Stonehill, RB | 1 |
Tauchnitz, C | 1 |
Storch, W | 1 |
Ellorhaoui, M | 1 |
Stradling, P | 1 |
Onisk, J | 1 |
Radecki, A | 2 |
Kanwiszer, H | 1 |
Krzanowska, E | 1 |
Donderowicz, A | 1 |
Zacara, A | 1 |
Woźniak, S | 1 |
Bignall, JR | 2 |
De March Ayuela, P | 1 |
Turell Gumá, J | 1 |
Böszörményi, M | 3 |
Feldmann, FM | 2 |
Lambert, HP | 1 |
Nair, NG | 1 |
Radhakrishna, S | 1 |
Rudoĭ, NM | 1 |
Fedorova, IE | 1 |
Afanas'eva, IuP | 1 |
Schaich, W | 1 |
Sunahara, S | 1 |
Lind, A | 2 |
Rist, N | 2 |
Stepanenko, VA | 1 |
Marr, JJ | 1 |
Yamamoto, M | 1 |
Isoe, K | 1 |
Fuse, M | 1 |
Selkon, JB | 1 |
Walton, M | 1 |
White, AB | 1 |
Matzel, W | 1 |
Lindemann, I | 1 |
Anastasatu, C | 1 |
Ulpian, C | 1 |
Weiss, P | 1 |
Susteric, J | 1 |
Vidinel, I | 1 |
Ozgen, ZS | 1 |
Hokama, S | 1 |
Krishnamurthy, DV | 2 |
Venkataraman, P | 1 |
Dissmann, E | 1 |
Foster-Carter, AF | 1 |
Rizzo, A | 1 |
Magalhães, M | 1 |
Moura, N | 1 |
Kolosovskaia, VP | 1 |
Lees, AW | 1 |
Tyrrell, WF | 1 |
Smith, J | 1 |
Allan, GW | 1 |
Grymiński, J | 1 |
Lyczewska, J | 1 |
Walczak, J | 1 |
Mkrtchian, SV | 1 |
Egorkina, ND | 1 |
Zachara, A | 3 |
Lukaszczyk, E | 1 |
Ignasiak, J | 1 |
Urbancik, B | 1 |
Antonijević, A | 1 |
Pannain, M | 1 |
Tarantino, AB | 1 |
Mac Dowell, A | 1 |
Costa, JA | 1 |
Cunha, JM | 1 |
Pantoja, W | 1 |
Ivanova, ES | 1 |
Komarova, AA | 1 |
Vasilik, GV | 2 |
Kaminskaia, AA | 1 |
Golitsina, LV | 1 |
Fegiz, G | 1 |
Organick, AB | 1 |
Wilson, EM | 1 |
Ropek, M | 1 |
Chetkowski, A | 1 |
Tarocińska, B | 1 |
Novák, M | 1 |
Jancíková, M | 1 |
Krátký, J | 1 |
Feitová, S | 1 |
Bukalska, Z | 1 |
Pickroth, G | 1 |
Kataria, YP | 1 |
Gajewska, E | 1 |
Petera, V | 1 |
Klapálek, D | 1 |
Paichl, P | 1 |
Pecený, A | 1 |
Grunert, M | 1 |
Reutgen, H | 1 |
Iwainsky, H | 1 |
McCurdy, PR | 1 |
Donohoe, RF | 1 |
Magovern, M | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB: a 3-arm Randomized Trial.[NCT03988933] | Phase 2 | 1,368 participants (Actual) | Interventional | 2019-09-20 | Active, not recruiting | ||
Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With Pulmonary Tuberculosis in the Kilimanjaro Region, Tanzania.[NCT00760149] | Phase 2 | 150 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
A Prospective, Randomized, Open, Active-controlled, Interventional, Exploratory, Phase II Trial to Evaluate the EBA, Safety and PK of Orally Administered LCB01-0371 in Adult Patients With Smear-positive Pulmonary Tuberculosis[NCT02836483] | Phase 2 | 79 participants (Actual) | Interventional | 2016-12-10 | Completed | ||
Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin to 3 Months After Culture Conversion (Hi-DoRi-3): A Phase 3, Multicenter, Randomized, Open-label, Clinical Trial[NCT04485156] | Phase 3 | 926 participants (Anticipated) | Interventional | 2020-09-30 | Not yet recruiting | ||
A Phase 2 Dose-ranging Trial to Evaluate the Bactericidal Activity, Safety, Tolerability and Pharmacokinetics of Linezolid in Adult Subjects With Newly Diagnosed Drug-Sensitive, Smear-Positive Pulmonary Tuberculosis.[NCT02279875] | Phase 2 | 113 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
Electronic Pillbox-enabled Self-administered Therapy Versus Standard Directly Observed Therapy for Tuberculosis Medication Adherence and Treatment Outcomes in Ethiopia: a Multicenter Randomized Controlled Trial[NCT04216420] | 114 participants (Actual) | Interventional | 2020-06-01 | Completed | |||
Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes in HIV-tuberculosis Co-infected Ugandan Adults[NCT01782950] | Phase 4 | 400 participants (Anticipated) | Interventional | 2013-02-28 | Recruiting | ||
Substitution of Ethambutol With Linezolid During the Intensive Phase of Treatment of Pulmonary Tuberculosis: A Prospective, Multicenter, Randomized, Open-label Phase II Trial[NCT01994460] | Phase 2 | 429 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
A Randomised Open-Label Controlled Trial of a 4-Month Gatifloxacin-Containing Regimen Versus Standard Regimen for the Treatment of Adult Patients With Pulmonary Tuberculosis[NCT00216385] | Phase 3 | 2,070 participants | Interventional | 2005-01-31 | Recruiting | ||
Delamanid, Linezolid, Levofloxacin, and Pyrazinamide for the Treatment of Patients With Fluoroquinolone-sensitive MDR-TB: A Phase 2/3, Multicenter, Randomized, Open-label, Clinical Trial[NCT02619994] | Phase 2 | 238 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
A Prospective, Randomized Open-Label Phase II Study of the Safety and Tolerability of Metformin in Combination With Standard Antimicrobial Treatment of Pulmonary Tuberculosis in People With TB and Co-infected With HIV[NCT04930744] | Phase 2 | 112 participants (Anticipated) | Interventional | 2021-08-03 | Recruiting | ||
Metformin as Adjunctive Therapy in Overweight and Obese Patients With Dengue: an Open-label Safety and Tolerability Trial[NCT04377451] | Phase 1/Phase 2 | 120 participants (Actual) | Interventional | 2020-07-27 | Completed | ||
Pharmacokinetics of Standard First and Second Line Anti-TB Drugs in the Lung and Lesions of Subjects Elected for Resection Surgery[NCT00816426] | Phase 1 | 19 participants (Actual) | Interventional | 2008-12-29 | Completed | ||
A Phase II Trial to Describe the Pharmacokinetics, Safety and Efficacy of Pharmacogenetics-guided Dosing of Isoniazid in Patients With HIV-associated TB[NCT05124678] | Phase 2 | 40 participants (Anticipated) | Interventional | 2021-12-07 | Recruiting | ||
A Randomized, Four-arm Open Label Phase Two-b Clinical Trial to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of High Dose Rifampicin in TB-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy[NCT03982277] | Phase 2 | 130 participants (Actual) | Interventional | 2019-04-30 | Completed | ||
Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis[NCT03827811] | 625 participants (Anticipated) | Observational | 2020-01-30 | Recruiting | |||
A Randomized Clinical Trial of Early Empiric Anti-Mycobacterium Tuberculosis Therapy for Sepsis in Sub-Saharan Africa[NCT04618198] | Phase 3 | 436 participants (Anticipated) | Interventional | 2021-12-10 | Recruiting | ||
A Randomised Placebo - Controlled Double Blind Trial Comparing 1) a Two Month Intensive Phase of Ethambutol, Moxifloxacin, Rifampicin, Pyrazinamide Versus the Standard Regimen (Ethambutol, Isoniazid, Rifampicin, Pyrazinamide) and 2) a Treatment Shortening[NCT00864383] | Phase 3 | 1,931 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
Using Biomarkers to Predict TB Treatment Duration[NCT02821832] | Phase 2 | 946 participants (Actual) | Interventional | 2017-06-21 | Active, not recruiting | ||
A Prospective, Randomized Controlled Study for the Efficacy and Safety of the Substitution of Pyrazinamide and Ethambutol With Moxifloxacin During the Intensive Phase of Treatment of Pulmonary Tuberculosis[NCT04187469] | 286 participants (Anticipated) | Interventional | 2020-03-01 | Not yet recruiting | |||
Beta-Lactam Containing Regimen for the Shortening of Buruli Ulcer Disease Therapy: Comparison of 8 Weeks Standard Therapy (Rifampicin Plus Clarithromycin) vs. 4 Weeks Standard Plus Amoxicillin/Clavulanate Therapy [RC8 vs. RCA4][NCT05169554] | Phase 2 | 140 participants (Anticipated) | Interventional | 2021-12-01 | Recruiting | ||
A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis[NCT05575518] | Phase 3 | 414 participants (Anticipated) | Interventional | 2023-08-11 | Recruiting | ||
Rifampin to Reduce Elevated Levels of Blood and Urine Calcium in Patients With Idiopathic Infantile Hypercalcemia[NCT03384121] | Phase 1 | 5 participants (Anticipated) | Interventional | 2018-02-22 | Recruiting | ||
A Phase IIA Dose Ranging Trial to Evaluate the Safety, Tolerability, Extended Early Bactericidal Activity and Pharmacokinetics of Higher Doses of Rifampicin in Adult Subjects With Newly Diagnosed, Uncomplicated, Smear-Positive, Pulmonary Tuberculosis[NCT01392911] | Phase 2 | 128 participants (Anticipated) | Interventional | 2011-06-30 | Completed | ||
A Phase II Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin Plus PA-824 Plus Pyrazinamide After 8 Weeks of Treatment in Adult Patients With Newly Diagnosed Drug-Sensitive or Multi D[NCT01498419] | Phase 2 | 207 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in the Treatment of Tuberculosis Patient With HIV Infection in South Africa: A Phase II Trial[NCT00640887] | Phase 2 | 48 participants (Anticipated) | Interventional | 2009-02-28 | Completed | ||
Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)[NCT01637558] | Phase 4 | 200 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
A Phase II Randomized, Open-label Trial of a Rifapentine Plus Moxifloxacin-Based Regimen for Intensive Phase Treatment of Smear-Positive Pulmonary Tuberculosis[NCT00728507] | Phase 2 | 121 participants (Actual) | Interventional | 2009-11-30 | Terminated (stopped due to Funding withdrawn) | ||
A Multiple Arm, Multiple Stage, Phase 2, OL, Randomized, Controlled Trial to Evaluate 4 Treatment Regimens of SQ109, Increased Doses of Rifampicin, and Moxifloxacin in Adults With Newly Diagnosed, Smear-positive Pulmonary Tuberculosis[NCT01785186] | Phase 2 | 365 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa.[NCT02348177] | Phase 4 | 96 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
TBTC Study 31 PK/PD: Population Pharmacokinetic and Pharmacodynamic Study of Efficacy and Safety of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis in the Study 31 Treatment Trial: Intensive PK Sampling[NCT02563327] | Phase 3 | 60 participants (Anticipated) | Interventional | 2016-05-30 | Recruiting | ||
Phase 2 Randomized Trial of a Moxifloxacin-Containing Regimen For Treatment of Smear-Positive Pulmonary Tuberculosis in Adults With and Without HIV Infection[NCT00082173] | Phase 2 | 170 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
DNA Sequencing of MDR TB in Eastern Siberia[NCT02508610] | 630 participants (Anticipated) | Observational | 2013-11-30 | Recruiting | |||
A Prospective Study of Shortening the Duration of Standard Short Course Chemotherapy From 6 Months to 4 Months in HIV-non-infected Patients With Fully Drug-Susceptible, Non-cavitary Pulmonary Tuberculosis With Negative Sputum Cultures After 2 Months of An[NCT00130247] | Phase 3 | 394 participants (Actual) | Interventional | 2002-04-08 | Completed | ||
Prophylactic Use of Entecavir to Reduce Hepatitis Flare in Highly Viremic HBV Patients With Active Tuberculosis Receiving Anti-tuberculous Treatment[NCT01724723] | Phase 4 | 50 participants (Anticipated) | Interventional | 2012-12-31 | Not yet recruiting | ||
International Multicenter Trial for the Evaluation of a Four-Drug Fixed Dose Combined Tablet Daily in the Initial Intensive Phase of Chemotherapy Followed by a Two-Drug Fixed Dose Combined Tablet Three Times a Week in the Continuation Phase for the Treatm[NCT00216333] | Phase 4 | 1,500 participants | Interventional | 2003-12-31 | Recruiting | ||
A Phase II Dose Ranging Trial to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of PA-824 in Adult Participants With Newly Diagnosed, Uncomplicated, Smear-Positive, Pulmonary Tuberculosis[NCT00944021] | Phase 2 | 69 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
Early Bactericidal Activity of Standard Drugs Used to Treat Mycobacterium Avium Complex: a Pilot Study[NCT04287049] | Phase 2 | 30 participants (Anticipated) | Interventional | 2020-02-24 | Recruiting | ||
A Phase II Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of the Following: TMC207 Alone, TMC207 Plus Pyrazinamide,TMC207 Plus PA-824,PA-824 Plus Pyrazinamide and PA-824 Plus Pyrazinamide and Moxifloxacin, in Adult Patients Wit[NCT01215851] | Phase 2 | 85 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
NexGen EBA Radiologic and Immunologic Biomarkers of Sterilizing Drug Activity in Tuberculosis[NCT02371681] | Phase 2 | 262 participants (Actual) | Interventional | 2015-02-25 | Completed | ||
A Phase 2 Randomized, Open-label Trial of Daily Rifapentine 450mg or 600mg in Place of Rifampicin 600mg for Intensive Phase Treatment of Smear-positive Pulmonary Tuberculosis[NCT00814671] | Phase 2 | 153 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
Randomized Clinical Trial to Assess the Efficacy of Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis[NCT00376012] | Phase 3 | 300 participants (Actual) | Interventional | 2001-02-28 | Active, not recruiting | ||
Evaluation of Two Different Preventive Therapy Regimens for Tuberculosis in HIV Infected Persons[NCT00351702] | Phase 3 | 650 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence[NCT03302299] | Phase 4 | 302 participants (Actual) | Interventional | 2017-04-07 | Completed | ||
TB Treatment Support Tools: Refinement and Evaluation of an Interactive Mobile App and Direct Adherence Monitoring on TB Treatment Outcomes[NCT04221789] | 555 participants (Actual) | Interventional | 2020-11-17 | Active, not recruiting | |||
The Treatment of Pulmonary Mycobacterium Tuberculosis in HIV Infection[NCT00001033] | Phase 3 | 650 participants | Interventional | Completed | |||
Efficacy of Simultaneous Versus Sequential Antiretroviral Therapy and Antituberculosis Treatment in Patients With AIDS and Active Tuberculosis. Open, Randomized and Controlled, Multisite Clinical Trial.[NCT00737724] | 63 participants (Actual) | Interventional | 2008-03-31 | Terminated (stopped due to Other published trials showed definitive expected superiority of Group 1) | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The secondary analysis of efficacy outcome was the proportion of patients who had bacteriologically or clinically defined failure or relapse within 18 months after randomization (a composite unfavorable outcome) based on MGIT. Culture-negative status was defined as two negative-culture results at different visits without an intervening positive result. The date of culture-negative status was defined as the date of the first negative-culture result. This status continued until there were two positive cultures, without an intervening negative culture, or until there was a single positive culture that was not followed by two negative cultures. Relapse strains were those shown to be identical on 24-locus Mycobacterial interspersed repetitive units (MIRU) analysis. (NCT00864383)
Timeframe: 18 months (within one year of completion of therapy)
Intervention | participants with failure or relapse (Number) |
---|---|
Regimen 1 - 2EHRZ/4HR (Control Regimen) | 65 |
Regimen 2 - 2MHRZ/2MHR | 98 |
Regimen 3 - 2EMRZ/2MR | 131 |
The primary efficacy outcome was the proportion of patients who had bacteriologically or clinically defined failure or relapse within 18 months after randomization (a composite unfavorable outcome). Culture-negative status was defined as two negative-culture results at different visits without an intervening positive result. The date of culture-negative status was defined as the date of the first negative-culture result. This status continued until there were two positive cultures, without an intervening negative culture, or until there was a single positive culture that was not followed by two negative cultures. Relapse strains were those shown to be identical on 24-locus Mycobacterial interspersed repetitive units (MIRU) analysis. For the final 18 month study visit when both L-J samples were contaminated or missing, if the subject could not be brought back, liquid medium culture results were used in place of solid medium culture results. (NCT00864383)
Timeframe: 18 months (within one year of completion of therapy)
Intervention | participants with failure or relapse (Number) |
---|---|
Regimen 1 - 2EHRZ/4HR (Control Regimen) | 43 |
Regimen 2 - 2MHRZ/2MHR | 78 |
Regimen 3 - 2EMRZ/2MR | 105 |
Number of patients who are TB MGIT culture negative at 8 weeks. (NCT00864383)
Timeframe: 8 weeks
Intervention | participants who are culture negative (Number) |
---|---|
Regimen 1 - 2EHRZ/4HR (Control Regimen) | 235 |
Regimen 2 - 2MHRZ/2MHR | 274 |
Regimen 3 - 2EMRZ/2MR | 260 |
Number of patients who are TB LJ culture negative at 8 weeks. (NCT00864383)
Timeframe: 8 weeks
Intervention | participants who are culture negative (Number) |
---|---|
Regimen 1 - 2EHRZ/4HR (Control Regimen) | 352 |
Regimen 2 - 2MHRZ/2MHR | 394 |
Regimen 3 - 2EMRZ/2MR | 401 |
The number of participants includes all patients who had at least one grade 3 or 4 adverse event. (NCT00864383)
Timeframe: 18 months (within one year of completion of therapy)
Intervention | participants with Grade 3 or 4 AEs (Number) |
---|---|
Regimen 1 - 2EHRZ/4HR (Control Regimen) | 123 |
Regimen 2 - 2MHRZ/2MHR | 127 |
Regimen 3 - 2EMRZ/2MR | 111 |
"Sensitivity Analysis of Primary Efficacy Results of All Randomized Subjects Imputing Favorable for Missing Outcomes. Analysis is the number of subjects with an unfavorable outcome. Favorable outcome is defined as the number of subjects with a negative TB culture status at 18 months (at or after 72 weeks), who had not already been classified as having an unfavorable outcome, and whose last positive TB culture result (isolated positive culture) was followed by at least two negative culture results." (NCT00864383)
Timeframe: 18 months
Intervention | participants with unfavorable outcome (Number) |
---|---|
Regimen 1 - 2EHRZ/4HR (Control Regimen) | 87 |
Regimen 2 - 2MHRZ/2MHR | 132 |
Regimen 3 - 2EMRZ/2MR | 132 |
"Sensitivity Analysis of Primary Efficacy Results of All Randomized Subjects Imputing Unfavorable for Missing Outcomes. Analysis is the number of subjects with an unfavorable outcome. Favorable outcome is defined as the number of subjects with a negative TB culture status at 18 months (at or after 72 weeks), who had not already been classified as having an unfavorable outcome, and whose last positive TB culture result (isolated positive culture) was followed by at least two negative culture results." (NCT00864383)
Timeframe: 18 months
Intervention | participants with unfavorable outcome (Number) |
---|---|
Regimen 1 - 2EHRZ/4HR (Control Regimen) | 172 |
Regimen 2 - 2MHRZ/2MHR | 219 |
Regimen 3 - 2EMRZ/2MR | 217 |
Culture negative for TB using LJ cultures. (NCT00864383)
Timeframe: 18 months
Intervention | Time to culture negative status / weeks (Median) |
---|---|
Regimen 1 - 2EHRZ/4HR (Control Regimen) | 6.0 |
Regimen 2 - 2MHRZ/2MHR | 6.0 |
Regimen 3 - 2EMRZ/2MR | 6.0 |
(NCT00864383)
Timeframe: 18 months
Intervention | Time to culture negative status / weeks (Median) |
---|---|
Regimen 1 - 2EHRZ/4HR (Control Regimen) | 11.9 |
Regimen 2 - 2MHRZ/2MHR | 8.0 |
Regimen 3 - 2EMRZ/2MR | 8.0 |
Estimation of the lower bound of a one-sided 95% confidence interval of the difference in success rates between arms B and C. If the lower bound is greater than -7%, this will be evidence that the treatment-shortening arm is not inferior to the standard duration arm. (NCT02821832)
Timeframe: 18 months
Intervention | Participants (Count of Participants) | ||||
---|---|---|---|---|---|
Cured | Confirmed relapses | Late withdrawal, lost to follow-up | Probable relapses | Treatment Failure | |
Arm A | 217 | 5 | 13 | 1 | 1 |
Arm B | 121 | 1 | 9 | 1 | 0 |
Arm C | 117 | 9 | 6 | 3 | 4 |
(NCT01498419)
Timeframe: 8 weeks
Intervention | percentage of participants (Number) |
---|---|
Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg) | 13 |
Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg) | 19 |
Drug Sensitive: Rifafour | 12 |
Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg) | 12 |
Sputum culture conversion is defined as a change from a positive growth of M. tuberculosis in a sputum sample to negative M. tuberculosis growth sputum sample in patients with pulmonary TB. This was measured at visit 24(Day 57). (NCT01498419)
Timeframe: Day 57 after eight weeks of daily treatment
Intervention | percentage of patients (Number) |
---|---|
Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg) | 65.7 |
Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg) | 71.4 |
Drug Sensitive: Rifafour | 37.8 |
Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg) | 50.0 |
Sputum culture conversion is defined as a change from a positive growth of M. tuberculosis in a sputum sample to negative M. tuberculosis growth sputum sample in patients with pulmonary TB. (Day 57) (NCT01498419)
Timeframe: Day 57 after eight weeks of daily treatment
Intervention | percentage of participants (Number) |
---|---|
Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg) | 82.9 |
Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg) | 94.3 |
Drug Sensitive: Rifafour | 87.5 |
Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg) | 62.5 |
The primary efficacy endpoint was bactericidal activity characterized by the daily rate of change in mean log10CFU counts during 8 weeks of treatment (bactericidal activity assessed by CFU on solid media for days 0-56). (NCT01498419)
Timeframe: 8 weeks
Intervention | log10CFU/ml/day (Mean) |
---|---|
Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg) | 0.133 |
Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg) | 0.155 |
Drug Sensitive: Rifafour | 0.112 |
Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg) | 0.117 |
Measurement of TTP in liquid culture media Mycobacteria growth indicator tube (MGIT) using standard procedures (NCT01498419)
Timeframe: 8 weeks
Intervention | log10hours/day (Mean) |
---|---|
Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg) | 0.020 |
Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg) | 0.020 |
Drug Sensitive: Rifafour | 0.017 |
Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg) | 0.015 |
liquid culture = Mycobacteria growth indicator tube (MGIT) Sputum culture conversion is defined as a change from a positive growth of M. tuberculosis in a sputum sample to negative M. tuberculosis growth sputum sample in patients with pulmonary TB (NCT01498419)
Timeframe: 8 weeks
Intervention | days (Median) |
---|---|
Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg) | 42.0 |
Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg) | 49.0 |
Drug Sensitive: Rifafour | 56.0 |
Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg) | 56.0 |
Sputum culture conversion is defined as a change from a positive growth of M. tuberculosis in a sputum sample to negative M. tuberculosis growth sputum sample in patients with pulmonary TB (NCT01498419)
Timeframe: 8 weeks
Intervention | days (Median) |
---|---|
Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg) | 28.0 |
Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg) | 28.0 |
Drug Sensitive: Rifafour | 35.0 |
Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg) | 35.0 |
LJ culture conversion (NCT00728507)
Timeframe: Week 8
Intervention | percentage of participants (Number) |
---|---|
HPZM | 78.3 |
HRZE | 84.3 |
"Pharmacokinetic parameters will be assessed for rifampicin, moxifloxacin and SQ109:~area under the plasma concentration curve from dosing to the end of the dosing interval (AUC 0-24) (in h*ng/mL)~the observed maximum concentration (Cmax( (in ng/mL)~time to reach Cmax (Tmax)(in hours)~the minimum observed plasma concentration 24 hours following the last dose (Cmin) (in hours),~clearance (Cl) (in mL/minute),~volume of distribution (Vd) (in L),~elimination half-life (T1/2,) (in hours)~free (protein-unbound) fraction (for rifampicin only) (in percent)." (NCT01785186)
Timeframe: 0 - 12 weeks
Intervention | Rifampicin AUC(mg*h/l) (Geometric Mean) |
---|---|
HRZQ | 17.4 |
Arm 1 (R35) | 170 |
HR20ZQ | 68.3 |
HR20ZM | 57.8 |
HRZE | 24.2 |
From enrollment, the time to stable culture conversion (2 consecutive negative weekly cultures) in liquid media. (NCT01785186)
Timeframe: 0 - 12 weeks
Intervention | days (Median) |
---|---|
Arm 1 (R35) | 48 |
HRZQ | 63 |
HR20ZQ | 66 |
HR20ZM | 55 |
HRZE | 62 |
All Adverse Events (AE), and AEs considered to be drug-related will coded using standard AE dictionaries. (NCT01785186)
Timeframe: 0 - 12 weeks
Intervention | participants (Number) | |
---|---|---|
Number of Patients with at least 1 AE | Number of patients with at least 1 SAE | |
Arm 1 (R35) | 53 | 4 |
HR20ZM | 49 | 4 |
HR20ZQ | 42 | 5 |
HRZE | 92 | 6 |
HRZQ | 49 | 4 |
Proportion of patients with Grade 3 or 4 adverse reactions attributable to study medications (NCT00082173)
Timeframe: 8 weeks
Intervention | Participants (Number) |
---|---|
Experimental Arm | 0 |
Control Arm | 0 |
Proportion of patients with sterile sputum cultures (NCT00082173)
Timeframe: 8 weeks
Intervention | Participants (Number) |
---|---|
Experimental Arm | 59 |
Control Arm | 45 |
(NCT00130247)
Timeframe: 2 years
Intervention | Participants (Number) |
---|---|
4-Month Arm | 0 |
6-Month Arm | 0 |
Patients who presented with TB after completion of study phase treatment but before the end of follow-up were classified as relapses. A bacteriologic relapse was defined as a patient who became consistently culture-positive [defined as at least 1 of the following]: (a) at least 1 sputum mycobacterial culture growing at least 10 colonies of MTB on solid medium; (b) 2 or more respiratory secretion cultures that are positive for MTB in liquid media; or (c) any culture from an extrapulmonary site that is positive for MTB during follow-up after successful completion of initial anti-TB treatment. (NCT00130247)
Timeframe: 30 months
Intervention | Participants (Number) |
---|---|
4-Month Arm | 13 |
6-Month Arm | 3 |
Patients who presented with TB after completion of study phase treatment but before the end of follow-up were classified as relapses. A bacteriologic relapse was defined as a patient who became consistently culture-positive [defined as at least 1 of the following]: (a) at least 1 sputum mycobacterial culture growing at least 10 colonies of MTB on solid medium; (b) 2 or more respiratory secretion cultures that are positive for MTB in liquid media; or (c) any culture from an extrapulmonary site that is positive for MTB during follow-up after successful completion of initial anti-TB treatment. (NCT00130247)
Timeframe: 30 months
Intervention | Participants (Number) |
---|---|
4-Month Arm | 13 |
6-Month Arm | 3 |
(NCT00130247)
Timeframe: 1 and 2 years after successful completion of initial anti-TB treatment
Intervention | Participants (Number) | |
---|---|---|
Relapses at 1 year | Relapses at 2 years | |
4-Month Arm | 10 | 13 |
6-Month Arm | 3 | 3 |
A culture-positive treatment failure was defined as initial culture conversion but subsequent reversion to culture positivity. A clinical treatment failure was defined as a patient with clinical and/or radiographic evidence of progressive tuberculosis not confirmed by a positive culture after 4 or more months of anti-TB treatment while still receiving treatment. Patients who defaulted before completing study treatment and returned later with culture-positive tuberculosis were termed failures after non-adherence. (NCT00130247)
Timeframe: 2 years
Intervention | Participants (Number) | |
---|---|---|
Treatment Failures | Relapses | |
4-Month Arm | 0 | 13 |
6-Month Arm | 0 | 3 |
A culture-positive treatment failure was defined as initial culture conversion but subsequent reversion to culture positivity. A clinical treatment failure was defined as a patient with clinical and/or radiographic evidence of progressive tuberculosis not confirmed by a positive culture after 4 or more months of anti-TB treatment while still receiving treatment. Patients who defaulted before completing study treatment and returned later with culture-positive tuberculosis were termed failures after non-adherence. (NCT00130247)
Timeframe: 2 years
Intervention | Participants (Number) | |
---|---|---|
Treatment Failures | Relapses | |
4-Month Arm | 0 | 13 |
6-Month Arm | 0 | 3 |
(NCT00944021)
Timeframe: 14 consecutive days of treatment
Intervention | log10CFU/ml/day (Mean) |
---|---|
PA-824 50 mg/qd | 0.063 |
PA-824 100mg/qd | 0.091 |
PA-824 150mg/qd | 0.078 |
PA-824 200mg/qd | 0.112 |
Rifafour e-275mg | 0.177 |
(NCT00944021)
Timeframe: Two consecutive days of treatment
Intervention | log10CFU/ml/day (Mean) |
---|---|
PA-824 50 mg/qd | 0.093 |
PA-824 100mg/qd | 0.111 |
PA-824 150mg/qd | -0.009 |
PA-824 200mg/qd | 0.160 |
Rifafour e-275mg | 0.470 |
(NCT00944021)
Timeframe: Days 2-14 of 14 consecutive days of treatment
Intervention | log10CFU/ml/day (Mean) |
---|---|
PA-824 50 mg/qd | 0.059 |
PA-824 100mg/qd | 0.088 |
PA-824 150mg/qd | 0.096 |
PA-824 200mg/qd | 0.104 |
Rifafour e-275mg | 0.128 |
(NCT00944021)
Timeframe: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12, 16, and 24 hours post-dose on Day 1 of treatment
Intervention | ng * hour/mL (Mean) |
---|---|
PA-824 50 mg/qd | 11923.94 |
PA-824 100mg/qd | 18408.59 |
PA-824 150mg/qd | 28654.83 |
PA-824 200mg/qd | 38485.04 |
(NCT00944021)
Timeframe: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12, 16, and 24 hours post-dose on Day 1 of treatment
Intervention | ng/mL (Mean) |
---|---|
PA-824 50 mg/qd | 465.3 |
PA-824 100mg/qd | 662.3 |
PA-824 150mg/qd | 994.7 |
PA-824 200mg/qd | 1183.0 |
(NCT00944021)
Timeframe: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12, 16, and 24 hours post-dose on Day 1 of treatment
Intervention | hours (Mean) |
---|---|
PA-824 50 mg/qd | 16.142 |
PA-824 100mg/qd | 18.597 |
PA-824 150mg/qd | 19.005 |
PA-824 200mg/qd | 21.092 |
(NCT00944021)
Timeframe: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12, 16, 24 and 30 hours post-dose on Day 14 of 14 consecutive days of treatment
Intervention | hour (Mean) |
---|---|
PA-824 50 mg/qd | 18.645 |
PA-824 100mg/qd | 19.274 |
PA-824 150mg/qd | 20.207 |
PA-824 200mg/qd | 23.811 |
(NCT00944021)
Timeframe: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12,16, 24, and 30 hours post-dose on Day 14 of 14 consecutive days of treatment
Intervention | ng/mL (Mean) |
---|---|
PA-824 50 mg/qd | 777.3 |
PA-824 100mg/qd | 1116.5 |
PA-824 150mg/qd | 1543.9 |
PA-824 200mg/qd | 2223.8 |
(NCT00944021)
Timeframe: Fourteen consecutive days of treatment
Intervention | hours/day (Mean) |
---|---|
PA-824 50 mg/qd | 2.621 |
PA-824 100mg/qd | 4.969 |
PA-824 150mg/qd | 4.633 |
PA-824 200mg/qd | 4.640 |
Rifafour e-275mg | 13.364 |
(NCT00944021)
Timeframe: Two consecutive days of treatment
Intervention | hours/day (Mean) |
---|---|
PA-824 50 mg/qd | 1.483 |
PA-824 100mg/qd | -1.345 |
PA-824 150mg/qd | 4.867 |
PA-824 200mg/qd | 3.096 |
Rifafour e-275mg | 37.016 |
(NCT00944021)
Timeframe: Days 2-14 of 14 consecutive days of treatment
Intervention | hours/day (Mean) |
---|---|
PA-824 50 mg/qd | 2.958 |
PA-824 100mg/qd | 5.744 |
PA-824 150mg/qd | 4.594 |
PA-824 200mg/qd | 5.391 |
Rifafour e-275mg | 9.422 |
Log10 CFU rates of change were calculated for each individual patient from the slopes β1 and β2 of the bi-linear regression fitted to the data for each individual patient (log10CFU versus Day). Mean log10 CFU changes from baseline were compared. A higher slope value indicates a greater change in log10 CFU from baseline. Note that to facilitate interpretation the sign of these slopes are reversed for logCFU. A positive slope value therefore indicates a reduction in log10 CFU from baseline. (NCT01215851)
Timeframe: 14 consecutive days of treatment
Intervention | log10CFU/ml/day (Mean) |
---|---|
TMC207 | 0.061 |
TMC207 and Pyrazinamide | 0.131 |
PA-824 and Pyrazinamide | 0.154 |
PA-824 and Moxifloxacin and Pyrazinamide | 0.233 |
Rifafour e-275 mg | 0.140 |
TMC207 and PA-824 | 0.114 |
Log10 CFU rates of change were calculated for each individual patient from the slopes β1 and β2 of the bi-linear regression fitted to the data for each individual patient (log10CFU versus Day). Mean log10 CFU changes from baseline were compared. A higher slope value indicates a greater change in log10 CFU from baseline. Note that to facilitate interpretation the sign of these slopes are reversed for logCFU. A positive slope value therefore indicates a reduction in log10 CFU from baseline. (NCT01215851)
Timeframe: Day 0-2
Intervention | log10CFU/ml/day (Mean) |
---|---|
TMC207 | -0.022 |
TMC207 and Pyrazinamide | 0.079 |
PA-824 and Pyrazinamide | 0.170 |
PA-824 and Moxifloxacin and Pyrazinamide | 0.315 |
Rifafour e-275 mg | 0.177 |
TMC207 and PA-824 | 0.114 |
Log10 CFU rates of change were calculated for each individual patient from the slopes β1 and β2 of the bi-linear regression fitted to the data for each individual patient (log10CFU versus Day). Mean log10 CFU changes from baseline were compared. A higher slope value indicates a greater change in log10 CFU from baseline. Note that to facilitate interpretation the sign of these slopes are reversed for logCFU. A positive slope value therefore indicates a reduction in log10 CFU from baseline. (NCT01215851)
Timeframe: Day 2-14
Intervention | log10CFU/ml/day (Mean) |
---|---|
TMC207 | 0.076 |
TMC207 and Pyrazinamide | 0.143 |
PA-824 and Pyrazinamide | 0.148 |
PA-824 and Moxifloxacin and Pyrazinamide | 0.222 |
Rifafour e-275 mg | 0.135 |
TMC207 and PA-824 | 0.114 |
Log10 CFU rates of change were calculated for each individual patient from the slopes β1 and β2 of the bi-linear regression fitted to the data for each individual patient (log10CFU versus Day). Mean log10 CFU changes from baseline were compared. A higher slope value indicates a greater change in log10 CFU from baseline. Note that to facilitate interpretation the sign of these slopes are reversed for logCFU. A positive slope value therefore indicates a reduction in log10 CFU from baseline. (NCT01215851)
Timeframe: Day 7-14
Intervention | log10CFU/ml/day (Mean) |
---|---|
TMC207 | 0.123 |
TMC207 and Pyrazinamide | 0.152 |
PA-824 and Pyrazinamide | 0.124 |
PA-824 and Moxifloxacin and Pyrazinamide | 0.175 |
Rifafour e-275 mg | 0.136 |
TMC207 and PA-824 | 0.114 |
The TTP was measured in the Mycobacterial Growth Indicator Tube (MGIT) (Bactec MGIT960) automated liquid culture system from overnight sputum. TTP rates of change were calculated for each individual patient from the slopes β1 and β2 of the bi-linear regression fitted to the data for each individual patient (TTP versus Day). (NCT01215851)
Timeframe: 14 Days
Intervention | time (h) to positive per day (Mean) |
---|---|
TMC207 | 5.414 |
TMC207 and Pyrazinamide | 9.970 |
PA-824 and Pyrazinamide | 8.805 |
PA-824 and Moxifloxacin and Pyrazinamide | 18.482 |
Rifafour e-275 mg | 11.841 |
TMC207 and PA-824 | 5.855 |
(NCT00814671)
Timeframe: 8 weeks
Intervention | percentage of participants w/LJ cx con (Number) |
---|---|
RPT450 | 85 |
RIF 600 | 94 |
RPT 600 | 96 |
area under the concentration time curve (AUC[0-24]) for rifapentine administered once daily at doses of 450 mg or 600 mg in the context of multi drug intensive phase TB treatment (NCT00814671)
Timeframe: 8 weeks
Intervention | ug x h/ml (Median) |
---|---|
Rifapentine 450 mg | 330 |
Rifapentine 600 mg | 435 |
Time (in days) to stable culture conversion on liquid MGIT media (NCT00814671)
Timeframe: 12 weeks
Intervention | days (Median) |
---|---|
RPT450 | 50 |
RIF 600 | 59 |
RPT 600 | 57 |
Time to stable culture conversion (in days) on Lowenstein Jensen solid medium (NCT00814671)
Timeframe: 12 weeks
Intervention | days (Median) |
---|---|
RPT450 | 37 |
RIF 600 | 43 |
RPT 600 | 36 |
percentage of participants discontinuing assigned treatment (NCT00814671)
Timeframe: 10 weeks
Intervention | percentage of participants (Number) |
---|---|
RPT450 | 2.0 |
RIF 600 | 8.3 |
RPT 600 | 2.0 |
Safety will be assessed by the occurrence of a Grade 3/4 hepatotoxicity at any time during the assigned treatment period. (NCT03302299)
Timeframe: Hepatotoxicity occurring during the six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.
Intervention | percent (Number) |
---|---|
INH and Vitamin B6 | 8.3 |
Lack of tolerability will be defined as any isoniazid (INH) treatment discontinuation prior to completion of the prescribed course (6 months of INH taken over a maximum period of 9 months) due to side effects or alanine transaminase (ALT)/aspartate transaminase (AST) elevations. (NCT03302299)
Timeframe: Six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.
Intervention | Participants (Count of Participants) |
---|---|
INH and Vitamin B6 | 32 |
Alanine transaminase (ALT) or aspartate transaminase (AST) elevations (>2x the upper limit of normal) at study screening (NCT03302299)
Timeframe: Study screening visit
Intervention | Participants (Count of Participants) |
---|---|
Study Screening | 80 |
Latent tuberculosis assessed at screening via tuberculin skin testing (TST). A TST induration >=5mm was considered positive for latent tuberculosis. (NCT03302299)
Timeframe: Study screening visit
Intervention | Participants (Count of Participants) |
---|---|
Study Screening | 308 |
INH concentration in hair (pmol/mg) will be measured at 3- and 6- months during INH therapy. (NCT03302299)
Timeframe: Measured at 3- and 6- months after INH initiation
Intervention | pmol/mg (Median) | |
---|---|---|
at 3 months | at 6 months | |
INH and Vitamin B6 | 36.0 | 37.8 |
Suboptimal INH adherence was defined as <90% of days with at least 1 electronic medication management (EMM) pill cap opening in the previous 90 days, at 3- and 6-months. (NCT03302299)
Timeframe: Adherence will be measured over the 6 months on INH or until INH discontinuation (whichever is shorter)
Intervention | percentage of participants (Number) | |
---|---|---|
at 3 months | at 6 months | |
INH and Vitamin B6 | 31.3 | 43.9 |
"Participants were asked In the past 30 days, how many days in total have you not taken your pill? and were presented with a visual analog scale (VAS) to indicate the percentage of INH taken in the past 30 days. We converted the VAS percentage into number of days out of 30 to match the first question. Our final self-report measure was the minimum number of the 2 self-reported measurements." (NCT03302299)
Timeframe: Self-reported INH medication adherence via VAS will be measured 3- and 6- months after starting INH
Intervention | days (Median) | |
---|---|---|
at 3 months | at 6 months | |
INH and Vitamin B6 | 30 | 30 |
The Self Rating Single Item (SRSI) adherence scale asks participants to rate their ability to take their medications as prescribed over the past 30 days. Participants reporting INH use in the prior 30 days at the 3- or 6-month interview are included here, and reported their INH adherence in the prior 30 days as excellent, very good, good, fair, poor, or very poor. (NCT03302299)
Timeframe: Self-reported INH medication adherence via SRSI will be measured 3- and 6- months after starting INH
Intervention | Participants (Count of Participants) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
At 3 months72558043 | At 6 months72558043 | |||||||||||
Excellent | Very good | Good | Fair | Poor | Very poor | |||||||
INH and Vitamin B6 | 160 | |||||||||||
INH and Vitamin B6 | 79 | |||||||||||
INH and Vitamin B6 | 38 | |||||||||||
INH and Vitamin B6 | 2 | |||||||||||
INH and Vitamin B6 | 124 | |||||||||||
INH and Vitamin B6 | 90 | |||||||||||
INH and Vitamin B6 | 41 | |||||||||||
INH and Vitamin B6 | 4 | |||||||||||
INH and Vitamin B6 | 0 | |||||||||||
INH and Vitamin B6 | 1 |
51 reviews available for pyrazinamide and Pulmonary Consumption
Article | Year |
---|---|
Tuberculosis treatment in children: The changing landscape.
Topics: Antitubercular Agents; Child; Drug Therapy, Combination; Duration of Therapy; Ethambutol; Humans; Is | 2020 |
Multiple tuberculomas in an immunocompetent patient and their diagnostic challenge in a high prevalence country: Case report and literature review.
Topics: Antitubercular Agents; Blindness; Brain; Brain Diseases; Cerebellar Ataxia; Dexamethasone; Drug Ther | 2020 |
Are We There Yet? Short-Course Regimens in TB and HIV: From Prevention to Treatment of Latent to XDR TB.
Topics: Anti-HIV Agents; Antitubercular Agents; Drug Interactions; Extensively Drug-Resistant Tuberculosis; | 2020 |
The Biology and Epidemiology of Mycobacterium africanum.
Topics: Africa, Western; Animals; Antitubercular Agents; Bacterial Typing Techniques; Genetic Variation; Gen | 2017 |
Severe disseminated tuberculosis in HIV-negative refugees.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Ethambutol; Fluorine Radioisotopes; HIV Infections; | 2019 |
PA-824 , moxifloxacin and pyrazinamide combination therapy for tuberculosis.
Topics: Animals; Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Combinations; Drug Res | 2013 |
Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model.
Topics: Follow-Up Studies; Humans; Meta-Analysis as Topic; Microbiological Techniques; Mycobacterium tubercu | 2013 |
Understanding pharmacokinetics to improve tuberculosis treatment outcome.
Topics: Antitubercular Agents; Diabetes Mellitus; Drug Monitoring; Ethambutol; HIV Infections; Humans; Isoni | 2014 |
Pyrazinamide: the importance of uncovering the mechanisms of action in mycobacteria.
Topics: Antitubercular Agents; Humans; Mycobacterium tuberculosis; Niacinamide; Pyrazinamide; Tuberculosis, | 2015 |
Month 2 culture status and treatment duration as predictors of recurrence in pulmonary tuberculosis: model validation and update.
Topics: Antitubercular Agents; Clinical Trials as Topic; Drug Therapy, Combination; Fluoroquinolones; Humans | 2015 |
Clinical research in the treatment of tuberculosis: current status and future prospects.
Topics: Antitubercular Agents; Biomedical Research; Clinical Trials as Topic; Drug Therapy, Combination; Flu | 2015 |
Tuberculosis and silicosis: epidemiology, diagnosis and chemoprophylaxis.
Topics: Antibiotics, Antitubercular; Brazil; Humans; Isoniazid; Occupational Exposure; Pyrazinamide; Rifampi | 2008 |
Efforts towards the development of new antitubercular agents: potential for thiolactomycin based compounds.
Topics: Animals; Antitubercular Agents; Drug Design; Ethambutol; Isoniazid; Microbial Sensitivity Tests; Mol | 2008 |
The near future: improving the activity of rifamycins and pyrazinamide.
Topics: Administration, Inhalation; Antitubercular Agents; Area Under Curve; Biological Availability; Dosage | 2010 |
Bronchiectatic air bronchograms in pulmonary tuberculosis: a case report and literature review.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Bronchiectasis; Bronchoalveolar Lavage; Bronchos | 2010 |
Pyrazinamide pharmacokinetics and efficacy in adults and children.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Child; Child, Preschool; Dose-Response R | 2012 |
Unilateral and painless development of isoniazid induced gynecomastia during re-treatment of pulmonary tuberculosis.
Topics: Adolescent; Anti-Bacterial Agents; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Gyn | 2011 |
Molecular biology of drug resistance in Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Biological Transport; Biotransformation; Drug Resistance, Multiple, Bacterial | 2013 |
Leprosy and tuberculosis co-infection: clinical and immunological report of two cases and review of the literature.
Topics: Adult; Brazil; Coinfection; Female; Humans; Immunity, Cellular; Interferon-gamma; Interleukin-12; Is | 2013 |
Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Drug Therapy, Combination | 2004 |
[The present state of short course chemotherapy including pyrazinamide in Japan].
Topics: Antitubercular Agents; Humans; Japan; Pyrazinamide; Tuberculosis, Pulmonary | 2004 |
[A case of fulminant hepatic failure associated with pyrazinamide in a woman with hypoalbuminemia].
Topics: Antitubercular Agents; Female; Humans; Hypoalbuminemia; Liver Failure; Middle Aged; Pyrazinamide; Tu | 2005 |
Advances in the treatment of tuberculosis.
Topics: Adamantane; AIDS-Related Opportunistic Infections; Animals; Anti-Bacterial Agents; Antitubercular Ag | 2007 |
New drugs in respiratory disorders: II.
Topics: Adult; Aged; Amantadine; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Cephalosporins; | 1983 |
Treatment of tuberculosis. The Mitchell lecture 1979.
Topics: Animals; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Drug Thera | 1980 |
Should isoniazid be used in retreatment of tuberculosis despite acquired isoniazid resistance?
Topics: Dose-Response Relationship, Drug; Drug Resistance, Microbial; Drug Therapy, Combination; Ethionamide | 1981 |
Bacteriologic basis of short-course chemotherapy for tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Guinea Pigs; | 1980 |
[Pharmacology, toxicology and clinical use of pyrazinamide (author's transl)].
Topics: Animals; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; H | 1981 |
Tuberculosis.
Topics: Alcohol Drinking; Carrier State; Chemical and Drug Induced Liver Injury; Ethambutol; Humans; Isoniaz | 1980 |
What's new in tuberculosis?
Topics: Aged; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; Isonia | 1981 |
Whither short-course chemotherapy?
Topics: Animals; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Humans | 1981 |
Outpatient management of tuberculosis.
Topics: Algorithms; Ambulatory Care; Antitubercular Agents; Drug Administration Schedule; Drug Interactions; | 1996 |
[Pyrazinamide-containing initial intensive short course chemotherapy of pulmonary tuberculosis].
Topics: Aged; Aged, 80 and over; Antitubercular Agents; Humans; Liver; Pyrazinamide; Risk Factors; Tuberculo | 1997 |
[Antitubercular chemotherapy].
Topics: Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Child; Clinical Protocols; Drug | 1997 |
[Short-course chemotherapy of tuberculosis with pyrazinamide].
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Drug Administration Schedule; Ethambutol; Humans | 1998 |
[Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
Topics: Animals; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; E | 2001 |
[Sharp syndrome complicating pulmonary tuberculosis: apropos of a case].
Topics: Adrenal Cortex Hormones; Adult; Antibodies, Antinuclear; Antitubercular Agents; Autoimmune Diseases; | 1999 |
Advances in the treatment of tuberculosis.
Topics: Aminosalicylic Acids; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Pyrazinamide | 1976 |
The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide.
Topics: Acetylation; Adolescent; Adult; Aged; Chemical and Drug Induced Liver Injury; Clinical Trials as Top | 1978 |
[Pharmacokinetic aspects of tuberculosis therapy with a fixed combination of rifampicin, isoniazide and pyrazinamide].
Topics: Biological Availability; Drug Therapy, Combination; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuber | 1991 |
The role of pyrazinamide in tuberculosis chemotherapy.
Topics: Humans; Pyrazinamide; Tuberculosis, Pulmonary | 1988 |
Antituberculosis agents.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Ethambutol | 1988 |
[Treatment of pleuropulmonary tuberculosis in 1985].
Topics: Aminoglycosides; Antitubercular Agents; Ethambutol; Humans; Isoniazid; Pyrazinamide; Rifampin; Thioa | 1985 |
[Results of chemotherapy in tuberculosis].
Topics: Ambulatory Care; Anti-Bacterial Agents; Antitubercular Agents; Drug Synergism; Ethambutol; Ethionami | 1971 |
General considerations in intermittent drug therapy of pulmonary tuberculosis.
Topics: Aminosalicylic Acids; Antitubercular Agents; Clinical Trials as Topic; Ethambutol; Ethionamide; Huma | 1971 |
The impact of chemotherapy on the care of patients with tuberculosis.
Topics: Antitubercular Agents; Aspirin; Bacteriological Techniques; BCG Vaccine; Drug Therapy, Combination; | 1974 |
Newer and second-line drugs in the treatment of drug-resistant tuberculosis in children.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Child, Preschool; Cycloserine; Drug Resistance, Microb | 1967 |
[Chemotherapeutic studies on advanced tuberculosis in mice].
Topics: Aminosalicylic Acids; Animals; Antitubercular Agents; Drug Resistance, Microbial; Drug Synergism; Et | 1965 |
Tuberculosis in Hong Kong ten years later.
Topics: Aminosalicylic Acids; BCG Vaccine; Child, Preschool; China; Cycloserine; Drug Resistance, Microbial; | 1973 |
[Results of 2 or 3 secondary drug combinations in the retreatment of chronic pulmonary tuberculosis].
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Cycloserine; Drug Synergism; Ethambutol; | 1968 |
Chemotherapy of pulmonary tuberculosis.
Topics: Aminosalicylic Acids; Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Hospitalization | 1969 |
208 trials available for pyrazinamide and Pulmonary Consumption
Article | Year |
---|---|
Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Area Under Curve; Biological | 2007 |
Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Area Under Curve; Biological | 2007 |
Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Area Under Curve; Biological | 2007 |
Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Area Under Curve; Biological | 2007 |
Early Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary Tuberculosis.
Topics: Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Middle Aged; Mycob | 2022 |
Treatment shortening of drug-sensitive pulmonary tuberculosis using high-dose rifampicin for 3 months after culture conversion (Hi-DoRi-3): a study protocol for an open-label randomized clinical trial.
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Multicenter Studies as Topic; P | 2022 |
Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results.
Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Isoniazid; Mice; Nitroimidazoles; Pyrazin | 2023 |
Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results.
Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Isoniazid; Mice; Nitroimidazoles; Pyrazin | 2023 |
Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results.
Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Isoniazid; Mice; Nitroimidazoles; Pyrazin | 2023 |
Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results.
Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Isoniazid; Mice; Nitroimidazoles; Pyrazin | 2023 |
Treatment Strategy for Rifampin-Susceptible Tuberculosis.
Topics: Antitubercular Agents; Diarylquinolines; Drug Administration Schedule; Drug Therapy, Combination; Et | 2023 |
Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status.
Topics: Adult; Antitubercular Agents; Ethambutol; Female; HIV Seropositivity; Humans; Incidence; Isoniazid; | 2019 |
Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Line | 2020 |
Telacebec (Q203), a New Antituberculosis Agent.
Topics: Administration, Oral; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Therapy, Combina | 2020 |
Electronic pillbox-enabled self-administered therapy versus standard directly observed therapy for tuberculosis medication adherence and treatment outcomes in Ethiopia (SELFTB): protocol for a multicenter randomized controlled trial.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Cost-Benefit Analysis; Directly Observed Therapy; El | 2020 |
Efficacy and safety of combined isoniazid-rifampicin-pyrazinamide-levofloxacin dry powder inhaler in treatment of pulmonary tuberculosis: A randomized controlled trial.
Topics: Dry Powder Inhalers; Humans; Isoniazid; Levofloxacin; Powders; Pyrazinamide; Rifampin; Tuberculosis, | 2021 |
Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.
Topics: Adult; Antibiotics, Antitubercular; Dose-Response Relationship, Drug; Double-Blind Method; Drug Ther | 2017 |
Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.
Topics: Adult; Antibiotics, Antitubercular; Dose-Response Relationship, Drug; Double-Blind Method; Drug Ther | 2017 |
Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.
Topics: Adult; Antibiotics, Antitubercular; Dose-Response Relationship, Drug; Double-Blind Method; Drug Ther | 2017 |
Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.
Topics: Adult; Antibiotics, Antitubercular; Dose-Response Relationship, Drug; Double-Blind Method; Drug Ther | 2017 |
Association of UGT2B7 polymorphisms with risk of induced liver injury by anti-tuberculosis drugs in Chinese Han.
Topics: Adult; Antitubercular Agents; Asian People; Chemical and Drug Induced Liver Injury; Drug Therapy, Co | 2017 |
Biomarkers of Tuberculosis Severity and Treatment Effect: A Directed Screen of 70 Host Markers in a Randomized Clinical Trial.
Topics: Adult; Aged; Antitubercular Agents; Biomarkers; Drug Combinations; Ethambutol; Female; Humans; Isoni | 2017 |
Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Substitution; Drug Therapy, Combination; | 2019 |
Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Artificial Intelligence; Dose-Response Relationship, Drug; | 2018 |
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, m
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Clinical Trials, Phase II as Topic; Clinical | 2019 |
Efficacy and safety of cholecalciferol-augmented anti-tuberculosis therapy for treatment of naïve patients with pulmonary tuberculosis: A randomized, controlled, clinical study.
Topics: Adult; Antitubercular Agents; Cholecalciferol; Drug Therapy, Combination; Egypt; Ethambutol; Female; | 2019 |
Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial.
Topics: Adult; Antibiotics, Antitubercular; Drug Combinations; Drug Therapy, Combination; Ethambutol; Humans | 2019 |
Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial.
Topics: Adult; Antibiotics, Antitubercular; Drug Combinations; Drug Therapy, Combination; Ethambutol; Humans | 2019 |
Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial.
Topics: Adult; Antibiotics, Antitubercular; Drug Combinations; Drug Therapy, Combination; Ethambutol; Humans | 2019 |
Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial.
Topics: Adult; Antibiotics, Antitubercular; Drug Combinations; Drug Therapy, Combination; Ethambutol; Humans | 2019 |
Safety of pyrazinamide-including regimen in late elderly patients with pulmonary tuberculosis: A prospective randomized open-label study.
Topics: Age Factors; Aged, 80 and over; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug | 2019 |
Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.
Topics: Adult; Antitubercular Agents; Area Under Curve; Coinfection; Drug Administration Schedule; Drug Dosa | 2013 |
Impact of tuberculosis treatment on CD4 cell count, HIV RNA, and p24 antigen in patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Biomarkers; CD4 Lymphocyte Count; Coinfection; Dietary Supplements; Dr | 2013 |
The pyrazinamide susceptibility breakpoint above which combination therapy fails.
Topics: Adolescent; Adult; Antitubercular Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Fem | 2014 |
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi | 2014 |
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi | 2014 |
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi | 2014 |
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi | 2014 |
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi | 2014 |
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi | 2014 |
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi | 2014 |
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi | 2014 |
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi | 2014 |
Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial.
Topics: Antitubercular Agents; Bangladesh; Clinical Protocols; Clofazimine; Drug Administration Schedule; Dr | 2014 |
Results at 30 months of a randomised trial of FDCs and separate drugs for the treatment of tuberculosis.
Topics: Africa; Antitubercular Agents; Asia; Dose-Response Relationship, Drug; Drug Combinations; Ethambutol | 2014 |
A four-month gatifloxacin-containing regimen for treating tuberculosis.
Topics: Adult; Antitubercular Agents; Blood Glucose; Drug Administration Schedule; Drug Therapy, Combination | 2014 |
A four-month gatifloxacin-containing regimen for treating tuberculosis.
Topics: Adult; Antitubercular Agents; Blood Glucose; Drug Administration Schedule; Drug Therapy, Combination | 2014 |
A four-month gatifloxacin-containing regimen for treating tuberculosis.
Topics: Adult; Antitubercular Agents; Blood Glucose; Drug Administration Schedule; Drug Therapy, Combination | 2014 |
A four-month gatifloxacin-containing regimen for treating tuberculosis.
Topics: Adult; Antitubercular Agents; Blood Glucose; Drug Administration Schedule; Drug Therapy, Combination | 2014 |
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Drug Administration Schedule; Drug Therapy, C | 2014 |
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera | 2015 |
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera | 2015 |
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera | 2015 |
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera | 2015 |
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera | 2015 |
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera | 2015 |
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera | 2015 |
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera | 2015 |
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera | 2015 |
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera | 2015 |
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera | 2015 |
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera | 2015 |
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera | 2015 |
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera | 2015 |
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera | 2015 |
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera | 2015 |
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera | 2015 |
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera | 2015 |
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera | 2015 |
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera | 2015 |
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera | 2015 |
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera | 2015 |
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera | 2015 |
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera | 2015 |
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera | 2015 |
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pul
Topics: Adolescent; Adult; Antitubercular Agents; Colony Count, Microbial; Drug Therapy, Combination; Ethamb | 2015 |
Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis.
Topics: Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; F | 2015 |
Effects on type 2 diabetes complicated with pulmonary tuberculosis: regiment of insulin, isoniazid, rifampicin, pyrazinamide and ethambutol versus the regiment plus Qi-boosting and Yin-nourishing decoction of Traditional Chinese Medicine.
Topics: Adult; Aged; Antitubercular Agents; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Drugs, Chi | 2015 |
Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Coinfection; Ethambutol; Femal | 2016 |
Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania.
Topics: Adult; Antitubercular Agents; Ethambutol; Female; Humans; Isoniazid; Male; Pyrazinamide; Tanzania; T | 2015 |
Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.
Topics: Anti-Bacterial Agents; Area Under Curve; Coinfection; Drug Dosage Calculations; Ethambutol; Female; | 2016 |
A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Dose-Response Relationship, Drug; Ethambutol; Female | 2016 |
A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.
Topics: Adult; Antitubercular Agents; Case-Control Studies; Drug Therapy, Combination; Female; Fluoroquinolo | 2016 |
Efficacy and Safety of 'Fixed Dose' versus 'Loose' Drug Regimens for Treatment of Pulmonary Tuberculosis in Two High TB-Burden African Countries: A Randomized Controlled Trial.
Topics: Adult; Africa; Aged; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Administration Sc | 2016 |
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E | 2017 |
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E | 2017 |
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E | 2017 |
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E | 2017 |
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E | 2017 |
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E | 2017 |
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E | 2017 |
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E | 2017 |
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E | 2017 |
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E | 2017 |
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E | 2017 |
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E | 2017 |
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E | 2017 |
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E | 2017 |
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E | 2017 |
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E | 2017 |
[Relapse rate of pulmonary tuberculosis within two years following completion of twice weekly intermittent chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Directly Observed Therapy; Drug Administratio | 2008 |
Pyrazinamide serum levels in childhood tuberculosis.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; Humans; Infan | 2008 |
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.
Topics: Adult; Antitubercular Agents; Aza Compounds; Brazil; Double-Blind Method; Drug Administration Schedu | 2009 |
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.
Topics: Adult; Antitubercular Agents; Aza Compounds; Brazil; Double-Blind Method; Drug Administration Schedu | 2009 |
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.
Topics: Adult; Antitubercular Agents; Aza Compounds; Brazil; Double-Blind Method; Drug Administration Schedu | 2009 |
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.
Topics: Adult; Antitubercular Agents; Aza Compounds; Brazil; Double-Blind Method; Drug Administration Schedu | 2009 |
Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis.
Topics: Adult; Antitubercular Agents; Drug Combinations; Drug Therapy, Combination; Ethambutol; Female; Huma | 2009 |
Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion.
Topics: Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; F | 2009 |
Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion.
Topics: Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; F | 2009 |
Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion.
Topics: Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; F | 2009 |
Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion.
Topics: Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; F | 2009 |
Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity.
Topics: Acetylcysteine; Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug Induced Liver Inju | 2010 |
Assessment of protective role of polyherbal preparation, Livina, against anti-tubercular drug induced liver dysfunction.
Topics: Adolescent; Adult; Alanine Transaminase; Antitubercular Agents; Aspartate Aminotransferases; Chemica | 2010 |
Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Male | 2011 |
Results at 30 months of a randomised trial of two 8-month regimens for the treatment of tuberculosis.
Topics: Adolescent; Adult; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Drug Combinations; Drug | 2011 |
Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.
Topics: Antitubercular Agents; Area Under Curve; Child, Preschool; Coinfection; Female; HIV Infections; Huma | 2011 |
Phase II dose-ranging trial of the early bactericidal activity of PA-824.
Topics: Adolescent; Adult; Antitubercular Agents; Drug Administration Schedule; Ethambutol; Female; Humans; | 2012 |
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.
Topics: Adult; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Double-Blind | 2012 |
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.
Topics: Adult; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Double-Blind | 2012 |
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.
Topics: Adult; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Double-Blind | 2012 |
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.
Topics: Adult; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Double-Blind | 2012 |
Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Deoxyc | 2013 |
A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture.
Topics: Antimalarials; Bacterial Load; Bacteriological Techniques; Diagnostic Techniques, Respiratory System | 2013 |
Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up.
Topics: Adult; Antitubercular Agents; Drug Combinations; Female; Humans; Isoniazid; Male; Mycobacterium tube | 2002 |
Results of a 12-month regimen for drug-resistant pulmonary tuberculosis.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Drug Administration Schedule; | 2002 |
Comparative evaluation of efficacy and safety profile of three anti-tuberculous regimens in Mangalore.
Topics: Adult; Antitubercular Agents; Dizziness; Drug Therapy, Combination; Ethambutol; Female; Follow-Up St | 2002 |
The clearance of theophylline is increased during the initial period of tuberculosis treatment.
Topics: Adult; Aged; Antitubercular Agents; Bronchodilator Agents; Drug Interactions; Drug Therapy, Combinat | 2003 |
Use of Rhu-GM-CSF in pulmonary tuberculosis patients: results of a randomized clinical trial.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Antitubercular Agents; Double-Blind Method; Female; Granu | 2003 |
[Assessment of the use of a multicomponent drug in the treatment of new cases of pulmonary tuberculosis].
Topics: Adolescent; Adult; Drug Combinations; Ethambutol; Female; Humans; Isoniazid; Male; Middle Aged; Myco | 2003 |
Split-drug regimens for the treatment of patients with sputum smear-positive pulmonary tuberculosis--a unique approach.
Topics: Adult; Antitubercular Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Ethambutol; Fem | 2004 |
The short-term effects of anti-tuberculosis therapy on plasma pyridoxine levels in patients with pulmonary tuberculosis.
Topics: Adult; Antitubercular Agents; Ethambutol; Female; Follow-Up Studies; HIV Infections; Humans; Isoniaz | 2004 |
Adjuvant interferon gamma in patients with drug - resistant pulmonary tuberculosis: a pilot study.
Topics: Adjuvants, Immunologic; Adult; Amikacin; Antitubercular Agents; Ciprofloxacin; Drug Resistance, Bact | 2004 |
Penetration of isoniazid, rifampicin and pyrazinamide in tuberculous pleural effusion and psoas abscess.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Female; Humans; Isoniazid; Male; Microbial Sensitivi | 2004 |
[Optimization of tuberculosis complex chemotherapy with the use of moxifloxacin].
Topics: Adolescent; Adult; Animals; Antitubercular Agents; Aza Compounds; Drug Therapy, Combination; Female; | 2004 |
Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus?
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Child; Child, Preschool; Dose-Response Relationship, | 2005 |
Evaluation of modified short course chemotherapy in active pulmonary tuberculosis patients with human immunodeficiency virus infection in University College Hospital, Ibadan, Nigeria--a preliminary report.
Topics: Acne Vulgaris; Adolescent; Adult; Age Distribution; Aged; Antitubercular Agents; Drug Therapy, Combi | 2004 |
Short-course chemotherapy for paediatric respiratory tuberculosis: 5-year report.
Topics: Antitubercular Agents; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combinat | 2005 |
[Randomized control study on domestic fixed-dose combinations in the initial treatment of smears positive tuberculosis].
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Protocols; Drug Therapy, Combination; Femal | 2004 |
Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.
Topics: Adult; Antitubercular Agents; Disease Progression; Drug Administration Schedule; Drug Therapy, Combi | 2006 |
Evaluation of a non-rifampicin continuation phase (6HE) following thrice-weekly intensive phase for the treatment of new sputum positive pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Bacte | 2007 |
Nutritional status of persons with HIV infection, persons with HIV infection and tuberculosis, and HIV-negative individuals from southern India.
Topics: Adult; AIDS-Related Opportunistic Infections; Anemia; Antitubercular Agents; Body Composition; Drug | 2008 |
Clinical evaluation and monitoring of adverse effects for fixed multidose combination against single drug therapy in pulmonary tuberculosis patients.
Topics: Adolescent; Adult; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Monitoring; Drug Th | 2008 |
Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report. Third East African/British Medical Research Council Study.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Clinical Trials as Topic; Drug Administration Schedu | 1980 |
Comparison of a conventional and an initial 2-month intensive drug regimen for treating pulmonary tuberculosis in Swaziland.
Topics: Adult; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, | 1984 |
Study of chemotherapy regimens of 5 and 7 months' duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary tuberculosis in South India.
Topics: Adult; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistanc | 1983 |
Controlled clinical trial of 4 short-couse regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedu | 1983 |
[Short-term chemotherapy of tuberculosis. Cooperative French trial].
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Drug Therapy, Combination; | 1983 |
Controlled clinical trial comparing a 6-month and a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Algerian working group/British Medical Research Council cooperative study.
Topics: Adolescent; Adult; Algeria; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Sch | 1984 |
A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. British Thoracic Society.
Topics: Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combina | 1984 |
[A comparison of PZA and EB in short course chemotherapy. Report of the 22nd series of controlled trial of chemotherapy].
Topics: Adult; Aged; Clinical Trials as Topic; Drug Therapy, Combination; Ethambutol; Humans; Middle Aged; M | 1984 |
Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Evaluation Studies as Top | 1984 |
[Pyrazinamide versus ethambutol in short-term therapy of lung tuberculosis. A randomized study].
Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Ethambutol; Humans; | 1983 |
A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second report: results during the 24 months after the end of chemotherapy. British Thoracic Association.
Topics: Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combina | 1982 |
[Short-term chemotherapy of pulmonary tuberculosis. Bacteriologic results].
Topics: Adolescent; Adult; Clinical Trials as Topic; Drug Therapy, Combination; Ethambutol; Humans; Isoniazi | 1980 |
[Controlled trial of isoniazid.rifampicin.ethambutol regimen and isoniazid.rifampicin.pyrazinamide regimen in the primary chemotherapy for pulmonary tuberculosis (author's transl)].
Topics: Adult; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, | 1980 |
Side-effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis. A controlled clinical study.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Clinical Tri | 1980 |
Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. East African/British Medical Research Councils Study.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedu | 1981 |
Pyrazinamide deamidase activity in tuberculous disease.
Topics: Antitubercular Agents; Clinical Trials as Topic; Drug Evaluation; Humans; Pyrazinamide; Random Alloc | 1981 |
A controlled trial of six months chemotherapy in pulmonary tuberculosis. First Report: results during chemotherapy. British Thoracic Association.
Topics: Adolescent; Adult; Clinical Trials as Topic; Drug Therapy, Combination; Ethambutol; Female; Humans; | 1981 |
Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedu | 1981 |
BTA short-course chemotherapy studies.
Topics: Clinical Trials as Topic; Ethambutol; Female; Hepatitis; Humans; Isoniazid; Liver Function Tests; Ma | 1981 |
A study of the characteristics and course of sputum smear-negative pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combi | 1981 |
Short-course chemotherapy for pulmonary tuberculosis. A 100-day interrupted regimen.
Topics: Adult; Antibiotics, Antitubercular; Clinical Trials as Topic; Drug Administration Schedule; Drug Com | 1981 |
Chemotherapy for tuberculosis today.
Topics: Antitubercular Agents; Clinical Trials as Topic; Ethambutol; Humans; Isoniazid; Pyrazinamide; Rifamp | 1982 |
[Comparative study of the treatment of pulmonary tuberculosis with isoprodian and pyrazinamide as well as isoprodian and rifampicin].
Topics: Adult; Aged; Antitubercular Agents; Dapsone; Drug Combinations; Drug Therapy, Combination; Humans; I | 1982 |
[Clinical trial of a combination of three drugs in fixed proportions in the treatment of tuberculosis. Groupe de Travail sur la Chimiothérapie de la Tuberculose].
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antitubercular Agents; Drug Therapy, Combination; Drug Tol | 1995 |
Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. The Makerere University-Case Western University Research Collaboration.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Drug Eruptions; Drug Hypersensitivity; Dru | 1994 |
A comparison of two short course tuberculosis chemotherapy regimens, both using Rifater during an intensive phase, with a 3 year follow-up.
Topics: Adolescent; Adult; Antitubercular Agents; Drug Combinations; Female; Follow-Up Studies; Humans; Ison | 1995 |
[Analysis of course and treatment results after treatment of pulmonary tuberculosis with early introduction of interrupted observation--preliminary report].
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, C | 1995 |
[Contemporary methods in the diagnosis and treatment of intrathoracic tuberculosis in children].
Topics: Administration, Oral; Child; Child, Preschool; Drug Therapy, Combination; Ethambutol; Follow-Up Stud | 1994 |
Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide.
Topics: Adolescent; Adult; Biological Availability; Cross-Over Studies; Dietary Carbohydrates; Dietary Fats; | 1995 |
[Compliance and tolerance of new antitubercular short-term chemopreventive regimens in childhood--a pilot project].
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Drug Administration Schedule; Drug Thera | 1994 |
[Six-month short course chemotherapy containing pyrazinamide for initial treatment of pulmonary tuberculosis].
Topics: Adolescent; Adult; Aged; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Male; Mid | 1994 |
A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Therapy, Combination; Etha | 1994 |
Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis.
Topics: Adult; Aged; Ciprofloxacin; Drug Therapy, Combination; Ethambutol; Female; HIV Seropositivity; HIV-1 | 1993 |
[Combined chemotherapy of patients with tuberculosis - new regimens and dosage forms].
Topics: Antitubercular Agents; Dosage Forms; Drug Administration Schedule; Drug Combinations; Drug Therapy, | 1993 |
Effect of pyrazinamide on rifampicin kinetics in patients with tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Drug Interactions; Drug Therapy, Combination; Humans; Male; Middle Age | 1993 |
Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy.
Topics: Adult; Biological Availability; Capsules; Drug Administration Schedule; Drug Combinations; Half-Life | 1993 |
Two-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa.
Topics: Adolescent; Adult; Africa, Western; AIDS-Related Opportunistic Infections; Antibiotics, Antitubercul | 1995 |
Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antitubercular Agents; Ciproflo | 1996 |
Pharmacokinetics of isoniazid in pulmonary tuberculosis--a comparative study at two dose levels.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Child; Dose-Response Relationship, Drug; Drug Th | 1996 |
A controlled trial of a 4-weekly supplement of rifampicin, pyrazinamide and streptomycin in the continuation phase of a 7-month daily chemotherapy regimen for pulmonary tuberculosis. Tanzania/British Medical Research Council Collaborative Investigation.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Black People; Body Weight; Drug Administration Sched | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Therapy, Combination; Fema | 1997 |
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Therapy, Combination; Fema | 1997 |
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Therapy, Combination; Fema | 1997 |
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Therapy, Combination; Fema | 1997 |
A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antitubercular Agents; Child; Drug Administration Sch | 1997 |
Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; F | 1998 |
Prospective study of corticosteroid as an adjunct in the treatment of endobronchial tuberculosis in adults.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Bronchoscopy; Chi-Square Distribution; Drug Therapy, | 1997 |
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Tr
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; D | 1998 |
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Tr
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; D | 1998 |
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Tr
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; D | 1998 |
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Tr
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; D | 1998 |
Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report.
Topics: Adolescent; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; F | 1998 |
[Lomefloxacin in complex treatment of acute progressive form of pulmonary tuberculosis].
Topics: Acute Disease; Adolescent; Adult; Animals; Anti-Infective Agents; Antibiotics, Antitubercular; Antit | 1998 |
Twice weekly tuberculosis preventive therapy in HIV infection in Zambia.
Topics: Adult; AIDS-Related Opportunistic Infections; Antibiotic Prophylaxis; Antibiotics, Antitubercular; A | 1998 |
[Long-term efficacy of full course intermittent short-course chemotherapy on new smear positive tuberculosis patients].
Topics: Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Follow-Up Studies; Humans; Isoniazid; | 1997 |
Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Combinations; Follow-Up Studies; Humans; I | 1999 |
[Hyperuricemia and arthralgia during pyrazinamide treatment].
Topics: Antitubercular Agents; Arthralgia; Drug Administration Schedule; Humans; Pyrazinamide; Retrospective | 1999 |
Twice weekly vs. daily chemotherapy for childhood tuberculosis.
Topics: Antitubercular Agents; Child, Preschool; Drug Administration Schedule; Female; Humans; Infant; Isoni | 2000 |
[Controlled clinical trial on efficacy of 5-month regimens and whole course intermittent 6-month regimens in treating bacillary pulmonary tuberculosis].
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; H | 1998 |
Modified short-course chemotherapy of pulmonary tuberculosis in Ibadan, Nigeria--a preliminary report.
Topics: Adolescent; Adult; Antitubercular Agents; Developing Countries; Drug Administration Schedule; Drug T | 2000 |
[Controlled clinical study on efficacy of fixed-dose compounds rifater/rifinah in antituberculous chemotherapy].
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; Isoniazid | 1998 |
Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Therapy, Combi | 2001 |
Treatment of childhood tuberculosis with a six month directly observed regimen of only two weeks of daily therapy.
Topics: Adolescent; Antibiotics, Antitubercular; Antitubercular Agents; Child; Child, Preschool; Directly Ob | 2002 |
Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antitubercular; Antitubercular Agents; Chil | 2002 |
Side-effects of drugs used in directly observed treatment short-course in newly diagnosed pulmonary tuberculosis subjects in Nigerians: a controlled clinical study.
Topics: Adolescent; Adult; Antitubercular Agents; Clinical Protocols; Directly Observed Therapy; Drug Therap | 2002 |
Short-course treatment in pulmonary tuberculosis.
Topics: Adolescent; Adult; Africa, Eastern; Antitubercular Agents; Humans; Isoniazid; Middle Aged; Pyrazinam | 1975 |
Short-course chemotherapy in pulmonary tuberculosis.
Topics: Clinical Trials as Topic; Developing Countries; Drug Therapy, Combination; Humans; Isoniazid; Pyrazi | 1977 |
Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis: first report: Third East African/British Medical Research Councils study.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedu | 1978 |
Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. First report of 4th study. East African and British Medical Research Councils.
Topics: Adolescent; Adult; Africa, Eastern; Aged; Clinical Trials as Topic; Drug Administration Schedule; Dr | 1978 |
Sputum-smear-negative pulmonary tuberculosis: controlled trial of 3-month and 2-month regimens of chemotherapy.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Male; | 1979 |
Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. First report.
Topics: Adolescent; Adult; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedule; Dr | 1978 |
The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide.
Topics: Acetylation; Adolescent; Adult; Aged; Chemical and Drug Induced Liver Injury; Clinical Trials as Top | 1978 |
Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis.
Topics: Adolescent; Adult; Alanine Transaminase; Antitubercular Agents; Clinical Trials as Topic; Drug Thera | 1979 |
Double blind controlled comparison of aspirin, allopurinol and placebo in the management of arthralgia during pyrazinamide administration.
Topics: Adolescent; Adult; Aged; Allopurinol; Aspirin; Clinical Trials as Topic; Double-Blind Method; Female | 1979 |
[Controlled trial of 6 to 8 month chemotherapeutic regimens in the treatment of pulmonary tuberculosis. A study of Hong Kong Chest Service/British Medical Research Council/].
Topics: Antitubercular Agents; Clinical Trials as Topic; Drug Therapy, Combination; Ethambutol; Hong Kong; H | 1978 |
[Short term chemotherapy of tuberculosis. Evaluation of an 18-week-long treatment including pyrazinamide (preliminary results)].
Topics: Antitubercular Agents; Clinical Trials as Topic; Drug Therapy, Combination; Ethambutol; Humans; Ison | 1978 |
A controlled trial of daily and intermittent rifampicin plus ethambutol in the retreatment of patients with pulmonary tuberculosis: results up to 30 months.
Topics: Antibody Formation; Body Weight; Clinical Trials as Topic; Cycloserine; Drug Combinations; Drug Resi | 1975 |
Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Second report. Second East African/British Medical Research Council Study.
Topics: Adolescent; Clinical Trials as Topic; Drug Therapy, Combination; Follow-Up Studies; Humans; Isoniazi | 1976 |
Investigations of allergic status and blood counts in Chinese patients receiving daily or intermittent rifampicin in Hong Kong.
Topics: ABO Blood-Group System; Blood Cell Count; China; Clinical Trials as Topic; Cycloserine; Drug Hyperse | 1975 |
Controlled trial of 6- and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong.
Topics: Adolescent; Adult; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Microbial; Female; | 1975 |
Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hon
Topics: Adolescent; Adult; Drug Administration Schedule; Drug Combinations; Drug Resistance, Microbial; Drug | 1991 |
Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
Topics: Adolescent; Adult; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Combination; Female; | 1991 |
Short-course chemotherapy for pulmonary tuberculosis under routine programme conditions: a comparison of regimens of 28 and 36 weeks duration in Algeria. Algerian Working Group/British Medical Research Council Cooperative Study.
Topics: Adolescent; Adult; Aged; Algeria; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, | 1991 |
[A therapeutic trial of a combination of 3 essential drugs in a short course of chemotherapy in tuberculosis. Results 6 months after the end of treatment].
Topics: Drug Combinations; Drug Resistance, Microbial; Follow-Up Studies; Humans; Isoniazid; Mycobacterium t | 1990 |
Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in south India.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Micro | 1990 |
USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results.
Topics: Adult; Antitubercular Agents; Centers for Disease Control and Prevention, U.S.; Data Interpretation, | 1990 |
Short-course chemotherapy for pulmonary tuberculosis with a rifampicin-isoniazid-pyrazinamide combination tablet.
Topics: Adult; Antitubercular Agents; Drug Combinations; Drug Therapy, Combination; Humans; Isoniazid; Male; | 1990 |
[Tisamide in the complex treatment of tuberculosis].
Topics: Adult; Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Middle Aged; Pyrazinamide; Rifamp | 1990 |
A randomized trial of fully intermittent vs. daily followed by intermittent short course chemotherapy for childhood tuberculosis.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Follo | 1990 |
Acceptability, compliance, and adverse reactions when isoniazid, rifampin, and pyrazinamide are given as a combined formulation or separately during three-times-weekly antituberculosis chemotherapy.
Topics: Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Humans; Isoniazid; Patie | 1989 |
[Therapeutic trial of a combination of isoniazid, rifampicin and pyrazinamide in the first 2 months of treatment of pulmonary tuberculosis].
Topics: Adolescent; Adult; Antitubercular Agents; Clinical Trials as Topic; Drug Combinations; Drug Therapy, | 1989 |
A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 5 years. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedu | 1989 |
[Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
Topics: Adult; Antitubercular Agents; Drug Combinations; Ethambutol; Female; Humans; Isoniazid; Male; Middle | 1989 |
Clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
Topics: Adolescent; Adult; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedule; Dr | 1985 |
Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combi | 1988 |
Adrenal function in tuberculosis.
Topics: Acute Disease; Adolescent; Adrenal Glands; Adrenocorticotropic Hormone; Adult; Aged; Child; Child, P | 1986 |
Controlled clinical trial of a regimen of two durations for the treatment of isoniazid resistant pulmonary tuberculosis.
Topics: Adolescent; Adult; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; | 1988 |
Comparison of a daily and three intermittent retreatment regimens for pulmonary tuberculosis administered under programme conditions.
Topics: Adolescent; Adult; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedule; Dr | 1988 |
Pulmonary tuberculosis treated with isoprodian and rifampicin or pyrazinamide.
Topics: Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Dapsone; Drug Combinations; Drug Thera | 1987 |
[Short-term chemotherapy of tuberculosis with 5-month regimens with and without pyrazinamide in the 2d phase (TA-82)].
Topics: Adolescent; Adult; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedule; Dr | 1986 |
Short-course chemotherapy of pulmonary tuberculosis in pneumoconiotic patients.
Topics: Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Iso | 1987 |
[Results of a shortened (6 months) schedule of treatment of pulmonary tuberculosis using INH, RMP and PZA].
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Female; Humans; Isoniazid; | 1987 |
United States Public Health Service Tuberculosis Therapy Trial 21: preliminary results of an evaluation of a combination tablet of isoniazid, rifampin and pyrazinamide.
Topics: Clinical Trials as Topic; Drug Combinations; Female; Humans; Isoniazid; Male; Patient Compliance; Py | 1987 |
Short-course tuberculosis chemotherapy studies conducted in Poland during the past decade.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedu | 1986 |
Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. East and Central African/British Medical Research Council Fifth Collaborative Study.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Drug Therapy, Combination; | 1986 |
A controlled clinical trial of 3- and 5-month regimens in the treatment of sputum-positive pulmonary tuberculosis in South India. Tuberculosis Research Centre, Madras, and National Tuberculosis Institute, Bangalore.
Topics: Adolescent; Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as | 1986 |
[Clinical trial of initial intensive short-course chemotherapy supplemented by pyrazinamide for pulmonary tuberculosis--report of the 26th A series of controlled trials of chemotherapy--Cooperative Study Unit of Chemotherapy of Tuberculosis of National Sa
Topics: Adult; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, | 1986 |
[Daily ultrashort chemotherapy and intermittent short-term chemotherapy with 4 drugs of communicable pulmonary tuberculosis treated for the first time. Results of a cooperative multicenter study].
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedu | 1986 |
Controlled clinical trial of three short-course regimens of chemotherapy for pulmonary tuberculosis in Nigeria--a preliminary report.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedu | 1986 |
Controlled clinical trial of two 6-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Tanzania/British Medical Research Council Study.
Topics: Adolescent; Adult; Clinical Trials as Topic; Drug Resistance, Microbial; Female; Humans; Isoniazid; | 1985 |
Operational evaluation of treatment for tuberculosis. Results of 8- and 12-month regimens in Peru.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Clinical Trials as Topic; Drug Th | 1985 |
[Which is the best drug combination for the short-term therapy of tuberculosis? A prospective randomized study with 190 patients].
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug | 1985 |
[Controlled study comparing 3 daily chemotherapy regimens for six months in pulmonary tuberculosis in routine practice in Algiers. Results at 30 months].
Topics: Antitubercular Agents; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combinati | 1985 |
Uric acid disposition during intermittent chemotherapy of pulmonary tuberculosis with regimens containing pyrazinamide & rifampicin.
Topics: Drug Administration Schedule; Drug Therapy, Combination; Humans; Pyrazinamide; Rifampin; Tuberculosi | 1985 |
The combination of ethambutol, capreomycin and a third drug in chronic pulmonary tuberculosis with bacterial polyresistance.
Topics: Administration, Oral; Aminosalicylic Acids; Antitubercular Agents; Capreomycin; Chronic Disease; Cli | 1970 |
General considerations in intermittent drug therapy of pulmonary tuberculosis.
Topics: Aminosalicylic Acids; Antitubercular Agents; Clinical Trials as Topic; Ethambutol; Ethionamide; Huma | 1971 |
Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis.
Topics: Administration, Oral; Adolescent; Adult; Antitubercular Agents; Clinical Trials as Topic; Drug Combi | 1972 |
Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Second report.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Resistance, Microbial; Female; Humans; Isoniazi | 1973 |
Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. East African-British Medical Research Councils.
Topics: Adolescent; Adult; Africa, Eastern; Clinical Trials as Topic; Drug Combinations; Drug Evaluation; Dr | 1974 |
Interaction aspects of antimycobacterial drugs in the chemotherapy of tuberculosis. I. Role of individual antituberculous drugs in drug regimens used in the chemotherapy of human tuberculosis.
Topics: Aminosalicylic Acids; Antitubercular Agents; Clinical Trials as Topic; Cycloserine; Drug Evaluation; | 1974 |
Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis.
Topics: Administration, Oral; Adolescent; Adult; Africa; Clinical Trials as Topic; Drug Combinations; Drug E | 1974 |
[Short-term treatment of pulmonary tuberculosis].
Topics: Adolescent; Antitubercular Agents; Clinical Trials as Topic; Drug Therapy, Combination; Evaluation S | 1974 |
Evaluation of results of chemotherapy in tuberculosis with special consideration of ethambutol.
Topics: Aminosalicylic Acids; Clinical Trials as Topic; Cycloserine; Drug Combinations; Electronic Data Proc | 1970 |
Streptomycin plus pas plus pyrazinamide in the retreatment of pulmonary tuberculosis in East Africa.
Topics: Aminosalicylic Acids; Clinical Trials as Topic; Drug Combinations; Humans; Pyrazinamide; Streptomyci | 1972 |
Ethambutol in the initial treatment of pulmonary tuberculosis. U.S. Public Health Service tuberculosis therapy trials.
Topics: Adolescent; Adult; Aminosalicylic Acids; Clinical Trials as Topic; Ethambutol; Evaluation Studies as | 1973 |
Streptomycin plus PAS plus pyrazinamide in the retreatment of pulmonary tuberculosis in East Africa: second report. A co-operative study in East African and British Medical Research Councils.
Topics: Administration, Oral; Adult; Aminosalicylic Acids; Clinical Trials as Topic; Female; Humans; Injecti | 1973 |
[Controlled comparison of daily and intermittent treatment regimens with rifampicin].
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Humans; Pyrazinamide; Rifampin; Time Factors; T | 1974 |
A Hong Kong Tuberculosis Treatment Services/Brompton Hospital/British Medical Research Council Investigation.
Topics: Adult; Antitubercular Agents; Clinical Trials as Topic; Cycloserine; Drug Administration Schedule; D | 1974 |
A controlled clinical trial of small daily doses of rifampicin in the prevention of adverse reactions to the drug in a once-weekly regimen of chemotherapy in Hong Kong: second report:-the results at 12 months.
Topics: Adolescent; Adult; Clinical Trials as Topic; Drug Administration Schedule; Drug Hypersensitivity; Dr | 1974 |
A controlled clinical trial of small daily doses of rifampicin in the prevention of adverse reactions to the drug in a once-weekly regimen of chemotherapy. A Hong Kong Tuberculosis Treatment Services-British Medical Research Council Investigation.
Topics: Adult; Alanine Transaminase; Antibodies; Ethambutol; Female; Fever; Humans; Jaundice; Male; Middle A | 1974 |
Clinical experience of intermittent treatment in the United Kingdom.
Topics: Aminosalicylic Acids; Clinical Trials as Topic; Humans; Isoniazid; Pyrazinamide; Streptomycin; Tuber | 1968 |
[Clinical studies on the ketogenic effect of certain antitubercular drugs in patients with diabetes and pulmonary tuberculosis].
Topics: Adult; Antitubercular Agents; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; E | 1968 |
[Toxic reactions during treament with pyrazinamide in pulmonary tuberculosis].
Topics: Adult; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Female; Humans; Male; Middl | 1968 |
[Results of treatment with a combined 3-drug regimen of secondary drugs in chronic cavernous pulmonary tuberculosis. A study under auspices of the International Union against Tuberculosis].
Topics: Adult; Aged; Clinical Trials as Topic; Cycloserine; Drug Resistance, Microbial; Ethionamide; Female; | 1968 |
A comparison of regimens of ethionamide, pyrazinamide and cycloserine in re-treatment of patients with pulmonary tuberculosis.
Topics: Clinical Trials as Topic; Cycloserine; Ethionamide; Humans; Isoniazid; Prospective Studies; Pyrazina | 1968 |
A controlled comparison of four regimens of streptomycin plus pyrazinamide in the retreatment of pulmonary tuberculosis.
Topics: Adolescent; Adult; Aspartate Aminotransferases; Clinical Trials as Topic; Drug Resistance, Microbial | 1969 |
Streptomycin plus pyrazinamide in the retreatment of pulmonary tuberculosis--second report. A co-operative study in East African hospitals, clinics and laboratories with the collaboration of the East African and British Medical Research Councils.
Topics: Africa, Eastern; Clinical Trials as Topic; Drug Resistance, Microbial; Follow-Up Studies; Humans; Mi | 1970 |
Streptomycin plus PAS plus pyrazinamide in the retreatment of pulmonary tuberxulisis in East Africa.
Topics: Adolescent; Adult; Aminosalicylic Acids; Clinical Trials as Topic; Costs and Cost Analysis; Drug Res | 1971 |
Controlled clinical trials with Isoxyl.
Topics: Clinical Trials as Topic; Cycloserine; Drug Combinations; Drug Synergism; Ethionamide; Evaluation St | 1970 |
Madras study of supervised once-weekly chemotherapy in the treatment of pulmonary tuberculosis: laboratory aspects.
Topics: Clinical Trials as Topic; Drug Resistance, Microbial; Drug Synergism; Humans; India; Isoniazid; Myco | 1968 |
A controlled comparison of a twice-weekly and three once-weekly regimens in the initial treatment of pulmonary tuberculosis.
Topics: Adolescent; Adult; Child; Humans; India; Isoniazid; Microbial Sensitivity Tests; Middle Aged; Pyrazi | 1970 |
[Comparison between morphazinamide and pyrazinamide in retreatment of pulmonary tuberculosis].
Topics: Antitubercular Agents; Clinical Trials as Topic; Humans; Pyrazinamide; Pyrazines; Tuberculosis, Pulm | 1965 |
798 other studies available for pyrazinamide and Pulmonary Consumption
Article | Year |
---|---|
Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis.
Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Diarylquinolines; Drug Synergism; Female; L | 2007 |
Metronidazole lacks antibacterial activity in guinea pigs infected with Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Female; Guinea Pigs; Isoniazid; Lung; Metro | 2008 |
Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes.
Topics: Adult; Antitubercular Agents; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Administra | 2010 |
Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis.
Topics: Acetamides; Animals; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Drug Discovery; E | 2010 |
Early phase of effective treatment induces distinct transcriptional changes in Mycobacterium tuberculosis expelled by pulmonary tuberculosis patients.
Topics: Adult; Antitubercular Agents; Ethambutol; Female; Humans; Isoniazid; Male; Mycobacterium tuberculosi | 2021 |
Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022.
Topics: Antitubercular Agents; Centers for Disease Control and Prevention, U.S.; Drug Administration Schedul | 2022 |
High Intrapulmonary Rifampicin and Isoniazid Concentrations Are Associated With Rapid Sputum Bacillary Clearance in Patients With Pulmonary Tuberculosis.
Topics: Adult; Antitubercular Agents; Bacillus; Ethambutol; Humans; Isoniazid; Pyrazinamide; Rifampin; Sputu | 2022 |
Drug concentration at the site of disease in children with pulmonary tuberculosis.
Topics: Adult; Antitubercular Agents; Child; Ethambutol; Humans; Infant; Isoniazid; Pyrazinamide; South Afri | 2022 |
Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study.
Topics: Adult; Antitubercular Agents; Clofazimine; Humans; Microbial Sensitivity Tests; Mycobacterium tuberc | 2023 |
Pharmacodynamics and Bactericidal Activity of Combination Regimens in Pulmonary Tuberculosis: Application to Bedaquiline-Pretomanid-Pyrazinamide.
Topics: Antitubercular Agents; Diarylquinolines; Humans; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberc | 2022 |
Individualising therapy for drug-sensitive tuberculosis.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Ethambutol; Humans; Is | 2019 |
Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Diabetes Complications; Diabetes Mellitus; Fe | 2019 |
Lack of Weight Gain During the First 2 Months of Treatment and Human Immunodeficiency Virus Independently Predict Unsuccessful Treatment Outcomes in Tuberculosis.
Topics: Adult; Antitubercular Agents; Brazil; Ethambutol; Female; HIV Seropositivity; Humans; Isoniazid; Mal | 2020 |
Are pretomanid-containing regimens for tuberculosis a victory or a victory narrative?
Topics: Diarylquinolines; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, P | 2019 |
Detection of Mutations in Mycobacterium tuberculosis pncA Gene by Modified High-Resolution Melting Curve Analysis of PCR Products.
Topics: Amidohydrolases; Antitubercular Agents; Base Sequence; Drug Resistance, Bacterial; Mycobacterium tub | 2019 |
Whole-genome sequencing in drug susceptibility testing of Mycobacterium tuberculosis in routine practice in Lyon, France.
Topics: Antitubercular Agents; Bacterial Proteins; DNA-Directed RNA Polymerases; Drug Resistance, Multiple, | 2020 |
Different macrophage polarization between drug-susceptible and multidrug-resistant pulmonary tuberculosis.
Topics: Adult; Antitubercular Agents; Cycloserine; Extensively Drug-Resistant Tuberculosis; Female; Humans; | 2020 |
Tuberculosis treatment: one-shot approach or cascade of regimens?
Topics: Diarylquinolines; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, P | 2020 |
Treatment outcome of tuberculosis treatment regimens in Kandahar, Afghanistan.
Topics: Adolescent; Adult; Afghanistan; Antitubercular Agents; Cohort Studies; Cough; Drug Therapy, Combinat | 2020 |
High prevalence of phenotypic pyrazinamide resistance and its association with pncA gene mutations in Mycobacterium tuberculosis isolates from Uganda.
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sens | 2020 |
An Unexpected Cause of Conjunctivitis in an Adolescent.
Topics: Adolescent; Antitubercular Agents; Conjunctivitis; Diagnosis, Differential; Ethambutol; Glucocortico | 2020 |
Irreversible neuropathy in extremely-drug resistant tuberculosis: An unfortunate clinical conundrum.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Clofazimine; Cycloserine; Deprescriptions; Diaryl | 2020 |
Gitelman-like syndrome: A rare complication of using aminoglycosides in tuberculosis - A case report.
Topics: Alkalosis; Antitubercular Agents; Capreomycin; Clofazimine; Cycloserine; Deprescriptions; Ethionamid | 2020 |
Drug Exposure and Minimum Inhibitory Concentration Predict Pulmonary Tuberculosis Treatment Response.
Topics: Antitubercular Agents; Humans; Microbial Sensitivity Tests; Pharmaceutical Preparations; Prospective | 2021 |
Effect of interval between food intake and drug administration at fasting condition on the plasma concentrations of first-line anti-tuberculosis drugs in Chinese population.
Topics: Administration, Oral; Adult; Antitubercular Agents; China; Drug Administration Schedule; Eating; Eth | 2020 |
Five-year microevolution of a multidrug-resistant Mycobacterium tuberculosis strain within a patient with inadequate compliance to treatment.
Topics: Adult; Antitubercular Agents; Argentina; Drug Resistance, Multiple, Bacterial; Female; Humans; Isoni | 2021 |
Two cases of tuberculous retropharyngeal abscess in adults.
Topics: Adult; Female; Humans; Male; Mycobacterium tuberculosis; Pyrazinamide; Retropharyngeal Abscess; Rifa | 2021 |
Pulmonary Tuberculosis in Older Adults: Increased Mortality Related to Tuberculosis Within Two Months of Treatment Initiation.
Topics: Aged; Antitubercular Agents; Humans; Pyrazinamide; Retrospective Studies; Tuberculosis; Tuberculosis | 2021 |
A recombinant selective drug-resistant M. bovis BCG enhances the bactericidal activity of a second-line anti-tuberculosis regimen.
Topics: Amikacin; Animals; Antigens, Bacterial; Antitubercular Agents; BCG Vaccine; Disease Models, Animal; | 2021 |
Association of CYP2B6 gene polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a Chinese population.
Topics: Adult; Alleles; Antitubercular Agents; Asian People; Chemical and Drug Induced Liver Injury; Cytochr | 2017 |
Metformin Adjunctive Therapy Does Not Improve the Sterilizing Activity of the First-Line Antitubercular Regimen in Mice.
Topics: Animals; Antitubercular Agents; Bacterial Load; Disease Models, Animal; Drug Synergism; Drug Therapy | 2017 |
Evaluation of a novel line probe assay to detect resistance to pyrazinamide, a key drug used for tuberculosis treatment.
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Te | 2018 |
Poncet's disease in human immunodeficiency virus: a case report.
Topics: Adult; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Arthritis, Reactive; Etha | 2017 |
Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Drug Combinations; Ethambutol; HIV Infections | 2017 |
Assessment of treatment response by colony forming units, time to culture positivity and the molecular bacterial load assay compared in a mouse tuberculosis model.
Topics: Animals; Antitubercular Agents; Bacterial Load; Colony Count, Microbial; Disease Models, Animal; DNA | 2017 |
Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis.
Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Female; Fluoroquinolones; | 2017 |
Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy.
Topics: Animals; Antitubercular Agents; Clostridiales; Drug Combinations; Dysbiosis; Gastrointestinal Microb | 2017 |
Massive choroidal granuloma as the presenting feature of disseminated tuberculosis in immunocompetent patients.
Topics: Adolescent; Adult; Antitubercular Agents; Choroid Diseases; Drug Combinations; Ethambutol; Female; G | 2018 |
Serum levels of soluble urokinase plasminogen activator receptor (suPAR) as a marker of tuberculosis treatment efficacy.
Topics: Adult; Aged; Antitubercular Agents; Biomarkers; Drug Monitoring; Drug Therapy, Combination; Ethambut | 2017 |
Assessment of Bactericidal Drug Activity and Treatment Outcome in a Mouse Tuberculosis Model Using a Clinical Beijing Strain.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Ethambutol; Femal | 2017 |
Prevalence of pyrazinamide resistance and Wayne assay performance analysis in a tuberculosis cohort in Lima, Peru.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Cohort Studies; Drug Resistance, Bacterial; Female; | 2017 |
The clinical recovery of tuberculosis patients undergoing specific treatment is associated with changes in the immune and neuroendocrine responses.
Topics: Adult; Antitubercular Agents; C-Reactive Protein; Case-Control Studies; Dehydroepiandrosterone; Etha | 2017 |
Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Biomedical Research; CD4 Lymphocyte Count; Coh | 2017 |
Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
Topics: Adult; Age Distribution; Aged; Alcohol Drinking; Aminosalicylic Acid; Antitubercular Agents; Cohort | 2017 |
Prescription practice of anti-tuberculosis drugs in Yunnan, China: A clinical audit.
Topics: Adult; Aged; Antitubercular Agents; Asian People; China; Clinical Audit; Ethambutol; Female; Fluoroq | 2017 |
Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide.
Topics: Adolescent; Adult; Africa South of the Sahara; Aged; Aged, 80 and over; Amidohydrolases; Antitubercu | 2017 |
Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
Topics: Anti-HIV Agents; Antitubercular Agents; Child; Drug Administration Schedule; Drug Combinations; Drug | 2018 |
Outcomes of pulmonary tuberculosis in patients with discordant phenotypic isoniazid resistance testing.
Topics: Aged; Antitubercular Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Ethambutol; Fema | 2017 |
A retrospective study on tuberculosis treatment outcomes at Jinka General Hospital, southern Ethiopia.
Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Drug Combinations; Ethambutol; Ethiopia; Fema | 2017 |
A Painful Red Eye.
Topics: Alcoholism; Antitubercular Agents; Conjunctival Diseases; Ethambutol; Eye Pain; Glucocorticoids; Hum | 2018 |
Treatment outcomes and tolerability of the revised WHO anti-tuberculosis drug dosages for children.
Topics: Antitubercular Agents; Child, Preschool; Cohort Studies; Female; HIV Infections; Humans; Infant; Inf | 2018 |
Antituberculosis Treatment in a Patient with Celiac Disease.
Topics: Aged; Antitubercular Agents; Celiac Disease; Diarrhea; Diet, Gluten-Free; Drug Compounding; Drug Sub | 2018 |
[DRESS syndrome secondary to pyrazinamide: An uncommon complication of tuberculosis treatment].
Topics: Adrenal Cortex Hormones; Adult; Antitubercular Agents; Coinfection; Drug Hypersensitivity Syndrome; | 2018 |
Tuberculosis treatment outcome and predictors in northern Ethiopian prisons: a five-year retrospective analysis.
Topics: Adolescent; Adult; Aftercare; Anti-Retroviral Agents; Antitubercular Agents; Coinfection; Directly O | 2018 |
Genotypic characterization of pyrazinamide resistance in Mycobacterium tuberculosis isolated from Lusaka, Zambia.
Topics: Amidohydrolases; Antitubercular Agents; DNA Mutational Analysis; Drug Resistance, Multiple, Bacteria | 2018 |
Development and characterization of high payload combination dry powders of anti-tubercular drugs for treating pulmonary tuberculosis.
Topics: Aerosols; Antitubercular Agents; Cell Line; Cell Survival; Chemistry, Pharmaceutical; Drug Combinati | 2018 |
[Management and treatment difficulties of multi-drug resistant pulmonary tuberculosis in a pediatric case].
Topics: Adult; Antitubercular Agents; Female; Humans; Infant; Isoniazid; Mycobacterium tuberculosis; Pyrazin | 2018 |
Perianal ulcerative skin tuberculosis: A case report.
Topics: Aged; Antitubercular Agents; Ethambutol; Fissure in Ano; Humans; Isoniazid; Male; Mycobacterium tube | 2018 |
Effect of Diabetes Mellitus on the Pharmacokinetics and Pharmacodynamics of Tuberculosis Treatment.
Topics: Adult; Antitubercular Agents; Diabetes Mellitus; Female; Glycated Hemoglobin; Humans; Isoniazid; Mal | 2018 |
Optic Perineuritis Due to Tuberculosis.
Topics: Adult; Antitubercular Agents; Bronchoscopy; Drug Therapy, Combination; Humans; Isoniazid; Magnetic R | 2019 |
Efficacy of pyrazinoic acid dry powder aerosols in resolving necrotic and non-necrotic granulomas in a guinea pig model of tuberculosis.
Topics: Aerosols; Animals; Antitubercular Agents; Bacterial Load; Disease Models, Animal; Drug Therapy, Comb | 2018 |
Differentially Detectable Mycobacterium tuberculosis Cells in Sputum from Treatment-Naive Subjects in Haiti and Their Proportionate Increase after Initiation of Treatment.
Topics: Adult; Antitubercular Agents; Colony Count, Microbial; Drug Therapy, Combination; Female; Haiti; Hum | 2018 |
Intestinal dysbiosis compromises alveolar macrophage immunity to Mycobacterium tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Disease Models, Animal; Drug-Related Side Effects and Adverse | 2019 |
Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization.
Topics: Adult; Antitubercular Agents; Decision Support Techniques; Disease Progression; Drug Administration | 2019 |
Tuberculosis in Older Adults: Seattle and King County, Washington.
Topics: Aged; Antitubercular Agents; Humans; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary; Washington | 2020 |
Serum pyrazinamide concentrations in patients with pulmonary tuberculosis.
Topics: Antitubercular Agents; Brazil; Dose-Response Relationship, Drug; Female; Humans; Male; Mycobacterium | 2019 |
A Rare Case of a Tuberculosis Patient with Sarcoidosis.
Topics: Adult; Antitubercular Agents; Deprescriptions; Ethambutol; Female; Glucocorticoids; Humans; Isoniazi | 2019 |
Model-Based Relationship between the Molecular Bacterial Load Assay and Time to Positivity in Liquid Culture.
Topics: Antitubercular Agents; Bacterial Load; Biological Assay; Biomarkers, Pharmacological; Computer Simul | 2019 |
Isoniazid- and streptomycin-resistant miliary tuberculosis complicated by intracranial tuberculoma in a Japanese infant.
Topics: Antitubercular Agents; Drug Substitution; Drug Therapy, Combination; Ethambutol; Ethionamide; Female | 2013 |
Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection.
Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Cycloserine; Drug Therapy, Combination; Etham | 2013 |
Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients.
Topics: Adult; Antitubercular Agents; Ethambutol; Female; Humans; Isoniazid; Male; Pyrazinamide; Rifampin; T | 2013 |
[Comparison of drug-induced hepatitis occurring in elderly and younger patients during anti-tuberculosis treatment with a regimen including pyrazinamide].
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug In | 2013 |
Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.
Topics: Adult; Antitubercular Agents; Area Under Curve; Drug Evaluation; Drug Therapy, Combination; Female; | 2013 |
Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.
Topics: Adult; Antitubercular Agents; Area Under Curve; Drug Evaluation; Drug Therapy, Combination; Female; | 2013 |
Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.
Topics: Adult; Antitubercular Agents; Area Under Curve; Drug Evaluation; Drug Therapy, Combination; Female; | 2013 |
Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.
Topics: Adult; Antitubercular Agents; Area Under Curve; Drug Evaluation; Drug Therapy, Combination; Female; | 2013 |
Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen.
Topics: Animals; Antitubercular Agents; Area Under Curve; Disease Models, Animal; Drug Evaluation, Preclinic | 2013 |
Serum drug concentrations predictive of pulmonary tuberculosis outcomes.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Area Under Curve; Female; Humans; Isoniazid; Male; M | 2013 |
Treating pyrazinamide mono-resistant pulmonary tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Drug Resistance, Bacterial; Drug | 2013 |
Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus.
Topics: Adult; Antitubercular Agents; Biological Availability; Diabetes Mellitus, Type 2; Drug Administratio | 2013 |
A case of skin and lung tuberculosis: diagnostic difficulties.
Topics: Antitubercular Agents; Bronchitis; Bronchoalveolar Lavage Fluid; Bronchoscopy; CD4-CD8 Ratio; Diagno | 2013 |
Host targeted activity of pyrazinamide in Mycobacterium tuberculosis infection.
Topics: Animals; Antitubercular Agents; Biomarkers; Cytokines; Disease Models, Animal; Female; Gene Expressi | 2013 |
Olfactory disturbance related to pyrazinamide.
Topics: Antitubercular Agents; Drug Combinations; Humans; Isoniazid; Male; Middle Aged; Olfaction Disorders; | 2014 |
Pharmacokinetics and serum concentrations of antimycobacterial drugs in adult Turkish patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antitubercular Agents; Area Under Curve; Directly Obs | 2013 |
Comparison of time to positive and colony counting in an early bactericidal activity study of anti-tuberculosis treatment.
Topics: Adult; Antitubercular Agents; Automation, Laboratory; Colony Count, Microbial; Drug Monitoring; Drug | 2013 |
Clonal expansion of Mycobacterium tuberculosis isolates and coexisting drug resistance in patients newly diagnosed with pulmonary tuberculosis in Hanoi, Vietnam.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Clone Cells; DNA, Bacterial; Drug | 2013 |
Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis.
Topics: Adult; Aged; Antitubercular Agents; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Ther | 2013 |
Rapid detection of Mycobacterium tuberculosis and pyrazinamide susceptibility related to pncA mutations in sputum specimens through an integrated gene-to-protein function approach.
Topics: Adult; Amidohydrolases; Antitubercular Agents; Humans; Microbial Sensitivity Tests; Molecular Diagno | 2014 |
Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
Topics: Adolescent; Adult; Amikacin; Antitubercular Agents; Cycloserine; Ethionamide; Female; Fluoroquinolon | 2014 |
[Thrombocytopenia induced by rifampicin not previously sensitized: a case presentation].
Topics: Adult; Antibiotics, Antitubercular; Ethambutol; Female; Humans; Immunization; Isoniazid; Purpura, Th | 2013 |
[A clinical investigation of seven patients with pulmonary tuberculosis who developed mixed liver injury during oral anti-tuberculosis treatment].
Topics: Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2013 |
Strategy to limit sampling of antituberculosis drugs instead of determining concentrations at two hours postingestion in relation to treatment response.
Topics: Antitubercular Agents; Female; Humans; Isoniazid; Male; Pyrazinamide; Rifampin; Tuberculosis, Pulmon | 2014 |
Reply to "strategy to limit sampling of antituberculosis drugs instead of determining concentrations at two hours postingestion in relation to treatment response".
Topics: Antitubercular Agents; Female; Humans; Isoniazid; Male; Pyrazinamide; Rifampin; Tuberculosis, Pulmon | 2014 |
[Antimicrobial resistance in tuberculosis].
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Ethambutol; | 2013 |
The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1.
Topics: Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Chemical and Drug Induced Liver Injury; | 2014 |
[Hypothermia due to anti-tuberculosis drugs: first case].
Topics: Aged; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Comb | 2014 |
Characterisation of pyrazinamide-resistant Mycobacterium tuberculosis strains isolated in Poland and Germany.
Topics: Amidohydrolases; Antitubercular Agents; Bacteriological Techniques; DNA Mutational Analysis; DNA, Ba | 2014 |
Prevalence of extended treatment in pulmonary tuberculosis patients receiving first-line therapy and its association with recurrent tuberculosis in Beijing, China.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; China; Cohort Studies; Cost of Il | 2014 |
Sterilizing activity of thioridazine in combination with the first-line regimen against acute murine tuberculosis.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Female; Isoniazid | 2014 |
Association of serum levels of iron, copper, and zinc, and inflammatory markers with bacteriological sputum conversion during tuberculosis treatment.
Topics: Adult; Antitubercular Agents; Biomarkers; C-Reactive Protein; Copper; Ethambutol; Hemoglobins; Host- | 2014 |
Novel bronchoscopic balloon dilation for patients with bronchostenosis caused by bronchial tuberculosis: a case report.
Topics: Antitubercular Agents; Bronchial Diseases; Bronchoscopy; Constriction, Pathologic; Dilatation; Etham | 2014 |
Isoniazid, pyrazinamide and rifampicin content variation in split fixed-dose combination tablets.
Topics: Chemistry, Pharmaceutical; Drug Combinations; Humans; Isoniazid; Pyrazinamide; Quality Control; Rifa | 2014 |
Pulmonary tuberculoma in a patient with chronic hepatitis C: a clinical pitfall in the treatment strategy.
Topics: Antitubercular Agents; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up St | 2014 |
False-positive rifampicin resistance on Xpert® MTB/RIF caused by a silent mutation in the rpoB gene.
Topics: Aged; Amikacin; Amino Acid Sequence; Antibiotics, Antitubercular; Bacterial Proteins; DNA-Directed R | 2014 |
Investigating gender disparities in the profile and treatment outcomes of tuberculosis in Ebonyi state, Nigeria.
Topics: Adult; Antitubercular Agents; Cohort Studies; Coinfection; Ethambutol; Female; Health Status Dispari | 2015 |
Treatment options and outcomes of hospitalised tuberculosis patients: a nationwide study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Child; Child, Preschool; Ethambut | 2015 |
Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antitubercular Agents; Aspartate A | 2015 |
Counting pyrazinamide in regimens for multidrug-resistant tuberculosis.
Topics: Adult; Aged; Antitubercular Agents; Female; Follow-Up Studies; Humans; Male; Mycobacterium tuberculo | 2015 |
Profile of adverse drug reactions in drug resistant tuberculosis from Punjab.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Arthralgia; Ataxia; Chemical and Drug Induced Liver | 2014 |
Six- vs. eight-month anti-tuberculosis regimen for pulmonary tuberculosis under programme conditions.
Topics: Adult; Antitubercular Agents; Ethambutol; Female; Follow-Up Studies; Humans; Isoniazid; Logistic Mod | 2015 |
Effective anti-tuberculosis therapy correlates with plasma small RNA.
Topics: Adult; Antitubercular Agents; Biomarkers; Coinfection; Ethambutol; Female; Gene Expression Profiling | 2015 |
New drug combination may shorten tuberculosis treatment, study says.
Topics: Antitubercular Agents; Female; Fluoroquinolones; Humans; Male; Nitroimidazoles; Pyrazinamide; Tuberc | 2015 |
New effective antituberculosis regimens.
Topics: Antitubercular Agents; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Nitroimidazoles; Pyrazi | 2015 |
Effectiveness of RHZE-FDC (fixed-dose combination) compared to RH-FDC + Z for tuberculosis treatment in Brazil: a cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Brazil; Cohort Studies; Drug Combinations; Et | 2015 |
Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children.
Topics: Adolescent; Antitubercular Agents; Area Under Curve; Child; Child, Preschool; Ethambutol; Ethnicity; | 2015 |
Advanced stage of chronic kidney disease is risk of poor treatment outcome for smear-positive pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Cardiovascular Diseases; Child; D | 2015 |
Pyridoxine induced rosacea-like dermatitis.
Topics: Antitubercular Agents; Drug Combinations; Drug Eruptions; Female; Humans; Isoniazid; Middle Aged; Py | 2015 |
IL-37 Expression is Upregulated in Patients with Tuberculosis and Induces Macrophages Towards an M2-like Phenotype.
Topics: Antitubercular Agents; Arginase; B7-2 Antigen; Cell Differentiation; Cells, Cultured; Ethambutol; Fe | 2015 |
Drug-induced myopathy in a patient with pulmonary tuberculosis.
Topics: Adult; Antitubercular Agents; Arthralgia; Creatine Kinase; Humans; Male; Muscle Weakness; Muscular D | 2015 |
The relationship between chitotriosidase activity and tuberculosis.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Biomarkers; Case-Control Studies; China; Etha | 2015 |
Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chromatography, Liquid; Drug Moni | 2016 |
Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chromatography, Liquid; Drug Moni | 2016 |
Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chromatography, Liquid; Drug Moni | 2016 |
Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chromatography, Liquid; Drug Moni | 2016 |
[The effect of renal replacement therapy on the plasma concentration of antituberculosis drugs].
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Female; Humans; Isoniazid; Kidney Diseases; Male; Mi | 2015 |
Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis.
Topics: Animals; Antitubercular Agents; Bacterial Load; Diarylquinolines; Disease Models, Animal; Drug Admin | 2016 |
Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Resistance, Bacterial; Genome, Bacteria | 2016 |
Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Resistance, Bacterial; Drug Therapy, Co | 2016 |
Repeat exposure to active tuberculosis and risk of re-infection.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Emergency Service, Hospital; E | 2016 |
Global Urine Metabolomics in Patients Treated with First-Line Tuberculosis Drugs and Identification of a Novel Metabolite of Ethambutol.
Topics: Adult; Aged; Aged, 80 and over; Aminobutyrates; Antitubercular Agents; Biotransformation; Case-Contr | 2016 |
Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with Standard Short-Course Chemotherapy for tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; China; Cohort Studies; Drug Resistance, Bacterial; Drug Th | 2016 |
Prevalence and transmission of pyrazinamide resistant Mycobacterium tuberculosis in China.
Topics: Adult; Amidohydrolases; Antitubercular Agents; China; DNA Mutational Analysis; Drug Resistance, Mult | 2016 |
Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Combinations; Female; Isoniazid; Mice; | 2016 |
Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China.
Topics: Adolescent; Adult; Aged; Amikacin; Antitubercular Agents; China; Drug Therapy, Combination; Female; | 2016 |
Multicenter Study of the Emergence and Genetic Characteristics of Pyrazinamide-Resistant Tuberculosis in China.
Topics: Adult; Age Factors; Aged; Amidohydrolases; Antitubercular Agents; China; Codon; Cross-Sectional Stud | 2016 |
Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.
Topics: Anti-Infective Agents; Antitubercular Agents; Asia; Fluoroquinolones; Humans; Microbial Sensitivity | 2016 |
A quantitative adaptation of the Wayne test for pyrazinamide resistance.
Topics: Adult; Antitubercular Agents; Area Under Curve; Calibration; Drug Resistance, Bacterial; Female; Hum | 2016 |
HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Area Under Cur | 2016 |
Bacterial Loads Measured by the Xpert MTB/RIF Assay as Markers of Culture Conversion and Bacteriological Cure in Pulmonary TB.
Topics: Antitubercular Agents; Area Under Curve; Bacterial Load; Bacteriological Techniques; Biomarkers; Eth | 2016 |
[EVALUATION OF THE EFFICIENCY OF TREATMENT AND THE CHOICE OF CONTROL COMPUTED TOMOGRAPHY TIME IN CHILDREN WITH MINOR FORMS OF INTRATHORACIC TUBERCULOSIS].
Topics: Antitubercular Agents; Child; Child, Preschool; Comparative Effectiveness Research; Drug Monitoring; | 2010 |
Comprehensive cost of treating one patient with MDR/pre-XDR-TB in Wellington, New Zealand.
Topics: Adult; Amikacin; Aminosalicylic Acid; Anti-Bacterial Agents; Antitubercular Agents; Bronchoscopy; Cl | 2016 |
The antifibrotic drug pirfenidone promotes pulmonary cavitation and drug resistance in a mouse model of chronic tuberculosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antitubercular Agents; Drug Resistance, Bacterial; | 2016 |
Association between TXNRD1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a prospective study.
Topics: Adult; Age Factors; Alleles; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Ethambut | 2016 |
Gitelman-like Syndrome with Kanamycin Toxicity.
Topics: Adult; Alkalosis; Anti-Bacterial Agents; Antitubercular Agents; Cycloserine; Ethionamide; Female; Fl | 2016 |
Role of Risorine in the Treatment of Drug - Susceptible Pulmonary Tuberculosis: A Pilot Study.
Topics: Adult; Alkaloids; Antitubercular Agents; Benzodioxoles; Cytochrome P-450 Enzyme Inhibitors; Drug Com | 2016 |
A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis.
Topics: Antitubercular Agents; Bayes Theorem; Biological Availability; Computer Simulation; Drug Administrat | 2017 |
The biodistribution of 5-[18F]fluoropyrazinamide in Mycobacterium tuberculosis-infected mice determined by positron emission tomography.
Topics: Amidohydrolases; Animals; Antitubercular Agents; Female; Fluorine Radioisotopes; Mice; Mice, Inbred | 2017 |
Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar.
Topics: Adult; Antitubercular Agents; Diabetes Complications; Dose-Response Relationship, Drug; Drug Therapy | 2017 |
Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Female; HIV | 2017 |
Factors Influencing Tuberculosis Treatment Outcome in Adult Patients Treated with Thrice-Weekly Regimens in India.
Topics: Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Drug Dosage Calculations; Drug Therapy, | 2017 |
Primary drug resistance against Mycobacterium tuberculosis in Karachi.
Topics: Adolescent; Adult; Antitubercular Agents; Bronchoscopy; Drug Resistance, Multiple, Bacterial; Ethamb | 2008 |
Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Diarylquinolin | 2008 |
Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Disease Models | 2008 |
Epidemiological survey of hyperuricemia as an adverse reaction to antituberculous therapy with pyrazinamide.
Topics: Antitubercular Agents; Data Collection; Female; Humans; Hyperuricemia; Male; Middle Aged; Pyrazinami | 2008 |
Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amidohydrolases; Amino Acid Substitution; Antitubercular | 2008 |
An unusual case of a pleural effusion with an abdominal mass.
Topics: Adult; Antitubercular Agents; Drainage; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; Ma | 2008 |
Tuberculosis in a patient on temozolomide: a case report.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antibiotics, Antitubercular; Ant | 2009 |
Gynecomastia: a rare adverse effect of isoniazid.
Topics: Adolescent; Antitubercular Agents; Diagnosis, Differential; Gynecomastia; Humans; Isoniazid; Male; P | 2008 |
Tuberculosis incidence among contacts of active pulmonary tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Brazil; Carrier State; Cohort Studies; Disease Transmissio | 2009 |
Pharmacokinetics of pyrazinamide in children with primary progressive disease of lungs.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Female; Humans; Male; Microbial Sensitiv | 2008 |
[A role of the HLA-DRB1* genotype in the complex therapy of pulmonary tuberculosis].
Topics: Alleles; Antibiotics, Antitubercular; Antitubercular Agents; Disease Progression; Drug Resistance, B | 2008 |
[Acute respiratory distress syndrome: a manifestation of immune reconstitution in an HIV-negative patient with tuberculosis].
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Female; HIV Seronegativity; Humans; Isoniaz | 2009 |
[Optimization of chemotherapy regimens in children with primary pulmonary tuberculosis].
Topics: Adolescent; Age Factors; Antibiotics, Antitubercular; Antitubercular Agents; Child; Child, Preschool | 2009 |
Coccidioides immitis and Mycobacterium tuberculosis diagnosed by endoscopic ultrasound.
Topics: Adult; Antibiotics, Antitubercular; Antifungal Agents; Antitubercular Agents; Coccidioides; Coccidio | 2009 |
Isoniazid induced gynaecomastia: a case report.
Topics: Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Gynecomastia; Humans; Isoniazid; Male; | 2009 |
[Fever and thin-walled cavitary lung lesions].
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Fever; Humans; Isoniazid; Male; | 2009 |
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E | 2009 |
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E | 2009 |
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E | 2009 |
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E | 2009 |
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E | 2009 |
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E | 2009 |
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E | 2009 |
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E | 2009 |
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E | 2009 |
Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Turkey.
Topics: Amidohydrolases; Amino Acid Substitution; Antitubercular Agents; DNA, Bacterial; Drug Resistance, Ba | 2009 |
Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.
Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination; | 2009 |
Pulmonary tuberculosis presenting as fever without source in a pediatric patient with acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antitubercular Agents; Azithromycin; Child, Preschoo | 2009 |
Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Isoni | 2009 |
Factors influencing time to smear conversion in patients with smear-positive pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Child; Drug Therapy, Combination; | 2009 |
Experimental ocular tuberculosis in guinea pigs.
Topics: Aerosols; Animals; Antitubercular Agents; Disease Models, Animal; DNA, Bacterial; Guinea Pigs; Isoni | 2009 |
[Relapse rate of tuberculosis treated with standard regimen of chemotherapy].
Topics: Adolescent; Aged; Aged, 80 and over; Child; Diabetes Complications; Drug Administration Schedule; Fe | 2009 |
Non conversion of sputum smears in new smear positive pulmonary tuberculosis patients in Yaoundé, Cameroon.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antitubercular; Antitubercular Agents; Came | 2009 |
Evaluation of standard chemotherapy in the guinea pig model of tuberculosis.
Topics: Animals; Animals, Outbred Strains; Antitubercular Agents; Biomarkers; CD8-Positive T-Lymphocytes; Di | 2010 |
Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients with pulmonary tuberculosis.
Topics: Adult; Antitubercular Agents; Case-Control Studies; Female; Humans; Intestinal Absorption; Isoniazid | 2009 |
Drug resistance pattern in multidrug resistance pulmonary tuberculosis patients.
Topics: Adult; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethionamide; Female; | 2010 |
Role of 2-month sputum smears in predicting culture conversion in pulmonary tuberculosis.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Ethambutol; Female; Humans; Isoniazid; Male; | 2011 |
[A 95 year old woman with bilateral nodular pulmonary pattern].
Topics: Aged, 80 and over; Antitubercular Agents; Drug Therapy, Combination; Dyspnea; Emergencies; Fatal Out | 2012 |
Impact of adverse drug reaction and predictivity of quality of life status in tuberculosis.
Topics: Antitubercular Agents; British Columbia; Ethambutol; Female; Humans; Isoniazid; Longitudinal Studies | 2010 |
Posttreatment reactivation of tuberculosis in mice caused by Mycobacterium tuberculosis disrupted in mce1R.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Disease Models, Animal; Female; Humans; Isoniazi | 2010 |
[Phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis isolated in Poland].
Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Ison | 2010 |
Molecular epidemiological study of pyrazinamide-resistance in clinical isolates of mycobacterium tuberculosis from South India.
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Bacterial; Humans; India; Microbial Sensiti | 2010 |
A nodulo-ulcerative lesion on the nose.
Topics: Aged, 80 and over; Antitubercular Agents; Chronic Disease; Ethambutol; Female; Humans; Isoniazid; Lu | 2010 |
Activity of pyrazinamide in the guinea pig model of tuberculosis.
Topics: Animals; Antitubercular Agents; CD8-Positive T-Lymphocytes; Disease Models, Animal; Drug Therapy, Co | 2010 |
[Sputum smear conversion during intensive TB treatment phase according to HIV status, in hospitalised patients in Togo].
Topics: Adult; Antitubercular Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Ethambutol; Female; F | 2011 |
Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice.
Topics: Animals; Anti-Inflammatory Agents; Antibiotics, Antitubercular; Antitubercular Agents; Cortisone; Di | 2011 |
Harnessing the full sterilising activity of rifamycins.
Topics: Animals; Antitubercular Agents; Drug Design; Humans; Pyrazinamide; Rifampin; Rifamycins; Time Factor | 2011 |
An apparently healthy young man with a peculiar-looking chest radiograph.
Topics: Adult; Antibiotics, Antitubercular; Drug Therapy, Combination; Ethambutol; Fever; HIV Seropositivity | 2011 |
[Pulmonary paragonimiasis].
Topics: Adult; Animals; Anthelmintics; Antitubercular Agents; Caulobacteraceae; Delayed Diagnosis; Ecuador; | 2011 |
[Cutaneous reaction after pyrazinamide initiation].
Topics: Adult; Antitubercular Agents; Drug Combinations; Drug Eruptions; Drug Therapy, Combination; Dysgeusi | 2011 |
Pulmonary tuberculosis in infants less than one year old: implications for early diagnosis.
Topics: Antitubercular Agents; Early Diagnosis; Family; Female; Hospitals, Pediatric; Hospitals, Teaching; H | 2011 |
Clinical response of newly diagnosed HIV seropositive & seronegative pulmonary tuberculosis patients with the RNTCP Short Course regimen in Pune, India.
Topics: Adult; Antitubercular Agents; Communicable Disease Control; Directly Observed Therapy; Enzyme-Linked | 2011 |
Metabolic regulation of mycobacterial growth and antibiotic sensitivity.
Topics: Acetyl Coenzyme A; Anaerobiosis; Animals; Antitubercular Agents; Bacterial Load; Bacterial Proteins; | 2011 |
Multifocal tuberculosis revealed by multiple cutaneous gummas in the immunocompetent.
Topics: Antitubercular Agents; Clavicle; Drug Therapy, Combination; Ethambutol; Humans; Immunocompetence; Is | 2011 |
Tuberculous damaged lung in a child.
Topics: Antitubercular Agents; Child; Drug Therapy, Combination; Ethambutol; Female; Granuloma; Humans; Ison | 2011 |
Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions.
Topics: Animals; Antitubercular Agents; Aza Compounds; Biological Availability; Disease Models, Animal; Drug | 2012 |
When tuberculosis comes back: who develops recurrent tuberculosis in california?
Topics: Adult; Antitubercular Agents; California; Drug Therapy, Combination; Female; HIV; HIV Infections; Hu | 2011 |
[Sudden decrease in visual acuity and pulmonary infiltrates].
Topics: Adrenal Cortex Hormones; Antitubercular Agents; Ethambutol; Humans; Isoniazid; Laser Coagulation; Ma | 2012 |
Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; I | 2012 |
A new approach for pyrazinamide susceptibility testing in Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Biological Transport; Biotransformation; Drug Resistance, Bacterial; Humans; | 2012 |
Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines.
Topics: Adolescent; Adult; Age Factors; Aged; Antitubercular Agents; Birth Weight; Drug Resistance, Multiple | 2012 |
Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines.
Topics: Adolescent; Adult; Age Factors; Aged; Antitubercular Agents; Birth Weight; Drug Resistance, Multiple | 2012 |
Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines.
Topics: Adolescent; Adult; Age Factors; Aged; Antitubercular Agents; Birth Weight; Drug Resistance, Multiple | 2012 |
Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines.
Topics: Adolescent; Adult; Age Factors; Aged; Antitubercular Agents; Birth Weight; Drug Resistance, Multiple | 2012 |
[Paradoxical radiologic progression despite appropriate anti-tuberculous therapy].
Topics: Aged; Antitubercular Agents; Bronchoalveolar Lavage Fluid; Bronchoscopy; Ethambutol; Humans; Isoniaz | 2012 |
Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Administra | 2012 |
Pyrazinamide-induced sideroblastic anaemia.
Topics: Adult; Anemia, Sideroblastic; Antitubercular Agents; Humans; Male; Pyrazinamide; Tuberculosis, Pulmo | 2012 |
Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis.
Topics: Antitubercular Agents; Area Under Curve; Body Weight; Drug Dosage Calculations; Ethnicity; Female; H | 2012 |
Management of and risk factors related to hepatotoxicity during tuberculosis treatment.
Topics: Adult; Age Factors; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Comorbidity; Drug | 2012 |
Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.
Topics: Adult; Aged; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; | 2012 |
Development and characterization of ligand-appended liposomes for multiple drug therapy for pulmonary tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Delivery Systems; Drug Therapy, Combination; Humans; Isoniazid; | 2013 |
[Directly observed treatment for tuberculosis in a Buenos Aires City hospital].
Topics: Adult; Antitubercular Agents; Argentina; Directly Observed Therapy; Drug Therapy, Combination; Etham | 2012 |
Tuberculosis treatment survival of HIV positive TB patients on directly observed treatment short-course in Southern Ethiopia: a retrospective cohort study.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Coinfection; Drug Administration Schedule; Fem | 2012 |
Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore.
Topics: Alanine Transaminase; Antitubercular Agents; Aspartate Aminotransferases; Bilirubin; Chemical and Dr | 2002 |
[The study on the duration of treatment in the standard short course chemotherapy containing pyrazinamide].
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; Pyrazinamide | 2002 |
Pulmonary alveolar proteinosis and tuberculosis in a diabetic patient: a rare or a seldom diagnosed association?
Topics: Adult; Diabetes Complications; Female; Humans; Isoniazid; Mycobacterium tuberculosis; Pulmonary Alve | 2002 |
[Chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis].
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Japan; Pyrazinamide; Reference | 2002 |
An ex vivo culture model for screening drug activity against in vivo phenotypes of Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; BCG Vaccine; Cells, Cultured; Culture Media; Female; Humans; Lucifer | 2002 |
Short-course rifamycin and pyrazinamide treatment for latent tuberculosis infection in patients with HIV infection: the 2-year experience of a comprehensive community-based program in Broward County, Florida.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Case-Control Studies; Coh | 2002 |
Tuberculosis re-treatment outcomes within the public service in Nairobi, Kenya.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; AIDS-Related Opportunistic Infections; Antitubercular Ag | 2002 |
[Pulmonary tuberculosis presenting as tubercular lupus].
Topics: Adolescent; Antitubercular Agents; Biopsy; Drug Combinations; Female; Humans; Isoniazid; Lupus Vulga | 2002 |
[Myrin P in the combined treatment of tuberculosis].
Topics: Adolescent; Adult; Antitubercular Agents; Drug Combinations; Drug Resistance, Multiple, Bacterial; E | 2002 |
Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antibiotics, Antitubercular; Child; Drug Therapy, Co | 2002 |
Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care Facilities; Anti-Bacterial Agents; Antib | 2002 |
[The evolution of threshold values of air conduction in the extended high frequency range (9-18 kHz) in patients suffering from the pulmonary tuberculosis treated with combination of SM, INH, RFM, and PZA].
Topics: Adult; Antitubercular Agents; Audiometry, Pure-Tone; Auditory Threshold; Case-Control Studies; Deafn | 2002 |
Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Confidence Intervals; D | 2003 |
Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Confidence Intervals; D | 2003 |
Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Confidence Intervals; D | 2003 |
Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Confidence Intervals; D | 2003 |
Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity.
Topics: Adolescent; Adult; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Chemical and Drug Induc | 2003 |
Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug In | 2003 |
Perianal tuberculosis: a rare case of skin ulceration?
Topics: Adult; Antitubercular Agents; Anus Diseases; Ethambutol; Humans; Male; Pyrazinamide; Skin Ulcer; Tre | 2002 |
Drug-resistant Mycobacterium tuberculosis among new tuberculosis patients, Yangon, Myanmar.
Topics: AIDS-Related Opportunistic Infections; Drug Resistance, Bacterial; Ethambutol; Humans; Isoniazid; My | 2003 |
The decline of high drug resistance rate of pulmonary Mycobacterium tuberculosis isolates from a southern Taiwan medical centre, 1996-2000.
Topics: Antitubercular Agents; Cycloserine; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial | 2003 |
Low level of compliance with tuberculosis treatment in children: monitoring by urine tests.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Child; Drug Therapy, Combination; Humans; Isonia | 2003 |
[Clinical evaluation on the duration of hospitalization for patients with pulmonary tuberculosis].
Topics: Antitubercular Agents; Humans; Length of Stay; Pyrazinamide; Retrospective Studies; Tuberculosis, Pu | 2003 |
Treatment outcome of tuberculosis among Saudi nationals: role of drug resistance and compliance.
Topics: Antibiotics, Antitubercular; Female; Humans; Isoniazid; Male; Mycobacterium tuberculosis; Prevalence | 2003 |
[Tuberculous peripheral multifocal choroiditis].
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Antitubercular Agents; Choroiditis; Drug Therapy, Co | 2003 |
Follow-up of compliance with tuberculosis treatment in children: monitoring by urine tests.
Topics: Antitubercular Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administratio | 2003 |
[The short-term and long-term treatment outcomes in patients with pulmonary tuberculosis positive for drug-resistant and sensitive strains].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Child; Drug Therapy, Combination; | 2003 |
[Follow-up observation on relapse of smear negative pulmonary tuberculosis after short-course chemotherapy].
Topics: Antitubercular Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Isoniazid; Male | 2003 |
Widespread pyrazinamide-resistant Mycobacterium tuberculosis family in a low-incidence setting.
Topics: Amidohydrolases; Antitubercular Agents; Case-Control Studies; DNA Transposable Elements; Drug Resist | 2003 |
Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Area Under Curve; Biocompatible Materia | 2003 |
[Determination of Mycobacterium tuberculosis' sensitivity to pyrazinamide on a BACTEC-960 bacteriological analyzer].
Topics: Antitubercular Agents; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyrazinamide | 2003 |
Pyrazinamide (aldinamide*) in the treatment of pulmonary tuberculosis.
Topics: Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
Observations on the combined use of pyrazinamide (Aldinamide) and isoniazid in the treatment of pulmonary tuberculosis; a clinical study.
Topics: Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
Observations on pyrazinamide (Aldinamide) in pulmonary tuberculosis.
Topics: Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
The chemotherapy of pulmonary tuberculosis with pyrazinamide used alone and in combination with streptomycin, para-aminosalicylic acid, or isoniazid.
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Streptomycin; Tube | 1954 |
Pyrazinamide-isoniazid in tuberculosis. I. Results in 58 patients with pulmonary lesions one year after the start of therapy.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
Experience with pyrazinamide.
Topics: Aminosalicylic Acid; Niacin; Nicotinic Acids; Pyrazinamide; Streptomycin; Tuberculosis; Tuberculosis | 1955 |
Pyrazinamide-isoniazid in tuberculosis. III. Observations with reduced dosage of pyrazinamide.
Topics: Clinical Protocols; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pu | 1955 |
Pyrazinamide-isoniazid: comparison with isoniazid-para-aminosalicylic acid in active pulmonary tuberculosis with the choice of regimens determined by chance.
Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Pyrimidines; Tuberculosis; Tu | 1956 |
[Possible therapeutic use of new preparations with antituberculous action (pyrazinamide and cycloserine); preliminary note].
Topics: Anti-Bacterial Agents; Cycloserine; Humans; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tub | 1956 |
[Possible therapeutic use of new preparations with antituberculous action (pyrazinamide and cycloserine); preliminary note].
Topics: Anti-Bacterial Agents; Cycloserine; Humans; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tub | 1956 |
[Possible therapeutic use of new preparations with antituberculous action (pyrazinamide and cycloserine); preliminary note].
Topics: Anti-Bacterial Agents; Cycloserine; Humans; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tub | 1956 |
[Possible therapeutic use of new preparations with antituberculous action (pyrazinamide and cycloserine); preliminary note].
Topics: Anti-Bacterial Agents; Cycloserine; Humans; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tub | 1956 |
[Clinical experiences with pyrazinamide].
Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Streptomycin; Tuberculosis; T | 1956 |
[Further observations on pyrazinamide].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Dermatologic Agents; Isoniazid; Pyrazinamide; Tu | 1956 |
Pyrazinamide together with oxytetracycline in patients with tubercle bacilli resistant to streptomycin, PAS and isoniazid.
Topics: Aminosalicylic Acid; Bacillus; Isoniazid; Lacticaseibacillus casei; Niacin; Nicotinic Acids; Oxytetr | 1957 |
[Treatment of chronic pulmonary tuberculosis with pyrazinamide].
Topics: Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
[Behavior of the Middlebrook-Dubos reaction and of phagocytosis in pulmonary tuberculosis treated with pyrazinamide].
Topics: Humans; Niacin; Nicotinic Acids; Phagocytosis; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Elimination of urinary 17-ketosteroids in pulmonary tuberculosis treated with pyrazinamide].
Topics: 17-Ketosteroids; Humans; Niacin; Nicotinic Acids; Pyrazinamide; Steroids; Tuberculosis; Tuberculosis | 1957 |
[Determination of prothrombin time (Quick test) and plasma fibrinogen in pulmonary tuberculosis treated with pyrazinamide].
Topics: Fibrinogen; Humans; Niacin; Nicotinic Acids; Prothrombin Time; Pyrazinamide; Tuberculosis; Tuberculo | 1957 |
[Blood iodine precipitation and cholesteremia in pulmonary tuberculosis treated with pyrazinamide].
Topics: Cholesterol; Humans; Iodine; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulm | 1957 |
[Peripheral blood picture in pulmonary tuberculosis treated with pyrazinamide].
Topics: Humans; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Blood proteins in pulmonary tuberculosis treated with pyrazinamide; electrophoresis and serodiagnosis].
Topics: Blood Proteins; Electrophoresis; Humans; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberc | 1957 |
[Pyrazinamide in the treatment of pulmonary tuberculosis].
Topics: Humans; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Liver function and pyrazinamide therapy of pulmonary tuberculosis].
Topics: Liver; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
Pyrazinamide-isoniazid in patients with previous isoniazid therapy.
Topics: Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Treatment of pulmonary tuberculosis with high alternating dosage of pyrazinamide and isoniazid].
Topics: Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Pyrazinamide in pulmonary tuberculosis; behavior of blood proteins].
Topics: Blood Proteins; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Pyrazinamide-isoniazid mixture in the treatment of chronic pulmonary tuberculosis].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
Comparative efficacy of the concurrent use of pyrazinamide and isoniazid with that of other forms of therapy in the treatment of pulmonary tuberculosis.
Topics: Isoniazid; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Pyrazinamide & pyrazinamide with isoniazid in pulmonary tuberculosis; comparison with other chemotherapeuticantibiotic combinations].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
Pyrazinamide and cycloserine in the treatment of pulmonary tuberculosis.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Cycloserine; Niacin; Nicotinic Acids; Pyrazinami | 1957 |
[Pyrazinamide and gastric functional response in pulmonary tuberculosis].
Topics: Humans; Niacin; Nicotinic Acids; Pyrazinamide; Stomach; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Pyrazinamide in therapy of cavitary tuberculosis resistant to usual therapy].
Topics: Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
Pyrazinamide and viomycin in the surgical treatment of pulmonary tuberculosis.
Topics: Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary; Viomycin | 1958 |
[Combined pyrazinamide and isoniazid in therapy of pulmonary tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Liver function tests of pulmonary tuberculosis patients treated with pyrazinamide].
Topics: Liver; Liver Function Tests; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulm | 1957 |
[Experience on the use of pyrazinamide in the treatment of pulmonary tuberculosis. I. Clinical results].
Topics: Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Experience on the use of pyrazinamide in the treatment of pulmonary tuberculosis. II. Hepatic function & blood proteins in the scope of clinical changes].
Topics: Blood Proteins; Liver; Pyrazinamide; Tuberculosis; Tuberculosis, Hepatic; Tuberculosis, Pulmonary | 1957 |
[Pyrazinamide and gastric functional response in pulmonary tuberculosis].
Topics: Niacin; Nicotinic Acids; Pyrazinamide; Stomach; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Radiological records of the results of combined pyrazinamide-streptomycin-isoniazid therapy].
Topics: Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Radiology; Streptomycin; Tuberculosis; Tuberculosi | 1958 |
Clinical and biological investigations on the new antituberculosis drugs (pyrazinamide and cycloserine).
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Cycloserine; Niacin; Nico | 1958 |
[Studies on the changes of the daily amount of tubercle bacilli present in sputum and its resistance against drugs, when patients have been treated with anti-tuberculous agents. I. Combined therapy with pyrazinamide and isonicotinic acid hydrazide].
Topics: Bacillus; Humans; Isoniazid; Lung; Pyrazinamide; Sputum; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
Pulmonary resection for tuberculosis under protection of viomycin, promizole and pyrazinamide.
Topics: Niacin; Nicotinic Acids; Pneumonectomy; Pyrazinamide; Sulfathiazole; Sulfathiazoles; Thiazoles; Tube | 1958 |
Treatment of drug-resistant cases of pulmonary tuberculosis with cycloserine and pyrazinamide.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Cycloserine; Niacin; Nicotinic Acids; Pyrazinami | 1958 |
Cycloserine combined with pyrazinamide in the treatment of pulmonary tuberculosis.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Cycloserine; Niacin; Nicotinic Acids; Pyrazinami | 1958 |
[Pyrazinamide in solution, for topical use, in the treatment of tuberculous empyema].
Topics: Empyema, Tuberculous; Humans; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pul | 1958 |
Pyrazinamide in low dosage in combination with isoniazid or paraaminosalicylic acid in the treatment of pulmonary tuberculosis.
Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, P | 1959 |
The use of pyrazinamide plus isoniazid in the treatment of pulmonary tuberculosis.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1959 |
[Tests of liver function during pyrazinamide therapy].
Topics: Child; Humans; Infant; Isoniazid; Liver; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberc | 1959 |
[Observations on therapy of pulmonary tuberculosis with viomycin pyrazinamide & cycloserine].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Cycloserine; Humans; Niacin; Nicotinic Acids; Py | 1959 |
[A clinical experience report on combined therapy of pulmonary tuberculosis with cycloserine-pyrazinamide].
Topics: Cycloserine; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
Retreatment of pulmonary tuberculosis. Experiences with various combinations of pyrazinamide, cycloserine, and kanamycin in patients excreting tubercle bacilli resistant to both streptomycin and isoniazid.
Topics: Anti-Bacterial Agents; Bacillus; Cycloserine; Humans; Isoniazid; Kanamycin; Pyrazinamide; Retreatmen | 1960 |
[Pyrazinamide in the treatment of pulmonary tuberculosis].
Topics: Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1960 |
[Cycloserine associated with other chemio-antibiotics in the treatment of pulmonary tuberculosis. Clinical contribution on pyrazinamidecycloserine association].
Topics: Anti-Bacterial Agents; Cycloserine; Humans; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
Retreatment of tuberculous patients: an experience with the combined use of high doses of isoniazid, pyrazinamide and cycloserine.
Topics: Cycloserine; Isoniazid; Pyrazinamide; Retreatment; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
[Experiences with a pyrazinamide-INH combination in the treatment of pulmonary tuberculosis].
Topics: Antitubercular Agents; Humans; Pyrazinamide; Tuberculosis, Pulmonary | 1960 |
Resectional therapy for pulmonary tuberculosis at Summount, 1950-1957; 807 cases. V. Resectional therapy for pulmonary tuberculosis under viomycin and pyrazinamide coverage.
Topics: Pyrazinamide; Tuberculosis, Pulmonary; Viomycin | 1961 |
Pyrazinamide-isoniazid treated tuberculous patients: a five year follow-up.
Topics: Follow-Up Studies; Humans; Isoniazid; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1959 |
[Therapy of pulmonary tuberculosis with pyrazinamide].
Topics: Antitubercular Agents; Humans; Pyrazinamide; Tuberculosis, Pulmonary | 1960 |
Treatment of pulmonary tuberculosis with isoniazid and pyrazinamide: experience in 114 cases.
Topics: Humans; Isoniazid; Pyrazinamide; Tuberculosis, Pulmonary | 1959 |
[The use of Piazofoline in the pre- and post-operative treatment of pulmonary tuberculosis].
Topics: Humans; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1962 |
[Piazofoline in the therapy of pulmonary tuberculosis].
Topics: Humans; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1962 |
[Results in the treatment of chronic pulmonary tuberculosis in adults with pyrazinamide in association with PAS].
Topics: Aminosalicylic Acid; Pyrazinamide; Tuberculosis, Pulmonary | 1962 |
[The treatment of pulmonary tuberculosis with the drugs of the 2d series (Aetina, d-cycloserine and pyrazinamide) with special reference to experiences with Aetina].
Topics: Cycloserine; Pyrazinamide; Tuberculosis, Pulmonary | 1962 |
Successful treatment of advanced isonizid- and streptomycin-resistant pulmonary tuberculosis with ethionamide, pyrazinamide, and isoniazid.
Topics: Drug Resistance; Drug Resistance, Microbial; Ethionamide; Humans; Isoniazid; Pyrazinamide; Streptomy | 1962 |
The tate of patients with drug-resistant tubercle bacilli and pulmonary tuberculosis.
Topics: Anti-Bacterial Agents; Bacillus; Cycloserine; Drug Resistance; Drug Resistance, Microbial; Ethionami | 1962 |
[On the treatment of adult-type pulmonary tuberculosis during puberty with isoniazid plus pyrazinamide].
Topics: Adult; Humans; Isoniazid; Puberty; Pyrazinamide; Sexual Maturation; Tuberculosis, Pulmonary | 1962 |
[The importance of medical treatment of pulmonary tuberculosis from a new viewpoint].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Dihydrostreptomycin Sulfate; Ethionamide; Ip | 1962 |
Re-treatment therapy with cycloserine-pyrazinamide. Response in cavity closure and disappearance of tubercle bacilli from sputum.
Topics: Bacillus; Cycloserine; Humans; Lacticaseibacillus casei; Pyrazinamide; Sputum; Tuberculosis; Tubercu | 1962 |
Ethionamide, pyrazinamide and cycloserine used successfully in the treatment of chronic pulmonary tuberculosis.
Topics: Cycloserine; Ethionamide; Humans; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1962 |
[Pyrazinamide in association with streptomycin, PAS and isoniazid in the therapy of pulmonary tuberculosis].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Humans; Isoniazid; Pyrazinamide; Streptomycin; Tuberculos | 1962 |
Bacteriological aspects of the use of ethionamide, pyrazinamide and cycloserine in the treatment of chronic pulmonary tuberculosis.
Topics: Cycloserine; Drug Resistance; Drug Resistance, Microbial; Ethionamide; Humans; Pyrazinamide; Tubercu | 1962 |
Pyrazinamide and ethionamide in the treatment of pulmonary tuberculosis in Hong Kong.
Topics: Ethionamide; Hong Kong; Humans; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1963 |
[Various biological tests on several groups of subjects with tuberculosis subjected respectively to monotherapy with isoniazid, viomycin, pyrazinamide, cycloserine, ethioniamide and kanamycin].
Topics: Cycloserine; Ethionamide; Isoniazid; Kanamycin; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary; | 1962 |
PYRAZINAMIDE COVERAGE AT THE TIME OF PULMONARY RESECTION FOR TUBERCULOSIS.
Topics: Humans; Pneumonectomy; Postoperative Complications; Preoperative Care; Pyrazinamide; Tuberculosis; T | 1963 |
[SYMPOSIUM: COUNTER-MEASURES IN INTRACTABLE PULMONARY TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Ethionamide; Isoniazi | 1963 |
[THE THERAPY OF PULMONARY TUBERCULOSIS WITH MORPHAZINAMIDE. CLINICAL CONTRIBUTION].
Topics: Antitubercular Agents; Humans; Pyrazinamide; Pyrazines; Tuberculosis; Tuberculosis, Pulmonary | 1963 |
MODERN DRUG TREATMENT OF MYCOBACTERIAL DISEASES.
Topics: Adrenal Cortex Hormones; Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Cycloseri | 1963 |
SIDE EFFECTS OF AN ANTITUBERCULOUS FIVE-DRUG REGIMEN: ETHIONAMIDE, CYCLOSERINE, PYRAZINAMIDE, VIOMYCIN AND ISONIAZID.
Topics: Amyloidosis; Antitubercular Agents; Cycloserine; Deafness; Drug Hypersensitivity; Duodenal Ulcer; Et | 1963 |
[PYRAZINAMIDE IN THE TREATMENT OF PULMONARY TUBERCULOSIS IN THE PRESENCE OF VARIOUS DEGRESS OF SENSITIVITY TO BASIC DRUGS].
Topics: Anti-Infective Agents, Local; Antitubercular Agents; Drug Resistance; Drug Resistance, Microbial; Hu | 1963 |
[PRELIMINARY FUNCTIONAL AND MORPHOLOGICAL HEPATIC FINDINGS IN PATIENTS TREATED WITH MORPHAZINAMIDE].
Topics: Antitubercular Agents; Fatty Liver; Humans; Liver Function Tests; Pyrazinamide; Pyrazines; Silicotub | 1963 |
[EXPERIENCE WITH A NONSPECIFIC ANTIINFLAMMATORY AGENT IN PULMONARY TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Inflammatory Agents; Cycloserine; Drug Resistance; D | 1963 |
DRUG RESISTANT MYCOBACTERIAL INFECTION AND ITS RESPONSE TO TREATMENT.
Topics: Cycloserine; Drug Resistance; Drug Resistance, Microbial; Humans; Isoniazid; Mycobacterium; Mycobact | 1963 |
[CHEMO-ANTIBIOTIC THERAPY IN PULMONARY TUBERCULOSIS].
Topics: Antitubercular Agents; Cycloserine; Ethionamide; Kanamycin; Pyrazinamide; Tuberculosis; Tuberculosis | 1963 |
RECENT ADVANCES IN TREATMENT OF ORGAN TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Child; Cycloserine; Ethionamide; I | 1964 |
CHEMOTHERAPY FOR PATIENTS WITH CULTURES RESISTANT TO STREPTOMYCIN, ISONIAZID AND PAS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Czechoslovakia; Drug Resistance; Drug Resist | 1963 |
[ETHIONAMIDE IN ASSOCIATION WITH PYRAZINAMIDE OR CYCLOSERINE IN THE TREATMENT OF CHRONIC PULMONARY TUBERCULOSIS].
Topics: Cycloserine; Drug Resistance; Drug Resistance, Microbial; Ethionamide; Pyrazinamide; Toxicology; Tub | 1963 |
[SOME CLINICAL ASPECTS OF DRUG RESISTANCE OF TUBERCLE BACILLI ISOLATED FROM PATIENTS WITH FIBRO-CAVERNOUS TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacillus; Culture Media; Drug Resistance; Drug Resistance | 1963 |
SOME PROBLEMS IN THE MANAGEMENT OF TUBERCULOSIS.
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Antitubercular Agents; | 1964 |
D-CYCLOSERINE IN THE TREATMENT OF PULMONARY TUBERCULOSIS RESISTANT TO THE STANDARD DRUGS: A STUDY OF 116 CASES.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Drug Resistance; Drug Resistance, Microbial; | 1964 |
[EFFECT OF PYRAZINAMIDE ON HEMOSTATIC FACTORS OF THE ORGANISM. (PRELIMINARY COMMUNICATION)].
Topics: Blood Coagulation; Blood Coagulation Tests; Blood Proteins; Hemostatics; Humans; Prothrombin Time; P | 1963 |
[ANTIMICROBIAL SCREEN IN PHTHISIOLOGICAL SURGERY].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Infective Agents; Antitubercular Agents; Collapse Th | 1963 |
[ANTIBACTERIAL TREATMENT IN PATIENTS AFFLICTED WITH PULMONARY TUBERCULOSIS CAUSED BY MYCOBACTERIA RESISTANT TO THE MAJOR CHEMO-ANTIBIOTICS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Antibiotics, Antitubercular; Colla | 1963 |
[THE RESULTS OBTAINED WITH THE COMBINATION OF PYRAZINAMIDE AND ISONIAZID IN THE TREATMENT OF PULMONARY TUBERCULOSIS].
Topics: Humans; Isoniazid; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1963 |
[TREATMENT OF TUBERCULOSIS AND DIABETES BECOMING SIMILAR].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Diabetes Mellitus; Ethionamide; Isoniazid; P | 1964 |
CLINICAL ASPECTS, MEDICAL AND SURGICAL, IN THE MANAGEMENT OF BATTEY-TYPE PULMONARY DISEASE.
Topics: Bronchiectasis; Calcification, Physiologic; Drug Resistance; Drug Resistance, Microbial; Epidemiolog | 1964 |
ANTIMICROBIAL THERAPY OF PULMONARY TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Infective Agents; Cycloserine; Dihydrostreptomycin S | 1963 |
[THE USE OF ANTIBACILLARY DRUGS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Drug Resistance; Drug Resistance, Microbial; | 1964 |
A SPUTUM SURVEY OF CASES OF PULMONARY TUBERCULOSIS TWO TO THREE YEARS AFTER STARTING TREATMENT IN A RURAL AREA IN KENYA.
Topics: Child; Drug Resistance; Drug Resistance, Microbial; Health Surveys; Humans; Infant; Isoniazid; Kenya | 1964 |
[THE TREATMENT OF TUBERCULOSIS WITH 2ND LINE DRUGS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Antibiotics, Antitubercular; Cyclo | 1964 |
[ANTIMICROBIAL TREATMENT OF TUBERCULOSIS WITH SUBSIDIARY DRUGS. 2ND LINE DRUGS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Infective Agents; Antitubercular Agents; Bacteriolog | 1964 |
INHIBITION OF PYRAZINAMIDE HYPERURICEMIA BY SMALL DOSES OF ACETYLSALICYLIC ACID.
Topics: Aspirin; Blood Chemical Analysis; Drug Therapy; Humans; Hyperuricemia; Pyrazinamide; Toxicology; Tub | 1964 |
[ASSOCIATION OF 4,4'-DIISOAMYLOXYTHIOCARBANILIDE AND PYRAZINAMIDE, AND 4,4'-DIISOAMYLOXYTHIOCARBANILIDE AND KANAMYCIN IN THE TREATMENT OF PULMONARY TUBERCULOSIS CAUSED BY BACTERIA RESISTANT TO THE 1ST LINE DRUGS].
Topics: Antitubercular Agents; Bacteria; Bacteriology; Drug Resistance; Drug Resistance, Microbial; Kanamyci | 1964 |
PULMONARY TUBERCULOSIS.
Topics: Adrenal Cortex Hormones; Aminosalicylic Acid; Aminosalicylic Acids; Child; Cycloserine; Drug Resista | 1964 |
A CONTROLLED COMPARISON OF STREPTOMYCIN PLUS PYRAZINAMIDE AND STREPTOMYCIN PLUS PAS IN THE RETREATMENT OF PATIENTS EXCRETING ISONIAZID-RESISTANT ORGANISMS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacteriology; Biomedical Research; Drug Resistance; Drug | 1964 |
A SIMPLE TABLET TEST FOR THE DETECTION OF PYRAZINAMIDE IN THE URINE.
Topics: Behavior; Biomedical Research; Chemical Phenomena; Chemistry; Drug Resistance; Drug Resistance, Micr | 1964 |
TREATMENT OF PATIENTS WITH CULTURES RESISTANT TO THE PRIMARY ANTI-TUBERCULOSIS DRUGS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Bacteriological Techniques; Biomed | 1964 |
[LUNG TUBERCULOMAS].
Topics: Adolescent; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Bronchoscopy; | 1963 |
[APROPOS OF ETHIONAMIDE JAUNDICE].
Topics: Alanine Transaminase; Alcoholism; Aminosalicylic Acid; Aminosalicylic Acids; Aspartate Aminotransfer | 1964 |
RELAPSE IN TREATED CASES OF PULMONARY TUBERCULOSIS. I. THREE-YEAR FOLLOW-UP OF 312 PATIENTS DISCHARGED FROM THE HOSPITAL WITH MEDICAL APPROVAL, 1947-1954.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Communicable Disease Control; Foll | 1964 |
[NEW DRUGS IN THE TREATMENT OF PULMONARY TUBERCULOSIS].
Topics: Cycloserine; Ethionamide; Kanamycin; Pyrazinamide; Toxicology; Tuberculosis; Tuberculosis, Pulmonary | 1964 |
[COMPLICATIONS IN THE TREATMENT OF PULMONARY TUBERCULOSIS WITH PYRAZINAMIDE].
Topics: Pyrazinamide; Toxicology; Tuberculosis; Tuberculosis, Pulmonary | 1963 |
[EFFECT OF PYRAZINAMIDE ON INACTIVE DUODENAL ULCER].
Topics: Chemical and Drug Induced Liver Injury; Drug Therapy; Duodenal Ulcer; Hepatitis; Liver Function Test | 1964 |
[CHEMO-ANTIBIOTIC THERAPY OF TUBERCULOSIS IN DIABETICS AND ITS REPERCUSSIONS ON GLUCIDE METABOLISM].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Blood Glucose; Carbohydrate Metabo | 1964 |
ALTERNATING REGIMENS OF STREPTOMYCIN-PYAZINAMIDE, ISONIAZID-PARA-AMINOSALICYLIC ACID AT BATTEY STATE HOSPITAL.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Resistance; Drug Resistance, Microbial; Drug Therapy | 1964 |
[CLINICAL EXPERIENCE WITH THE COMBINED APPEARANCE OF TUBERCULOSIS AND VIRUS HEPATITIS].
Topics: Adrenocorticotropic Hormone; Aminosalicylic Acid; Aminosalicylic Acids; Collapse Therapy; Drug Thera | 1964 |
INFECTION OF MICE WITH MYCOBACTERIUM TUBERCULOSIS, STRAIN H37RA.
Topics: Animals; Isoniazid; Lung; Mice; Mycobacterium bovis; Mycobacterium tuberculosis; Pharmacology; Pyraz | 1964 |
[ENZYMATIC STUDY OF THE LIVER IN PULMONARY TUBERCULOSIS. RESEARCH ON A POSSIBLE HEPATOTOXIC EFFECT OF ANTIBACTERIAL MEDICATIONS].
Topics: Alanine Transaminase; Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Aspartate Am | 1964 |
CHEMOTHERAPY OF PREVIOUSLY TREATED PATIENTS WITH PULMONARY TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Drug Hypersensitivity; Drug Resistance; Drug | 1964 |
RE-TREATMENT OF DRUG-RESISTANT PULMONARY TUBERCULOSIS AT BATTEY STATE HOSPITAL.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Drug Resistance; Drug Resistance, Microbial; | 1964 |
A PRELIMINARY REPORT ON A NEW ANTITUBERCULOUS DRUG 4-AMINO-2-HYDROXY-PHENYL-1, 3, 4,-OXADIAZOL-2-OL WS 127.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Biomedical Research; Blood; Cyclos | 1964 |
ANTITUBERCULOUS DRUGS AND SIDEROBLASTIC ANAEMIA.
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Anemia; Anemia, Hypochromic; Anemia, Siderobl | 1965 |
[AMBULATORY AND HOSPITAL THERAPY OF TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antit | 1964 |
DRUG RESISTANCE IN PULMONARY TUBERCULOSIS; TREATMENT WITH ETHIONAMIDE IN VARIOUS DRUG COMBINATIONS.
Topics: Cycloserine; Drug Combinations; Drug Resistance; Drug Resistance, Microbial; Drug Therapy; Drug Tole | 1965 |
PYRAZINAMIDE AND ETHIONAMIDE IN RESISTANT PULMONARY TUBERCULOSIS IN AFRICANS. AN 18-MONTH FOLLOW-UP OF 32 PATIENTS.
Topics: Drug Therapy; Ethionamide; Follow-Up Studies; Pyrazinamide; Toxicology; Tuberculosis; Tuberculosis, | 1965 |
THE USE OF ETHIONAMIDE IN COMBINED DRUG REGIMENS IN THE RE-TREATMENT OF ISONIAZID-RESISTANT PULMONARY TUBERCULOSIS.
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Drug Resi | 1965 |
[STUDY ON LIVER TOLERANCE TO N-(4-MORPHOLINOMETHYL-PYRAZINAMIDE) IN THE TREATMENT OF PULMONARY TUBERCULOSIS].
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Tolerance; Hepatitis; Humans; Py | 1964 |
[EXPERIENCES AND RESULT WITH SECONDARY DRUGS (ETHIONAMIDE, D-CYCLOSERINE, PYRAZINAMIDE AND VIOCIN) IN SURGICAL TREATMENT OF PULMONARY TUBERCULOSIS].
Topics: Antitubercular Agents; Cycloserine; Ethionamide; Humans; Pneumonectomy; Pyrazinamide; Tuberculosis; | 1964 |
A CONTROLLED CLINICAL TRIAL OF ETHIONAMIDE, CYCLOSERINE AND PYRAZINAMIDE IN PREVIOUSLY TREATED PATIENTS WITH PULMONARY TUBERCULOSIS.
Topics: Cycloserine; Drug Therapy; Ethionamide; Isoniazid; Pyrazinamide; Radiography, Thoracic; Streptomycin | 1965 |
CHEMOTHERAPY REGIMENS USED IN RETREATMENT OF PULMONARY TUBERCULOSIS. I. OBSERVATIONS ON THE EFFICACY OF COMBINATIONS OF KANAMYCIN, ETHIONAMIDE AND EITHER CYCLOSERINE OR PYRAZINAMIDE.
Topics: Cycloserine; Drug Resistance; Drug Resistance, Microbial; Drug Therapy; Ethionamide; Kanamycin; Pyra | 1965 |
CHEMOTHERAPY REGIMENS USED IN RETREATMENT OF PULMONARY TUBERCULOSIS. II. OBSERVATIONS ON THE EFFICACY OF COMBINATIONS OF ETHAMBUTOL, CAPREOMYCIN AND COMPANION DRUGS, INCLUDING 4-4 DIISOAMYLOXYTHIOSEMICARBANILIDE.
Topics: Antitubercular Agents; Capreomycin; Cycloserine; Drug Resistance; Drug Resistance, Microbial; Drug T | 1965 |
[Application of pyrazinamide in our thoracic surgery].
Topics: Pulmonary Surgical Procedures; Pyrazinamide; Thoracic Surgery; Thoracic Surgical Procedures; Tubercu | 1959 |
[Early therapeutic effects of pyrazinamide treatment of pulmonary tuberculosis].
Topics: Pyrazinamide; Tuberculosis, Pulmonary | 1960 |
[Primary pulmonary tuberculosis treated with pyrazinamide. Immediate clinical and radiological results and results after prolonged treatment with streptomycin and isoniazid].
Topics: Humans; Isoniazid; Pyrazinamide; Radiology; Streptomycin; Tuberculosis, Pulmonary | 1959 |
[Endocavitary aspiration with the aid of local introduction of prednisolone derivatives and chemoantibiotics].
Topics: Cycloserine; Prednisolone; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1959 |
An investigation of the value of ethionamide with pyrazinamide or cycloserine in the treatment of chronic pulmonary tuberculosis. A report from the Research Committee of the British Tuberculosis Association.
Topics: Antitubercular Agents; Cyclopropanes; Cycloserine; Ethionamide; Humans; Pyrazinamide; Tuberculosis; | 1961 |
[Clinical results of the use of pyrazinamide in aerosols in pulmonary tuberculosis].
Topics: Aerosols; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
[Pyrazinamide in the treatment of pulmonary tuberculosis].
Topics: Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1962 |
[Combined therapy of massive doses of isoniazid, pyrazinamide, and sulfisoxazole for patients with pulmonary tuberculosis resistant to streptomycin, paraaminosalicylic acid, and isoniazid].
Topics: Aminosalicylic Acid; Humans; Isoniazid; Psychotherapy, Multiple; Pyrazinamide; Streptomycin; Sulfani | 1961 |
[Role of pyrazinamide in the treatment of pulmonary tuberculosis].
Topics: Pyrazinamide; Tuberculosis, Pulmonary | 1961 |
[A study on the clinical efficacy of a combination regimen with levofloxacin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis].
Topics: Adolescent; Adult; Antitubercular Agents; Capreomycin; Drug Therapy, Combination; Female; Humans; Le | 2003 |
[A clinical study on tuberculosis among young adults in Japan: analysis on patients admitted to national hospitals in Kanto- and Kinki-areas in the year 2000].
Topics: Adult; Age Factors; Antitubercular Agents; Drug Resistance, Bacterial; Female; Hospitals, Public; Hu | 2003 |
[Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Topics: Adult; Aged; Antitubercular Agents; Cohort Studies; Drug Therapy, Combination; Female; Humans; Isoni | 2003 |
Relative versus absolute noncontagiousness of respiratory tuberculosis on treatment.
Topics: Academic Medical Centers; Adult; Alberta; Antibiotics, Antitubercular; Antitubercular Agents; Colony | 2003 |
Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis.
Topics: Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
Cavitatory pulmonary tuberculosis in a 52-day-old infant.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Asia; Drug Therapy, Combination; Female; Humans; | 2004 |
Side effects of antituberculosis therapy.
Topics: Antitubercular Agents; Dose-Response Relationship, Drug; Humans; Maximum Tolerated Dose; Proportiona | 2004 |
Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminosalicylic Acid; Antitubercular Agents; Cohort Studi | 2004 |
Characteristics and outcome of tuberculosis patients whose sputum smears are positive at or after 5 months of treatment.
Topics: Adult; Antitubercular Agents; Ethambutol; Female; Follow-Up Studies; Health Surveys; Humans; Isoniaz | 2004 |
Prescriptions and dosages of anti-tuberculosis drugs in the National Tuberculosis Control Programme of Malawi.
Topics: Administration, Oral; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Body Weight; Commun | 2004 |
A 32-year-old man with tuberculosis, fever, and rash.
Topics: Adult; Antitubercular Agents; Diagnosis, Differential; Drug Hypersensitivity; Ethambutol; Exanthema; | 2004 |
Successful treatment of multidrug-resistant tuberculosis following drug-induced hepatic necrosis requiring liver transplant.
Topics: Adult; Anti-Infective Agents; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Ciprofl | 2004 |
[Efficiency of an intensive stage of chemotherapy for tuberculosis in elderly and senile patients].
Topics: Age Factors; Aged; Aged, 80 and over; Antibiotics, Antitubercular; Antitubercular Agents; Diabetes C | 2004 |
[Bactericidal therapy in patients with tuberculosis].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Chlortetracycline; Drug R | 2004 |
Tuberculosis: medical management update.
Topics: Adult; Antitubercular Agents; Child; Dental Staff; Ethambutol; Humans; Infectious Disease Transmissi | 2004 |
Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis.
Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; | 2004 |
The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis.
Topics: Antitubercular Agents; Directly Observed Therapy; Drug Resistance, Bacterial; Drug Resistance, Multi | 2004 |
Tuberculosis control and the private health sector in Bolivia: a survey of pharmacies.
Topics: Antitubercular Agents; Bolivia; Communicable Disease Control; Community Pharmacy Services; Cooperati | 2004 |
[Case of pulmonary tuberculosis in late stage of pregnancy].
Topics: Adult; Antitubercular Agents; Cesarean Section; Cross Infection; Drug Therapy, Combination; Ethambut | 2004 |
Treatment outcome of new culture positive pulmonary tuberculosis in Norway.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Cohort Studies; Drug Resist | 2005 |
[Effectiveness of an intensive chemotherapy stage in new cases of pulmonary tuberculosis and diabetes mellitus].
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Data Interpretation, Statistical; Diabetes Melli | 2004 |
Adverse events and treatment completion for latent tuberculosis in jail inmates and homeless persons.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Cohort Studi | 2005 |
Protective effect of a 50% hydroalcoholic fruit extract of Emblica officinalis against anti-tuberculosis drugs induced liver toxicity.
Topics: Animals; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Fruit; Hepatocytes; Humans; | 2005 |
Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana.
Topics: Adult; Antitubercular Agents; Botswana; Comorbidity; Ethambutol; Female; HIV Infections; Humans; Iso | 2005 |
Population pharmacokinetics of pyrazinamide in elephants.
Topics: Administration, Oral; Administration, Rectal; Animals; Antitubercular Agents; Area Under Curve; Elep | 2005 |
[Improvement on chest X-ray findings after two months of antituberculous treatment].
Topics: Aged; Antitubercular Agents; Female; Humans; Male; Middle Aged; Pyrazinamide; Radiography, Thoracic; | 2005 |
Reactivation of tuberculosis after apparently adequate chemoprophylaxis.
Topics: Adolescent; Antitubercular Agents; Chemoprevention; Contact Tracing; Disease Transmission, Infectiou | 2005 |
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
Topics: Animals; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combinati | 2006 |
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
Topics: Animals; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combinati | 2006 |
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
Topics: Animals; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combinati | 2006 |
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
Topics: Animals; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combinati | 2006 |
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
Topics: Animals; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combinati | 2006 |
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
Topics: Animals; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combinati | 2006 |
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
Topics: Animals; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combinati | 2006 |
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
Topics: Animals; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combinati | 2006 |
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
Topics: Animals; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combinati | 2006 |
Multidrug-resistant tuberculosis in military recruits.
Topics: Adult; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Female; Humans; Isoniazid; Milit | 2006 |
[Treatment outcome of patients with multidrug-resistant pulmonary tuberculosis during pregnancy].
Topics: Adult; Aminosalicylic Acid; Amoxicillin-Potassium Clavulanate Combination; Antitubercular Agents; Cy | 2006 |
Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Therapy, C | 2006 |
Impact of country of origin on drug-resistant tuberculosis among foreign-born persons in British Columbia.
Topics: Adolescent; Adult; Age Factors; Aged; Analysis of Variance; Anti-Bacterial Agents; Antibiotics, Anti | 2006 |
Impact of DOTS expansion on tuberculosis related outcomes and costs in Haiti.
Topics: Antitubercular Agents; Cost of Illness; Directly Observed Therapy; Drug Therapy, Combination; Ethamb | 2006 |
Ocular tuberculosis in acquired immunodeficiency syndrome.
Topics: Abscess; Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lympho | 2006 |
Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment.
Topics: Antitubercular Agents; Humans; Isoniazid; Models, Biological; Nonlinear Dynamics; Pyrazinamide; Rifa | 2006 |
Moxifloxacin-induced arthropathy.
Topics: Aged, 80 and over; Antitubercular Agents; Arthritis; Aza Compounds; Drug Therapy, Combination; Fluor | 2007 |
[A case of tuberculosis showing immune reconstitution syndrome after the initiation of antiretroviral therapy for HIV infection].
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antitubercular Agents; Drug Therapy, Com | 2007 |
[Aseptic cerebral venous thrombosis and multiple cerebral tuberculomas associated with pulmonary miliary tuberculosis].
Topics: Acenocoumarol; Aged; Anticoagulants; Antitubercular Agents; Confusion; Drug Therapy, Combination; Fe | 2007 |
Trend of anti-tuberculosis drug resistance in Korea, 1994-2004.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Ethambutol; Humans; Isoniazid; Korea; Middle | 2007 |
Tuberculous sacro-ileitis: two cases and radiological findings.
Topics: Abscess; Adult; Antitubercular Agents; Arthritis, Infectious; Brucellosis; Diagnosis, Differential; | 2007 |
Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model.
Topics: Administration, Oral; Animals; Antibiotics, Antitubercular; Antitubercular Agents; Drug Evaluation, | 2007 |
[Principles in the performance of chemotherapy in dispensary group VI children and adolescents].
Topics: Adolescent; Antitubercular Agents; Child; Dose-Response Relationship, Drug; Drug Administration Sche | 2007 |
[Case of fatal liver failure due to anti-tuberculous therapy].
Topics: Aged; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Fatal Outcome; Female; Humans; I | 2007 |
Pattern of adverse drug reactions experienced by tuberculosis patients in a tertiary care teaching hospital in Western Nepal.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Antitubercular Agents; Aspa | 2008 |
[A surgically treated case of ileus caused by small intestinal tuberculosis during treatment for pulmonary tuberculosis].
Topics: Adult; Antitubercular Agents; Ethambutol; Humans; Ileal Diseases; Ileus; Isoniazid; Male; Pyrazinami | 2007 |
Treatment of isoniazid-resistant pulmonary tuberculosis.
Topics: Adult; Aged; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Drug T | 2008 |
Peak plasma rifampicin level in tuberculosis patients with slow culture conversion.
Topics: Adult; Antitubercular Agents; Case-Control Studies; Female; Humans; Male; Mycobacterium; Mycobacteri | 2008 |
Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.
Topics: Animals; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Drug | 2008 |
An unusual case of chylothorax complicating childhood tuberculosis.
Topics: Antitubercular Agents; Bronchoalveolar Lavage; Bronchoalveolar Lavage Fluid; Bronchoscopy; Chest Tub | 2008 |
[Morphazinamide--clinical tolerance and side effects].
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Ethionamide; Female; Gastrointestinal Diseases; Huma | 1967 |
Pulmonary alveolar proteinosis. Treatment in a case complicated by tuberculosis.
Topics: Acetylcysteine; Aminosalicylic Acids; Cycloserine; Ethionamide; Heparin; Humans; Isoniazid; L-Lactat | 1967 |
Pyrazinamide-isoniazid: its apparent influence on the reactivation rate in pulmonary tuberculosis.
Topics: Adult; Aminosalicylic Acids; Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Middle Aged; | 1967 |
Pyrazinamide fulminant hepatitis: an old hepatotoxin strikes again.
Topics: Adult; Chemical and Drug Induced Liver Injury; Humans; Male; Pyrazinamide; Tuberculosis, Pulmonary | 1981 |
Drug-resistant Mycobacterium tuberculosis in Korean isolates.
Topics: Adult; Capreomycin; Drug Resistance, Microbial; Ethambutol; Humans; Isoniazid; Korea; Mycobacterium | 1982 |
[Value of pyrazinamide in the short-term treatment of tuberculosis].
Topics: Humans; Pyrazinamide; Time Factors; Tuberculosis, Pulmonary | 1983 |
[Current treatment of pulmonary tuberculosis].
Topics: Adult; Aged; Antitubercular Agents; Child; Ethambutol; Humans; Isoniazid; Pyrazinamide; Rifampin; Tu | 1984 |
Compliance of patients and physicians: experience and lessons from tuberculosis-II.
Topics: Attitude of Health Personnel; Drug Administration Schedule; Drug Information Services; Drug Therapy, | 1983 |
[In vitro studies on the inhibitory effects of rifampicin, pyrazinamide and their combination on mycobacteria with photometric measurement of turbidity].
Topics: Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Photomet | 1983 |
[Pharmacokinetics of antitubercular agents in man].
Topics: Absorption; Antitubercular Agents; Half-Life; Humans; Isoniazid; Kinetics; Mycobacterium tuberculosi | 1984 |
The role of pyrazinamide in primary chemotherapy for pulmonary tuberculosis.
Topics: Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Mycobac | 1984 |
[Short-course chemotherapy for tuberculosis in Chile. Operational considerations].
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; Isoniazid; P | 1984 |
[Short-course treatment of tuberculosis on a 7-month schedule with an initial intensive phase of 1 month (TA-81)].
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; H | 1984 |
[Effectiveness of pyrazinamide combined with rifampicin and ethambutol in animal experiments].
Topics: Animals; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Ethambutol; Mi | 1984 |
[The hepatotoxicity of pyrazinamide].
Topics: Chemical and Drug Induced Liver Injury; Humans; Kinetics; Male; Pyrazinamide; Tuberculosis, Pulmonar | 1984 |
A successful supervised outpatient short-course tuberculosis treatment program in an open refugee camp on the Thai-Cambodian border.
Topics: Adolescent; Adult; Ambulatory Care Facilities; Antitubercular Agents; Cambodia; Child; Drug Therapy, | 1984 |
[Effect of pyrazinamide on the liver of tuberculosis patients. Electron microscopic study].
Topics: Adolescent; Adult; Aged; Alcoholism; Antitubercular Agents; Drug Therapy, Combination; Humans; Liver | 1984 |
[Tuberculosis treatment today].
Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Pyrazinamide; Rifampin; Streptomycin; Tubercul | 1984 |
[Studies on short-course chemotherapy of tuberculosis. II. Liver function during 6-month chemotherapy of tuberculosis with hydrazide, rifampicin and pyrazinamide].
Topics: Humans; Isoniazid; Liver; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary | 1984 |
Role of rifampicin in arthralgia induced by pyrazinamide.
Topics: Drug Therapy, Combination; Humans; Joint Diseases; Pain; Pyrazinamide; Rifampin; Tuberculosis, Pulmo | 1983 |
The tolerability and efficacy of a 6-month antituberculosis regimen containing rifampicin, isoniazid and pyrazinamide.
Topics: Adolescent; Adult; Drug Therapy, Combination; Drug Tolerance; Female; Humans; Isoniazid; Male; Middl | 1983 |
[Comparison of 3 6-month chemotherapy regimes in pulmonary tuberculosis in routine practice in Algiers. 18th-month results].
Topics: Adolescent; Adult; Antitubercular Agents; Drug Evaluation; Drug Resistance, Microbial; Drug Therapy, | 1983 |
[Short course chemotherapy for pulmonary tuberculosis. 3. Initial intensive regimens including pyrazinamide].
Topics: Adult; Aged; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; | 1983 |
[Short-term treatment of tuberculosis with and without pyrazinamide in the second phase (TA-80)].
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Pyrazinamide; Rifampin; Strepto | 1983 |
Shortest possible acceptable effective chemotherapy in ambulatory patients with pulmonary tuberculosis. Part II. Results during the 24 months after the end of chemotherapy.
Topics: Ambulatory Care; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Eth | 1984 |
The early bactericidal activity of drugs in patients with pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Therapy, Comb | 1980 |
The early bactericidal activity of drugs in patients with pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Therapy, Comb | 1980 |
The early bactericidal activity of drugs in patients with pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Therapy, Comb | 1980 |
The early bactericidal activity of drugs in patients with pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Therapy, Comb | 1980 |
The early bactericidal activity of drugs in patients with pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Therapy, Comb | 1980 |
The early bactericidal activity of drugs in patients with pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Therapy, Comb | 1980 |
The early bactericidal activity of drugs in patients with pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Therapy, Comb | 1980 |
The early bactericidal activity of drugs in patients with pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Therapy, Comb | 1980 |
The early bactericidal activity of drugs in patients with pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Therapy, Comb | 1980 |
[Sensitivity of M. tuberculosis to pyrazinamide (author's transl)].
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; In Vitro Techniques; Mycobacterium tubercu | 1981 |
Studies in short-course chemotherapy for tuberculosis. Basis for short-course chemotherapy.
Topics: Animals; Drug Therapy, Combination; Humans; Isoniazid; Mice; Mice, Inbred Strains; Mycobacterium tub | 1981 |
Tuberculosis therapy.
Topics: Chemical and Drug Induced Liver Injury; Drug Resistance, Microbial; Drug Therapy, Combination; Human | 1983 |
A comparative evaluation of drug combinations used in the treatment of pulmonary tuberculosis.
Topics: Antitubercular Agents; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Male; Pyrazinamid | 1983 |
Hepatic complications of antituberculosis therapy revisited.
Topics: Adolescent; Adult; Aged; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Drug Thera | 1983 |
Adverse effects of antituberculosis drugs causing changes in treatment.
Topics: Antitubercular Agents; Humans; Isoniazid; Kanamycin; Pyrazinamide; Rifampin; Streptomycin; Tuberculo | 1982 |
Successful intermittent treatment of smear-positive pulmonary tuberculosis in six months: a cooperative study in Poland.
Topics: Adolescent; Adult; Aged; Drug Therapy, Combination; Follow-Up Studies; Humans; Isoniazid; Middle Age | 1982 |
Short-course chemotherapy for pulmonary tuberculosis. Points of interest.
Topics: Adult; Ambulatory Care; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combination; F | 1982 |
Modern treatment of tuberculosis.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combi | 1982 |
[Mycobacterium malmoense in the Federal Republic of Germany].
Topics: Aged; Agglutination Tests; Amides; Germany, West; Humans; Hydrolases; Isoniazid; Lipids; Male; Middl | 1982 |
[Arthralgia and uricemia produced by pyrazinamide].
Topics: Adolescent; Adult; Aged; Female; Humans; Joint Diseases; Male; Middle Aged; Pyrazinamide; Tuberculos | 1982 |
Shortest possible acceptable, effective ambulatory chemotherapy in pulmonary tuberculosis: preliminary report I.
Topics: Ambulatory Care; Antitubercular Agents; Drug Administration Schedule; Ethionamide; Female; Humans; I | 1981 |
Liver alterations in antituberculosis regimens containing pyrazinamide.
Topics: Adolescent; Adult; Aged; Alcoholism; Antitubercular Agents; Cholestasis; Diabetes Complications; Dia | 1981 |
Serum uric acid concentrations and arthralgia among patients treated with pyrazinamide-containing regimens in Hong Kong and Singapore.
Topics: Humans; Joint Diseases; Pyrazinamide; Tuberculosis, Pulmonary; Uric Acid | 1981 |
Monitoring regularity of drug intake in tuberculous patients by means of simple urine tests.
Topics: Color; Drug Administration Schedule; Humans; Isoniazid; Patient Compliance; Pyrazinamide; Rifampin; | 1980 |
A service program of antituberculosis chemotherapy with five drugs for four months in the treatment of drug addicts and prisoners with pulmonary tuberculosis in Hong Kong. Hong Kong Chest Service/British Medical Research Council.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Ethambutol; Heroin | 1980 |
Controlled double-blind study of the effect of rifampin on humoral and cellular immune responses in patients with pulmonary tuberculosis and in tuberculosis contacts.
Topics: Adolescent; Adult; Antibody Formation; Double-Blind Method; Female; Humans; Immunity, Cellular; Ison | 1980 |
[Side effects of various combinations of rifampin and isoniazid with ethambutol or streptomycin and pyrazinamide in short-term chemotherapy of newly-detected pulmonary tuberculosis].
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Administration Schedule; Drug Hypersensitivity; | 1980 |
Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis.
Topics: Acetaminophen; Adult; Capreomycin; Ciprofloxacin; Drug Combinations; Drug Overdose; Ethambutol; Fema | 1994 |
Oxidative stress during antituberculous therapy in young and elderly patients.
Topics: Adult; Age Factors; Aged; Allantoin; Antitubercular Agents; Drug Therapy, Combination; Female; Human | 1995 |
Relapse rates in tuberculosis patients.
Topics: Antitubercular Agents; Drug Combinations; Ethambutol; Female; Follow-Up Studies; Humans; Isoniazid; | 1995 |
Drugs for tuberculosis.
Topics: Adult; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Combinations; Ethambutol; Hum | 1995 |
[Allopurinol hypersensitivity. A possible cause of hepatitis and mucocutaneous eruptions in a patient undergoing antitubercular treatment].
Topics: Adult; Allopurinol; Chemical and Drug Induced Liver Injury; Drug Eruptions; Drug Hypersensitivity; D | 1995 |
Chemoprophylaxis of multidrug-resistant tuberculous infection in HIV-uninfected individuals using ciprofloxacin and pyrazinamide. A decision analysis.
Topics: Adult; Ciprofloxacin; Decision Support Techniques; Decision Trees; Health Personnel; HIV Seronegativ | 1995 |
Short-course chemotherapy for tuberculous pleural effusion and culture-negative pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antitubercular Agents; Drug Therapy, Combination; Fe | 1995 |
Silicotuberculosis: long-term outcome after short-course chemotherapy.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Follow-Up Studies; Humans; Isoniazid; Male; | 1995 |
Antituberculous therapy and acute liver function.
Topics: Antitubercular Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hong Kong; Humans; Isoni | 1995 |
[Therapy of tuberculosis in the adult].
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Dose-Response Relationship, Dru | 1995 |
Replacement of one lung by a large bulla in active tuberculosis.
Topics: Aged; Drug Therapy, Combination; Humans; Isoniazid; Male; Pyrazinamide; Rifampin; Tuberculosis, Pulm | 1995 |
Antituberculous therapy and acute liver function.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Fatal Outcome; Female; Humans; Isoniazid; L | 1995 |
[Pulmonary tuberculosis in infants. Apropos of 6 cases].
Topics: BCG Vaccine; Drug Therapy, Combination; Ethambutol; Female; Humans; Infant; Isoniazid; Male; Pyrazin | 1994 |
Cytogenetic study of tuberculosis patients before and after tuberculostatic drug treatment.
Topics: Adult; Antitubercular Agents; Cell Division; Chromosome Aberrations; Drug Combinations; Female; Huma | 1995 |
Isoniazid is not always the cause of hepatitis during treatment of tuberculosis.
Topics: Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Male; Middle Aged; Pyrazinamide; Tubercul | 1994 |
4-, 5- and 6-month regimens containing isoniazid, rifampicin, pyrazinamide and streptomycin for treatment of pulmonary tuberculosis under program conditions in Hong Kong.
Topics: Adolescent; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; F | 1994 |
Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Child; Clinical Pro | 1994 |
[Two pulmonary tuberculosis cases with HIV infection].
Topics: Adult; Female; HIV Infections; Humans; Isoniazid; Male; Pyrazinamide; Rifampin; Streptomycin; Tuberc | 1994 |
Clinical features, diagnosis, and treatment of tuberculosis in infants.
Topics: Drug Therapy, Combination; Female; Humans; Infant; Isoniazid; Male; Mycobacterium tuberculosis; Pyra | 1994 |
Human immunodeficiency virus type-1 infection in Zambian children with tuberculosis: changing seroprevalence and evaluation of a thioacetazone-free regimen.
Topics: Adolescent; Child; Child, Preschool; Drug Hypersensitivity; Drug Therapy, Combination; Female; HIV I | 1994 |
Follow-up of tuberculosis patients undergoing standard anti-tuberculosis chemotherapy by using a polymerase chain reaction.
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Follow-Up Studies; Humans; Isoniazid; Mycobacteriu | 1994 |
Serum concentrations of rifampicin and isoniazid in tuberculosis.
Topics: Adolescent; Child; Child, Preschool; Drug Therapy, Combination; Female; Half-Life; Humans; Infant; I | 1993 |
Treatment of tuberculosis in patients with pre-existing liver disease or following hepatotoxic drug reactions.
Topics: Chemical and Drug Induced Liver Injury; Clinical Protocols; Contraindications; Humans; Isoniazid; Li | 1993 |
[Clinical aspects and outcome of recurrent pulmonary tuberculosis].
Topics: Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Middle Aged; Pyrazinamide; Recurrence; R | 1993 |
Chemotherapy of tuberculosis for patients with renal impairment.
Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Kidney Failure, Chronic; Pyrazinamide; Rifampi | 1993 |
Cost-effectiveness analysis of three short-course anti-tuberculosis programmes compared with a standard regimen in Thailand.
Topics: Adolescent; Adult; Antitubercular Agents; Cost-Benefit Analysis; Drug Administration Schedule; Femal | 1993 |
Critical assessment of smear-positive pulmonary tuberculosis patients after chemotherapy under the district tuberculosis programme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Administration Schedule; Dru | 1993 |
CDC recommends four-drug treatment of tuberculosis in multidrug-resistant era.
Topics: Adult; Centers for Disease Control and Prevention, U.S.; Child; Drug Therapy; Drug Therapy, Combinat | 1993 |
Bacteriological investigations for short-course chemotherapy under the tuberculosis programme in two districts of India.
Topics: Adolescent; Adult; Aged; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Isoniazid; M | 1993 |
Increased insulin requirement in a patient with type 1 diabetes on rifampicin.
Topics: Blood Glucose; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Humans; Insulin; Isonia | 1993 |
Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Colony Count, Microbial; Dose-Response Relationship, | 1996 |
Clinical manifestation and outcome of tuberculosis in children with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; AIDS-Related Opportunistic Infections; Antibiotics, | 1996 |
Short-course therapy of pulmonary tuberculosis: doctor's compliance.
Topics: Adult; Alcoholism; Ambulatory Care; Antitubercular Agents; Clinical Competence; Drug Combinations; F | 1996 |
Growth inhibition of Mycobacterium tuberculosis by polyoxyethylene stearate present in the BACTEC pyrazinamide susceptibility test.
Topics: Antitubercular Agents; Cell Division; Drug Resistance, Microbial; Humans; In Vitro Techniques; Indic | 1996 |
The duration of excretion of viable bacilli in elderly patients on treatment for cavitating pulmonary tuberculosis.
Topics: Aged; Antitubercular Agents; Black People; Ethambutol; Female; Humans; Isoniazid; Male; Mycobacteriu | 1996 |
Human immunodeficiency virus infection in children with tuberculosis in Santo Domingo, Dominican Republic: prevalence, clinical findings, and response to antituberculosis treatment.
Topics: AIDS Serodiagnosis; Antibiotics, Antitubercular; Antitubercular Agents; Child, Preschool; Dominican | 1996 |
The management of mycobacterial infections in HIV seropositive individuals. Jefferiss Wing Therapeutics and Protocols Group.
Topics: Adrenal Cortex Hormones; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitu | 1996 |
Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antitubercular Agents; Arthralgia; Child; C | 1996 |
Multiple small bowel perforations in a patient on treatment of tuberculosis.
Topics: Adult; Antitubercular Agents; Drug Combinations; Female; Humans; Intestinal Perforation; Isoniazid; | 1996 |
Concurrent mucosal leishmaniasis and pulmonary tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Contraindications; Drug Therapy, Combin | 1996 |
Grand rounds--Hammersmith Hospital. Persistent fever in pulmonary tuberculosis.
Topics: Antitubercular Agents; Chronic Disease; Drug Resistance; Fever; Humans; Intestinal Absorption; Isoni | 1996 |
Changes in the size of adrenal glands in acute pulmonary tuberculosis with therapy.
Topics: Adolescent; Adrenal Glands; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Female; Human | 1996 |
[Tuberculosis of the middle ear: a rare extrapulmonary manifestation].
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Diagnosis, Differential; Ear Diseases; Ear, Midd | 1996 |
Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis.
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Microbial; Genes, Bacterial; Humans; Mutati | 1997 |
Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms.
Topics: Amidohydrolases; Antitubercular Agents; Chromosomes, Bacterial; DNA, Bacterial; Drug Resistance, Mic | 1997 |
[Hematologic abnormalities in pulmonary tuberculosiss].
Topics: Anemia; Antitubercular Agents; Ethambutol; Hematologic Diseases; Humans; Leukopenia; Pancytopenia; P | 1997 |
Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin.
Topics: Adolescent; Adult; Alanine Transaminase; Antitubercular Agents; Chemical and Drug Induced Liver Inju | 1997 |
[Liver injury under tuberculostatic treatment].
Topics: Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Combinations; Female; Huma | 1997 |
Pyrazinamide-induced granulomatous hepatitis.
Topics: Antitubercular Agents; Biopsy; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Gr | 1997 |
Tolerance of pyrazinamide in short course chemotherapy for pulmonary tuberculosis in children.
Topics: Adolescent; Antitubercular Agents; Blood Sedimentation; Child; Child, Preschool; Drug Tolerance; Fem | 1997 |
[The results of retreatment of pulmonary tuberculosis using a short 6-month protocol 1985-1991 in the pneumo-phthisiology department of the Point G hospital in Bamako].
Topics: Adolescent; Adult; Age Factors; Antibiotics, Antitubercular; Antitubercular Agents; Child; Drug Comb | 1997 |
Problems of diagnosis and treatment of tuberculosis following renal transplantation.
Topics: Adolescent; Adult; Antitubercular Agents; Bronchoalveolar Lavage Fluid; Drug Therapy, Combination; E | 1997 |
[Pulmonary tuberculosis caused by Mycobacterium bovis with primary resistance to Isoniazide and pyrazinamide].
Topics: Adult; Antitubercular Agents; Humans; Isoniazid; Male; Mycobacterium bovis; Pyrazinamide; Tuberculos | 1997 |
[Isolation obligation and therapy in tuberculosis].
Topics: Antitubercular Agents; Bronchoalveolar Lavage Fluid; Female; Humans; Isoniazid; Mycobacterium tuberc | 1997 |
[Effects of intermittent short-course chemotherapy under full-course supervision on the treatment of smear positive pulmonary tuberculosis].
Topics: Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Follow-Up Studies; Humans; Isoniazid; | 1996 |
[A severe form of urinary tuberculosis in children].
Topics: Adolescent; Antitubercular Agents; Atrophy; Bacteriuria; BCG Vaccine; Child; Cystitis; Hematuria; Hu | 1997 |
[First-time standard setting for therapy of pulmonary tuberculosis after revision of the Medical Treatment Standard--special reference to results of questionnaire survey on reality of early stage short-term PZA therapy and occurrence of the adverse effect
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy; Gout; Humans; Japan; Li | 1997 |
[Surgical treatment of patients with multi-resistant pulmonary tuberculosis--case reports].
Topics: Adult; Antitubercular Agents; Bronchial Fistula; Drug Therapy, Combination; Ethambutol; Fatal Outcom | 1997 |
[Reasons for chronic expectoration--case reports].
Topics: Adult; Aged; Antitubercular Agents; Capreomycin; Cycloserine; Drug Resistance, Microbial; Drug Thera | 1997 |
[Thrombocytopenia following a re-introduction of rifampicin in a daily treatment. Apropos of a case].
Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Chemical and Drug Induced Liver Injury; D | 1995 |
Two excellent management tools for national tuberculosis programmes: history of prior treatment and sputum status at two months.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Humans; | 1998 |
How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis.
Topics: AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Antitubercular Agents; Drug Admi | 1998 |
Should we take a history of prior treatment, and check sputum status at 2-3 months when treating patients for tuberculosis?
Topics: Adult; Ambulatory Care; Antibiotics, Antitubercular; Antitubercular Agents; Cohort Studies; Confiden | 1998 |
Short-course chemotherapy for isoniazid-resistant pulmonary tuberculosis.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combi | 1998 |
Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients.
Topics: Adult; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Drug Monitoring; Drug Therapy, Comb | 1998 |
[Analysis of short-term effects of short-course intermittent chemotherapies of the World Bank Loaned Project].
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; My | 1996 |
Drug-resistant tuberculosis of the brain in a two-year-old child.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Brain Diseases; Child, Preschool; Drug Therapy, | 1998 |
[Recurrent tuberculosis in a psychiatric hospital, recurrent outbreaks during 1987-1996].
Topics: Antitubercular Agents; Disease Outbreaks; Drug Therapy, Combination; Follow-Up Studies; Hospitals, P | 1998 |
Current HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone-free antituberculosis treatment in Yaounde, Cameroon.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; AIDS-Related Opportunistic Infections; Antitubercular Ag | 1998 |
[Eruption after the 1st dose of standard antitubercular chemotherapy. Thoughts on pyrazinamide].
Topics: Aged; Antitubercular Agents; Child; Drug Combinations; Drug Eruptions; Ethambutol; Exanthema; Female | 1998 |
[Resistance and multiresistance to antitubercular drugs in Argentina and in other Latin American countries].
Topics: Acquired Immunodeficiency Syndrome; Antitubercular Agents; Argentina; Drug Resistance, Microbial; Dr | 1998 |
Sequential evaluation of serum adenosine deaminase in patients treated for tuberculosis.
Topics: Adenosine Deaminase; Adolescent; Adult; Antitubercular Agents; Biomarkers; Drug Therapy, Combination | 1998 |
Phenomenon of rifampicin-induced discolouration of body fluids.
Topics: Aged; Antibiotics, Antitubercular; Antitubercular Agents; Chromogenic Compounds; Drug Interactions; | 1993 |
Primary tuberculous tracheitis.
Topics: Antitubercular Agents; Cough; Ethambutol; Female; Humans; Isoniazid; Middle Aged; Pyrazinamide; Resp | 1998 |
Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of the British Thoracic Society.
Topics: Adult; Antitubercular Agents; Child; Child, Preschool; Disease Notification; Drug Administration Sch | 1998 |
Longitudinal trends in serum levels of mycobacterial secretory (30 kD) and cytoplasmic (65 kD) antigens during chemotherapy of pulmonary tuberculosis patients.
Topics: Antibodies, Bacterial; Antigens, Bacterial; Antitubercular Agents; Drug Therapy, Combination; Enzyme | 1998 |
[Fulminant hepatitis in the course of antitubercular treatment (apropos of 2 cases)].
Topics: Adult; Anti-Bacterial Agents; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Th | 1995 |
Shock and cerebral infarct after rifampin re-exposure in a patient infected with human immunodeficiency virus.
Topics: Adult; Anaphylaxis; Antibiotics, Antitubercular; Antitubercular Agents; Cerebral Infarction; Drug Hy | 1998 |
Tuberculosis of the pyriform fossa--a rare entity.
Topics: Adult; Antitubercular Agents; Diagnosis, Differential; Drug Therapy, Combination; Ethambutol; Humans | 1998 |
The management of pulmonary tuberculosis in adults notified in Scotland in 1993.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Clinical Protocols; Disease Notif | 1998 |
Therapeutic dilemma: crescentic mesangiocapillary glomerulonephritis type 1 in a patient on antituberculous therapy with rifampicin.
Topics: Aged; Antitubercular Agents; Clarithromycin; Female; Glomerulonephritis, Membranoproliferative; Huma | 1999 |
Good news and not such good news.
Topics: Antitubercular Agents; Drug Combinations; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuberculosis, P | 1999 |
Pharmacokinetics of pyrazinamide in children suffering from pulmonary tuberculosis.
Topics: Antitubercular Agents; Child; Female; Humans; Male; Pyrazinamide; Tuberculosis, Pulmonary | 1999 |
-Skin eruption after the first dose of antitubercular quadri-therapy: consideration of pyrazinamide-.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Child; Drug Combinations; Drug Eruptions; Ethamb | 1998 |
[Six-months chemotherapy (2HRZS or E/4HRE) of new cases of pulmonary tuberculosis--six year experiences on its effectiveness, toxicity, and acceptability].
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Diabetes Complications; Drug T | 1999 |
[Efficacy of unfixed continuation phase short-course chemotherapy].
Topics: Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follo | 1997 |
[pncA gene mutations in clinical isolates of tubercle bacillus by polymerase chain reaction-direct sequencing method: in relationship to pyrazinamide resistance].
Topics: Adult; Aged; Aged, 80 and over; Amidohydrolases; Drug Resistance, Microbial; Female; Genes, Bacteria | 1999 |
The spectrum of mycobacterial disease in a Dublin teaching hospital.
Topics: Adult; Antitubercular Agents; Female; Hospitals, Teaching; Humans; Isoniazid; Lung Neoplasms; Male; | 1999 |
Four-month, four-drug preventive therapy for inactive pulmonary tuberculosis.
Topics: Adult; Aged; Antitubercular Agents; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Ad | 1999 |
Chronic ulceration of the tongue and laryngitis: first clinical sign of asymptomatic pulmonary tuberculosis.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Laryngitis; Male; Pyrazi | 1999 |
[Breast abscess and pregnancy toxemia revealing multidrug resistant tuberculosis].
Topics: Abscess; Adult; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Antitubercular Agents; Breas | 1999 |
Reply to Davis and colleagues: Twice weekly, directly observed treatment for HIV-infected and uninfected tuberculosis patients: cohort study in rural South Africa.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Drug Resistance, Mu | 1999 |
Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Resistance; Dr | 1999 |
Spinal intramedullary tuberculous lesion: medical management. Report of four cases.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Clinical Protocols; Female; F | 2000 |
Kinetics of circulating antibodies, immune complex and specific antibody-secreting cells in tuberculosis patients during 6 months of antimicrobial therapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibodies, Bacterial; Antibody-Producing Cells; Antigen-Antibod | 2000 |
[Efficiency of shorter chemotherapy courses for intrathoracic tuberculosis in children].
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combinati | 2000 |
[Intracranial tuberculomas developing during treatment of pulmonary tuberculosis: case report].
Topics: Adult; Antitubercular Agents; Humans; Isoniazid; Magnetic Resonance Imaging; Male; Pyrazinamide; Rif | 2000 |
Relation of leptin and tumor necrosis factor alpha to body weight changes in patients with pulmonary tuberculosis.
Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Body Mass Index; Body Weight; Drug Therap | 1999 |
Lipid biochemistry takes a stand against tuberculosis.
Topics: Acetyltransferases; Antitubercular Agents; Bacterial Proteins; Drug Therapy, Combination; Fatty Acid | 2000 |
Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Enzyme Inhibitors; Fatty Acid Synthases; Humans; | 2000 |
The comparison of tuberculosis treatments: a short course therapy and the directly observed short course treatment (DOTS), East Java Province, Indonesia.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Humans; | 2000 |
Hypercalcemia in renal transplant patients with tuberculosis.
Topics: Adult; Antitubercular Agents; Blood Urea Nitrogen; Calcitriol; Calcium; Ethambutol; Humans; Hypercal | 2000 |
Tuberculosis after renal transplantation.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Female; Follow-Up Studies; Huma | 2000 |
Paradoxical worsening of tuberculosis after anti-TB therapy in a kidney transplant recipient.
Topics: Adult; Antitubercular Agents; Disease Progression; Drug Therapy, Combination; Ethambutol; Female; Hu | 2000 |
Normouricemia in the syndrome of inappropriate antidiuretic hormone secretion.
Topics: Acquired Immunodeficiency Syndrome; Ethambutol; Humans; Hyponatremia; Inappropriate ADH Syndrome; Lu | 2001 |
[The effectiveness of pyrazinamide-containing six-month short course chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Diabe | 2000 |
Tuberculosis treatment: dangerous regimens?
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Humans; | 2001 |
Increasing resistance of M. tuberculosis to anti-TB drugs in Saudi Arabia.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Female; Humans; Isoniazid; Male; Micr | 2001 |
New TB drug approved.
Topics: Antitubercular Agents; Drug Combinations; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuberculosis, P | 1995 |
[Effectiveness of chemotherapy of intrathoracic tuberculosis in children: late follow-up data].
Topics: Adolescent; Age Factors; Antibiotics, Antitubercular; Antitubercular Agents; Child; Child, Preschool | 2001 |
Pyrazinamide induced photoallergy.
Topics: Adult; Antitubercular Agents; Dermatitis, Photoallergic; Drug Hypersensitivity; Female; Humans; Pyra | 2001 |
Side effects of antituberculosis treatment.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, | 2001 |
Rapid detection of pyrazinamide-resistant Mycobacterium tuberculosis by a PCR-based in vitro system.
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Te | 2002 |
Can serial qualitative polymerase chain reaction monitoring predict outcome of pulmonary tuberculosis treatment?
Topics: Antitubercular Agents; Ethambutol; Female; Follow-Up Studies; Humans; Isoniazid; Male; Pyrazinamide; | 2001 |
Tuberculous pericarditis in an infant evolving during triple chemotherapy.
Topics: Antitubercular Agents; Child, Preschool; Drug Therapy, Combination; Echocardiography; Female; Humans | 2002 |
Death associated with rifampin and pyrazinamide 2-month treatment of latent mycobacterium tuberculosis.
Topics: Aged; Antibiotics, Antitubercular; Antitubercular Agents; Drug Therapy, Combination; Humans; Liver F | 2002 |
[Medication-induced hepatic lesions in patients with pulmonary tuberculosis].
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Ethionamide; Humans; Pyrazinamide; Ri | 2002 |
Use of molecular techniques to distinguish between treatment failure and exogenous reinfection with Mycobacterium tuberculosis.
Topics: Adult; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Bacterial Typing Techniques; DNA Fi | 2002 |
[Role of pyrazinamide in the treatment of pulmonary tuberculosis in the light of comparison of the data of the International Antituberculosis Union in Istanbul in 1977 and the materials of the conference in Białystok].
Topics: Congresses as Topic; Humans; International Cooperation; Poland; Pyrazinamide; Tuberculosis, Pulmonar | 1979 |
Short-course chemotherapy for pulmonary tuberculosis.
Topics: Africa, Eastern; Aminosalicylic Acids; Antitubercular Agents; Drug Resistance, Microbial; Drug Thera | 1975 |
Short-course chemotherapy for pulmonary tuberculosis.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Isoniazid; Pyr | 1975 |
Hepatic complications of antituberculous therapy.
Topics: Aminosalicylic Acids; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Hypersensi | 1975 |
Short-course treatment in pulmonary tuberculosis.
Topics: Adolescent; Humans; Isoniazid; Pyrazinamide; Rifampin; Streptomycin; Thioacetazone; Time Factors; Tu | 1977 |
Short-course (6-month) treatment of pulmonary tuberculosis (Second East African/British Medical Research Council Study).
Topics: Africa, Eastern; Drug Therapy, Combination; Humans; Isoniazid; Pyrazinamide; Rifampin; Streptomycin; | 1976 |
Short-term chemotherapy of pulmonary tuberculosis. A controlled trial. The Research Committee of the Tuberculosis Association of India.
Topics: Drug Therapy, Combination; Ethambutol; Humans; India; Isoniazid; Pyrazinamide; Streptomycin; Thioace | 1976 |
Short-course chemotherapy for tuberculosis.
Topics: Adult; Ambulatory Care; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Humans; | 1979 |
Basic mechanisms of chemotherapy.
Topics: Aminosalicylic Acid; Animals; Antitubercular Agents; Drug Resistance, Microbial; Drug Therapy, Combi | 1979 |
Adverse reactions to short-course regimens containing streptomycin, isoniazid, pyrazinamide and rifampicin in Hong Kong.
Topics: Aminosalicylic Acids; Arthritis; Chemical and Drug Induced Liver Injury; Drug Eruptions; Drug Therap | 1976 |
[Determination of the sensitivity of mycobacteria to pyrazinamide and nicotinamide (author's transl)].
Topics: Drug Resistance, Microbial; Humans; Microbial Sensitivity Tests; Mycobacterium; Niacinamide; Pyrazin | 1978 |
[Current questions in the treatment of patients with chronic destructive pulmonary tuberculosis].
Topics: Antitubercular Agents; Cycloserine; Ethionamide; Humans; Kanamycin; Prothionamide; Pyrazinamide; Tub | 1976 |
Recent advances in antituberculosis chemotherapy.
Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Pyrazinamide; Rifampin; Streptomycin; Tubercul | 1979 |
[Therapy of tuberculosis].
Topics: Alanine Transaminase; Aspartate Aminotransferases; Drug Resistance, Microbial; Ethambutol; Humans; I | 1979 |
Modern management of tuberculosis.
Topics: Adolescent; Adult; Aminosalicylic Acid; Child; Cycloserine; Drug Administration Schedule; Drug Thera | 1979 |
[Effect and toxicity on the combined use of pyrazinamide, ethionamide and kanamycin in the retreatment of pulmonary tuberculosis (author's transl)].
Topics: Adolescent; Adult; Antitubercular Agents; Drug Therapy, Combination; Ethionamide; Female; Humans; Ka | 1979 |
[Interactions of reserve antitubercular agents in combined administration].
Topics: Amides; Drug Therapy, Combination; Ethambutol; Humans; Pyrazinamide; Rifampin; Thioamides; Tuberculo | 1978 |
[Intermittent chemotherapy of pulmonary tuberculosis (review of the literature)].
Topics: Aminosalicylic Acid; Antitubercular Agents; Drug Administration Schedule; Drug Evaluation; Drug Ther | 1978 |
[Short term chemotherapy of tuberculosis. Current status of short term chemotherapy].
Topics: Antitubercular Agents; Drug Resistance, Microbial; Humans; Prognosis; Pyrazinamide; Tuberculosis; Tu | 1978 |
Reappraisal of the activity of morphazinamide against M. tuberculosis.
Topics: Animals; Female; Formaldehyde; Humans; Hydrolysis; Mice; Mycobacterium tuberculosis; Pyrazinamide; P | 1975 |
Cycloserine plus ethionamide plus pyrazinamide in the treatment of patients excreting isoniazid-resistant tubercle bacilli following previous chemotherapy.
Topics: Adult; Cycloserine; Drug Resistance, Microbial; Drug Therapy, Combination; Ethionamide; Female; Huma | 1976 |
Management of tuberculosis: altered role of the primary care physician.
Topics: Adolescent; Adult; Aminosalicylic Acid; Antitubercular Agents; Child; Cycloserine; Ethambutol; Ethio | 1977 |
Controlled trial of 6-month and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. The results up to 30 months.
Topics: Adolescent; Adult; Drug Administration Schedule; Drug Evaluation; Drug Resistance, Microbial; Hong K | 1977 |
[Chemotherapy of lung tuberculosis].
Topics: Cyclacillin; Ethambutol; Ethionamide; Humans; Isoniazid; Pyrazinamide; Streptomycin; Tuberculosis, P | 1977 |
[Pyrazinamide treatment of patients with tuberculosis associated with gastroduodenal ulcer].
Topics: Adult; Aged; Duodenal Ulcer; Female; Humans; Male; Middle Aged; Peptic Ulcer; Pyrazinamide; Stomach | 1977 |
Letter: Tuberculosis care in general hospitals: Arizona's experience.
Topics: Economics, Medical; Hospitalization; Humans; Isoniazid; Pyrazinamide; Rifampin; Streptomycin; Tuberc | 1976 |
[Treatment of tuberculosis. A care program carried out by a working group in the Swedish Pulmonary Medical Society].
Topics: Ambulatory Care; Antitubercular Agents; Drug Interactions; Ethambutol; Eye Diseases; Female; Follow- | 1976 |
Hong Kong tuberculosis treatment services/British Medical Research Council Study of 6- and 9-month regimens of daily and intermittent streptomycin, isoniazid and pyrazinamide for pulmonary tuberculosis.
Topics: Adult; Hong Kong; Humans; Isoniazid; Pyrazinamide; Streptomycin; Time Factors; Tuberculosis, Pulmona | 1976 |
Hong Kong Tuberculosis Treatment Services/British Medical Research Council study of short-course regimens of streptomycin, isoniazid and pyrazinamide: latest results.
Topics: Adult; Drug Evaluation; Humans; Isoniazid; Pyrazinamide; Streptomycin; Tuberculosis, Pulmonary | 1975 |
Exacerbation of porphyria during treatment of pulmonary tuberculosis.
Topics: 5-Aminolevulinate Synthetase; Adult; Animals; Diet; Enzyme Induction; Humans; Liver; Male; Porphyria | 1976 |
[Concentration of ethambutol and pyrazinamide in the blood and the resected lungs of patients with tuberculosis].
Topics: Ethambutol; Humans; Lung; Lymph Nodes; Pyrazinamide; Tuberculoma; Tuberculosis, Pulmonary | 1976 |
Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in presence of hepatic dysfunction.
Topics: Adult; Aged; Aged, 80 and over; Chemical and Drug Induced Liver Injury; Drug Monitoring; Drug Therap | 1992 |
Fixed dose combination short course chemotherapy in the treatment of pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Drug Combinations; Drug Therapy, Combination; Humans; Isoniazid; Middle Age | 1992 |
Case holding in patients with tuberculosis in Botswana.
Topics: Botswana; Drug Therapy, Combination; Humans; Isoniazid; National Health Programs; Patient Compliance | 1992 |
[Therapy of pulmonary tuberculosis].
Topics: Adult; Antitubercular Agents; Ethambutol; Female; Follow-Up Studies; Humans; Inpatients; Isoniazid; | 1992 |
[2 complications of primary pulmonary tuberculosis in children].
Topics: Child; Drug Administration Schedule; Humans; Medication Errors; Pyrazinamide; Pyrilamine; Tuberculos | 1992 |
[2 complications of primary pulmonary tuberculosis in children].
Topics: Child; Humans; Medication Errors; Pyrazinamide; Pyrilamine; Tuberculosis, Pulmonary | 1992 |
Effect of simultaneous isoniazid administration on pharmacokinetic parameters of pyrazinamide.
Topics: Adult; Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Metabolic Clearance Rate; Middle | 1991 |
AIDS and tuberculosis in Spain. A report of 140 cases.
Topics: Acquired Immunodeficiency Syndrome; Drug Therapy, Combination; Ethambutol; Female; Humans; Incidence | 1991 |
[Standardized controlled antitubercular therapy and results in 755 patients].
Topics: Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid | 1991 |
Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; Drug Administration Schedule; Drug Therapy, Combination; | 1991 |
Short course chemotherapy for pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Drug Therapy, Combination; | 1991 |
The management of pulmonary tuberculosis in adults notified in England and Wales in 1988. The British Thoracic Society Research Committee and the Medical Research Council Cardiothoracic Epidemiology Group.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; England; Humans; Iso | 1991 |
Efficacy of intermittent pyrazinamide in experimental murine tuberculosis.
Topics: Animals; Colony Count, Microbial; Drug Administration Schedule; Drug Therapy, Combination; Isoniazid | 1991 |
[Persistent fever syndrome in a case of childhood tuberculosis].
Topics: Child, Preschool; Fever; Fever of Unknown Origin; Humans; Hydrazines; Male; Pyrazinamide; Rifampin; | 1991 |
The disposition of antituberculous drugs in plasma of elderly patients. I. Isoniazid and hydrazine metabolite.
Topics: Acetylation; Adult; Aged; Aged, 80 and over; Aging; Female; Humans; Isoniazid; Male; Middle Aged; Py | 1991 |
The disposition of antituberculous drugs in plasma of elderly patients. II. Isoniazid, rifampicin and pyrazinamide.
Topics: Adult; Aged; Aged, 80 and over; Aging; Female; Humans; Isoniazid; Male; Metabolic Clearance Rate; Mi | 1991 |
Effect of vitamin D on efficacy of pyrazinamide in pulmonary tuberculosis.
Topics: Adolescent; Adult; Drug Synergism; Drug Therapy, Combination; Humans; Middle Aged; Pyrazinamide; Tub | 1991 |
Chromosomal aberrations in tuberculosis patients before and after treatment with short-term chemotherapy.
Topics: Chromosome Aberrations; Drug Therapy, Combination; Humans; Isoniazid; Mutagens; Pyrazinamide; Rifamp | 1991 |
A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Aspartate Aminotransferases; Cost-Benefit Analysis; | 1990 |
[In 76% of patients with active tuberculosis treated with triple therapy (isoniazid-rifampicin-pyrazinamide) cultural conversion precedes microscopic conversion].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Humans; Isoniazid; Ma | 1990 |
Any questions? How should a patient be managed who is being treated for sputum positive pulmonary tuberculosis and becomes jaundiced in the third week of chemotherapy?
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Jaundice; Pyrazinamide; Rifampi | 1990 |
Effects of two pulmonary tuberculosis drug treatments and acetylator status on liver function in a Zimbabwean population.
Topics: Alanine Transaminase; Alkaline Phosphatase; Chemical and Drug Induced Liver Injury; Drug Therapy, Co | 1990 |
Pyrazinamide in the chemoprophylaxis of tuberculosis.
Topics: Animals; Drug Therapy, Combination; Humans; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary | 1990 |
[Treatment of tuberculosis. Drug combinations, therapeutic problems and results in a 10-year case load].
Topics: Antitubercular Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Isoniazid; Male | 1990 |
[Clinical and laboratory studies in patients with pulmonary tuberculosis treated with pyrazinamide].
Topics: Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Py | 1990 |
[Clinico-pharmacokinetic interactions of rifampicin, pyrazinamide and isoniazide].
Topics: Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Humans; Infusions, Intravenous; I | 1990 |
[Fulminant hepatitis induced by pyrazinamide].
Topics: Aged; Chemical and Drug Induced Liver Injury; Humans; Male; Pyrazinamide; Tuberculosis, Pulmonary | 1990 |
Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis.
Topics: Antitubercular Agents; Drug Evaluation; Drug Resistance, Microbial; Ethambutol; Humans; Isoniazid; M | 1986 |
180 doses in 26 weeks vs 56 doses in 24 weeks of chemotherapy in pulmonary tuberculosis: a preliminary report.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Administration Schedule; Ethambutol; Female; Hu | 1988 |
[Tuberculous ulcer of the tongue: clinical case].
Topics: Adult; Female; Humans; Isoniazid; Pyrazinamide; Rifampin; Tongue Diseases; Tuberculosis; Tuberculosi | 1989 |
[Experience with intensive short-term chemotherapy of patients with recently diagnosed destructive pulmonary tuberculosis].
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Female; Humans; Isoniazid; Male; Middle Aged; Pyrazi | 1989 |
Importance of rifampicin in combined daily/intermittent chemotherapy for tuberculosis.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Dapsone; Drug Combinations; Drug Evaluation; Drug Th | 1989 |
The tuberculosis situation in east European countries.
Topics: Adult; BCG Vaccine; Europe, Eastern; Humans; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary | 1989 |
Tubulointerstitial nephritis associated with pyrazinamide.
Topics: Acute Kidney Injury; Adult; Humans; Male; Nephritis, Interstitial; Pyrazinamide; Tuberculosis, Pulmo | 1989 |
Good tolerance of pyrazinamide in children with pulmonary tuberculosis.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Drug Therapy, Combination; Humans; Infan | 1989 |
Effect of pyrazinamide on serum and urinary uric acid levels.
Topics: Adolescent; Adult; Child; Female; Humans; Male; Middle Aged; Pyrazinamide; Time Factors; Tuberculosi | 1987 |
[Fully supervised ambulatory short-course chemotherapy with an intermittent regimen for newly diagnosed smear-positive pulmonary tuberculosis].
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combinat | 1987 |
[Long-term results of short-course chemotherapy in pulmonary tuberculosis (final report). The third study: comparative study of two regimens, 6RHZ and -6RHS (treatment was continued for 6 months after negative conversion of sputum by culture)].
Topics: Adult; Aged; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Isoniazid; Male; Middle A | 1988 |
Primary antituberculosis drug resistance and acquired rifampicin resistance in Gujarat, India.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Humans; India; Isoniazid; Microbial Sensitivity T | 1988 |
Airway obstruction secondary to tuberculosis lymph node erosion into the trachea: drainage via bronchoscopy.
Topics: Airway Obstruction; Bronchoscopy; Drainage; Female; Humans; Infant; Isoniazid; Pyrazinamide; Radiogr | 1988 |
[New and future drugs in pulmonary tuberculosis].
Topics: Antitubercular Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Ethambutol; Humans; Is | 1988 |
Management and outcome of pulmonary tuberculosis in adults notified in England and Wales in 1983. Medical Research Council Tuberculosis and Chest Diseases Unit.
Topics: Adolescent; Adult; Antitubercular Agents; Bangladesh; Drug Administration Schedule; England; Ethambu | 1988 |
Pyrazinamide and pyrazinoic acid pharmacokinetics in patients with chronic renal failure.
Topics: Adult; Humans; Kidney Failure, Chronic; Male; Middle Aged; Pyrazinamide; Renal Dialysis; Tuberculosi | 1988 |
[Antituberculous chemotherapy: a constraining adverse effect of pyrazinamide].
Topics: Adult; Drug Therapy, Combination; Headache; Humans; Joint Diseases; Male; Paresthesia; Pyrazinamide; | 1988 |
Interaction between allopurinol and pyrazinamide.
Topics: Adult; Allopurinol; Drug Interactions; Drug Therapy, Combination; Humans; Joint Diseases; Male; Pain | 1988 |
Pyrazinamide induced thrombocytopenia.
Topics: Adult; Humans; Male; Pyrazinamide; Thrombocytopenia; Tuberculosis, Pulmonary | 1988 |
Pyrazinamide and rifampicin regimens for patients on maintenance dialysis.
Topics: Adolescent; Chromatography, High Pressure Liquid; Female; Humans; Kidney Failure, Chronic; Male; Mid | 1988 |
[Kidney function in patients with pulmonary tuberculosis during treatment with antitubercular agents, with special reference to pyrazinamide].
Topics: Adult; Aged; Antitubercular Agents; Glomerular Filtration Rate; Humans; Kidney; Middle Aged; Pyrazin | 1987 |
Convulsions after treatment with pyrazinamide.
Topics: Humans; Infant; Male; Pyrazinamide; Seizures; Tuberculosis, Pulmonary | 1987 |
[Observations on the effect of PZA, EB and RFP on uric acid metabolism].
Topics: Adolescent; Adult; Arthritis; Drug Therapy, Combination; Ethambutol; Female; Gout; Humans; Male; Mid | 1986 |
New approach to treatment of pulmonary and extrapulmonary tuberculosis. Possible ramifications of cutaneous mycobacterial infections.
Topics: Ethambutol; Humans; Isoniazid; Pyrazinamide; Rifampin; Streptomycin; Tuberculosis, Cutaneous; Tuberc | 1987 |
From the Centers for Disease Control. Conference on new approaches for tuberculosis preventive therapy.
Topics: Antitubercular Agents; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary | 1987 |
[Chemotherapy of pulmonary tuberculosis. Sputum culture conversion in 8 weeks in 84% of patients].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Evaluation; Drug Therapy, Co | 1987 |
[Long-term results of short-course chemotherapy of pulmonary tuberculosis (second study--A). Results up to 6 years after the end of treatment with 4-6 month chemotherapy of pulmonary tuberculosis].
Topics: Adult; Aged; Antitubercular Agents; Follow-Up Studies; Humans; Male; Pyrazinamide; Recurrence; Time | 1987 |
Dosage schedules for tuberculosis patients.
Topics: Drug Administration Schedule; Humans; Pyrazinamide; Tuberculosis, Pulmonary | 1987 |
Short-course antituberculous chemotherapy for pulmonary and pleural disease: 5 years' experience in clinical practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Administration Schedule; Eth | 1987 |
[Studies of short-term chemotherapy of tuberculosis. III. Early and late results of 6 months' treatment of tuberculosis. Analysis of failures and recurrences during 1-5 years' observation].
Topics: Adolescent; Adult; Aged; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Isoniazid; Ma | 1986 |
[Results of a therapeutic trial comparing a 6-month regimen to a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Final report: results 3 years after the onset of treatment].
Topics: Adult; Algeria; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Eth | 1986 |
Short-course tuberculosis therapy--a new combination product.
Topics: Drug Combinations; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary | 1986 |
[Tuberculostatics-induced systemic lupus erythematosus].
Topics: Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Lupus Eryth | 1986 |
Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide.
Topics: Adolescent; Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Child, Pres | 1986 |
Short-course chemotherapy of pulmonary tuberculosis: a new approach to drug dosage in the initial intensive phase.
Topics: Antitubercular Agents; Body Weight; Drug Therapy, Combination; Humans; Isoniazid; Pyrazinamide; Rifa | 1986 |
Safety of thrice-weekly rifampicin for tuberculosis in South-East Asian refugees.
Topics: Adolescent; Adult; Aged; Asia, Southeastern; Australia; Chemical and Drug Induced Liver Injury; Chil | 1985 |
[Effects of pyrazinamide on the liver in patients with tuberculosis. An ultrastructural study].
Topics: Adolescent; Adult; Aged; Alcoholism; Antitubercular Agents; Endoplasmic Reticulum; Humans; Liver; Ma | 1985 |
The action of antituberculosis drugs in short-course chemotherapy.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Humans; Isoniazid; Models, Biological | 1985 |
[Chemotherapeutic treatment of pulmonary tuberculosis].
Topics: Antitubercular Agents; Ethambutol; Humans; Hydrazines; Pyrazinamide; Rifampin; Streptomycin; Tubercu | 1985 |
Tuberculosis in an Indochinese refugee camp: epidemiology, management and therapeutic results.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; Female | 1985 |
Field trial of short course chemotherapy for pulmonary tuberculosis: results at 30 months.
Topics: Adolescent; Adult; Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Pyrazinamide; Rifampi | 1985 |
Ultrashort-course chemotherapy for culture-negative pulmonary tuberculosis--a qualified success.
Topics: Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Follow-Up Studies; Humans; Isoniazid; | 1985 |
Failure of a prothionamide-containing oral antituberculosis regimen.
Topics: Administration, Oral; Antitubercular Agents; Dapsone; Drug Combinations; Drug Therapy, Combination; | 1985 |
Results after retreatment of advanced pulmonary tuberculosis with rifampin and other drugs.
Topics: Adult; Aged; Anti-Bacterial Agents; Antitubercular Agents; Cycloserine; Drug Resistance, Microbial; | 1971 |
The first clinical experiences with ethambutol in chronic pulmonary tuberculosis and basilar meningitis.
Topics: Adult; Aminosalicylic Acids; Capreomycin; Chronic Disease; Cycloserine; Drug Combinations; Drug Resi | 1970 |
Clinical experience with ethambutol.
Topics: Aminosalicylic Acids; Blood Chemical Analysis; Capreomycin; Drug Combinations; Drug Hypersensitivity | 1970 |
Clinical results of rifampicin treatment.
Topics: Administration, Oral; Adult; Aged; Capreomycin; Chronic Disease; Drug Combinations; Ethambutol; Fema | 1970 |
Shorter chemotherapy in tuberculosis.
Topics: Developing Countries; Drug Combinations; Economics; Humans; Isoniazid; Pyrazinamide; Rifampin; Strep | 1972 |
Technical and bacteriological aspects of a continuous survey of drug resistance in tuberculosis in South Africa.
Topics: Aminosalicylic Acids; Computers; Cycloserine; Diffusion; Drug Resistance, Microbial; Ethionamide; Hu | 1972 |
Treatment of resistant pulmonary tuberculosis in Hong Kong with regimens of second-line drugs.
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Chemical and Drug Induced Liver Injury; Cycloserine; | 1972 |
[Proceedings: Ambulatory chemotherapy of tuberculosis in Finland (organization)].
Topics: Ambulatory Care; Aminosalicylic Acids; Antitubercular Agents; Capreomycin; Ethambutol; Ethionamide; | 1973 |
Short-course treatment in pulmonary tuberculosis.
Topics: Adolescent; Adult; Africa, Eastern; Antitubercular Agents; Humans; Isoniazid; Mycobacterium tubercul | 1973 |
Management of drug failure cases.
Topics: Adult; Aged; Aminosalicylic Acids; Antitubercular Agents; Collapse Therapy; Congresses as Topic; Cyc | 1972 |
Tuberculosis Chemotherapy Centre, Madras.
Topics: Antitubercular Agents; Cycloserine; Diet Therapy; Drug Resistance, Microbial; Ethionamide; Home Care | 1968 |
Comparison of various drug regimens in domiciliary chemotherapy.
Topics: Adolescent; Adult; Costs and Cost Analysis; Home Care Services; Humans; Isoniazid; Middle Aged; Myco | 1970 |
[Pulmonary tuberculosis resistant to streptomycin and isoniazid and treated wtih a combination of ethionamide, pyrazinamide, and cycloserine (200 cases)].
Topics: Adolescent; Adult; Age Factors; Aged; Aminosalicylic Acids; Child; Cycloserine; Drug Resistance, Mic | 1973 |
[Use of drugs of secondary group in complex therapy of children with chronic tuberculosis].
Topics: Adolescent; Child; Child, Preschool; Chronic Disease; Cycloserine; Ethionamide; Female; Humans; Male | 1971 |
[Therapy of pulmonary tuberculosis in its current aspects].
Topics: Aminosalicylic Acids; Anti-Bacterial Agents; Antitubercular Agents; Cycloserine; Ethionamide; Humans | 1965 |
The results of treatment in patients with cultures resistant to streptomycin, isoniazid and PAS: a five-year follow-up.
Topics: Aminosalicylic Acids; Cycloserine; Drug Resistance, Microbial; Ethionamide; Follow-Up Studies; Human | 1967 |
Treatment of pulmonary tuberculosis.
Topics: Aminosalicylic Acids; Drug Resistance, Microbial; Humans; Isoniazid; Kanamycin; Pyrazinamide; Strept | 1967 |
A continuing study of patients with "open negative" status at Battey State Hospital.
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Child; Cycloserine; Female; Follow-Up Studies; Georgi | 1968 |
[Preparations of the 2d series in the complex treatment of middle-aged and elderly patients with pulmonary tuberculosis].
Topics: Aged; Antitubercular Agents; Cycloserine; Ethionamide; Female; Humans; Kanamycin; Male; Middle Aged; | 1967 |
Ethambytol in the retreatment of pulmonary tuberculosis. United States Public Health Service cooperative trial.
Topics: Cycloserine; Drug Resistance, Microbial; Ethambutol; Ethionamide; Humans; Isoniazid; Kanamycin; Pyra | 1968 |
The treatment of drug resistant chronic pulmonary tuberculosis with new tuberculostatics.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Cycloserine; Drug Resistance, Microbial; Ethambutol; E | 1968 |
[Treatment of drug resistant chronic pulmonary tuberculosis with a number of tuberculostatics].
Topics: Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Drug Resistance, Microbial; Ethambutol; Et | 1968 |
The problem of the chronic excretor of tubercle bacilli.
Topics: Adult; Age Factors; Aged; Aminosalicylic Acids; Chronic Disease; Cycloserine; Czechoslovakia; Drug R | 1968 |
[Therapy of pulmonary tuberculosis with reserve drugs in the light of our personal observations].
Topics: Adult; Cycloserine; Drug Resistance, Microbial; Ethionamide; Female; Humans; Male; Middle Aged; Pyra | 1970 |
[The course and results of treatment of pulmonary tuberculosis as a function of the dosage of Pyrazinamide].
Topics: Cycloserine; Ethionamide; Female; Humans; Male; Pyrazinamide; Tuberculosis, Pulmonary; Viomycin | 1970 |
Ethambutol in the treatment of 26 patients with chronic active pulmonary tuberculosis.
Topics: Chronic Disease; Cycloserine; Drug Resistance, Microbial; Ethambutol; Humans; Isoniazid; Kanamycin; | 1969 |
Treatment of patients with drug-resistance in economically developed countries.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Costs and Cost Analysis; Cycloserine; Drug Resistance, | 1969 |
Chemotherapy of tuberculosis.
Topics: Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Ethambutol; Ethionamide; Humans; Isoniazid | 1970 |
Drug therapy of resistant cases of pulmonary tuberculosis in Indian patients.
Topics: Adult; Antitubercular Agents; Cycloserine; Drug Resistance, Microbial; Ethionamide; Female; Humans; | 1967 |
[Kanamycin and florimycin in the clinical course of pulmonary tuberculosis].
Topics: Adolescent; Adult; Albuminuria; Aminosalicylic Acids; Antitubercular Agents; Chronic Disease; Cyclos | 1971 |
Treatment of drug-resistant tuberculosis.
Topics: Aminosalicylic Acids; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Cycloserine; Dr | 1971 |
Hypocalcemia, hypomagnesemia and hypokalemia during chemotherapy of pulmonary tuberculosis.
Topics: Alkalosis; Humans; Hypocalcemia; Hypokalemia; Magnesium; Male; Middle Aged; Phosphorus; Pyrazinamide | 1972 |
[Duration of the after-control of the tuberculous patients following the termination of the treatment].
Topics: Adolescent; Adult; Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Ethambutol; Ethionamide | 1972 |
[Experience in treatment of patients with chronic destructive pulmonary tuberculosis in a suburban tuberculosis hospital].
Topics: Adult; Antitubercular Agents; Chronic Disease; Cycloserine; Drug Evaluation; Ethambutol; Ethionamide | 1974 |
[Centrilobular parenchymal necrosis of the liver. A contribution to the knowledge of drug induced lesions of the liver (author's transl)].
Topics: Biopsy; Chemical and Drug Induced Liver Injury; Ethionamide; Humans; Liver; Necrosis; Pyrazinamide; | 1973 |
Hong Kong Treatment Services-Royal Postgraduate Medical School-British Medical Research Council Co-operative study of rifampicin plus ethambutol in daily and intermittent regimens. Clinical observations on adverse reactions.
Topics: Acute Kidney Injury; Adolescent; Cycloserine; Drug Therapy, Combination; Dyspnea; Ethambutol; Ethion | 1973 |
Therapeutic effects and side effects of rifampicin administered daily or twice-weekly.
Topics: Adult; Body Weight; Drug Therapy, Combination; Ethambutol; Exanthema; Female; Fever; Follow-Up Studi | 1973 |
Shorter treatment.
Topics: Animals; Drug Combinations; Humans; Isoniazid; Pyrazinamide; Recurrence; Rifampin; Time Factors; Tub | 1972 |
[Therapeutic effect of rifampicin on re-treatment cases of pulmonary tuberculosis. The second study: a study on the combined therapy of rifampicin with ethambutol and pyrazinamide, especially on intermittent therapy].
Topics: Adult; Ethambutol; Female; Humans; Male; Middle Aged; Pyrazinamide; Rifampin; Tuberculosis, Pulmonar | 1972 |
[A controlled comparison of daily and intermittent administration of rifampicin in retreatment of pulmonary tuberculosis].
Topics: Adult; Female; Humans; Male; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary | 1972 |
Treatment of pulmonary tuberculosis with ethionamide, cycloserine and pyrazinamide in Hong Kong.
Topics: Adolescent; Adult; Aged; Cycloserine; Ethionamide; Female; Follow-Up Studies; Hong Kong; Humans; Mal | 1972 |
Ethionamide, pyrazinamide and cycloserine in drug resistant cases.
Topics: Cycloserine; Drug Resistance, Microbial; Ethionamide; Female; Humans; Male; Pyrazinamide; Tuberculos | 1973 |
Transfer factor therapy in a patient with progressive primary tuberculosis.
Topics: Adult; Aminosalicylic Acids; Anemia, Aplastic; Cell Migration Inhibition; Ethambutol; Female; Humans | 1973 |
[Treatment with pyrazinamide given in increased doses twice a week in combination with other drugs].
Topics: Adult; Aged; Antitubercular Agents; Chronic Disease; Drug Hypersensitivity; Drug Synergism; Drug Tol | 1973 |
[Megaloblastic anemia caused by pyrazinamide].
Topics: Adult; Anemia, Macrocytic; Female; Folic Acid; Humans; Pyrazinamide; Tuberculosis, Pulmonary | 1973 |
Successive manifestations of tuberculosis in a recalcitrant patient.
Topics: Adult; Aminosalicylic Acids; Communicable Disease Control; Hospitalization; Humans; Isoniazid; Male; | 1973 |
[Chronic tuberculous meningitis in a case of known Mycobacterium kansasii infection].
Topics: Adult; Burns; Cell Count; Cerebrospinal Fluid; Cerebrospinal Fluid Proteins; Drug Therapy, Combinati | 1974 |
The management of drug-resistant pulmonary tuberculosis.
Topics: Aminosalicylic Acids; Antitubercular Agents; Attitude; Bacteriological Techniques; Drug Resistance, | 1968 |
Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues.
Topics: Animals; Cortisone; Cross Infection; Drug Resistance, Microbial; Isoniazid; Mice; Mycobacterium tube | 1966 |
Microbial persistence. II. Characteristics of the sterile state of tubercle bacilli.
Topics: Animals; Drug Resistance, Microbial; Isoniazid; Mice; Mycobacterium tuberculosis; Pyrazinamide; Tube | 1966 |
Kanamycin in the therapy of pulmonary tuberculosis in the United States.
Topics: Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Ethionamide; Humans; Isoniazid; Kanamycin; | 1966 |
A comparison of various measures of sensitivity of M. tubercolosis to pyrazinamide.
Topics: Culture Media; Drug Resistance, Microbial; Humans; Hydrochloric Acid; Hydrogen-Ion Concentration; Mi | 1970 |
[Restoration of drug sensitivity in Mycobacterium tuberculosis to streptomycin and isoniazid during treatment with preparations of the 1st series].
Topics: Chronic Disease; Cycloserine; Drug Resistance, Microbial; Ethionamide; Humans; Isoniazid; Mycobacter | 1970 |
[Intermittent chemotherapy of pulmonary tuberculosis].
Topics: Aminosalicylic Acids; Antitubercular Agents; Home Care Services; Hospitals; Humans; Long-Term Care; | 1971 |
[Internal medicine treatment of pulmonary tuberculosis].
Topics: Ambulatory Care; Aminosalicylic Acids; Anti-Bacterial Agents; Antitubercular Agents; Cycloserine; Dr | 1970 |
[Refractory tuberculosis: concept and clinical cases].
Topics: Adult; Aged; Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Drug Resistance, Microbial; E | 1971 |
A comparison of regimens of ethionamide, pyrazinamide and cycloserine in re-treatment of patients with pulmonary tuberculosis.
Topics: Adolescent; Adult; Chemical and Drug Induced Liver Injury; Cycloserine; Ethionamide; Gastrointestina | 1969 |
Acute psychotic reaction probably caused by ethionamide.
Topics: Adult; Ethionamide; Humans; Isoniazid; Male; Prednisolone; Psychoses, Substance-Induced; Pyrazinamid | 1972 |
[Renal function in patients with minor forms of pulmonary tuberculosis in the course of treatment with 2d series drugs].
Topics: Adult; Antitubercular Agents; Ethionamide; Female; Humans; Kidney; Kidney Function Tests; Male; Pyra | 1972 |
Recent developments in the treatment of infectious diseases. V. Management of tuberculosis in the community hospital.
Topics: Aminosalicylic Acids; Cross Infection; Ethambutol; Humans; Isoniazid; Pyrazinamide; Rifampin; Sanita | 1971 |
[Clinical evaluation of rifampicin in advanced pulmonary tuberculosis resistant to conventional antituberculosis drugs. Combination therapy with rifampicin and pyrazinamide].
Topics: Adult; Female; Humans; Male; Middle Aged; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary | 1971 |
Drug resistant pulmonary tuberculosis treated with ethambutol and rifampicin in North East England.
Topics: Aminosalicylic Acids; Chronic Disease; Cycloserine; Drug Resistance, Microbial; Ethambutol; Ethionam | 1971 |
[Liver toxicity of aetina and pyracinamide and their control by determination of LAP activity in blood serum].
Topics: Adult; Alanine Transaminase; Antitubercular Agents; Aspartate Aminotransferases; Chemical and Drug I | 1969 |
[Centrilobular liver necrosis following antimycobacterial treatment].
Topics: Antitubercular Agents; Biopsy; Chemical and Drug Induced Liver Injury; Ethionamide; Humans; Liver Di | 1971 |
Clinical efficiency of cycloserine in association with other tuberculostatics.
Topics: Adult; Aminosalicylic Acids; Cycloserine; Drug Resistance, Microbial; Ethionamide; Female; Humans; M | 1970 |
The effect of cycloserine in different chemotherapy combinations on chronic pulmonary tuberculosis.
Topics: Chronic Disease; Cycloserine; Ethionamide; Humans; Pyrazinamide; Tuberculosis, Pulmonary | 1970 |
A comparison of ethionamide-cycloserine and ethionamide-pyrazinamide regimens in patients resistant to major chemotherapeutics.
Topics: Cycloserine; Ethionamide; Humans; Pyrazinamide; Tuberculosis, Pulmonary | 1970 |
General survey of the clinical results of treatment of pulmonary tuberculosis with cycloserine in Turkey.
Topics: Cycloserine; Ethionamide; Humans; Isoniazid; Pyrazinamide; Tuberculosis, Pulmonary | 1970 |
Comparative studies of various antituberculosis drug regimens by means of serum antimycobacterial activity tests in man.
Topics: Adolescent; Adult; Aminoisobutyric Acids; Antitubercular Agents; Cycloserine; Drug Resistance, Micro | 1967 |
Concentrations of pyrazinamide attained in serum with different doses of the drug.
Topics: Aspartate Aminotransferases; Humans; Pyrazinamide; Tuberculosis, Pulmonary | 1968 |
Toxicity of pyrazinamide, administered once weekly in high dosage, in tuberculous patients.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Bilirubin; Blood Chemical Analysis; Female | 1968 |
Experience with cycloserine.
Topics: Cycloserine; Depression; Drug Resistance, Microbial; Ethionamide; Humans; Pyrazinamide; Tetany; Tube | 1970 |
[Improved therapy of tuberculosis with a well tolerated INH derivative (INHG)].
Topics: Cycloserine; Ethambutol; Ethionamide; Glucuronates; Humans; Isoniazid; Middle Aged; Pyrazinamide; St | 1969 |
Chronic tuberculosis in refractory patients--therapeutic aspects.
Topics: Aminosalicylic Acids; Antitubercular Agents; Chronic Disease; Cycloserine; Drug Resistance, Microbia | 1969 |
[Triple reserved scheme in the treatment of resistent forms of pulmonary tuberculosis (preliminary results)].
Topics: Adolescent; Adult; Antitubercular Agents; Cycloserine; Drug Resistance, Microbial; Ethionamide; Fema | 1969 |
[Comparative evaluation of several functional tests of the liver in patients with pulmonary tuberculosis with side-reactions to tuberculostatic preparations].
Topics: Adult; Antitubercular Agents; Cycloserine; Ethionamide; Female; Humans; Isoniazid; Kanamycin; Liver; | 1969 |
Four regimens of streptomycin plus pyrazinamide in retreatment: East African-British Medical Research Council investigation.
Topics: Drug Resistance, Microbial; Humans; Pyrazinamide; Streptomycin; Tuberculosis, Pulmonary | 1970 |
Ethambutol in the retreatment of chronic pulmonary tuberculosis.
Topics: Aminosalicylic Acids; Chronic Disease; Cycloserine; Depression, Chemical; Drug Synergism; Ethambutol | 1970 |
Evaluation of the hepatotoxic effect of antituberculous drugs in tuberculosis patients abusing alcohol.
Topics: Acute Disease; Adult; Alcoholism; Aminosalicylic Acids; Antitubercular Agents; Chemical and Drug Ind | 1970 |
[Comparative study of specific blood activity in patients with fibrous-cavernous pulmonary tuberculosis during administration of different combinations of antibacterial preparations].
Topics: Blood Bactericidal Activity; Cycloserine; Ethionamide; Humans; Isoniazid; Pyrazinamide; Time Factors | 1970 |
Late results in re-treatment of patients with pulmonary tuberculosis.
Topics: Cycloserine; Drug Resistance, Microbial; Ethionamide; Follow-Up Studies; Humans; Pyrazinamide; Sputu | 1970 |
Report on the therapeutic results obtained with rifampicin.
Topics: Aminosalicylic Acids; Chronic Disease; Drug Combinations; Ethambutol; Humans; Pyrazinamide; Rifampin | 1970 |
[Effect of pyrazinamide on the blood coagulation system and fibrinolysis].
Topics: Adolescent; Adult; Aged; Blood Coagulation; Female; Fibrinolysis; Humans; Liver; Male; Middle Aged; | 1970 |
Clinical experience with Myambutol in the treatment of polyresistant chronic tuberculosis.
Topics: Adult; Cycloserine; Drug Combinations; Ethambutol; Ethionamide; Female; Humans; Isoniazid; Kanamycin | 1970 |
Report on experiences with ethambutol.
Topics: Chronic Disease; Cycloserine; Drug Combinations; Ethambutol; Ethionamide; Humans; Phenylthiourea; Py | 1970 |
International conference.
Topics: Antitubercular Agents; Child; Cycloserine; Ethionamide; Humans; International Cooperation; Mass Ches | 1967 |
[Toxicity of the primary tuberculostatics].
Topics: Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Humans; Isoniazid; Pyrazinamide; Streptomy | 1967 |
[Autonomous treatment of pulmonary tuberculosis with delayed-action drugs].
Topics: Adult; Aged; Antitubercular Agents; Cycloserine; Delayed-Action Preparations; Ethionamide; Female; H | 1967 |
[Immediate results of treatment of tuberculosis patients with drugs of the second series].
Topics: Adult; Aged; Antitubercular Agents; Cycloserine; Ethionamide; Female; Humans; Male; Middle Aged; Pyr | 1967 |
[Treatment of patients with pulmonary tuberculosis with antibacterial preparations of the second series].
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antitubercular Agents; Aspartate Aminotransferases; E | 1967 |
[Tuberculostatic preparations of the 2d series in the clinical treatment of pulmonary tuberculosis].
Topics: Antitubercular Agents; Chlortetracycline; Cycloserine; Ethionamide; Humans; Kanamycin; Pyrazinamide; | 1967 |
[Cheotherapy of chronic pulmonary tuberculosis with resistant mycobacteria].
Topics: Aminosalicylic Acids; Antitubercular Agents; Chronic Disease; Cycloserine; Drug Resistance, Microbia | 1967 |
The use of second line drugs in patients with drug resistance to standard tuberculostatics.
Topics: Ambulatory Care; Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Drug Hypersensitivity; Dr | 1968 |
Multiple drugs in retreatment of chronic pulmonary tuberculosis. Results with capreomycin and ethambutol.
Topics: Adult; Aged; Anti-Bacterial Agents; Antitubercular Agents; Chronic Disease; Drug Resistance, Microbi | 1968 |
[Combination of ethambutol with ethionamide, cycloserine and-or pyrazynamide in retreatment of pulmonary tuberculosis].
Topics: Cycloserine; Ethambutol; Ethionamide; Humans; Pyrazinamide; Tuberculosis, Pulmonary | 1968 |
[Comparison among single, double and triple drug regimens in retreatment. (the seventh series of the trial, B)].
Topics: Cycloserine; Drug Resistance, Microbial; Ethionamide; Humans; Kanamycin; Pyrazinamide; Tuberculosis, | 1968 |
[Functional state of the liver in patients with pulmonary tuberculosis during treatment with chemopreparations of the 2d series].
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Ethionamide; Female; Humans; Liver; Liver Function T | 1968 |
[Results of treatment of pulmonary tuberculosis in adults with second line drugs].
Topics: Adult; Cycloserine; Ethionamide; Humans; Pyrazinamide; Tuberculosis, Pulmonary | 1968 |
Results of the second chemotherapy trial of the IUAT. Bacteriological part.
Topics: Antitubercular Agents; Cycloserine; Drug Resistance, Microbial; Ethambutol; Humans; Pyrazinamide; Tu | 1968 |
[Certain aspects of new combinations of drugs for the treatment of drug-resistant tuberculosis].
Topics: Aminosalicylic Acids; Antitubercular Agents; Drug Resistance, Microbial; Ethionamide; Humans; Isonia | 1968 |
[Treatment of chronic polyresistant pulmonary tuberculosis using ethionamide, pyrazinamide and cycloserine].
Topics: Adult; Chronic Disease; Cycloserine; Drug Resistance, Microbial; Drug Synergism; Ethionamide; Humans | 1968 |
A note on the relapse rate over a four-year period in patients with quiescent pulmonary tuberculosis following treatment with reserve regimens.
Topics: Cycloserine; Ethionamide; Follow-Up Studies; Humans; Pyrazinamide; Streptomycin; Tuberculosis, Pulmo | 1968 |
[Late results of treatment of chronic, cavernous pulmonary tuberculosis with reserve drugs].
Topics: Chronic Disease; Cycloserine; Ethionamide; Humans; Pyrazinamide; Retrospective Studies; Tuberculosis | 1968 |
[Administration of reserve antitubercular drugs in a single daily dose].
Topics: Cycloserine; Ethionamide; Humans; Pyrazinamide; Tuberculosis, Pulmonary | 1968 |
[Liver damage in tuberculosis].
Topics: Bile Acids and Salts; Bilirubin; Biopsy; Chemical and Drug Induced Liver Injury; Ethionamide; Fatty | 1968 |
Absorption, metabolism and excretion of pyrazinamide in man.
Topics: Countercurrent Distribution; Humans; Intestinal Absorption; Pyrazinamide; Statistics as Topic; Time | 1969 |
Observations on human infection with Mycobacterium bovis.
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Animals; Cattle; Drug Resistance, Microbial; Humans; | 1969 |
[Metabolism of morphazinamide in patients with pulmonary tuberculosis].
Topics: Antitubercular Agents; Humans; Pyrazinamide; Pyrazines; Tuberculosis, Pulmonary | 1965 |
[Comparison of the effect of morphazinamide and pyrazinamide in the treatment of chronic tuberculosis].
Topics: Antitubercular Agents; Humans; Pyrazinamide; Pyrazines; Tuberculosis, Pulmonary | 1965 |
[On the metabolism of morphazinamide in the treatment of chronic pulmonary tuberculosis].
Topics: Blood Proteins; Humans; Pyrazinamide; Pyrazines; Tuberculosis, Pulmonary | 1965 |
[On the problem of chronic liver damage following drug therapy of tuberculosis].
Topics: Adult; Aminosalicylic Acids; Antitubercular Agents; Biopsy; Chemical and Drug Induced Liver Injury; | 1965 |
[On qualitative demonstration of tuberculostatics in the control of taking of drugs].
Topics: Aminosalicylic Acids; Cycloserine; Ethionamide; Humans; Isoniazid; Pyrazinamide; Streptomycin; Tuber | 1965 |
Late results of treatment of chronic drug-resistant pulmonary tuberculosis.
Topics: Cycloserine; Drug Resistance, Microbial; Drug Tolerance; Ethionamide; Humans; Prognosis; Pyrazinamid | 1966 |
Reversible sideroblastic anemia caused by pyrazinoic acid (Pyrazinamide).
Topics: Adult; Aminosalicylic Acids; Anemia; Anemia, Sideroblastic; Erythropoiesis; Ethionamide; Female; Fol | 1966 |
[Triple drug regimen with reserve drugs: ETA, PZA and CS in the treatment of chronic pulmonary tuberculosis].
Topics: Adult; Cycloserine; Ethionamide; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pyrazinamide; | 1966 |